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Assigning  function  to  genome  wide  association  study 























based  assays,  large  scale  microarrays  and  high‐throughput  generation  sequencing 
platforms  this  thesis aims  to  identify  the  functional effects of disease  loci, with particular 










have  identified  eight  genomic  different  loci  as  associated with  coeliac  disease  but  none 
have been functionally characterised. To  investigate the effect that genotype has on gene 










assaying  for  SNP  effects on  gene  expression was developed.  This  allele  specific method, 




































































































































































































found  it  too  hard  to  cope,  or  had  a  major  disagreement  with  your  supervisor  and  I 
wondered what  I had got myself  into. For  three years  I kept wondering  if something  like 
that was going to happen to me, but it never did. I have genuinely enjoyed every moment 
of the last three years, even at the times when nothing seemed to work.  
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discussion (some of which was about genetics) with Karen, Patrick, Lude and more recently 
Nick and Vanisha. Finally I would not have got anywhere near a finished thesis without the 
help  and  support of  family but most  importantly my partner  Serene without whom  this 
thesis would never have got off the ground.  
Science can’t happen without collaborators, and I would like to thank in particular everyone 
in  the  Wijmenga  Lab  in  Groningen  (especially  Cisca  for  putting  me  up  in  her  guest 










This  thesis  was  conducted  as  an  intercalated  PhD  during  an  undergraduate  (MBBS) 
medicine degree.  I started medicine  in 2003 hoping to qualify as a doctor  in 2008. During 
the  course  of my  studies,  however,  I  got  bitten  by  the  research  bug  and  after  a  BSc  in 
medical science and physiology I couldn’t resist doing a PhD. As I head back to finish off my 












images produced by others have been acknowledged within  the  text but are  reproduced 
here  for  clarity.  The  large  scale  genetical  genomics  scan  of  all  genes  and  transcripts 
(Chapter  4)  was  performed  by  Dr  Lude  Franke  (UMCG,  Groningen,  The  Netherlands). 
IL18RAP  re‐sequencing  was  conducted  by  Gosia  Trynka  (UMCG,  Groningen,  The 
Netherlands). The methylation analysis was conducted in part by Dr Thomas Down (Gurdon 
Institute, Cambridge), with several of his figures reproduced here;  I had substantive  input 
into  the scientific method at all stages. The “reference  transcriptome”  reference genome 
was  created  by  Dr  Barry  Healey  (CIMR,  Cambridge,  UK).  The  allele  specific  expression 
analysis was conducted in parallel with Dr Vincent Plagnol (CIMR, Cambridge, UK). The data 
included  in Chapter 6 was produced and analysed by me with the exception of the power 
calculation and  figures and  tables as explicitly stated  (Chapter 6.3). The replication of  the 
allele specific findings was conducted by Jennie Yang and Kate Downes (CIMR, Cambridge, 
UK), while the eQTL replication was undertaken by Dr Lude Franke (UMCG, Groningen, The 
Netherlands).   Genotyping of  leucofilter  individuals on  the whole genome SNP array was 


















































in  three  European  populations  with  coeliac  disease.  Hum  Mol  Genet.  2009  Mar 
15;18(6):1148‐55. 
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ASE    ‐  Allele Specific Expression 
bp    ‐  Base Pair 
cDNA    ‐  Complementary DNA 
ChIP    ‐  Chromatin Immunoprecipitation 
CNV    ‐  Copy Number Variation 
cRNA    ‐  Complementary RNA 
Ct    ‐  Cycle Threshold 
dbSNP    ‐  NCBI SNP Database 
dNTP    ‐  Deoxynucleic Acid 
ddNTP    ‐  Dideoxy Nucleic Acid 
EAE    ‐  Experimental Autoimmune Encephalitis 
EBV    ‐  Epstein ‐ Barr Virus 
ELISA    ‐  Enzyme Linked Immunosorbent Assay 
EMA    ‐  Anti endomysium antibody 
eQTL    ‐  Expression Quantitative Trait Loci 
GA    ‐  Genome Analyzer II (Illumina, USA) 
Gb    ‐  Gigabase 
gDNA     ‐  Genomic DNA 
GWA    ‐  Genome‐Wide Association 
HLA    ‐  Human Leucocyte Antigen 
hnRNA    ‐  Heterogeneous nuclear RNA 
IEL    ‐  Intra Epithelial Lymphocyte 
IFN    ‐  Interferon 
IL    ‐  Interleukin 
Indel    ‐  Small Insertion/Deletion 
LD    ‐  Linkage Disequilibrium 
LPS    ‐  Lipopolysaccharide 
Me‐DIP   ‐  Methylated DNA Immunoprecipitation 
MHC    ‐  Major Histocompatibility Complex 
mRNA    ‐  Messenger RNA 
NBS    ‐  National Blood Service 
NCBI     ‐  National Center for Biotechnology Information 
PBMC    ‐  Peripheral Blood Mononuclear Cell  
PCR    ‐  Polymerase Chain Reaction 
poly(A)    ‐  Poly‐adenylated transcript 
qPCR    ‐  Quantitative real time PCR 
QTL    ‐  Quantitative Trait Locus 
Rh    ‐  Recombinant Human 
RNA‐Seq  ‐  Whole transcriptome cDNA Sequencing 
RT    ‐  Reverse Transcription 
SD    ‐  Standard Deviation 
SEM    ‐  Standard Error of the Mean 
SNP    ‐  Single Nucleotide Polymorphism 
Tb    ‐  Terabyte 
TG2    ‐  Tissue Transglutaminase 2 
TH    ‐  T helper Cell (1/2/17) 
T1D    ‐  Type 1 Diabetes Mellitus 
T2D    ‐  Type 2 Diabetes Mellitus 































and  cytosine  (C)  base  pairs.  These  sequences  are  usually  identical  between  individuals, 
however,  approximately  every  100‐200  bases,  a  difference  can  be  detected  (Ahituv, 
Kavaslar et al. 2007). These differences can take many forms.  If they are present  in  just a 
single  individual, they are termed mutations, but  if the mutation  is stably  inherited down 
through  families  and  becomes  prevalent  in  the  population  as  a  whole,  at  a  frequency 
greater than 1%, the mutation becomes known as a polymorphism (it should be noted that 
this  1%  cut  off  is  somewhat  arbitrary).  There  are  five  classes  of  common  DNA 
polymorphism  that  are  widely  used  in  genetic  analysis  (Nakamura  2009).  The  earliest 
variants  to  be  used  for  genetic  analysis  were  the  restriction  fragment  length 
polymorphisms, which  introduce  a  new  endonuclease  digestion  site  for  an  enzyme.  The 
second and  third  forms of polymorphism to be used were the variable number and short 
tandem  repeat  sequences  (microsatellites)  respectively, which  generate  different  alleles 
due to differential repeat numbers between  individuals. The fourth polymorphism to gain 








Single nucleotide polymorphisms arise  from single base differences  in  the DNA sequence. 







linkage  disequilibrium.  This  phenomenon  results  when  recombination  occurs  between 
chromatids during meiosis. This recombination can occur anywhere along a chromosome, 
but  the probability of a  specific  region being  interrupted  is  low. This  results  in blocks of 





To  date  approximately  80 million  SNPs  have  been  submitted  to  the National  Center  for 
Biotechnology Information (NCBI) SNP database (May 2009, Build 130), of which about 18 
million have been assigned an rs# number. Designation with an rs# number identifies them 
as non‐redundant, but  it does not necessarily  indicate that they have been  independently 
validated. In order to assess association between a trait and all SNPs in the genome, it is not 









Common  variation  can be  captured  in  the  genome using  a  ‘tagging’ method.  In  this example  the 
genotype at all  four haplotypes can be captured using the genotypes from  just two SNPs  (in RED). 






genotyped  four  distinct  ethnic  groups  comprising  30  parent‐offspring  trios  from  Yoruba, 
Nigeria  (YRI),  30  trios  from UTAH, USA  (CEPH),  45  unrelated Han  Chinese  (CHB)  and  44 
unrelated  Japanese  individuals  (JPT)  (The  HapMap  Consortium,  2005).  The  aim  of  the 
project was  to  identify  SNP  genotype  frequencies within  populations  for  existing  SNPs. 
Phase 1 aimed  to genotype one SNP, with a minor allele  frequency of at  least 0.05  (5%, 
equivalent  to one minor allele  in 20 people) every 5kb  (The HapMap Consortium, 2005). 
The  second  phase  of  the HapMap  project  extended  genotyping  to  a  further  2.1 million 
common SNPs resulting in a detailed map with a resolution of approximately one SNP every 
1kb (Frazer, Ballinger et al. 2007). Phase three extended genotyping of 1.6 million SNPs into 
7  further  populations  comprising  1,301  samples  (including  the  original  participants).  In 
order  to  generate  a  detailed  genotype  frequency map  in  a  large  number  of  SNPs  in  4 
populations, a detailed  repository of all known SNPs was  required. As  research  institutes 
and companies  from around  the world  identified new SNPs,  the data was deposited  into 
The  National  Centre  for  Biotechnology’s  (NCBI),  dbSNP  database  (Sherry  ST  2001).  This 
database  contained 2.8 million  candidate SNPs when  the HapMap project was begun, at 
present it has over 18 million (May 2009, Build 130) (Figure 1.2). The recent growth in SNP 






























































































give  rise  to  this  heritability  (Strachan  and  Read  2004).  Linkage  analysis  has  had  a  lot  of 
success  in  identifying  genomic  regions  which  are  co‐inherited  with  disease  causing 
mutations  and  it  is  especially  useful  for monogenic Mendelian  disorders  such  as  Cystic 
Fibrosis  (Riordan, Rommens et al. 1989). The power of  linkage  studies  is high enough  to 
capture  single  variants  that  are  highly  penetrant  and  associated with  disease.  Complex, 
polygenic, disorders such as Crohn’s disease and coeliac disease, however, are unlikely to 
be associated with a  single mutation,  instead  they  are more  likely  to be associated with 
many  smaller  genomic  regions,  each  with  a  low  effect  size  (Gregersen  2005).  Linkage 
analysis has thus had less success in identifying regions that are co‐inherited with complex 
diseases. These regions require significantly more statistical power to detect than a single 








sequence  of  DNA  that  varies  in  length  (typically  2‐8bp);  the  variation  in  repeat  length 







test  all  variants  in  the  genome  for  association with  disease  carriage. Microsatellites  are 
fairly prevalent in the genome (over 100,000 have been annotated, 2009), but are difficult 
to  genotype  on  a  large  scale  (Tamiya,  Shinya  et  al.  2005;  Nakamura  2009).  Although 
microsatellites  have  been  successfully  used  in  genome‐wide  studies,  as  technology  has 
improved, and it has became possible to genotype bi‐allelic SNPs with greater accuracy and 
in  greater  numbers,  attention  has  turned  to  the  use  of  SNPs  in  association  studies 
(Gregersen 2005; Tamiya, Shinya et al. 2005; Kawashima, Tamiya et al. 2006).  
 











The SNPs can be  randomly distributed across  the genome, or  specifically designed  to  tag 
common haplotypes. By comparing  the SNP allele  frequency between cases and controls, 
using e.g. a 2 by 2 contingency table Pearson’s χ2 test,  it  is possible to  identify SNP alleles 
that are more likely to occur in cases than controls, or vice versa. Testing large numbers of 
SNPs  in  this manner  generates  a  large multiple  testing  problem;  this  can  be  overcome 
through  computation  of  a  false  discovery  rate  and  altering  the  p  value  significance 
threshold;  for example when  testing 500,000 SNPs, a  commonly used  level  for  statistical 
significance, would be p < 5 x 10‐7. Only association tests reaching this level of significance 
allow rejection of the null hypothesis of no association (The Wellcome Trust Case Control, 




















environmental  influences.  Each  of  these  variants  is  unlikely  to  represent  anything  other 
than  a  very  small  effect on  an  individual’s  risk;  the  sum of  all  the  variants  an  individual 
possesses  together  generates  the  true  disease  risk.  This  effect  had  been  elegantly 
demonstrated  in  Type  2  Diabetes  (T2D)  where  possession  of  an  increased  number  of 
associated SNP variants  increases  the  risk of T2D development  (Weedon, McCarthy et al. 
2006). An  alternative  hypothesis  is  that  common  diseases  are  caused  by  a  collection  of 
fewer,  rarer, more  deleterious  variants  that  have  arisen more  recently  in  individuals  or 
populations.  Polygenic  diseases  are  not  inherited  in  a Mendelian  fashion  although  they 
clearly run in families, and are caused by a number of variants. It seems likely that given the 
wide natural variation  in allele frequency for all the variants  in the genome, both of these 











association  studies  were  published  (Duerr,  Taylor  et  al.  2006;  Sladek,  Rocheleau  et  al. 
2007). A myriad of studies in a range of diseases were subsequently published at a rate of 
around  2  per  month  thereafter.  By  the  end  of  the  2007,  over  45  studies  have  been 

















































































































































unsuccessful at  identifying major  components of  the heritability of  these  chronic disease 
traits, with many conditions entering the genome‐wide association study era with no well 
replicated findings. Many of these studies were conducted by collaborations based within a 
single  country,  each  identifying  a  few  novel,  but  low  risk,  alleles.  It was  soon  realised, 
however,  that  even  greater patient  sample numbers would be needed  to  gain  sufficient 
statistical power to  identify alleles with small odds ratios. 2008 was the year that saw the 
successful  pooling  of  large  collections  of  genome‐wide  association  study  data  between 
groups, thus  increasing statistical power and  leading to the  identification of further alleles 
in  conditions  such  as  type  1  diabetes  (T1D),  T2D,  Crohn’s  disease  and  colorectal  cancer 

















disease,  idiopathic  pulmonary  fibrosis  and  atherosclerosis.  This  thesis  centres  on  coeliac 
disease, but also involves elements of Crohn’s disease and T1D genetics. All three of these 
conditions  are  chronic  inflammatory  conditions,  with  elements  of  shared  heritability 
(Smyth, Plagnol et al. 2008; Zhernakova, Festen et al. 2008).  
 
Two  common  and  debilitating  gastrointestinal  disorders  can  be  used  to  illustrate  the 
journey that many complex diseases have been following; Crohn’s disease, an inflammatory 
response  to  luminal  gut  bacterial  antigens,  and  coeliac  disease,  an  autoimmune 
inflammatory  response  in  the  small  bowel  to  ingested wheat  gluten. At  the  turn  of  the 
millennium, genetic studies in Crohn’s disease genetic had identified a single linkage region 
on  chromosome  16,  but  no  definitive  loci  had  been mapped  (Hugot,  Laurent‐Puig  et  al. 
1996). As of 2009,  the  loci count  stands at 31, with  several of  these harbouring multiple 
independent protective and risk variants (Hugot, Laurent‐Puig et al. 1996; Barrett, Hansoul 
et al. 2008). Studies into coeliac disease, on the other hand, identified a major determinant 
of  the  heritability  in  the  1970s,  which  was  later  refined  to  the  identification  of  an 




















Coeliac disease results from an  immune response to  ingested dietary gluten  in genetically 
susceptible  individuals.  Disease  development  follows  a  bimodal  distribution,  presenting 
either in the first few years of life (after solid feeding has commenced) or in middle age. In 
susceptible  individuals,  ingestion of gluten and  its  related peptides  in  the  form of wheat, 
barley and rye cereals leads to malabsorption in the small intestine. The classical symptoms 
arising  from  coeliac disease  include  steatorrhea  (diarrhoea due  to malabsorption of  fat), 
weight  loss, weakness,  and malaise. These  classical  symptoms  are becoming  increasingly 
rare as better diagnostic  tests detect patients earlier, when only mild  symptoms or  signs 
such  as  indigestion  and  anaemia  are  present, despite  the presence of manifest mucosal 
lesions  (Maki  and  Collin  1997;  Lo,  Sano  et  al.  2003).  Coeliac  disease  is  indicated  by  the 
presence of a combination of auto‐antibodies, but a histological diagnosis via endoscopic 
biopsy  of  the  small  bowel  is  almost  always  required  for  a  definitive  diagnosis. A  biopsy 
sample from the small bowel, of a coeliac disease patient, reveals crypt hyperplasia, villous 
atrophy  and  intra‐epithelial  lymphocyte  infiltration  into  the  lamina  propria  (Figure  1.5) 





obtained  by  sampling  large  numbers  of  people  from  the  population  and  testing  for  the 
presence of coeliac disease auto‐antibodies. Despite this estimated prevalence of 1%, only 
approximately 0.14% of the UK population is diagnosed with coeliac disease (van Heel and 







of  monomeric,  alcohol  soluble  gliadins  (responsible  for  the  elasticity  of  dough),  and 
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concordance rate between dizygotic  twins  is still high at 11%  (Greco, Romino et al. 2002; 
Nistico, Fagnani et al. 2006). This strong heritability  is also evident  in family studies where 
the  risk  of  coeliac  disease  is  approximately  10%  for  a  sibling  of  an  affected  individual 
(Bourgey, Calcagno et al. 2007). By way of a comparison, the concordance rate for Crohn’s 










et al. 1983). HLA‐DR3, HLA‐B8 and HLA‐DQ2 are  in  strong  linkage disequilibrium and are 
inherited  on  the  same  ancestral  haplotype  (Price, Witt  et  al.  1999).  The  DQ2  serotype 
association with  coeliac  disease  is mediated  entirely  through  the  DQ2.5  haplotype,  the 
other haplotype  found with  the DQ2  serotype, DQ2.2, does not appear  to predispose  to 
disease (Sollid, Markussen et al. 1989). The HLA‐DQ2.5 haplotype contains both the alpha 






with  each parent  supplying one  chain  (van Heel, Hunt  et  al.  2005; Dubois  and  van Heel 
2008).  
 
Possession  of  the  HLA‐DQ2  serotype  is  a  very  strong  risk  factor  for  coeliac  disease 
development. A  study of  just over 1000 European  coeliac patients  found  that  just under 
90% possessed the DQ2 serotype (Karell, Louka et al. 2003). The remaining patients tend to 
possess  a  related  DQ8  serotype  or  at  least  one  chain  of  the  DQ2  heterodimer  (e.g. 
DQA1*0501 or DQB1*0201 but not both)  (Karell, Louka et al. 2003; van Heel, Hunt et al. 
2005).  The  exact  configuration  of  HLA‐DQ  molecules  that  a  person  inherits  directly 
influences their coeliac disease risk. A gene dosage effect has been observed for carriage of 
the  DQ2.5  haplotype  with  homozygotes  at  four  to  six  times  increased  risk  of  disease 




Although a genetic association between coeliac disease and variants  in  the HLA  region  is 
useful for the purposes of diagnostic criteria and risk prediction, the true goal of all genetic 
studies  should  be  to  gain  an  insight  into  the  biology  of  a  condition.  As  such,  after  the 
identification  of  the  genetic  association  between  coeliac  disease  and  the  HLA  complex, 
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much  attention  was  focused  on  the  mechanism  of  this  association  with  a  view  to 
understanding  the  pathogenesis  of  the  disease.  The  HLA  region  is  a  4Mb  region  on 
chromosome  6p21.  It  contains  all  the  human major  histocompatibility  genes  as well  as 
numerous other immune and non‐immune system functioning genes. The primary function 
of class  II MHC molecules,  like HLA‐DQ,  is  to present exogenously derived antigen on  the 
cell  surface  to  T  cell  receptors.  In  the  case  of  coeliac  disease,  antigen  presenting  cells 
present gluten peptides derived  from  the gut  lumen  to T  cells,  thus eliciting an  immune 
response. The heterodimers  formed  from  the DQ2.5 and DQ2.2 haplotypes differ  in  their 
peptide  binding  affinity  for  gluten  peptides  (van  de Wal,  Kooy  et  al.  1997).  The  coeliac 
disease  associated  heterodimer,  DQ2.5,  binds  α‐gliadin  derived  epitopes  with  a  much 






















Anti‐endomysium  (EMA) and anti‐gliadin  IgA antibodies can be detected  in the peripheral 





al.  1992;  Lerner,  Kumar  et  al.  1994;  Catassi,  Fanciulli  et  al.  2000).  Apart  from  being  an 
extremely useful diagnostic and screening tool, the detection of EMA provides a key insight 
into the pathogenesis of the disease. In 1997 Dieterich et al identified the epitope of EMA 
as tissue transglutaminase  (Transglutaminase Type 2, TG2), an  intracellular enzyme  found 
in the lamina propria that was known to interact with gliadin in the human jejunal mucosa 





Kooy  et  al.  1998a).  For  the many  gluten  derived  epitopes  that  have  been  identified  as 
putative HLA‐DQ2 binding molecules, deamidation by TG2 appears to be a prerequisite for 
binding and antigen presentation  (Sjostrom, Lundin et al. 1998).   TG2  is expressed  in  the 
small  bowel,  particularly  in  the  lamina  propria  and  there  is  some  evidence  that  its 
expression may be increased in coeliac disease (Bruce, Bjarnason et al. 1985; Brusco, Muzi 
et al. 1999; Skovbjerg, Hansen et al. 2004). Intestinal deposits of TG2 IgA are a hallmark of 
coeliac  disease  and may  occur  even  in  a  latent  form  of  disease  prior  to  villous  atrophy 
development  (Koskinen,  Collin  et  al.  2008).  The  physiological  function  of  TG2  is  not 
completely understood, but it does seem to play a role in wound healing (Haroon, Hettasch 
et  al.  1999;  Johnson,  Skill  et  al.  1999),  cellular  apoptosis  (Autuori,  Farrace  et  al.  1998; 
Piacentini,  Farrace  et  al.  2002)  and  stabilization  of  extracellular  matrix  proteins  (ECM) 
(Greenberg,  Birckbichler  et  al.  1991;  Jones,  Nicholas  et  al.  1997).  TG2  is  ubiquitously 
expressed and has no known human inherited defect syndrome; in addition TG2 (‐/‐) knock‐
out mice appear developmentally normal with only minor fibroblast and thymocyte defects 
(De  Laurenzi  and  Melino  2001;  Nanda,  Iismaa  et  al.  2001).  Whether  the  anti‐bodies 
produced against TG2 are actually deleterious in coeliac disease has yet to be determined, 










lamina  propria, most  TG2  enzymes will  be  cross‐linked with  proteins,  but  even  so  they 
appear  to be  capable of deamidating  some  gliadin proteins  (Skovbjerg, Anthonsen  et  al. 





How  TG2  antibodies  develop  in  the  first  place  is  not  yet  fully  understood.  The  original 
proposition was a hapten‐carrier  like model. Here TG2 specific B cells, that are universally 
present, were hypothesized  to  endocytose  a TG2‐gliadin dimer, degrade  it  intracellularly 




Pinkas  et  al  that  TG2  undergoes  a  large  conformational  change  upon  calcium  induced 
activation  opens  the  intriguing  possibility  that  the  antibodies may  be  directed  against  a 
“neo‐epitope” that  is not present on un‐activated TG2 and therefore shielded from T cells 
during thymic selection (Pinkas, Strop et al. 2007). Since the antibody based assay to detect 
IgA  requires calcium, and  site directed mutagenesis of  the TG2 gliadin binding active  site 
abrogates  IgA antibody binding,  it appears that calcium activated TG2  is the  target of  the 
IgA antibody response  in coeliac disease. What cellular processes activate TG2  in the  first 





Once  gliadin  has  been  presented  to  CD4
+  T  cells  in  the  context  of HLA‐DQ2,  the  T  cells 
release a number of cytokines that mediate disease. Coeliac disease is classically thought to 






(Nilsen,  Lundin  et  al.  1995). Although  thought  of  as  a  TH1  disease,  IL‐12,  the major  TH1 




in  vitro  (Monteleone, Pender et al. 2001a;  Leon, Garrote et al. 2006).  IL‐18, another TH1 
polarising cytokine, has been found to be elevated in coeliac disease mucosa compared to 
controls  (Salvati, MacDonald et al. 2002). Recent work by De Sabatino et al has provided 
some  important  insights  into the mechanisms of TH1 cell differentiation  in the absence of 
IL‐12.  Mucosal  dendritic  cells  from  coeliac  patients  demonstrated  elevated  levels  of 
Interferon α  (IFNα),  IL‐18 and  IL‐23p19   compared  to controls, however, only blockage of 
IFNα inhibited the gliadin induced IFNγ increase in cultured gut biopsy explants from coeliac 
patients (Di Sabatino, Pickard et al. 2007). IFNα has been previously demonstrated to cause 
crypt hyperplasia  in a  foetal gut model upon  concomitant CD3  stimulation of T  cells and 
may play a role in the differentiation of TH1 cells in coeliac disease (Monteleone, Pender et 
al. 2001b).  In  the mucosa of  coeliac disease patients, elevated  levels of  the TH1 defining 
transcription  factor,  T‐bet  have  been  observed  (Monteleone,  Monteleone  et  al.  2004; 
Johrens, Anagnostopoulos  et  al.  2005).  This  induction  appears  to be dependent on  IFNγ 
(Monteleone, Monteleone et al. 2004).  
 
Recently  work  has  focused  more  on  the  newly  identified  cytokine  IL‐21  as  a  possible 
candidate for induction of T‐bet, IFNγ and hence TH1 polarisation in coeliac disease. There is 
already  evidence  that  IFNα  can  induce  IL‐21  secretion  from  activated  T  cells  (Strengell, 
Julkunen et al. 2004). IL‐21 is secreted upon CD3 stimulation of T cells as well as by NK cells. 
The cytokine  itself  is similar  in structure to both IL‐2 and IL‐15 (Parrish‐Novak, Dillon et al. 
2000). Although some murine work has suggested that IL‐21 may be a TH2 inducing factor, 
in humans, treatment of CD4 T cells with  IL‐21  leads to a significant  increase  in T‐bet and 
IFNγ production as well as IL‐2Rα, IL‐12Rβ2, IL‐18R and MyD88 (Parrish‐Novak, Dillon et al. 
2000; Wurster, Rodgers et al. 2002). Several groups have demonstrated an  increase  in the 
levels of  IL‐21  in  the mucosa of coeliac disease patients compared  to controls  (van Heel, 
Franke et al. 2007; Fina, Sarra et al. 2008). Inhibition of IL‐21 in gut biopsy samples ablated 
the  IFNγ  response  to  a  gliadin  digest,  however,  inhibition  of  another  related  cytokine 




an autocrine  factor  from cells already activated to maintain the secretion of  IFNγ. One of 
the central problems that investigators encounter when studying coeliac disease is that the 
best  system  to  understand  how  the  immune  cells  and mucosa  interact  involves  in  vitro 
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cultured gut biopsy  samples. These provide a good  indication of cellular  interactions and 
have been  instrumental  in  identifying the causes of the  IFNγ response to gliadin but have 
made  it difficult  to  identify exactly which cell  type  is  responsible. The compartment with 
the  largest  contribution  to  IFNγ  appears  to  be  the  intra‐epithelial  lymphocytes  (IEL) 
(Olaussen,  Johansen  et  al.  2002).  If  IL‐21  is  acting  to maintain  the  IFNγ  response,  it  is 
possible that  it may act directly on these cells; however, given that  IL‐15  is also necessary 















Of particular  interest to coeliac disease  is the  interaction of IL‐21 and IL‐15, both of which 
are central to the activation and expansion of the IEL compartment upon gluten ingestion in 
coeliac  disease.  The  IELs  comprise  a  mixture  of  cells  with  the  majority  being 
TCRαβ+ CD8+CD4− or TCRγδ+ CD8−CD4− (Sollid 2004). The varied functions of IL‐21 and how it 






+ cells  in the  lamina propria may represent the key  link between the 
adaptive  and  innate  responses  to  gluten  ingestion  in  coeliac  disease. NKG2D  is  an  IL‐15 
induced  receptor  that  acts  as  a  co‐stimulatory molecule  on  CD8
+  cells  from  the  jejunal 
mucosa which lack CD28 (Roberts, Lee et al. 2001; Maasho, Opoku‐Anane et al. 2005). MIC 
(MHC  class  I  chain‐related, A‐E)  genes  represent  a  class  of  non‐classical HLA  genes  that 
serve as ligands for NKG2D (Bahram, Bresnahan et al. 1994; Hue, Mention et al. 2004). The 
expression  of  these  genes  is  highly  regulated  and  normally  restricted  to  the  epithelium 
(Hue, Mention  et  al.  2004). MICA  is  induced  in  dendritic  cells  by  IL‐15,  and  neutralising 
monoclonal  antibodies  directed  against  IL‐15  inhibit  MICA  increase  in  coeliac  explants 
treated with  gliadin digests  (Jinushi,  Takehara  et  al.  2003; Hue, Mention  et  al.  2004).  In 
coeliac  disease, MICA  expression  in  the  intestinal  epithelium  is  highly  upregulated  from 







with  IL‐15,  which  stimulates  IFNγ  from  cells  within  the  epithelium  resulting  in  the 
characteristic villous remodelling seen  in coeliac disease (Ebert 2005). The exact nature of 
the  IL‐15  ‐  IL‐21  interaction  is unknown and at  this point  it  is only possible  to  speculate 
based on the cytokines’ functions in other tissues. Perhaps the most interesting question to 
answer will be how NKG2D, IL‐15 and IL‐21 interact and in particular how they influence the 



















cells, has been  identified as a possible  innate  immune system activator  in disease (Maiuri, 
Ciacci  et  al.  2003).  Several  groups  have  demonstrated  that  gliadin  peptide  digests  can 














al. 2003).   Recent work by  Lammers  et  al has  identified  that  gliadin binds  specifically  to 
CXCR3 on enterocytes, inducing a MyD88 induced release of zonulin, resulting in a greater 
epithelial permeability  (Lammers, Lu et al. 2008). The  story  is  further complicated by  the 
finding  that  the  immunodominant  33‐mer  α‐gliadin  fragment  can  pass  though  epithelial 








2008). An  increase  in CD14+  cells has previously been observed  in  the  lamina propria of 




individuals,  producing  zonulin  from  enterocytes  and  IL‐1β  from  peripheral  blood 
mononuclear cells  (Harris, Fasano et al. 2008). The magnitude of  the release  is, however, 
far  greater  in  coeliac  individuals  than  in healthy  controls.  Peripheral blood mononuclear 
cells  elicit weak  IFNγ  responses  to  gluten  in  HLA‐DQ2  positive  healthy  subjects  after  a 
previous period on a gluten  free diet, a response that  is not enhanced by deamidation of 
the gluten  (Anderson, van Heel et al. 2005). Some  fragments of un‐deamidated  α‐gliadin 
may therefore act as a generalised immune activating factor. The progression to disease is 











thought  to  be  due  to  a  combination  of  genetic  and  environmental  factors  (Figure  1.7). 
Studies using twins, which are assumed to share environmental factors, have estimated the 
percentage of non‐HLA genetic variants which predispose to disease as approximately 60% 













HLA‐DQ2.5 carriage  is necessary for disease development, but  it  is not sufficient. A combination of 
other genetic factors  influencing the mucosal barrier, the adaptive and the  innate  immune system 
also  impact the  likelihood of disease development. Wheat  ingestion  is a known environment factor 
that is necessary for disease development, but on top of this a number of factors such as timing of 
gluten  ingestion  and  breast  feeding  cessation may  also  influence  disease  development  (Ivarsson, 
Persson et al. 2000).   
 
In  coeliac disease,  like many  common diseases,  linkage  scans were  fairly unsuccessful  at 
locating  variants  that  segregated  with  disease.  Linkage  was  found  to  various  regions 
including  5q  and  19p, however,  the only  genomic  region  that was  replicated with  some 
reliability in other populations was 2q33, a region that contains the CTLA4, ICOS and CD28 
genes  (van  Heel,  Hunt  et  al.  2005).  Even  for  this  region,  however,  replication  was 
inconsistent  (Amundsen,  Naluai  et  al.  2004).  CTLA4  is  an  excellent  candidate  gene  for 
involvement in coeliac disease not only due to its integral involvement in the suppression of 
immune  responses  but  also  because  it  has  been  implicated  as  a  genetic  variant  that 





















RGS1  0.0012  5.11 x 10‐9  0.1  0.0011  2.58 x 10‐11 
rs917997 
IL1RL1, IL18R1, 
IL18RAP, SLC9A4  9.06 x 10‐5  1.97 x 10‐6  0.55  3.61E‐06  8.49 x 10‐10  1.27 (1.15–1.40) 
rs6441961  CCR1, CCR3  0.0028  3.21 x 10‐5  0.21  0.002  3.14 x 10‐7  1.21 (1.10–1.32) 
rs17810546  IL12A, SCHIP1  0.00034  7.77 x 10‐7  0.00025  0.00064  1.07 x 10‐9  1.34 (1.19–1.51) 
rs1464510  LPP  7.65 x 10‐5  1.21 x 10‐5  0.085  0.29  5.33 x 10‐9  1.21 (1.11–1.31) 
rs13119723  IL2, IL21  2.51 x 10‐7  1.23 x 10‐7  0.013  0.00011  5.94 x 10‐13  0.73 (0.65– 0.82) 
rs1738074  TAGAP  0.0016  1.19 x 10‐5  0.014  0.00082  6.71 x 10‐8  1.21 (1.11–1.31) 
rs653178 
SH2B3(LNK), 
ATXN2  0.00065  2.98 x 10‐5  0.16  0.017  8.00 x 10‐8  1.19 (1.10–1.30) 
rs3087243  CTLA4  1.26x10‐6  0.85 (0.80‐0.90) 













As  sample  cohorts  have  become  larger,  and  genotyping  technologies  improved,  it  has 
become possible to perform association studies between a population of cases and controls 
using single nucleotide polymorphisms (SNP). This simple genetic analysis is very useful for 
following up  linkage  signals and  for  testing  candidate genes  for association with disease, 






In  the  past  few  years  it  has  been  possible  to  design  genome‐wide  association  studies 
involving hundreds of  thousands of common SNPs  spread across  the genome. The major 
advantages to this methodology are the increased power over linkage studies (derived from 
the large cohorts), the better resolution mapping of the association and the hypothesis free 





which,  if  any,  of  these  genes  are  affected  by  the  associated  variant,  given  the  known 
immunology for IL21, it is an excellent candidate. A follow up to this study in larger sample 
cohorts from the UK, Ireland and The Netherlands identified a further seven variants (Table 
1.2) associated with disease. All of  these  regions contain at  least one gene with a known 
immunological  function. These variants also allow  some  interesting parallels  to be drawn 
with the pathogenesis of coeliac and other autoimmune disorders. The remarkable finding 
from  the  studies  undertaken  to  date  is  that  almost  all  of  the  genes  (identified  in  a 
hypothesis‐free  manner)  are  involved  in  the  coeliac  disease  pathogenesis  pathways 
identified to date. It is also interesting to note the absence of other pathways. For example 
no variants have so far been identified, and replicated in other populations, in the mucosal 
barrier or  in  the  tissue  transglutaminase genes.  It  is possible  this belies  the evolutionary 
importance of the mucosal barrier, while  lymphocyte gene variation may have provided a 
survival  advantage.  It  is worth  noting  that Homo  sapiens  only  began  consuming  cereals 
about  10,000  years  ago  (Nestle  1999),  with  the  advent  of  agriculture,  so  the  variants 
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identified  by  genome‐wide  association  studies,  all  of which  are  common  (and  therefore 





heritability;  together with  the HLA  region  (which  explains  about  34%),  two‐thirds  of  the 
heritability is still unaccounted for (Figure 1.8) (Hunt, Zhernakova et al. 2008). This problem 
of missing heritability is not unique to coeliac disease, and is shared by all common complex 
diseases.  Where  this  missing  heritability  lies  is  at  present  not  known,  (Maher  2008). 
Genome‐wide studies are designed to capture only common variants so rare variants with 
larger effect  sizes may contribute  to a  large  fraction of  this heritability.  It  is also possible 









however,  only  34%  of  the  heritability  has  been  explained.  The  identification  of  HLA‐DQ2.5 
association  in  the  1970s  still  explains  the  largest  percentage  of  heritability  (~35%). New  variants 
identified by genome‐wide association have only added an additional 3‐4%  to  this  figure  leaving a 





Inflammatory  Bowel  Disease  is  a  collective  term  for  both  ulcerative  colitis  and  Crohn’s 
disease.  Although  both  diseases  can  lead  to  colitis  and  inflammation  of  the  distal 
gastrointestinal tract, there are marked differences between the two conditions. In Crohn’s 




locations  (Xavier and Podolsky 2007)  (Figure 1.9).  Inflammation  is deep,  trans‐mural and 
occurs  in patchy, well defined areas, known as  ‘skip  lesions’  (Allez and Modigliani 2000). 
Ulcerative  colitis,  by  contrast,  causes  a  continuous  area  of  shallow,  ulcerating  colonic 
inflammation  (Allez  and  Modigliani  2000).  Granulomatous  lesions,  sometimes  seen  in 
Crohn’s  disease,  are  uncommon  in  patent’s  with  ulcerative  colitis  (Papadakis  2004). 
Patients with  Crohn’s  disease  often  present with  bloody  diarrhoea  and  abdominal  pain. 
Treatment  involves  immunosuppressive  and  anti‐inflammatory  drugs  and  in many  cases 
surgery to remove sections of damaged bowel (Mathew 2008). The prevalence of Crohn’s 
disease may be  lower  than coeliac disease  (0.38%), but  the disease still causes significant 












disease  has  been  treated  as  a  TH1  mediated  autoimmune  disease,  however,  genetic 
evidence and mouse work has begun  to challenge  this  theory and  it  looks  likely  that  this 
view maybe too simplistic to fully understand this complex disease (Parronchi, Romagnani 
et al. 1997). Complex, multifactorial diseases,  such as Crohn’s disease,  require defects  in 
both  the  adaptive  and  innate  immune  systems.  In Crohn’s disease,  genetic defects have 
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Although  the  genetic  background  of  a  person will  dictate  to  some  extent  the  risk  of  developing 
disease,  the environment plays a  central  role. Genes associated with Crohn’s play  central  roles  in 
adaptive  immunity e.g. IL23R, and  innate  immunity (particularly phagocytosis) e.g. ATG16L1, IRGM. 
The pathways of both of these genes are of  immense  importance  in the way the gut interacts with 
the trillions of microbes in the lumen and the mucosa. Adapted from (Xavier and Podolsky 2007). 
 
What  is clear  from existing data  is  that both genetics and a person’s environment play a 
central role in the development of disease (Figure  1.10) (Xavier and Podolsky 2007). This is 
clearly  evidenced  by  the  role  of microbes  in  disease  development.  IL‐10  deficient mice, 
which develop  a  spontaneous  colitis,  reared under  specific pathogen  free  conditions  are 
unlikely to develop disease (Kullberg, Ward et al. 1998). If faecal contents are diverted away 
from the terminal ileum or colon, human Crohn’s disease patients are disease free until the 
contents  are  reintroduced  (D'Haens,  Geboes  et  al.  1998).  The  role  of microbes  in  the 
pathogenesis  of  disease  is  becoming  better  understood  and  Crohn’s  disease  is  now 
regarded  as  an  inappropriate  host  response  to  intestinal  flora  (Baumgart  and  Carding 
2007).  The mucosal  immune  system  in  the  gut  is  crucial  to maintaining  oral  tolerance, 
which prevents immune responses being mounted to common dietary antigens. In Crohn’s 
disease,  luminal  antigens  gain  entry  to  the  underlying  mucosa  (Baumgart  and  Carding 











more SNPs,  in  the hope of  identifying additional associations. One of  the  first  large  scale 
genome‐wide  association  scans,  published  at  the  end  of  2006,  was  also  conducted  in 
Crohn’s  disease,  and  identified  associations within  the  IL23R  gene  in  two  separate  case 
control cohorts (Duerr, Taylor et al. 2006). Although the sample size was not considerably 
different  from  the  first  study,  the major  advance  came  in  the  use  of  high  density  SNP 
arrays, allowing approximately 300,000 haplotype tagging SNPs, primarily derived from the 
International HapMap  project,  to  be  genotyped  at  once.  These  high  density  SNP  arrays 
made  a huge  impact on  complex disease  genetics. By  the  start of 2007, Crohn’s disease 
geneticists  had  three  genes;  CARD15,  TNFSF15  and  IL23R  that  could  be  confidently 
associated with the condition as a result of association studies and  linkage results, as well 
as the 5q31 and  IBD5 gene regions. This number was raised over the course of 2007 by a 




A  recent  meta‐analysis,  conducted  on  data  from  three  complete  genome‐wide  scans, 
replicated association at eleven  loci  from  the  individual  scans and  identified a  further 21 
loci  (Barrett, Hansoul et al. 2008). Despite  this, however, estimates suggest  that  these 31 
loci only explain about 20% of  the heritability of Crohn’s disease. This  figure  comes with 
several caveats. It  is often postulated that  identifying the missing heritability will be aided 
by finding the real causal variants, and there now appears to be some evidence for this. For 




ratios  for many  of  the  reported  associations  (WTCCC,  2007).  The  recent meta‐analysis 
which was able  to  impute genotypes  from data across  two different platforms, however, 








Crohn’s disease, yet  is protective  for ulcerative colitis  (Mahid, Minor et al. 2006). Despite 




interestingly perhaps  is the overlap between  these  findings and associations with Crohn’s 
disease. By  comparing  the  results obtained  from  the  two ulcerative  colitis  genome‐wide 
association  scans,  together  with  a  replication  of  Crohn’s  disease  variants  in  ulcerative 
colitis, to the results of the recent Crohn’s disease meta‐analysis,  it  is possible to see that 








also  suggests a  role  for  IL23  in  the pathogenesis of  these  three  conditions. Both Crohn’s 
disease lamina propria mononuclear cells and psoriatic lesions display elevated levels of IL‐
23, a cytokine believed to be involved in the maintenance of a pro‐inflammatory subset of T 
cells,  termed  TH‐17  cells  (Bettelli,  Carrier  et  al.  2006;  Chan,  Blumenschein  et  al.  2006). 
Sarcoidosis and Crohn’s are both granulomatous inflammatory diseases that share common 
clinical  features, but  rarely co‐occur. A  joint GWA study between  the  two conditions was 
able to identify a common susceptibility variant that, after fine mapping, was located to the 
C10ORF67  gene  (Franke,  Fischer  et  al.  2008).  This  study  elegantly  demonstrates  that 
conditions that share clinical features, as well as conditions that co‐occur, can be associated 
with similar common susceptibility variants. Each condition, however, can also be expected 
















also  often  express  peripheral  blood  antibodies  to  tissue  transglutaminase  (a  diagnostic 
marker  in coeliac disease) (Williams, Norcross et al. 2001). The reason for this association 
has  never  been  fully  elucidated,  but  common mechanisms within  the  pathogenesis  and 
genetics of the two conditions may provide some insights.  
 
T1D  results  from  the  autoimmune  destruction  of  the  insulin  producing  islet  β‐cells,  and 
clusters within families. Like coeliac disease, T1D also has very a strong association to the 
HLA  region,  with  DQB1*0302,  DQB1*0201,  DRB1*0401  and  HLA‐B  all  being  implicated 
(Nejentsev, Howson et al. 2007). One of the strongest T1D associations arises from the two 
coeliac  associated  alleles,  HLA‐DQ2  and  HLA‐DQ8  but  especially  when  encoded  as  a 
heterozygous  genotype  (Thorsby  1997).  Interestingly  this  genotype  presents  only  a 
moderately  increased risk for coeliac disease (Dubois and van Heel 2008). The mechanism 
behind  the  association  with  coeliac  disease  is  well  documented,  with  the  heterodimer 
presenting deamidated gluten peptides (Vader, Stepniak et al. 2003). The association with 
diabetes  is  less well understood, although  it  is reasonable to suppose that unique peptide 





a  myriad  of  other  immunological  diseases.  Carriage  of  this  haplotype  predisposes 
individuals  to  systemic  lupus  erythematosus,  common  variable  immunodeficiency,  IgA 
deficiency,  myasthenia  gravis,  scleroderma,  impaired  survival  after  HIV  infection  and 





al.  2008).  Of  particular  interest  is  the  IL‐2,  IL21  region  which  displays  independent 
associations  to T1D and coeliac disease  (WTCCC, 2007; van Heel, Franke et al. 2007). The 
region  is  analogous  to  the  Idd3,  diabetes  associated,  region  in  the  non‐obese  diabetic 
(NOD) mouse. In this model IL‐21 is essential for diabetes development (Spolski, Kashyap et 
al.  2008). Apart  from  coeliac  disease  and  T1D,  this  region  also  displays  association with 
rheumatoid arthritis (Zhernakova, Alizadeh et al. 2007), Grave’s disease (Todd, Walker et al. 
2007) and psoriatic arthritis (Liu, Helms et al. 2008). Whether the same gene or variant  is 








for  association  in  the  other,  and  vice  versa  in  an  attempt  to  identify  any  common 
susceptibility  loci  (Smyth, Plagnol  et  al. 2008). The  results demonstrate  the  considerable 
overlap  between  the  two  conditions  and  offer  some  further  explanation  for  the 
epidemiological  overlap.  Out  of  the  eight  coeliac  disease  susceptibility  loci,  six  showed 
evidence of association with T1D (although the susceptibility allele differed for IL18RAP and 
TAGAP).  Of  the  17  T1D  loci,  eight  showed  evidence  of  association  in  coeliac  disease, 
including CTLA4.  The CTLA4  locus  received  considerable  attention  as  a  linkage peak  and 
candidate  gene  for  coeliac  disease  but  replication was  inconsistent  and  as  result  it was 
never  accepted  as  a  true  susceptibility  locus  (van  Belzen,  Mulder  et  al.  2004;  Hunt, 
McGovern et al. 2005). The  result  is  that  seven  loci are  shared between T1D and coeliac 
disease, which given the relatively small number of total variants identified to date in each 
condition,  represents  a  remarkable  shared  susceptibility.  These  studies  demonstrate  the 
important common genetic backgrounds of the two conditions, and indicate there may be a 
common  genetic  contribution, which  is modified  by  a  further  subset  of  disease  specific 
genes  and  environmental  insults,  leading  to  either  T1D  or  coeliac  disease.  The  variants 











The  loci  currently  associated with  T1D,  coeliac  disease,  Grave’  disease,  rheumatoid  arthritis  and 
multiple  sclerosis  have  been  represented  by  their  nearest  gene.  *The  association  between  the 
IL2/IL21  linkage  disequilibrium  block  locus  with  coeliac  disease  and  T1D/Graves’  appears  to  be 
different.  
 
From  the data collected  to date,  the hypothesis has been suggested  that  there may be a 
general set of autoimmunity susceptibility genes, which are modulated by disease specific 








number  and  type of  associated  variants will  increase.  The ultimate  aim of  these  genetic 
studies is not just to be able to predict disease risk, but to illuminate disease pathways. This 
understanding will  demonstrate  how  immunological  and  physiological  processes  interact 
with  environmental  variables  on  a  person’s  genetic  background,  with  the  final  aim  of 
developing  a meaningful  effective  treatment  for  disease. As work  in  the  field  of  coeliac 





some  of  this  missing  heritability,  researchers  are  adopting  several  complementary 
strategies.  Larger  cohorts  of  cases  are  being  collected,  either  through  further  patient 




perform  genome‐wide  association  studies using  common  copy  number  variation probes. 
Studies such as  these are currently ongoing. Many groups are  looking  to high‐throughput 
sequencing  technology, with  the aim of  sequencing  candidate gene  regions  identified by 






Perhaps  the  greatest  challenge  that  faces  geneticists  in  the  post‐gene  chip  era  is 
determining the functional effects of an associated variant, to identify how it contributes to 
disease  development.  This  would  ideally  be  performed  once  the  causal  variant  was 
conclusively  identified  by  association  analysis;  however,  often  the  nature  of  linkage 
disequilibrium around common SNPs makes this more difficult. An alternative approach  is 
to  identify  which  of  the  variants  in  linkage  disequilibrium  has  a  functional  effect,  thus 
increasing  the probability  that  it  is  the  causal  variant over  a non‐functional  variant.  The 
effect that an associated variant has on a condition cannot be explained until the effect has 






firstly,  an  analysis  of  the  functional  effects  of  known  variants;  and  secondly,  the 
identification  of  the  true  causal  variant  (if  this  is  distinct  from  the  genetic  marker). 












PTPN22  was  originally  identified  as  T1D  gene  (Bottini,  Musumeci  et  al.  2004).  The 
associated  variant  causes  a  non‐synonymous  change  in  the  amino  acid  sequence  of  the 
lymphoid‐specific phosphatase  (LYP) encoded by PTPN22. The  authors hypothesised  that 
since  LYP  is  expressed  in  lymphocytes,  and  T1D  is  primarily  a  lymphocytes  mediated 
disease, the non synonymous change may alter lymphocyte function (Bottini, Musumeci et 
al. 2004). When LYP was expressed  in an  in vitro cell  line,  the wild  type variant bound a 











study demonstrated  that  transfection of  the 1007fs variant prevented LPS  induced NF‐κB 
activity (Ogura, Bonen et al. 2001).  In Crohn’s disease, an  increase  in NF‐κB activation has 
48 
 
been  observed  (Schreiber,  Nikolaus  et  al.  1998),  yet  the  associated  variant,  present  at 
higher levels in Crohn’s patients, in a gene dosage dependent manor, appeared to function 
by reducing NF‐κB signalling. This apparently paradoxical action  is confused further by the 
finding  from  some  in  vivo murine  experiments  that  animals  transfected with  the  1007fs 
variant have  increased NF‐κB  responses  (Maeda, Hsu et al. 2005). CARD15 deficient mice 
themselves have little intestinal pathology, while human patients homozygous for CARD15 




ligand  induced  PBMC  cytokine  responses.  Homozygous  individuals  for  the  frame  shift 
mutation produce no IL‐18 in response to CARD15 ligand stimulation at any dose (van Heel, 
Ghosh et al. 2005). Homozygotes for the other non‐synonymous variants produced reduced 
cytokine  responses  at  low  doses  of  ligand  (van  Heel,  Ghosh  et  al.  2005).  These  results 
indicate genotype at CARD15 loci may affect the ability of cells to respond to low doses of 





CTLA‐4 has been  convincing  replicated as a T1D  susceptibility gene  (Ueda, Howson et al. 
2003;  WTCCC,  2007).  The  CTLA‐4  protein  functions  as  a  negative  regulator  of  T  cell 
activation by competing with CD28 for ligand binding to CD80 and CD86 (Ueda, Howson et 
al. 2003). Two notable  isoforms of CTLA4 exist; a full  length form and a soluble form that 
lacks  the  transmembrane domain containing exon. A disease  susceptibility haplotype has 
been  demonstrated  to  produce  elevated  levels  of  the  full  length  form,  relative  to  the 




A  similar  study,  involving  17  individuals  identified  SNPs  within  the  3’  ICOS  gene  as 
regulating CTLA4 levels in resting, but not stimulated CD4
+ T cells (Kaartinen, Lappalainen et 





PTPN22 and CARD15 have  the highest odds  ratios of all  the variants  identified  to date  in 




















































healthy  donors.  Blood  was  collected  in  10ml  heparinised  Vacutainer©  tubes  (Becton 





10R with  a  BS4402/A  (3360)  bucket  rotor  at  1000g  (2200rpm)  for  10 minutes  at  room 
temperature without the brake engaged. The mononuclear cell monolayer suspension was 




UK, A0171),  0.1mM  EDTA  (Gibco,  Invitrogen, UK,  155575‐038),  culture  grade H20  (Sigma 
Aldrich,  UK))  for  10  minutes.  The  solution  was  centrifuged  on  the  Heraeus  Megafuge 
centrifuge  for 10 minutes at 250g  (1100rpm) to pellet the mononuclear cells, which were 
resuspended in 30ml PBS, followed by a further centrifuge. Pelleted cells were resuspended 









Ltd. (Cleveland, USA) with  IRB approval. Cells were delivered frozen  in  liquid nitrogen and 
were  stored  in  a  vapour  phase  liquid  nitrogen  system  upon  receipt  (Statebourne 
Biosystems 24, AppletonWoods, UK). Cryopreserved PBMCs were a mix of Caucasian and 
Hispanic  donors,  from  the  United  States  of  America,  of  both  sexes  ranging  in  age  at 
donation  from  19  to  67.  Cryopreserved  cells were  thawed  rapidly  according  to  Cellular 
Technology Ltd.  instructions. Cells were then diluted  in 30ml X‐Vivo‐15 serum free culture 
media  and  the  culture  was  spun  on  the  Heraeus  Megafuge  for  10  minutes  at  250g 








+  human  cells  were  extracted  from  leucofilters  obtained  from  the  National 
Blood Service  (NBS) as an excess product  for research. A  leucofilter  is show  in Figure 2.1. 
Filters were kept at 4°C from the time of donation until collection  less than 24 hours  later 
by pre‐arrangement with NBS. A 50ml  syringe was carefully  fitted  to  the  tubing  supplied 
with the filters to allow elution. Cells were eluted carefully from the filters by back flushing 







at room  temperature  followed by  the addition of 30ml PBS 2%  foetal bovine serum  (FBS, 




PBS prior  to centrifugation on  the Heraeus Megafuge  for 10 minutes at 250g  (1100rpm). 
Erythrocytes  were  removed  from  cell  pellets  by  resuspension  in  10ml  of  red  cell  lysis 
solution  (10mM KHCO3, 155mM NH4Cl & 0.1mM EDTA) and  incubation  for 10 minutes at 





Trypan  Blue  staining  in  an  automated  haemocytometer  (Nexcelom  Cellometer  Auto  T4, 
Nexcelom  Bioscience, USA).    Samples were  rejected  if  viability was  below  90%. Viability 
exceeded  93%  for  all  samples  tested.  CD4
+  purity was  assessed  by  double  staining  flow 











When  appropriate,  cells  were  activated  with  either  plate‐bound  or  bead‐bound  anti‐
CD3/CD28 antibodies (αCD3/αCD28). Plate bound activation was achieved by culturing cells 
in 96 well plates pre‐coated with CD3 antibodies (Becton Dickinson, UK, 354725), followed 
by  the  addition  of  soluble  CD28  antibody  (eBioscience,  US,  16‐0289‐85).  Bead  bound 
activation  involved culturing cells with differing ratios of ferromagnetic beads coated with 
αCD3/αCD28 antibodies (Invitrogen, UK, 111‐31D). Beads were washed  in 2 ml of PBS  in a 














2x106  cultured  cells  were  pelleted  in  the  Heraeus  Megafuge  for  10  minutes  at  250g 
(1100rpm). Genomic DNA was extracted using a commercial DNA extraction kit (PUREGENE, 
Qiagen, UK). Briefly,  the  supernatant was  removed  from  the pelleted  cells,  and 300μl of 
PUREGENE Cell Lysis Solution (Qiagen, UK, 158906) was added. The solution was mixed by 
pipetting prior  to  addition of 100μl of PUREGENE Protein Precipitation  Solution  (Qiagen, 
UK, 158910). Samples were vortexed vigorously for 20 seconds on a Vortex Shaker (Genie2, 
Scientific  Industries, USA) prior  to  the pellet being  centrifuged  for  3 minutes  at  15,000g 
using an Eppendorf 5417R MiniCentrifuge with a FA45‐30‐11 rotor  (Eppendorf, UK). After 
pelleting  the  protein  debris,  the  supernatant  was  added  to  150μl  of  100%  2‐propanol 





DNase  free  H2O  (Sigma  Aldrich,  UK,  W4502)  before  1.2μl  of  DNA  was  quantified  by 







96  head  robot  attachment  (BioMek  FX©,  Beckman  Coulter,  Germany).  After  sealing 
(ABGene, UK, AB‐0558) the 384 well plates were centrifuged at 2000g for 1 minute (4K/15R 
centrifuge, Sigma Aldrich). Plates were allowed to dry at 37°C until no moisture was visible. 
19.2μl  of  20x  TaqMan  5’  exonuclease  assay mix was  added  to  172.8μl  DNase  free  H2O 






















For RNA  cell  culture  experiments,  cells were  cultured  at  a density of 3x106 per well per 
condition  in 24 well cell culture plates  (VWR, UK, 734‐0020). After 22 hours of culture at 
37°C,  5%  CO2,  cell  culture  supernatants  were  removed  and  spun  down  in  1.5ml 





all  cells  were  lysed,  transferred  to  a  microcentrifuge  tube  and  stored  at  ‐80°C.  Once 
thawed, 200μl of chloroform  (Sigma Aldrich, UK, C2432) was added  to  the  lysate mixture 
and  vortexed  vigorously  (Genie2,  Scientific  Industries, USA)  for  15  seconds.  The  solution 
was spun at 11,000rpm at 4°C using an Eppendorf 5417R MiniCentrifuge (Eppendorf, UK). 
The  aqueous  layer was  transferred  to  a  separate microcentrifuge  tube  containing  500μl 





70%  ethanol  added  and  the  tube  spun  at  12,000  rpm  for  5  minutes  (at  4°C).  The 








Columns  (Qiagen, UK,  74104) with  the  on‐column DNase  digestion  (Qiagen, UK,  79254). 
100µl TRIzol  isolated RNA  in RNase  Free H2O  (Sigma Aldrich, UK, W4502) was  combined 
with 350µl of Buffer RLT (Qiagen, UK) and 250µl ethanol (VWR, UK, 10107) and added to an 
RNeasy Mini Spin Column  (Qiagen, UK). The column was spun at 9,000g on an Eppendorf 















+  cells were  lysed  in 600µl RLT Buffer  (Qiagen, UK) with added  β‐ME 
(Sigma Aldrich, UK). QIAshredder columns  (Qiagen, UK, 79654) were used  to homogenize 
the  lysate which was  centrifuged  through  the  columns  at  13,000g  for  2 minutes  on  the 
Eppendorf  5418  centrifuge.  595µl  of  70%  ethanol was  then  added  to  the  homogenized 

















Transcriptase  (ABI,  USA),  1μl  RNase  Inhibitor  (Roche,  Ambion,  USA,  AM2682),  3.2μl 
Nuclease‐free  H2O  per  reaction  (plus  10%  overage) was made.  10µl  of master mix was 
added  to  10µl  (50ng/ml)  RNA  in  0.2ml  PCR  tubes  (VWR,  UK,  732‐0548)  and mixed  by 












by  incubation  at  37°C  for  30  minutes  on  a  MJ  Research  DNA  Tetrad  2  PCR  Machine 





Polymerase  Chain  Reaction  (PCR) was  performed  on  a MJ  Research  DNA  Tetrad  2  PCR 
Machine  (MJResearch, USA). 19μl of PCR master mix was added  to 1μl of  cDNA or 25ng 
genomic DNA  in 0.2ml PCR  tubes  (VWR, UK, 732‐0548). PCR master mix contained 1 unit 
AmpliTaq Gold® DNA  Polymerase  (Applied  Biosystems, USA, N8080245),  1x  (K+)  Buffer  II 
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A  loading  buffer  containing  25ml  glycerol  (Sigma Aldrich, UK, G8773),  2ml  0.5mM  EDTA 
(Gibco,  Invitrogen, UK, 155575‐038), 25mg Bromophenol Blue  (Sigma Aldrich, UK, B0126) 















Quantitative  PCR  TaqMan  (qPCR)  primers  and  probes  were  obtained  from  Applied 























qPCR  data  is  expressed  relative  to  a  housekeeping  gene  based  on  ΔCt  method.  The 
geometric mean of triplicate measurements with standard deviations (SD) less than 0.3 (or 






recommended  in  Applied  Biosystems  User  Bulletin  #1  Guide  to  Performing  Relative 
Quantification of Gene Expression Using Real‐Time Quantitative PCR. The geometric mean 














of  FACS  buffer  was  added  to  the  tube  followed  by  centrifugation  at  1250rpm  on  the 






Gene  Expression  microarray  analysis  was  carried  out  using  the  Illumina  Sentrix  Gene 
Expression System (Illumina, USA) as described below. MIAME compliant (Brazma, Hingamp 







USA).  Capillary  electrophoresis  was  undertaken  on  an  Agilent  RNA  Nano  Chip,  with  all 
components obtained from the Agilent RNA 6000 Nano Kit (Agilent, USA, 5067‐1511). RNA 
analysis  was  undertaken  according  to  manufacturer’s  instructions.  Briefly,  550μl  of 
acrylamide gel (RNA 6000 Nano gel matrix) was added to a filter microcentrifuge tube, and 
spun at 1500g for 10 minutes at room temperature on an Eppendorf 5418 centrifuge with a 












RNA  that  passed  quality  control  was  amplified  via  the  Ambion  Illumina  TotalPrep 
Amplification Kit (Ambion, USA, AMIL1791). 250ng of RNA was diluted to 11µl in RNase free 
H2O  in a 96 well plate  (ABGene, UK, AB‐0600) and  sealed  (ABGene, UK, AB‐0558). 9μl of 




stranded DNA  copy of  the  input RNA. Double  stranded  cDNA was  added  to 250µl  cDNA 
binding  buffer  (Ambion,  USA)  prior  to  addition  to  a  column  contained  within  a  1.5ml 
microcentrifuge  tube and centrifugation at 10,000g  for 1 minute. cDNA was washed with 
500μl wash  buffer,  followed  by  centrifugation  at  10,000g  for  1 minute.  cDNA was  then 
eluted from the membrane with 19µl of H2O preheated to 55°C in an Illumina Hybridisation 
Oven followed by centrifugation at 10,000g for 1 minute. 7.5μl of Master Mix 3 (Table 2.1) 
was  added  to  the purified double  stranded  cDNA before  the  samples was  incubated  for 





was  then eluted  from  the membrane with 100µl of H2O preheated  to 55°C  in an  Illumina 
Hybridisation  Oven  followed  by  centrifugation  at  10,000g  for  1  minute.  The  resultant 








Hyb  Chambers  were  assembled  with  the  addition  of  200μl  of  HYC  (Illumina,  USA)  to 
reservoirs. Assay samples were preheated  to 65°C  for 10 minutes on a MJ Research DNA 






























  10x First Strand Buffer 2µl     T7 Enzyme Mix 2.5µl
  dNTP Mix 4µl     Biotin‐NTP Mix 2.5µl
  RNase Inhibitor 1µl        
  ArrayScript Reverse Transcriptase 1µl        
             





       
  10x Second Strand Buffer 10µl        
  dNTP Mix 4µl        
  DNA Polymerase 2µl        





















(Illumina, USA, FC‐102‐1001). Cluster  reagents were obtained  from  the  Single  (or Paired) 
end  cluster  generation  kits  as  appropriate  (Illumina,  USA,  FC‐103‐2001  &  PE‐103‐2001) 





5‐10μg  of  genomic DNA  (gDNA) was  diluted  in  50μl  of  TE  (Illumina, USA)  and  added  to 
150μl  hybridisation  buffer  (Illumina,  USA).  The  sample  was  added  to  a  1.5ml 
microcentrifuge tube and placed in a Bioruptor sonicator (Diagenode, USA), with the basin 











RNA  (resuspended  in 88μl of nuclease  free H2O was added  to 10μl of 0.1X DNase Buffer 
(Ambion, UK) and 2μl of Turbo DNase‐free  (Ambion, UK)  in a 1.5ml microcentrifuge  tube. 
The  tube  was  mixed  gently  to  prevent  de‐activation  of  the  DNase.  The  sample  was 
incubated  for  30 minutes  at  37°C  in  an  Eppendorf  Thermomixer  compact  heating  block 
65 
 
(VWR, UK, 5350 000.013). 10μl of DNase  inactivation  reagent was mixed  gently  into  the 





mRNA  samples  were  subsequently  prepared  for  sequencing  according  to  a  pre‐release 





mRNA  was  double  purified  using  poly(T)  coated  supra‐magnetic  beads  to  isolate  poly 
adenylated RNA (poly(A)). The DNase treated RNA sample was heated to 65°C for 5 minutes 
in  the Eppendorf heat block  to disrupt any RNA secondary structure, and  then placed on 
ice. 100µl of Dynal oligo(dT) beads (Invitrogen, UK 610‐06) were placed into a 1.5ml RNase 
free  non‐sticky microcentrifuge  tube  (Ambion,  UK).  The  beads were washed  twice with 
100µl  of  Binding  Buffer  (Invitrogen,  UK,  610‐06),  by  placing  the  tube  in  a  1.5ml 





















For  mRNA,  fragmentation  was  achieved  using  a  divalent  cation  buffer  to  chemically 
fragment the RNA. 1 µl of 10X Fragmentation Buffer (Ambion, UK, AM8740) was added to 
9μl of the mRNA obtained after poly(A) selection. This was placed on the MJ Research DNA 
Tetrad PCR  thermocycler, pre‐heated  to 70°C  for  exactly 5 minutes. 1μl of  stop  solution 
(Ambion, UK, AM8740) was then added to the sample and the tube was placed on ice. The 
RNA was subsequently purified by addition of 1 µl of 3M sodium acetate (NaOAC), pH 5.2 
(Sigma Aldrich, UK), 2 µl of  glycogen  (5µg/µl, Ambion, UK, AM9510),  and 30 µl of 100% 
ethanol  (VWR, UK).  This was  incubated  at  ‐80°C  for  30 minutes  and  centrifuged  on  the 
Eppendorf 5417R for 25 minutes at 14,000g at 4°C. After removal of the supernatant, the 











5× first strand buffer (Invitrogen, UK, 18064‐014)    4µl   
100mM DTT (Invitrogen, UK, 18064‐014)      2µl 






Step 1:    25°C  10 min   
Step 2:    42°C  50 min     








140µl   2M Tris pH8     (Sigma Aldrich, UK, T3069) 
110µl   2M Tris pH7.5    (USB, USA, 77514) 
50µl   1M MgCl2    (Ambion, UK, AM9530G) 















placed  through  exactly  the  same  fragmentation  and  samples  prep  protocols  described 
above.  The  only  differences  being  that  the  poly(T)  selection  step  was  omitted.  During 
fragmentation,  11µl  of  10x  Fragmentation  Buffer was  added  to  100µl  of  total  RNA.  The 
sample was incubated in a PCR thermocycler at 70°C for exactly 5 minutes, before 12 µl of 
Stop Buffer was added. The sample was purified by the addition of 11 µl of 3M NaOAC (pH 














minutes.  The  RNA  was  then  added  to  supra‐magnetic  beads  and  allowed  to  incubate. 
Ribosomal depleted RNA was  removed after placing  the  tube  in a 1.5ml microcentrifuge 
tube magnet. The sample was cleaned up with the addition of 1µl glycogen (Ambion, UK), 
46µl  3M NaOAC  (Sigma Aldrich, UK),  1400μl  100%  Ethanol  (VWR, UK),  and  560µl of  the 
eluted RNA. This solution was  incubated  for 30 minutes at  ‐80°C before centrifugation at 






double  stranded  section  of  DNA  is  produced.  To  this  double  stranded  DNA  adapter 
sequences are added to allow PCR purification and binding to the sequencing flow cell. All 
samples are prepped in the same manner for this section unless described otherwise using 
the  Illumina genomic DNA  sample prep protocol with  small modifications  (Illumina, USA, 
FC‐102‐1001).   
 




dsDNA from sample prep DNA        30µl 
H2O               45µl 
T4 DNA ligase buffer with 10mM ATP      10µl 
dNTP mix (10mM)           4µl 
T4 DNA polymerase (3U/µl)        5µl 
Klenow DNA polymerase (5U/µl)      1µl 





The  sample was  subsequently purified with  the QIAquick PCR  spin  column  and eluted  in 
32µl of EB solution (Qiagen, UK). 
 
A  single  adenine  base  overhang  is  added  by  a  Klenow  DNA  polymerase  (with  a  3’‐5’ 
exonuclease activity) to create a ligation site for the adapters.  
 
Eluted DNA        32µl 
Klenow buffer        5µl 





on  a QIAquick MinElute  column  (QIAGEN, UK 28006),  and  elution  in 10µl of  EB  solution 
(Qiagen, UK).   
 
Adaptor  ligation  ratios were varied according  to  the DNA sample  input  to prevent excess 
adapter  dimers.  For mRNA  and  RiboMinus  the  following  reaction  was  constructed  and 
incubated at  room  temperature  for 15 minutes prior  to clean‐up on a QIAquick MinElute 
column and eluted in 10µl of EB solution.  
 
Eluted DNA        10µl   
DNA Ligase buffer      25µl   
Adaptor oligo mix      1µl 
DNA Ligase (1U/µl)       5µl 












Eluted DNA        10µl   
DNA Ligase buffer      25µl   
Adaptor oligo mix      4µl 
DNA Ligase (1U/µl)       5µl 








to prevent  cross  contamination. The gel was  run at 120V  for 60min before a 2mm  thick 
section of gel was cut out under ultraviolet light (2011 Macrovue Transilluminator, LKB) at 
the  350bp  level.  The  gel was  purified  according  the QIAquick  gel  extraction  kit  (Qiagen, 
#28706) with the addition of isopropanol where appropriate. 
 
Subsequent  to  gel  purification  for  size  selection,  the  library  was  enriched  by  PCR.  The 
following reaction was constructed: 
 
Phusion Buffer HF (Finnzymes Oy, Finland)    25µl    
PCR primer 1.1  (Illumina, USA)        1µl 
PCR primer 2.1  (Illumina, USA)        1µl 
For gDNA/Total RNA 
DNA              1μl  
H20               22μl 
For mRNA/RiboMinus 
DNA              30μl  

























Prior  to clustering a sample,  the  library was quantified by spectrophotometer  (Nanodrop, 
Nanodrop Technologies, USA). The library was assayed for size by running 1μl of the sample 

















Samples  were  diluted  to  10nM  after  using  the  formula  described  to  calculate  the  molar 
concentration (y) of the  library (nM). The DNA base pair weight assumed that the  library  is double 
stranded.  The  formula  takes  into  account  the  concentration  of DNA  library  in  ng/µl  (c),  average 
molecular weight of a DNA base (x = 324.5) and the resultant size of the DNA library (s).  
 
All  cluster  generation was performed on  the  Illumina Cluster Generation  System using  a 
second  generation  Genome  Analyzer  (GA  II)  1.4mm  flow  cell  and  paired  end  cluster 






















v1.3.  The  GOAT  pipeline  was  used  to  call  bases  and  generate  sequence  files,  not  for 






obtained  from  http://ww.novocraft.com.  Novoindex  (http://ww.novocraft.com) was  first 
used to generate an  indexed copy of the genome, with a hash table splitting the genome 
into ‐k mer sections. This ‐k value can be altered to vary the speed and memory usage, but 
not  the accuracy of  the alignment process. The step  (‐s) size of all  the  indexes used here 
was  set  at  one,  to  maximise  speed  of  the  alignment,  but  as  a  consequence  this  also 
maximises RAM usage. The alignment  tool  itself, novoalign, uses  the Needleman‐Wunsch 
algorithm to match the sequenced reads to the indexed genome. This alignment generates 





differed  substantially  throughout  this  thesis,  but  the  three  genomes  used  extensively 
include: 
 
• The  human  genome  (hg18,  Build  36,  derived  from  the  1000  genomes  project, 
available from ftp.1000genomes.ebi.ac.uk. 
• A  spliceosome  genome,  constructed  to  include  the  first  and  last  40bp  of  each 
possible exon combination  in  the genome. Data was extracted  from Ensembl v52 
using  the  Ensembl  Perl  API  running  from  the  Ensembl  registry  at 
ensembldb.ensembl.org. Version 1 of this genome was compiled by Dr Barry Healey 
(CIMR, Cambridge, UK). Subsequent versions  (version 3 was used  throughout  this 
thesis) where generated using custom scripts. 
• A  reference  human  transcriptome  genome,  built  to  contain  all  the  canonical 
reference  RNA  human  transcripts,  all  human  introns,  and  the  human  genome 






graphical  output  and  some  statistical  analysis  performed  in  R  2.7.0  (http://www.r‐
project.org/) (R Development Core Team, 2007). A bi‐directional interface was constructed 
between R and Perl allowing R commands to be called from Perl. Two Perl modules were 
utilised  for  this  purpose,  RSPerl  (available  from 
http://www.omegahat.org/RSPerl/RFromPerl.html)  and  Statistics::R  (available  from 
http://cpan.uwinnipeg.ca/dist/Statistics‐R). Detailed  information  on  scripts  is  provided  in 
individuals  chapters. All  analysis was  performed  on  a Hewlett  Packard  server  containing 
four  64bit  quad  core  Intel  Xeon  processors  with  x86_64  architecture,  64Gb  RAM  and 
running Red Hat Enterprise Linux Server release 5.3 (Tikanga). Data was stored on a 10Tb 
disk storage array  (reduced  to 7.4Tb after RAID5) with a  tape backup system. SSH Secure 
Shell client v3.2.9 Build 282 was used  to connect  to  the server, which was housed at  the 
Barts  and  The  London Genome Centre.  Scripts were written  in  the programmers’  editor 
ConTEXT (available from http://www.contexteditor.org/).  For  base  specific  analysis 
such  as  allele  specific  expression  analysis,  data was  converted  to  a  pileup  file.  This  file 
format converts  the data so each  line corresponds  to a single base  in  the genome. A 1kb 
genome would  thus  consist of 1000  lines  each  containing  all  the  alignment data  at  that 
74 
 
position,  as  shown  in  Figure  2.3.  Pileup  file were  generate  by  novoPile,  a  custom  script 




The  example  file  here  demonstrates  five  lines  from  a  pileup  file.  The  columns  contain  the 
chromosome, position, reference base and the read depth over the locus. The next column contains 






All high‐throughput  sequencing data  in  this  thesis has been  submitted  to  the NCBI  short 














































































is  primarily  T  cell mediated,  but  defects  in  the  innate  immune  system  have  also  been 
described.  Several different  types of T  cells have been  implicated  in  the pathogenesis of 
Crohn’s disease. T cells within the human body are typically categorised according to their 
cytokine production profile and the effect they have on surrounding cells (Figure 3.1) (Roitt 




extra  cellular  clearance,  whilst  T  suppressor  cells  act  to  control  inappropriate  immune 
system activation. Although the pathogenesis of a myriad of diseases has been associated 










These mice  developed  a  severe  wasting  disease  and  were  observed  to  have  extensive 
intestinal  inflammation  post mortem  (Morrissey,  Charrier  et  al.  1993). Mice which were 
repopulated  with  CD4+CD45RB







exogenous  recombinant  murine  IL‐10  (Powrie,  Leach  et  al.  1994)  but  not  by  the  TH2 
cytokine  IL‐4  (Powrie, Correa‐Oliveira  et  al. 1994).  Targeted disruption of  the  IL‐10  gene 





























response  (Jewell  and  Patel  1985),  possibly  directed  against  intestinal  luminal  antigens 




pathogen  free  conditions,  the  intestinal  inflammation  is  markedly  diminished  (Berg, 
Davidson et al. 1996). Kullberg et al (Kullberg, Ward et al. 1998) used IL‐10 deficient animals 
reared  under  these  specific  pathogen  free  conditions  to  investigate  the  antigens  that 
induce  colonic  inflammation.  They  were  able  to  induce  classical murine  colitis  through 
inoculation  of  mice  with  H.  hepaticus  (Kullberg,  Ward  et  al.  1998).  The  observed 
inflammation was accompanied not only by histological grade colitis, but also by significant 
TH1  cell  activation,  evidenced  by  elevated  IFNγ,  TNFα  and  nitric  oxide  levels.  The 
understanding  that colitis  in murine  inflammatory bowel disease may be directed against 
intestinal flora represented a significant landmark in the understanding of the disease.  
 







p19  lead  to  significantly  elevated  p19  secretion  as  well  as  evidence  of  heterodimer 
formation. This p40/p19 heterodimer appeared  to be  secreted by plasmacytoid dendritic 
cells and had a distinct STAT4 dependent IFNγ inducing action upon αCD3/αCD28 activated 
memory T cells. The  receptor  for p40/p19,  renamed  interleukin 23  (IL‐23) by  the authors 
did not appear to be common to IL‐12, and the actions of the two cytokines on both T cells 











12RB1).  The  unique  individual  chain  generates  the  unique  ligand  binding  as  well  as  providing 
domains  for  STAT  1  and  3  binding.  IL‐23  binding  to  the  IL23  receptor  produces  significantly  less 
STAT4 phosphorylation than IL12 binding to its receptor (Parham, Chirica et al. 2002).  
 
Early experiments with  IL‐23  involved over expressing  the p19  subunit  in murine models. 






to  IL‐12 deficient animals (p35  ‐/‐) (Decken, Kohler et al. 1998). The  livers of Cryptococcus 
infected mice  also  displayed  a marked  difference  between  the  two  animal  groups.  p35 
deficient animals, as well as wild  type  infected animals displayed granulomatous  lesions; 
however, p40 deficient animals displayed no granulomatous lesions, and instead displayed 
“cystic”  lesions  (Decken,  Kohler  et  al.  1998).  This  early  data  gives  an  insight  into  the 
possibility of two separate inflammatory pathways involving IL‐12 or IL‐23. 
 
The  understanding  of  IL‐23  induced  inflammation  was  advanced  by  two  important 
publications at the beginning of 2003. The first was the discovery by Aggarwal et al that IL‐
17A,  and  its  related  cytokine  IL‐17F  were  released  upon  dendritic  cell  derived  IL‐23 
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activation  of memory  T  cells,  and  not  IL‐12  activation  as  had  been  previously  thought 
(Aggarwal, Ghilardi et al. 2003). Elevated levels of IL‐17 have since been isolated in several 
autoimmune  diseases,  including  the  mucosa  and  peripheral  blood  of  Crohn’s  disease 
patients (Fujino, Andoh et al. 2003). The second major development was the creation of an 
IL‐23 p19 deficient mouse by Cua et al (Cua, Sherlock et al. 2003). Unlike the p40 deficient 
mice, this animal was only deficient  in  IL‐23 only and not  IL‐12.  Induction of experimental 
autoimmune  encephalitis  (EAE)  in  this  murine  model  resulted  in  inflammation  and 
lymphocyte infiltration into the spinal cord in control and IL‐12 p35 deficient mice only. IL‐









2005). Since naïve T cells cannot be polarised  to an  IL‐17 secreting phenotype  (Aggarwal, 
Ghilardi  et  al.  2003)  it  had  been  assumed  that  the  IL‐17  producing  T  cells  were  a 
differentiation of a TH1 helper T cell as a result of IL‐23 action. This idea was challenged by 
Harrington et al. who proposed  that  they may  in  fact  represent a unique T  cell  subtype, 
expanding upon Mosmann’s 1986 TH1/TH2 effector cell dichotomy  (Mosmann, Cherwinski 




effector cells, which can be  induced  in vitro and  in vivo with a cytokine milieu containing 
TGFß and IL‐6 (Mangan, Harrington et al. 2006; Veldhoen, Hocking et al. 2006a; Veldhoen, 
Hocking  et  al.  2006b)  and  characterised  by  its  cytokine  profile  and  transcription  factor 
expression (RORγt) (Ivanov, McKenzie et al. 2006). The role of TGFß in the differentiation of 
TH‐17  cells  generates  a  close  relationship  between  proinflammatory  IL‐17  cells  and 
regulatory  T  cells.  Indeed  naïve  T  cells  polarised  in  just  TGFß  develop  into  an 
immunoregulatory phenotype, whilst  the addition of  IL‐6  results  in  the TH‐17 phenotype. 
This close relationship allows close regulation of the  inflammatory/anti‐inflammatory cells 
by  the  local  cytokine  milieu.  IL‐23  itself  appears  to  function  as  a  key  gateway  in  the 






The  original  hypothesis  that  IL‐12  was  responsible  for  Crohn’s  disease  associated 
inflammation stemmed  from  the  finding  that  IL‐10 deficient mice developed a colitis  that 
was both IL‐12 p40 dependent and characterised by IFNγ production (Kullberg, Ward et al. 
1998). The discovery of IL‐23 cast these findings in a new light. It is IL‐23, and not IL‐12 that 
is necessary  for  colitis development  in most of  these disease models  (Yen, Cheung et al. 





One  of  the  problems when  attempting  to  draw  conclusions  about  human  disease  from 
animal models  is  that often  the  same animal can behave differently depending upon  the 
colitis model used. A good example  is the dextran sulphate or TNBS model of colitis. Both 
substances produce an  irritant  colitis  in animals.  If p19 deficient animals are used  in  the 
TNBS model of  colitis,  instead of a  reduction  in  colitis, as would be expected  from  IL‐10 
deficient models,  an  increase  in  colitis  is  observed with  an  increase  in  IL‐12  production 
(Becker,  Dornhoff  et  al.  2006).  Administration  of  an  IL‐12/IL‐23  p40  antibody  to  these 
animals subsequently ameliorates symptoms  (Becker, Dornhoff et al. 2006). These results 
demonstrate  the  cross  regulation between  IL‐12 and  IL‐23 pathways. They  also  illustrate 
the key differences that the differing method of colitis induction may play.  
 
IL‐23  is responsible for both  innate and T cell mediated  intestinal  inflammation. Hue et al 
(Hue,  Ahern  et  al.  2006)  used  two  complementary murine models  to  demonstrate  that 
inoculation of Rag deficient animals with H. hepaticus antigen resulted in an increased p19 
and  p40  secretion  from  dendritic  cells,  but  not  a  rise  in  p35  secretion.  This  increased 
secretion  was  restricted  to  the  intestinal  mucosa,  and  was  not  evident  within  the 
mesenteric lymph nodes or spleen. This rise in IL‐23 resulted in a localised increase in IL‐17 
production,  despite  the  Rag  background  of  the  animals,  indicating  an  innate  immune 
















as well as new T cells subsets. The  interactions and  the delicate balance between all  the different 
groups of T cells are likely to be crucially important in human disease. The figure depicts a very basic 
understanding of the current  interactions between cytokines and peripheral T cells within humans. 

























Naïve  T  cells  polarised  under  TH‐17  conditions  undergo  acetylation  and methylation  at 
specific H3 histone residues resulting in an increase in the availability of the IL‐17A and IL‐
17F  locus  to  the  transcriptional  apparatus  (Akimzhanov,  Yang  et  al.  2007).  IL‐17  ligand 
binding  to  its  specific  receptor  results  in  activation  of  MAPK  leading  to  IL‐6  and  IL‐8 
production,  thereby  resulting  in  neutrophil  recruitment  (Laan,  Cui  et  al.  1999).  IL‐17F, 
present  in all  types of CD4




17F  acts  as  a  pro‐inflammatory  cytokine  stimulating  production  of  GM‐CSF  (Kawaguchi, 
Kokubu et al. 2004) and inducing neutrophilia (Wright, Guo et al. 2007). The importance of 




The  cytokine  produced  by  TH‐17  cells  play  a  crucial  link  between  adaptive  and  innate 
immune  systems.  Stark  et  al  (Stark, Huo  et  al.  2005)  demonstrated  the  subtle  negative 
feedback  mechanism  that  IL‐17  creates.  Interleukin  17  is  a  potent  inducer  of  G‐CSF 
production;  the  result  is  granulopoiesis  and  an  increase  in  circulating neutrophils. When 
neutrophils  migrate  to  tissues,  become  apoptotic  and  are  phagocytised  by  dendritic 
cells/macrophages,  the dendritic  cells  reduce production of  IL‐23,  thereby  reducing  IL‐17 













in keratinocytes  (Liang, Tan et al. 2006). Despite  its designation as an  interleukin,  it does 
not appear  to mediate  leucocyte  to  leucocyte signalling.  IL‐22 has been  implicated  in  the 
pathogenesis of psoriasis, a chronic inflammatory skin disease with many commonalities to 
Crohn’s disease. Not only did  TH‐17 polarising  conditions  give  rise  to  IL‐22  and  IL‐17  co‐
producing cells, but also IL‐22+/IL‐17‐ cells. Indeed while classical TH‐17 polarising conditions 
of  IL‐6, TGFß, anti‐IL‐4, and anti‐IFNγ give  rise  to  IL‐17 and  some  IL‐22,  removal of TGFß 
dramatically  enhances  IL‐22  production  at  the  expense  of  IL‐17  (Zheng, Danilenko  et  al. 
2007). This may be an important difference, particularly in light of the vital role of TGFß in 
the  regulatory  immune  system,  but  also  in  terms  of murine  ‐  human  differences,  since 
human cells differentiate into IL‐22 producing cells readily, but not IL‐17 (Zheng, Danilenko 
et al. 2007). IL‐23 induced dermal inflammation appears to be primarily mediated by IL‐22 





















The  discovery  of  an  IL‐10  producing  subset  further  complicates  the  picture  of  TH‐17 
function.  Data  from McGeachy  et  al  (McGeachy,  Bak‐Jensen  et  al.  2007)  suggests  that 
restimulation  of  existing  TH‐17  phenotypes  with  TGFβ  and  IL‐6  only  results  in  IL‐17 
production  in  the  presence  of  IL‐23.  In  the  absence  of  IL‐23,  IL‐10  is  produced.  This 
represents  another  feedback mechanism by  the  adaptive  immune mechanism  to  control 
the  abundance  and  cytokine  production  of  proinflammatory  cells.  Jankovic  &  Trinchieri 





cells  (Stumhofer,  Silver  et  al.  2007).  It  seems  more  likely  now  that  this  dichotomy 
represents the integral link between suppressor T cells and TH‐17 cells. Both TH‐17 cells and 
TH2  cells  have  been  shown  to  have  a  degree  of  phenotypic  plasticity,  especially  in  the 
presence  of  retinoic  acid  and  the  correct  cytokine  milieu  (Tato  and  Cua  2008a).  It  is 
possible, therefore, that the IL‐10 that has been reported results from the switching of TH‐







Much of  the work  in TH‐17 cells has been conducted  in murine models. Although at  first 
some  differences  were  reported,  it  now  seems  that  the  two  cells  behave  in  a  similar 
manner  in  both  species.  Murine  TH‐17  cells  can  be  identified  by  expression  of  the 
chemokine receptors CCR6 and CCR4, as well as expression of the transcription factor RORC 






2007). TH‐17  like cells could be  isolated  from  the peripheral blood,  tonsils and mucosa of 




(Suryani  and  Sutton  2007).  There  appear  to  be  contrasting  reports  about  not  only  the 
presence of T‐bet in TH‐17 cells, but also its role in different models of disease, for example 
T‐bet deficient mice develop enhanced experimental autoimmune myocarditis, but reduced 
experimental  autoimmune  encephalitis  (Rangachari,  Mauermann  et  al.  2006;  Gocke, 
Cravens  et  al.  2007).  A  further  complication  exists  with  the  discovery  that  IRF4,  a  TH2 
specific  transcription  factor  is  also  essential  for  TH‐17 mediated  EAE  in  a murine model 
(Brustle, Heink  et  al. 2007).  The  literature now points  to murine  TH‐17  cells  as  requiring 
both TH1 and TH2 polarising transcription factors depending upon the experimental method. 
The difference  in experimental method may  lead  in a different site of action for the cells, 
resulting in a change in the required response; this alters the local cytokine milieu resulting 
in  a  slightly  different  polarisation  profile.  This  is  a  unique  insight  into  the  intricate 
regulation and balance  that exists between TH1, TH2 and TH‐17 cells and also  reflects  the 
plasticity that exists between them.  
 



















for TH‐17  cells  in  the pathogenesis of disease  (Schmidt, Giese et al. 2005). This elevation 
appears to be unique to Crohn’s disease; it is not observed in ulcerative colitis or common 
variable  immunodeficiency associated colitis  (IL‐12 mediated)  (Schmidt, Giese et al. 2005; 
Mannon, Fuss et al. 2006).  
   




(Brand, Beigel et al. 2006), although  the exact  role of  IL‐22  in promoting barrier  integrity 
has yet to be fully determined. Recent evidence also points towards a role for IL‐22  in the 
prevention of systemic LPS induced inflammation by up regulating lipopolysaccharide (LPS) 
binding  proteins  in  hepatocytes  (Wolk, Witte  et  al.  2007).  In  a  TH2 mediated model  of 
colitis, IL‐22 appears to prevent inflammation (Sugimoto, Ogawa et al. 2008), indicating that 





display  elevated  levels  of  IL‐23  (Chan,  Blumenschein  et  al.  2006).  The  common  genetic, 
functional  and  animal  models  for  Crohn’s  disease  and  psoriasis  suggest  some  form  of 
common  pathogenesis  and  the mucosal  and  skin  homing  chemokine  receptors  on  TH‐17 
cells T cells suggests a role for these cells in both conditions (Acosta‐Rodriguez, Rivino et al. 
2007).  Importantly,  IL‐12  p40  antibodies  produce  a  significant  clinical  alleviation  of 
symptoms  in both patients with Crohn’s disease and psoriasis  (Mannon, Fuss et al. 2004; 
Chan, Blumenschein et al. 2006). IL‐12 p40 antibodies also cause a down regulation of IL‐23 
levels  (Fuss,  Becker  et  al.  2006).  Although  originally  attributed  to  its  effect  on  IL‐12 
suppression, it now seems likely the effect is mediated through IL‐23 suppression, and not 
IL‐12. Elevated  IL‐17  and  IL‐23  levels have  also been  implicated  in  the uveitis  associated 
with  the  systemic  autoimmune  disease Vogt‐Koyanagi‐Harada. Daniel Cua has  suggested 
that  the  high  level  of  IL‐23  present  in  the  gut  may  be  necessary  to  overcome  the 
predominantly  suppressive  phenotype  of  gut  cells  (Tato  and  Cua  2008b).  If  the  balance 
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+  cells,  cultured with dendritic  cells exposed  to peptidoglycan  (PGN), which  is 
metabolised intracellularly to the CARD15 ligand muramyl dipeptide (MDP), are polarised to 
a TH‐17 phenotype (van Beelen, Zelinkova et al. 2007). Van Beelan et al identified that this 
polarisation  was  due  to  the  secretion  of  IL‐1β  and  IL‐23,  as  expected  from  studies 
conducted in human TH‐17 cells. A Crohn’s disease associated NOD2 variant, which prevents 









Bak‐Jensen  et  al.  2009). Given  the  relatively  low odds  ratios  associated with disease  for 
associated variants,  it  is  likely  that many variants within  the  same pathways are  likely  to 
lead to disease. It seems probable that different variants in different genes may ultimately 
lead to the same condition  if they occur  in the same pathway. Although pathway analysis 






of  which  map  close  to,  or  directly  over,  genes  involved  in  the  immune  response, 









One  of  the  first  identified  Crohn’s  disease  susceptibility  variants  that  has  now  been 




allele,  to  1.57  for  the most  deleterious  allele  (Duerr,  Taylor  et  al.  2006).  This  gene  is 
particularly interesting, not only because of its plausible biological relevance through TH‐17 
cells, but also because a genetic association has now been  found between  this gene and 
psoriasis  (Cargill,  Schrodi  et  al.  2007),  ulcerative  colitis  (Duerr,  Taylor  et  al.  2006)  and 
ankylosing spondylitis (TASC, 2007). Epidemiological evidence of a greater risk of psoriasis 
(Yates, Watkinson  et  al.  1982)  and  ankylosing  spondylitis  (Moll  2007)  in  Crohn’s  disease 
patients underlies  the  importance of  a  common  genetic  component of both diseases.  In 
ankylosing  spondylitis  (TASC,  2007),  the  strongest  association  is  seen  at  the  marker 
rs11209032 (~13kb 3’ of IL23R) with a minor allele frequencies of 38% in cases and 32% in 
controls.  In  Crohn’s  disease,  reports  from  several  groups  suggest multiple  independent 
association  signals  with  both  protective  and  deleterious  haplotypes  (including  a  non‐
synonymous variant, rs11209026 ‐ Arg381Gln at the protein level) in IL23R as predisposing 
to  disease  (Figure  3.4)  (Duerr,  Taylor  et  al.  2006;  2007;  Libioulle,  Louis  et  al.  2007; 
Tremelling,  Cummings  et  al.  2007).  In  psoriasis,  the  strongest  evidence  for  association 





of  more  than  two  haplotypes  at  this  locus  (evidenced  by  differing  allele  frequencies) 
(Barnes 2007).  
 
Given  the  common  association  of  variants  in  IL23R with  Crohn’s  disease,  psoriasis  and 
ankylosing spondylitis, and the known  involvement of TH‐17 cells  in the pathogenesis of at 
least the first two conditions, IL23R is an excellent candidate gene for disease susceptibility. 
















The  interleukin  23  receptor  is  a  heterodimeric  cytokine  receptor  of  the  hemopoietic 
cytokine  family.  It  is  composed  of  two  subunits,  IL‐12Rβ1,  which  is  shared  with  the 
interleukin 12  receptor, and a unique  IL23R  chain  (Parham, Chirica et al. 2002).  IL‐23R  is 
expressed primarily on memory CD4
+ T cells and NK cells, but is also present on cells of the 
innate  immune  systems  (Belladonna,  Renauld  et  al.  2002).  Binding  of  IL‐23  to  the  IL‐
12Rβ1/IL23R dimer  leads  to  cross‐phosphorylation of  the  tyrosine kinases  JAK2 and Tyk2 
(Parham, Chirica et al. 2002). These tyrosine kinases phosphorylate tyrosine residues in the 
cytoplasmic  domains  of  IL‐12Rβ1  and  IL23R,  which  creates  binding  sites  for  the  SH‐2 




as  transcription  factors  (Haan,  Kreis  et  al.  2006).  The  IL23R  chain  of  the  interleukin  23 
receptor  is  a  single  transmembrane  protein with  intra‐  and  extra‐cellular  domains.  The 





subunit of  the  IL‐12R receptor. The shared subunits of  IL‐12 and  IL‐12R with  IL‐23 and  IL‐
23R  underlie  the  common  genetic  origins  of  the  dimers.  The  human  form  of  IL23R 










cell  lines  and  have  yet  to  be  reliably  described  in  primary  human  tissue.  Of  these  six 
alternatively  spliced  variants,  two  lack  the  extracellular  domain  and  two  lack  the 
transmembrane domain (Zhang, Zhang et al. 2006). Two of these known human variants of 
IL23R have also been discovered  in Pan  troglodytes. The Pan  troglodytes  IL23R  Isoform 2 
(XM_001163823)  protein  has  99%  amino  acid  sequence  identity  to  the  Homo  sapiens 
RefSeq sequence (NM_144701) and the Pan troglodytes  IL23R  Isoform 1 (XM_001163787) 











allele  carriage  increases  disease  risk, while  the  other  five  SNPs  displayed  negative  odds 
ratios, indicating that they were protective against disease development.  
 
The position of  the associated SNPs along  the  transcript’s genomic  sequence can give an 
insight into the manner in which the variant affects function. It should be noted, however, 
that  large  scale association  studies of  this  type,  in particular using  the  Illumina BeadChip 
platform  as  used  for  the  IL23R  association,  often  deliberately  choose  haplotype  tagging 
SNPs,  and  are  not  necessarily  the  best  functional  candidates.  Six  IL23R  Crohn’s  disease 
associated SNPs lie within IL23R intronic sequences, two lie 3’ in the direction of the open 
reading  frame,  one  is  present  in  the  3’  untranslated  region  while  another  is  a  non‐
synonymous  (amino‐acid  changing)  SNP.  rs11209026,  the  non‐synonymous  SNP,  initially 
represents the best functional candidate to explain the association with disease. This SNP 
results  in an  arginine  to glutamine  substitution within exon  ten, which also  contains  the 
transmembrane  domain  of  the  protein. A  bioinformatic  search  using  the  Protein‐Predict 
server  (Rost,  Yachdav  et  al.  2004),    however,  reveals  that  despite  this  change  the 
substitution  does  not  appear  to  alter  the  conformation  or membrane  spanning  of  the 
protein, nor does it appear to disrupt any enzyme binding sites (analysis conducted 2007). 





Multiple  separate  variants  within  the  interleukin  23  receptor  have  been  identified  as 










































IL‐10  Immunotools, Germany 21339108 Matched Pair 1 in 2000
TNFα  Immunotools, Germany 21333018 Matched Pair 1 in 2000
IL‐1β  Immunotools, Germany 21170011 Matched Pair 1 in 2000
IL‐8  Immunotools, Germany 21339088 Matched Pair 1 in 2000
IFNγ  Immunotools, Germany 21333538 Matched Pair 1 in 2000
IL‐22  PeproTech, USA  900‐K246 Matched Pair 1 in 200
IL‐10  Immunotools, Germany 11340102 Recombinant Protein  2000 pg/ml
TNFα  Immunotools, Germany 11343013 Recombinant Protein  2000 pg/ml
IL‐1β  FirstLink, UK  hrIL‐1β Recombinant Protein  2000 pg/ml
IL‐8  Immunotools, Germany 11340080 Recombinant Protein  1000 pg/ml
IFNγ  PeproTech, USA  300‐02 Recombinant Protein  1000 pg/ml





















to  create a  standard  curve. Samples were  incubated  for one hour on a  shaking platform 
(KCH‐VIBRAX). After washing  samples  five  times with >200μl of ELISA wash, 100μl of  the 




added and  incubated  for 30 minutes at room  temperature on a shaking platform. After a 
final  series  of  five  ELISA  washes,  100μl  of mixed  BD  OptEIA™  TMB‐H202  substrate  (BD 
Bioscience, UK, 555214) was added to each well and incubated at room temperature for 15‐
20 minutes on the shaking platform. The reaction was terminated with 50μl of 1mM H4PO4 
(Sigma  Aldrich,  UK,  P6560)  followed  by  dual  absorbance  measurement  at  450nm  and 
subtraction of  570nm background  (680 Microplate Reader, BioRad).    The  same principle 
was followed for IL‐2 and IL‐17A which were measured using pre‐formed kits (ELISA Ready‐























in  100µl MACS  buffer  (PBS,  0.5%  BSA  (Sigma  Aldrich,  UK,  A9418),  2mM  EDTA  (Gibco, 
Invitrogen,  UK,  155575‐038),  pH  7.2,)  prior  to  adding  25µl  of  a  biotinylated  conjugated 
antibody cocktail (Miltenyi Biotech, UK, 130‐091‐155), designed to bind all cells except CD4
+. 
This was  followed by  an  incubation  at 4°C  for 10 minutes. Addition of  a  further 75µl of 





A Miltenyi  Biotech  LS  column  (Miltenyi  Biotech,  UK,  130042401)  was  placed  in  a Midi 
Magnetic  Separator  (Miltenyi Biotech, UK, 130‐042‐302) attached  to a metal Multi‐stand 
(Miltenyi Biotech, UK, 130‐042‐303). 3ml of MACS buffer was allowed  to run  through  the 
column prior  to adding 500µl of  the cell and bead  suspension,  followed by 3ml of MACS 
buffer. Unlabelled pure CD4







































Illumina  Bead  Studio  gene  expression module  v3.2.2  (Illumina,  USA). Where  parametric 
testing was appropriate, data  is presented as  the mean difference between groups  (Diff), 
with  the  95%  confidence  interval  (95% CI). Confidence  intervals  are not  shown  for non‐
parametric  data.  The  coefficient  of  determination  was  calculated  based  on  a  two  way 
ANOVA  analysis  of  results  comparing  genotype  to  dose  effects  using  genotype  and  the 
residual squares (sum of squares and mean square), using the omega2 method.  As a result 






graphs  using  GraphPad  Prism  v  4.03.  This  was  chosen  over  the  alternative  method, 
































































































Extracellular domain of Interleukin 23 receptor  Polyclonal goat IgG  Biotinylated  R&D Systems, UK  BAF1400 
CD4  Mouse IgG1 κ  APC Becton Dickinson, UK 555349
CD8  Mouse IgG1 κ Cy5 Becton Dickinson, UK 555368
Biotinylated Antibodies Streptavidin  PE AbD Serotec, UK STAR4A
Non‐Human Mouse IgG1 κ APC Becton Dickinson, UK 555751
Non‐Human Mouse IgG1 κ Cy5 Becton Dickinson, UK 555750
















in  the presence or absence of  αCD3/αCD28  coated antibody beads. An endpoint RT‐PCR 
reaction with exon spanning primers for the interleukin 23 receptor (Primers IL‐23a F, IL23a 
R) was performed. The  results,  shown  in Figure 3.6, demonstrate an upregulation of  the 
IL23R mRNA  in PBMCs after 22 hours  in culture compared  to a  β‐actin control. This data 








individuals  (Lanes  1 &  3  and  2 &  4).  Cells were  cultured  in  the  presence  (Activated)  or  absence 
(Unactivated) of αCD3/αCD28 antibody coated beads to activate the T cells. A positive controls (+ve 






















3.7  d).  The  upregulation  of  the  IL23R  agrees with  data  from  isolated  cell  subsets  in  the 
literature (Vanden Eijnden, Goriely et al. 2005), and validates PBMCs as a valid method for 








+  (b & d) cells within  the  lymphocyte  fraction with appropriate  isotype control 





























































+ cells  is upregulated  in PBMCs upon  in vitro activation 
with αCD3/αCD28 beads. To investigate the effect that interleukin 23 administration had on 
the  cytokine  profile  of  these  cells  (signalled  through  the  interleukin  23  receptor),  fresh 
PBMCs  obtained  from  the  peripheral  blood  of  a  healthy  donors  were  stimulated  and 
treated with a dose response of IL‐23. After optimisation of the assay, with a range of cell 
concentrations  and bead doses,  an ELISA was performed on  cell  culture  supernatants  to 
access secreted cytokines. PBMCs were chosen to  investigate  IL23R and the  IL‐23  induced 
cytokine  profile  to  provide  a more  realistic  cytokine milieu  compared  to  isolated  T  cell 
subset  experiments.  A  simple  linear  regression  analysis  was  performed  to  define  dose 
response changes. The ELISA results, shown  in Figure 3.8, demonstrate a dose dependent 
increase in IFNγ (P=0.0019), IL‐10 (P<0.0001), and IL‐17A (P=0.0040) from administration of 
IL‐23,  but  only  upon  αCD3/αCD28  activation.  The  data  is  representative  of  at  least  two 





















PBMCs  extracted  from  healthy  patients  using  leukophoresis  were  obtained.  Figure  3.9 
demonstrates  the  cytokine  response  in  cryopreserved  PBMC  and  fresh  PBMCs  from 
different healthy donors measured by ELISA.  αCD3/αCD28 beads and  cell  concentrations 
per  cell were optimised  to provide  a maximal  response  to  IL‐23  (measured  as  IL‐10  fold 
change),  resulting  in  cells  being  plated  at  a  density  of  1.5x105  cells  per  well  with  an 
αCD3/αCD28 bead  to cell  ratio of 1:2. Although  the  level of  IL‐10  induction  is  reduced  in 






5%  CO2,  were  treated  with  either  IL‐23  or  IL‐12  100ng/ml  followed  by  ELISA  measurement  of 
secreted IL‐10. Similar responses were obtained in both cryopreserved and fresh PBMCs. Error bars 
represent  SEM  from  triplicate  wells.  IL‐23  was  obtained  from  eBioscience.  ANOVA  p  values  for 
cryopreserved PBMCs (P <0.0001) and fresh PBMCs (P<0.0001), p values for Dunnett’s ANOVA post 
































At  the  time  of  this  experiment  (2006),  two  recombinant  forms  of  human  interleukin  23 
were  commercially  available;  a  recombinant  form  of  IL‐23  that was  constructed  by  co‐
expression  of  the  p40  and  p19  subunits  in  baclovirus  infected  insect  cells  (Full  Length) 
(eBioscience,  IL‐23)  and  a  form  that  is  expressed  as  a  fusion  protein  heterodimer, 
containing  both  the  p40  and  p19  subunits  linked  by  a  21  amino  acid  linker  chain 
(Heterodimer)  (R&D  Systems,  IL‐23).  Interleukin  23  expressed  as  a  linker  chain  had  a 









22 hours at 37°C 5%CO2. The  full  length  isoform  induces a  larger  fold  induction of  IL‐10  than  the 
heterodimeric compound. The errors bars  represent 95% confidence  intervals  for  the  fold  change 





In order  to  set up  an experiment  to measure  genotypic effects between  individuals, not 

























measurement), but  as many  variables  as possible must be  controlled. To  investigate  if  a 
better  response  to  IL‐10  could  be  obtained  using  isolated  cells,  CD4
+  and  CD8+  cells 
(analysed by flow cytometry to be >90% pure) were negatively selected from a buffy coat 
fraction  of  PBMCs.  Isolated  CD4
+  cells  were  cultured  for  22  hours  with  a  range  of 
αCD3/αCD28  bead  doses  in  the  presence  of  IL‐23.  CD8




IFNγ  (not  shown).  Indeed  IL‐23  did  not  lead  to  a  statistically  significant  increase  in  the 
secretion of any of  the cytokines. As such, PBMCs, which create a more realistic cytokine 















IL23R, a panel PBMCs  from  forty  individuals was cultured  in the presence and absence of 
αCD3/αCD28 beads with a dose range of IL‐23 (0.1‐100ng/ml), LPS (100ng/ml) (which acts 
























10,  IL‐17A  and  IL‐2  levels  (Figure  3.12).  Variance  due  to  experimental  conditions  was 
minimised by culturing  in parallel previously cryo‐preserved vials of PBMCs  from all  forty 
donors at  the  same  time, with  reagents and media of  the  same batch. Cells  that did not 




was observed  for  IL‐10  (Linear  regression P<0.0001), but not  for  IL‐17A or  IL‐2. Activated 
PBMCs stimulated with 100ng/ml IL‐23 produced a mean 3.2 fold increase in IL‐10 (95% CI 
2.8 to 3.5, P=8.0x10‐7), and a modest mean 1.5  fold  increase  in  IL‐17A  (95% CI 1.3 to 1.7, 




Cells  derived  from  the  n=36  individuals  were  also  cultured  with  100ng/ml  of  the 
heterodimeric IL‐23 recombinant protein (Figure 3.13). As in Figure 3.10 the heterodimeric 












































































































HapMap  to ensure no gross discrepancies existed  (Table 3.4). Any  small discrepancies  in 
frequency which did arise were most  likely  to result  from  the relatively small sample size 
used. Genotypes for two SNP pairs (rs2201841 / rs10889677 and rs11209026 / rs11465804) 
were  identical  in  the  forty  samples and  therefore only one of each pair was  selected  for 
further analyses. 
      Minor Allele Frequency




rs1343151  A  G 0.39
 
0.32
rs1004819  A  G 0.29 0.32
rs10889677 A  C 0.28 0.29
rs2201841  G  A 0.28 0.29
rs7517847  C  A No Data  0.42
rs10489629 G  A 0.48 0.46
rs11209026 A  G 0.06 0.04
rs11209032 A  G 0.3 0.29












fluctuations  in  cell  number  and  inter‐individual  difference  in  degree  of  αCD3/αCD28 




















The  statistical  power  calculation  suggested  that  a  minimum  of  six  samples  would  be 
required in each genotype group; therefore minor allele homozygotes for some SNPs were 
excluded from analysis.  Three heterozygous donors and no minor allele homozygotes were 




significantly  influence  IL‐10 secretion, whilst  two other SNPs had no effect  (Fig. 3.14). An 
IL23R genotype dependent effect was not seen with IL‐10 response to IL‐12 stimulation for 
any SNP. The most significant IL‐23 effect was found with rs11209032 (P=0.00030), where 
the minor allele  (that  is more common  in Crohn’s disease patients)  led  to  increased  IL‐10 
secretion. No genotype effects were observed for IL‐17A or IL‐2 cytokine secretion. 
 
As  the  removal  of  any  group  with  less  than  six  subjects  loses  some  data,  the  rare 
homozygous  and  heterozygous  group  were  subsequently  combined  to  represent  a 
dominant model of inheritance (in contrast to the standard multiplicative effect model). In 
the  dominant  model,  rather  than  the  SNP  having  a  dosage  effect  where  minor  allele 
homozygotes have a greater risk than heterozygotes, it is assumed that the risk is equal.  To 
ensure  that  both  genetic  models  are  appropriate  for  the  IL23R  rs11209032  findings, 
imputed  SNP  genotype  data  from  the  Welcome  Trust  Case  Control  Consortium  was 















































































































































































































































































































































































































































































































































































































































The  most  significant  IL‐23  response  effect  under  the  additive  model  was  found  with 
rs11209032  (P=0.00030);  this  SNP  still  retained  the  largest  effect  under  the  dominant 
model, (P= 0.00050). A coefficient of determination calculation (omega2) indicated that up 
to  46%  of  the  variance  in  IL‐10  secretion  from  IL‐23  treatment  seen  in  the  sample 
population  can  be  explained  by  genotype  at  the  rs11209032  locus  for  the  genotypes 
analysed.   
 





the  IL‐10  secretion  functional  test  are  in  partial  linkage  disequilibrium with  rs11209032 
(r2=0.48 with rs1004819 and r2=0.56 with rs10889677)  (van Heel, Franke et al. 2007). The 


















Genotype groups analysed  AG,GG AC,CC AG,GG AA,AG,GG AA,AC AG,GG not tested  
p value (see Fig. 3.12)  P=0.0048 P=0.0050 P=0.00030 P=0.070  P=0.86 P=0.023  







  G C G G C A G 23.4 
  A A A A A G G 23.1 
  G C G A A G G 18.1 
  G C G G C G G 8.7 
  G C G G C A A 4.9 


















2.8 times  (95% CI 1.5  ‐ 4.1, uncorrected P=0.039) by  IL‐23 treatment (Fig. 3.15). Only one 
other  cytokine  was  significantly  different  in  IL‐23  stimulated  PBMCs  (Table  3.6):  IL22 






























TNFRSF8  72.5  <0.00001 98.9 <0.00001 0.008 
HS.561721  138.4  <0.00001 167.1 <0.00001 0.018 
SPIC  53.2  <0.00001 44.3 <0.00001 0.019 
HS.540557  42.9  0.0081 35.3 0.79 0.019 
HS.545705  37.2  0.42 44.6 <0.00001 0.025 
LOC653949  50.9  <0.00001 42.7 0.0081 0.025 
HS.563458  36.0  0.67 43.8 0.0015 0.026 
IQCG  156.6  <0.00001 219.8 <0.00001 0.027 
HS.188910  40.5  0.046 33.6 0.94 0.027 
KIAA0802  35.3  0.77 42.3 0.0081 0.028 
FLJ20309  53.8  <0.00001 45.4 <0.00001 0.029 
LOC284009  55.4  <0.00001 65.1 <0.00001 0.034 
HS.124250  42.3  0.015 49.9 <0.00001 0.034 
CC2D1B  62.5  <0.00001 52.2 <0.00001 0.034 
CCPG1  134.8  <0.00001 111.3 <0.00001 0.037 
IL17F  462.0  <0.00001 1258.3 <0.00001 0.039 
C11ORF30  52.6  <0.00001 61.7 <0.00001 0.040 
PIGR  41.3  0.029 34.6 0.86 0.040 
HS.543406  53.2  <0.00001 44.8 <0.00001 0.041 
LOC647456  52.5  <0.00001 44.7 <0.00001 0.041 
NOTCH2NL  52.3  <0.00001 43.4 0.0022 0.041 
TAC3  51.8  <0.00001 44.2 <0.00001 0.042 
HS.149759  41.0  0.038 34.3 0.89 0.042 
ATXN7L4  42.9  0.0074 35.6 0.74 0.042 
SUCNR1  158.1  <0.00001 190.8 <0.00001 0.042 
HS.87734  52.1  <0.00001 42.6 0.0081 0.043 
FBXW7  184.7  <0.00001 152.2 <0.00001 0.043 
HS.171043  37.6  0.35 44.2 <0.00001 0.044 
PCDHAC2  47.1  <0.00001 54.9 <0.00001 0.044 
TMTC3  43.5  0.0052 36.9 0.49 0.045 
LOC652433  36.8  0.50 43.3 0.0030 0.045 
HS.568979  41.9  0.019 49.2 <0.00001 0.045 
HS.525400  44.5  0.0015 37.9 0.30 0.045 
LOC652903  36.5  0.56 43.5 0.0030 0.045 
IL22  153.2  <0.00001 196.6 <0.00001 0.046 
FAM5B  39.0  0.15 45.7 <0.00001 0.048 
HS.576431  59.5  <0.00001 50.6 <0.00001 0.049 










To  confirm  the  IL17F  finding  from  the  microarray  study,  PBMCs  from  the  same 
cryopreserved  individuals,  but  from  different  cellular  aliquots,  were  cultured  with 
αCD3/αCD28 beads  in the presence and absence of  IL‐23 100ng/ml. TaqMan Quantitative 
PCR was carried out on  the samples, as no human ELISA was commercially available. The 
geometric  mean  of  triplicate  wells  was  normalised  to  the  housekeeping  gene,  GUSB. 
Housekeeping gene selection was based on an observed  lower coefficient of variation  for 
GUSB than ACTB, or the geometric mean of ACTB and GUSB combined. We excluded four 
activated  samples  from  IL17F  measurement,  without  knowledge  of  genotype,  due  to 
unacceptable  variance  in  triplicate  Ct  values  (standard  deviation  in  triplicate  Ct  values 
greater than 0.3). One activated  IL‐23 stimulated sample was also excluded from all qPCR 













IL17F  expression  (activated  and  IL‐23  stimulated  PBMC  /  activated  PBMC  ratio)  was 
stratified by rs11209032 genotype. An  increase  in IL17F expression was seen in  leucocytes 
with rs11209032 AG genotype versus GG genotype (P=0.026, Diff = 1.7, 95% CI 0.24  ‐ 3.2) 
(Figure 3.17). Similar to the  IL‐10 results, the dominant model of  inheritance resulted  in a 
similar  level  of  significance  (P=0.0064,  Diff  =  1.7,  95%  CI  0.5328  to  2.896).  rs11209032 
appears to result  in not  just an  increase  in  IL‐10 with minor allele possession, but also an 




















Seven  IL23R  splice  isoforms  (including  the  reference  sequence)  of  human  IL23R  were 
reported in a study of normal human lymphoid cells and tumour cell lines (Zhang, Zhang et 




TaqMan  quantitative  PCR  assays  to  assess  six  of  the  seven  published  isoforms  were 
designed (Table 2.2). It was not possible to design a specific assay for the IL23R1 isoform by 
this method, as the only possible design would have generated a PCR product  longer than 
assay  limits.  The  IL23R_A  assay, which  detects  six  of  seven  reported  isoforms  including 
IL23R RefSeq and  IL23R1, was up‐regulated  in activated versus unactivated  leucocytes as 
expected  (P=1.8x10‐8,  Figure  3.18)  confirming  the  earlier  endpoint  PCR  data  on  a much 











Two  splice variants  (IL23R B,  IL23R C) were detectable at  single copy numbers  (Ct values 
~35) in some but not all activated cell donor samples (Figure 3.19). The six samples that had 
detectable  levels  of  IL23R  C  all  also  had  detectable  levels  of  IL23R  B.  The  very  low 













23  administration,  IL23R  A  qPCR  data  was  stratified  by  rs11209032  genotype.  Higher 
expression of the IL23R_A assay (measures RefSeq sequence NM_144701), was observed in 
activated leucocytes of rs11209032 AG genotype compared to GG genotype (p = 0.046 Fig 







Activated  leucocyte  IL23R_A  quantitative  PCR  expression  data  was  stratified  by  rs11209032 
genotype  (data  from  n=14  AG,  n=18  GG  genotype  donors).  Bars  show  group medians.  p  value 
derived from a Wilcoxon Matched Pairs test (p = 0.046).   
 
This  genotype  effect was  also observed  in RNA obtained  from  activated  cells  stimulated 
with  100ng/ml  IL23  (P=0.017).  This  effect  on  genotype  was  also  observed  under  the 
dominant genetic model for cells stimulated with IL‐23 (P=0.021), but with less significance 
for  stimulated  cells  alone  (P=  0.083).  It was  not  possible  to  determine  if  the  genotype 
difference  was  associated  with  a  general  change  in  expression,  or  due  to  a  specific 






The work  in  this chapter  indicates  that  leucocytes  from  individuals with Crohn’s or other 
IL23R associated diseases may have a higher  sensitivity  to  IL‐23  (on average, because of 
higher frequencies of deleterious IL23R haplotypes in the population). The lack of genotypic 
effects  in  any  of  the  IL‐12  stimulated  cells  supports  the  hypothesis  that  the  differences 
observed  result  from  IL23R genotype and not cellular artefacts. This work has specifically 
shown that individuals who possess the deleterious haplotype are likely to produce more of 
the  anti‐inflammatory  cytokine  IL‐10  and  the pro‐inflammatory  cytokine  IL‐17F.  In  the  in 
vitro assay, a supra‐physiological T cell activation stimulus was applied to a heterogeneous 
population of PBMC. How the balance between these two cytokines of potentially opposing 
effects  is altered  in vivo  in  the  relevant  intestinal  leucocyte subsets,  is unclear.  It may be 
related to  the  identification of murine  IL‐10 producing TH‐17 cells or the ability of cells to 
cycle between immuneregulatory and suppressive phenotypes based on the cytokine milieu 
(Jankovic and Trinchieri 2007; McGeachy, Bak‐Jensen et al. 2007; Tato and Cua 2008a). It is 
highly  likely that the complex  interactions of cytokines  in vivo will  involve other pathways 
which have not been identified here.  
 
It has been  suggested  that  IL‐22  levels  in Crohn’s disease patients’  sera  are higher  than 
controls,  confirming  previous  data  from  bowel  biopsies  (Brand,  Beigel  et  al.  2006). 
Interestingly,  IL‐22  levels  in  sera  were  greater  in  patients  possessing  minor  allele  risk 


















This  is  in  agreement with  the data  in  this  chapter  that  the protective haplotype had no 







In  these primary human  leucocyte  assays  IL‐10  secretion  and  IL17F production were  the 
main effects of  IL‐23  stimulation. Mouse  studies have primarily  studied  IL17A,  and most 
literature  referring  to  IL‐17  in  practice  refers  to  IL‐17A;  they  suggest  that  IL‐17A  is  the 
critical  cytokine  driving  TH‐17  responses  (Steinman  2007).  IL‐10  secretion  and  IL17F 




been  conducted  to  characterise  its  function  compared  to  IL‐17A.  It  acts  as  a  pro‐
inflammatory  cytokine  stimulating  production  of  granulocyte  macrophage  colony 

















Translating  the  results  of  genome‐wide  association  studies  into  functional,  plausible, 
biological mechanisms is the next major challenge that faces geneticists. Here a functional 
consequence of genotype at the Crohn’s disease, ulcerative colitis, psoriasis, and ankylosing 
spondylitis  associated  gene  IL23R  has  been  presented.  The  primary  human  leucocyte  in 
vitro  assay  is  likely  to be more  representative of human  in  vivo  immune  responses  than 
mouse studies or studies using transfected cell lines. The IL23R variants tested are probably 
tag  markers  strongly  correlated  with,  rather  than  the  precise  and  as  yet  unidentified, 
disease‐causing,  functional  variant.  The  rs11209032  AA  and  AG  genotypes  are  more 
common  in  individuals  with  Crohn’s  disease  and  ankylosing  spondylitis  compared  to 
controls  (Duerr, Taylor et al. 2006; TASC, 2007).  It has been  shown here  that  leucocytes 
from  individuals who possess  the AG genotype may have an enhanced  response  to  IL‐23 
versus the rs11209032 GG genotype. The mechanism of this gain of function may possibly 
be  via higher  IL23R expression, although  the  statistical  significance  is borderline and  the 
experiment probably underpowered. In our in vitro assays, an effect for several other IL23R 





Mendelian  disorders  that  result  in  susceptibility  to mycobacterial  disease  are  commonly 
mediated  through mutations  in  the  shared  IL‐12/IL‐23  receptor  IL12RB1  chain  leading  to 



















This  experiment  demonstrates  some  of  the  problems  that  can  be  encountered  when 
attempting to study common variants that have a small effect on disease susceptibility. The 
first problem is the large natural variation found in an outbred population. Since the effect 
of  these variants  is  small  (as observed by  the  small odds  ratio  for association)  the assay 










expected  effect  of  variants  before  study,  and  the  SNPs  identified  by  GWA  studies  are 
usually  only  tagging  SNPs, which  provide  no  clue  as  the  biological  effect  of  the  variant. 
Experiments are best carried on in human tissues, to gain realistic insights into how human 
cells are affected by the variant, however, to escape the inherent variance that is present in 
































ten years, coupled with  the haplotype data obtained  from projects  such as  the HapMap, 
allows the investigation of how common variants may alter phenotype. Using genome‐wide 
microarray technology it is possible to elucidate the effects of common variants on the RNA 






Nap 2001)  is used  to describe  the  combining of data derived  from genome‐wide genetic 





In  classical  genetics,  a monogenic  trait  can  be mapped  to  a  single  locus  using  linkage 
analysis  within  a  family.  Polygenic  traits,  however,  with  numerous  genes  affecting  a 
phenotype will  not map  to  a  single  locus,  but  instead multiple  loci.  These  loci,  termed 
quantitative  trait  loci,  (QTL),  are  regions  of  the  genome  associated with  transmission  of 
quantitative  traits  and  are  likely  to  contain  gene  variants  that  regulate  that  trait.  QTL 
mapping has been performed in human disease with some success (Peltonen and McKusick 
2001), however, the inherent genetic variability combined with the large number of genes, 






By  treating  gene  expression  as  a  quantitative  trait  it  is  possible  to  identify  genomic 
locations  that  are  co‐inherited with expression  (Alberts,  Fu et  al. 2005). These QTLs,  are 











far  away  from  the  gene,  possibly  on  a  different  chromosome  (Alberts,  Fu  et  al.  2005), 
(Figure  4.1).  Cis  acting  effects  can  be  explained  by  direct  effects  on  the  binding 
transcriptional apparatus due to changes in promoter/enhancer sequences, splicing, micro 










a  pair  of  hindwings,  termed  halters,  behind  the main wings  on  the mesothroax  (Levine 
2002). Butterflies which are insects of the order Lepidoptera form complete wings, instead 
of forming halters as seen  in Drosophila.  It  is possible to observe distinct gene expression 
differences  exist  between  these  populations,  and  these  differences  play  a  key  role  in 
creating  the variation  in phenotypes  (Yan, Yuan et al. 2002).The Hox gene Ubx protein  is 
expressed  ubiquitously  in  both  halters  and  complete  hind  wings,  where  it  acts  as  a 
repressor of transcription. Formation of halters  in Drosophila depends on the presence of 
‘cis regulatory elements’ within the DNA sequence close to key growth genes that increase 
the  binding  of Ubx  to  the DNA  (Levine  2002).  As more  growth  genes  accrue  increasing 
numbers  of  germ  line  mutations  within  the  DNA,  they  allow  more  Ubx  to  bind,  thus 
repressing expression of the growth genes and preventing the formation of complete wings 
(Levine  2002).  This  process  does  not  occur  in  Lepidoptera,  allowing  the  formation  of 
complete wings. By measuring the messenger RNA levels of the growth genes, it would be 







of a particular gene. These associations can either be cis  (a), where a marker  (such as Marker B) alters expression of Gene X, which  is on the same genetic  locus as the 









within human populations  is  complicated not only by  the  large  amount of  variation  that 
exists, within lots of genes, all across a relatively large genome, but also the small amount 
of  phenotypic  variation  that  a  single  allelic  change  generates  (Yan,  Yuan  et  al.  2002). 
Despite  this, however,  it  is possible  to analyse  the effect of DNA polymorphisms on gene 
expression within human populations. By looking at the same gene, expressed in the same 
cell  in  heterozygote  individuals with  allele  specific  fluorescent markers,  it  is  possible  to 
identify allele specific differences in expression (Yan, Yuan et al. 2002) (Chapter 6.1). Yan et 




of  genes  analysed  (326  out  of  602)  displayed  allele  specific  expression  (Lo, Wang  et  al. 
2003).  Like  Yan  et  al,  similar  small  scale  studies  have  shown  that  gene  expression  can 
display  significant association with SNP genotype  in human  tissues  (Bray, Buckland et al. 
2003; Lo, Wang et al. 2003; Pastinen, Sladek et al. 2004). Gene expression was  therefore 





Gene  expression  levels  in  the  Caucasian  population  are more  likely  to  be  correlated  in 
related  individuals;  for  example,  the  variance  is  three  to  eleven  times  greater  for  some 
genes between unrelated individuals compared to monozygotic twins (Cheung, Conlin et al. 
2003).  Twin  studies  have  consistently  demonstrated  that  genes  vary  more  between 
unrelated  individuals  than between monozygotic  twins  (Sharma, Sharma et al. 2005; Tan, 
Christensen et al. 2005). Samples of peripheral blood  taken  from  the  same donor over a 
period of time, do not cluster around the  individual;  if, however, the subset of genes with 











If a gene’s expression  is regulated by genotype,  then  like  the Drosophila example, one of 
the possible mechanisms for genotype to affect expression  is by  interrupting or creating a 
regulatory  element.  This  alteration  in  expression  generates  a  possible  mechanism  for 
disease associated variants to have a functional effect within the cell. Allele specific assays, 
interrogate a  transcripts expression using allele  specific probes within a quantitative  real 
time reverse  transcription PCR or tandem mass spectrometry reaction. This approach can 
be  used  to  investigate  polymorphisms  within  exons,  using  mRNA,  or  in  introns,  using 
heterogeneous nuclear RNA  (hnRNA)  (Pastinen, Sladek et al. 2004).  In order  to assay  the 
alleles, a SNP must be present within  the reverse  transcribed portion of  the gene. As  the 
SNP  lies  within  the  transcribed  portion  of  the  gene,  it  is  likely  to  be  either  directly 
responsible for affecting transcription by interrupting a regulatory sequence, or else it may 
be  in  linkage disequilibrium with a polymorphism  in an enhancer or promoter    (Pastinen 
and Hudson 2004).  
 
Cis acting eQTLs can  function via alterations  in  the DNA sequence of  the  regions  flanking 























The work by Cheung et al.  (Cheung, Conlin et al. 2003), who  compared  gene expression 
levels  in monozygotic  twins,  and  others,  demonstrating  that  gene  expression  variation 
within human cells is heritable, sits well with concurrent work from yeast and plant biology 
where genetical genomics has  its  roots. Work  in plants and yeast has  the advantage  that 
segregating populations and experimental crosses can be used to perform highly powered 
linkage  studies with  small  recombination  blocks. Methods  for  analysing  all  the  variation 
within  large  outbred  population  such  as  humans,  however,  are  also  needed.  Instead  of 
analysing only heterozygous  individuals, for a small number of SNPs and genes, Morley et 
al.,  used  the  same  approach  adopted  in  segregating  plant  populations  to  measure 
expression  of  a  relatively  large  number  of  genes  (3,554)  by microarray  analysis.  Using 






validate  an  association  based  approach  to  genome‐wide  gene  expression  analysis,  by 
comparing genotypes at each SNP to expression at each gene (Morley, Molony et al. 2004). 
A  larger  scale  analysis  of  15 members  of  the  Caucasian  HapMap  population  for  23,499 
genes using a linkage based approach followed by an association based method, like Morley 
et al, also described an over  representation of  trans effects  in detectable eQTLs  (>5 Mb 
from gene) (Monks, Leonardson et al. 2004). The complex regulatory mechanisms involved 
in  these  pathways make  the  identification  of  subtle  cis  effects  difficult with  low  sample 






traditionally performed with  linkage markers,  followed by an association study  follow up, 
this approach  is not so amenable to human studies (GuhaThakurta, Xie et al. 2006). Since 




HapMap project, dense SNP  frequency data  is available, which can be collated on a  large 
number  of  unrelated  individuals;  this  can  then  be  used  to map  eQTLs  to much  smaller 
genomic  locations  than  linkage  analysis.  Linkage  analysis  requires  that  the  marker  co‐
segregates with the phenotype, whilst association based tests require the phenotypic allele 





Until 2005, most eQTLs discovered  in humans had been  found  as a  follow up  to  linkage 
studies  (Schadt, Monks et al. 2003; Monks, Leonardson et al. 2004; Morley, Molony et al. 
2004; Cheung, Spielman et al. 2005), and had primarily  identified trans acting eQTLs from 
relatively small samples of EBV  transformed cells  from <30 HapMap  individuals. The over 




unlike  linage  based  approaches,  no  trans  effects  passed  multiple  correction  testing 
(Stranger,  Forrest  et  al.  2005).  The  higher  power  associated with  the  association  based 
approach  (Risch and Merikangas 1996) and the complex nature of pathways, suggest that 
association based approaches would be more  successful at  identifying  cis effects  (Sladek 




same  rate  of  cis  effects,  but  they  have  a  much  higher  false  discovery  rate  (Petretto, 
Mangion et al. 2006). The same high false discovery rate would also be observed in human 
based  linkage approaches; possibly accounting  for the overrepresentation of  trans effects 
seen  in  some  human  linkage  based  genetical  genomics  studies.  A  large  scale  linkage 
experiment in human lymphocytes from more than 1000 individuals estimated that the vast 











one  of  the  first  large  scale  genetical  genomics  associations  studies  to  be  undertaken  in 
humans (Dixon, Liang et al. 2007). This approach essentially involves testing each individual 
SNP  for  an  effect on  every  transcript,  and  then mapping  the  SNPs  to delineate  cis  from 
trans  effects  (Dixon,  Liang  et  al.  2007).  Due  to  the  large multiple  testing  problem  this 
creates,  it  is normal practice to define a cis effect as a SNP within a specific distance (e.g. 
500kb) from a transcript, and only test SNPs that fall within this window. Dixon et al. found 
approximately  2,000  significant  eQTLs,  a  stark  contrast  to  the  small  numbers  found  by 
previous efforts. This  is a direct  result of  the  sample  size used  (Dixon, Liang et al. 2007). 
Trans effects, although numerous, had much weaker effect sizes than cis effects, consistent 
with findings from previous studies (Stranger, Forrest et al. 2005; Dixon, Liang et al. 2007). 
There  was,  however,  evidence  for  trans  regulatory  ‘Hot‐Spots’  where  a  SNP  within  a 
presumably  regulatory  region  affects  multiple  transcripts  (Dixon,  Liang  et  al.  2007). 
Although  the  comprehensive  analysis  of  EBV  cells  provides  good  evidence  for  cis  eQTLs 
within  human  cells,  the  evidence  for  trans  effects  is  still  not  clear  cut.  Recent  evidence 
suggests that while some trans effects may exist they may be much less important for gene 



























reference  genome”  (Aitman,  Dong  et  al.  2006),  have  attracted  much  attention  as  an 
alternative method of genetic variation and disease susceptibility. CNVs have already been 
demonstrated  to  affect  disease  susceptibility  as well  as  gene  expression  in murine  and 
human models  (Stranger, Forrest et al. 2007). Since CNVs are a viable method of altering 
gene expression,  in  the  same manner as a SNP,  they  can be mapped  though association 










regions  of  the  DNA,  that  directly  affect  transcription, many  post  transcriptional  events 
affect  the  expression  of  a  gene  at  the  protein  level.  Although mRNA  levels  are  easy  to 
measure, they exhibit a significant amount of phenotypic variance. It could be argued that 
mRNA  levels will only have a significant effect on biology  if  they also alter protein  levels. 
Large  scale  analysis  of  protein  levels  in  a  genome‐wide  fashion  is  not  yet  technically 
feasible, but  it  is possible to measure specific proteins  in e.g. serum. A  large scale analysis 
of  1,200  individuals  for  levels of  42 proteins  identified  significant protein QTLs  for  eight 
genes  (Melzer,  Perry  et  al.  2008).  It  should  be  noted  that,  none  of  these  genes  were 
associated with known eQTLs, although at the time of the study no eQTL studies had been 
published  in peripheral blood, the tissue of study for the protein QTLs (NB: none of these 
genes are  significant eQTLs  in  the peripheral blood  samples  studied  in  this Chapter, 4.3). 
137 
 
One of  the most  important effects  that a SNP  could have  is  to affect alternative  splicing 
(Faustino  and  Cooper  2003).  Alternative  splicing  of  pre‐mRNA  transcripts  has  a  well 




genes  associated  with  disease  (Faustino  and  Cooper  2003).  Splicing  is  regulated  by 
intracellular  machinery  that  binds  to  the  DNA  at  specific  sites  and  recruits  protein 
complexes to cleave intronic regions before export from the nucleus (Kwan, Benovoy et al. 
2008). The DNA sequences that the splicing machinery binds to are crucial in the regulation 
of  splicing.  A  polymorphism  in  one  of  these  sequences  could  prevent  or  enhance  the 
likelihood of  splicing occurring,  thus  altering  the  translated protein. Alternatively  spliced 
transcripts  have  been  demonstrated  to  be  heritable  (Alberts  2002;  Lewin  2004;  Kwan, 
Benovoy et al. 2007), indicating that DNA polymorphisms could be responsible for altering 
splicing. Traditional microarray platforms use multiple copies of a single oligonucleotide (50 
or 25 base pairs  long)  to  assay  a  single  transcript.  This oligonucleotide hybridises  to  the 
target  sequence which  is  designed  towards  the  3’  end.  If  a  gene  has  several  identified 
variants with different 3’ ends, more than one oligonucleotide may be present for a single 




predicted  exons,  gives  a much  greater  insight  into  the  structure of  the  transcript.  These 
“Exon arrays” (Affymetrix, USA), have been used in a similar approach to traditional arrays 
for genetical genomics. With this approach it is possible to not just identify genetic variants 
that affect  transcript quantity, but also  the affect on  transcript exon structure and hence 
alternative  splicing  (Birney,  Stamatoyannopoulos  et  al.  2007).  Kwan  et  al. were  able  to 
show  that  out  of  17,897  genes  tested,  324  displayed  significant  evidence  of  an  eQTL  in 
Caucasian HapMap EBV transformed cells (Kwan, Benovoy et al. 2008). 55% of these were 
due  to  alternative  splicing  associated  with  SNP  genotype.  This  number  is  similar  to  a 
computational  screen  of  publically  available  EST  and  exon  array  data which  also  found 
abundant  SNP effects on  transcript  isoform  structure  (Nembaware,  Lupindo et al. 2008). 
Several  groups  have  now  performed  further  genome‐wide  association  scans  looking  at 
alternative splicing with similar results; that it is a heritable process significantly affected by 







of  the mechanism  of  gene  regulation  at  the  epigenetic,  transcriptional  and  translational 
level.  Data  from  the  ENCODE  project,  which  sequenced  1%  of  the  genome  and 
corresponding  transcriptome  produced  a  surprising  result.  They  identified  that  almost 
every DNA base, at some time, is transcribed  into RNA (Birney, Stamatoyannopoulos et al. 
2007).  The  significance  of  this  result  and whether  it will  remain  after  validation  is  still 
unknown but  seems  to  suggest  that non‐coding RNAs may play much more of  a  role  in 
cellular  regulation  than  once  suggested  and  even  seems  to  run  counter  to Watson  and 















interrupted can change  the  intracellular  localisation of the mRNA transcript  (e). miRNAs  that act  in  the cytoplasm  to silence RNA molecules require exact binding sites, 

































extracted  from  treated coeliac disease patients by Prof D A van Heel and Dr L Denison  in 
the  coeliac  disease  clinic  at  St  Bartholomew’s  Hospital,  London  and  The  John  Radcliffe 
Hospital,  Oxford.  All  patients  had  previously  been  diagnosed  with  coeliac  disease  and 
possessed either a past positive endomysial antibody  test and a  small bowel endoscopic 
biopsy diagnosis of coeliac disease, or  just a biopsy diagnosis. Long  term coeliac patients 
were  enrolled  to minimise  the  risk  of  ongoing  inflammation.  In  total  115  patients were 
included  in this study. Blood was also obtained from 22 healthy control volunteers. Blood 





2.5ml  of  peripheral  blood  was  collected  into  a  PAXgene  tube  (Becton  Dickinson,  UK, 
762165), mixed gently and incubated at room temperature for two hours. All reagents were 
obtained  from  the  PAXgene  Blood  RNA  isolation  kit  (Qiagen,  UK,  762174).  Tubes were 
frozen at ‐20°C for at least 24 hours followed by storage at ‐80°C. The process of extraction 
was  followed according  to  the manufacturer’s  instructions. Defrosted  tubes were spun at 
4,000g on a Sorvall RT 7 centrifuge with a swing out rotor for 10 minutes. The supernatant 




binding buffer  (Qiagen, UK, BR2) was added  followed by 40µl proteinase K  (Qiagen, UK). 
The solution was incubated at 55°C for 10 minutes on an Eppendorf Thermomixer compact 
shaker‐incubator  (Eppendorf, UK)  set at 400rpm. The  lysate was added  to a QIAshredder 
spin column (Qiagen, UK, 79654), followed by centrifugation at 16,000g for 6 minutes on an 





remaining  RNA  containing  solution  until  all  RNA  had  bound  to  the  membrane.  The 
membrane was washed with 350µl of wash buffer 1 (Qiagen, UK, BR3) and spun at 13,000g 
















MIAME  (Minimum  Information About  a Microarray Experiment)  (Brazma, Hingamp et  al. 
2001)  compliant microarray data was  submitted  to  the Gene  Expression Omnibus  (GEO) 









using  R.  A  combination  of  linear  regression,  non‐parametric  ANOVA  and  Spearman’s 












correlation coefficient  is  calculated. Three example SNPs are displayed  in  this  figure, with no association between genotype and expression  (a), with a very  significant 







Data  mapping  and  normalisation  was  performed  by  Dr  Lude  Franke.  Briefly,  all  probe 
sequences  were  first  mapped  to  the  Ensembl  v45  cDNA  sequence  and  NCBI  Build  36 





3)  comparing  the  genotype  to  the  gene expression  level  for  all  samples  to  generate  a p 
value  (Figure  4.4).  The non‐parametric  statistic has  the  advantage of  assaying  SNPs  that 
have a non‐Gaussian distribution of gene expression values. The  false discovery  rate was 
calculated  by  permutation  (1,000  times). Differential  expression was  calculated  using  an 
empirical bayes method built into the R package limma (Smyth 2004).  
 









Recombinant human  IL‐18  (R&D systems, B001‐5) was diluted  in X‐Vivo 15 media  (Lonza, 
UK, BE04‐418F)  to a dose concentration  ranging  from 0.1ng/ml – 100ng/ml. Thawed and 
washed  frozen  PBMCs  were  added  to  each  well  in  a  96  well  plate,  in  triplicate,  at  a 





















coeliac disease. Gene expression  levels  for all  samples were analysed by hybridisation  to 
Illumina Ref  8v2  gene  chips, which  analyse  22,185  gene  transcripts. All  individuals were 
genotyped previously  for 310,605 SNP markers  (van Heel, Franke et al. 2007). 22 healthy 
control  samples were also analysed. Samples and  control markers were anonymised and 
randomly  arranged on  arrays with  a  random  assignment  to  amplification  kits  to prevent 
bias. The average age of the coeliac disease patients was 51 (23 ‐ 88), with an average age 
at diagnosis of 42  (1  ‐ 75). The median  length of  treatment on a gluten  free diet was 9.4 
years (1  ‐ 47). 70% of coeliac disease patients were female, a proportion replicated  in the 
control population. 66.6% of adult cases diagnosed with coeliac disease  in the population 








arrays. These  included  three  technical  replicates, where  the same RNA was hybridised  to 








A  representative  sample  correlation  for  two  technical  replicate  samples  from  a  single  peripheral 




A null distribution of  r2  values,  comparing  the  correlation of  all  genes  in  a  sample  to  all 
other  samples, was  generated  for  all  individuals,  resulting  in  11,222  correlations  (same 
sample  correlations  excluded).    This  represents  the  correlation  that would  be  expected 
from  two  random samples. The median  r2 of  the null distribution was 0.94, with a heavy 
negative  skew. Table 4.1 demonstrates  that when  compared  to  this null distribution,  the 
replicate sample correlations are not significantly, but they are higher than expected. The 
replicate values have higher  r2 values  than  the null distribution of data  in general  (Figure 
4.6), although  there  is some  inherent variation, generated within  the sample preparation 
steps.  
 
As  a  further  quality  control  measure,  probe  intensity  levels  across  all  samples  were 



















































be  compliant with  a  gluten  free  diet.  To  ensure  that  no  individuals  contained  excessive 
numbers  of  inflammatory  cells,  gene  expression  levels,  for  a  selection  of  known  coeliac 
inflammatory genes such as IFNγ (Ciclitira and Ellis 1998), IL‐18 (Leon, Garrote et al. 2006), 
and  IL‐2  (Lahat, Shapiro et al. 1999)  from all  samples were generated, and examined  for 






To  ensure  there  had  been  no  sample  labelling  errors,  expression  levels  of  transcripts 
mapping  to  non‐pseudo‐autosomal  regions  of  the  Y  chromosome  were  analysed  and 
compared between males and  females. Two  samples appeared  to be an obvious  sample 
mix  up  (Figure  4.8);  but  to  ensure  there was  no  genetic  abnormality  causing  the  signal 
intensity  changes, both  samples were  removed  from  further  analysis  leaving 110 unique 
cases.  
 
To  further  enhance  this  analysis,  gene  expression  levels  for  all  gene  transcripts  were 
stratified by  individuals’ sex, resulting  in a  list of differentially expressed transcripts (Table 
4.2). As a result of this analysis, a  list of genes that were differentially expressed  in males 
and  females  was  generated,  with  all  significant  genes  being  present  on  the  X  or  Y 
chromosome  as  expected.  Although  taking  an  average  of  all  genes  that map  to  the  Y 
chromosome  can  give  a  reliable  indication of  a patient’s  sex,  some  transcripts  are more 
informative than others (due to differential peripheral blood expression). As an example, a 
























Gene Name Chromosome  Probe ID Wilcoxon p value Median Expression Male  Median Expression Female Detection Comment 
 
EIF1AY  Y 1780270 9.8x10‐12 748.7079 ‐6.663506 Below Detection Limit In Females 
PRKY  Y 2900048 9.8x10‐12 272.7349 3.110333 Below Detection Limit In Females 
RPS4Y1  Y 3180075 9.8x10‐12 2872.2655 ‐4.784544 Below Detection Limit In Females 
UTY  Y 5420224 9.8x10‐12 103.56849 11.91895 Below Detection Limit In Females 
SMCY  Y 6560452 9.8x10‐12 289.07715 ‐1.733103 Below Detection Limit In Females 
CYORF15B Y 4730458 3.5x10‐11 70.35915 ‐3.22904 Below Detection Limit In Females 
USP9Y  Y 6290398 2.5x10‐10 82.23056 9.617576 Below Detection Limit In Females 
UTY  Y 5310196 2.9x10‐10 63.29119 5.810353 Below Detection Limit In Females 
CYORF15A Y 2190192 4.4x10‐10 173.32215 1.441168 Below Detection Limit In Females 
DDX3Y  Y 2810273 4.1x10‐9 76.64443 11.27938 Below Detection Limit In Females 
UTX  X 270731 1.6x10‐7 172.98465 290.6216  
PRKX  X 2100187 8.5x10‐7 178.48385 245.07  
EIF1AX  X 6760333 1.6x10‐6 297.9754 433.7739  
HDHD1A  X 5820315 3.0x10‐6 179.4166 261.877  
EIF2S3  X 5670521 8.2x10‐6 1372.0195 1744.254  
RPS4X  X 6290274 2.2x10‐5 4240.2695 6154.792  
CA5B  X 7560162 1.4x10‐3 250.1878 325.3474  















to  females  as  in  the  healthy  group.  A  differential  gene  expression  analysis  was  then 
undertaken  using  the  Illumina  Custom  Differential  Gene  Expression  algorithm  (similar 
results  were  obtained  for  a  Wilcoxon  Signed‐Ranks  test  approach).  No  differentially 
expressed  genes  were  identified  that  passed  multiple  correction  analysis.  Although  no 
genes passed multiple corrections testing, some genes were differentially expressed and it 
is plausible that they may reach a significant threshold with  larger samples sizes. Since all 
coeliac  individuals  were  on  gluten  free  diets,  and  were  observed  to  not  possess 
inflammatory  gene  expression,  no  large  gene  expression  differences would  be  expected 
unless there were major differences in cellular composition. The top findings are identified 
in Table 4.3.  Interestingly, out of the nine genes below, four are HLA genes. Although this 
may  reflect  a  real  difference  in  transcript  expression,  polymorphisms  within  the  probe 
binding  sites  would  first  need  to  be  excluded,  especially  since  the  HLA  region  is  so 
















HLA‐DPB1  237.2  159.0 5.7x10‐6 rs3117222  1.49  Immune
HLA‐DRB1  350.4  1281.3 4.0x10‐4   3.66  Immune
KIR2DL4  276.9  193.4 4.7x10‐4   1.43  Immune
HLA‐DQB1  408.5  273.3 8.4x10‐4   1.49  Immune
CHURC1  791.4  461.6 0.0011 rs1957425  1.71  Unknown
CAMKK2  250.2  388.4 0.0014   1.55  Signalling
LOC441268  271.8  429.3 0.0015   1.58  Unknown
HLA‐DRB4  4691.5  3108.0 0.0020 rs2395163  1.50  Immune












The whole genome  cis association analysis  (Table 4.4) was performed by Dr  Lude Franke 
and  data  was  then  subsequently  analysed  in  collaboration  (UMCG,  Groningen, 
Netherlands). The non‐parametric p value for association of the SNP and gene expression 
levels was calculated as described  in Chapter 4.2.5. Gene expression  levels were analysed 
for correlation with genotype  for 19,867  transcripts at 257,013 SNPs  that mapped within 
500kb of the centre of each transcript’s probe. This resulted in 1,850,599 tests. Using a false 
discovery  rate  of  0.05,  2,178  different  SNP‐transcript  effects  eQTLs were  observed.  This 
reflected 658 unique probes, and 2,035 unique SNPs. The results of this scan are displayed 
in  Table  4.4.  A  similar  analysis  was  also  conducted  on  a  published  data  set  of  gene 
expression  values  derived  from  the  HapMap  CEU  EBV  transformed  cell  lines  (Stranger, 
Forrest et al. 2005), the results are shown in Table 4.4 for comparison. Figure 4.9 shows the 
cumulative distribution of SNPs around the midpoint of the eQTL causing probe. Cis eQTLs 
identified  in  the  PAXgene  data  showed  an  over‐representation  of  the  “immunity  and 
defence”  gene  ontology  category  compared  to  the  HapMap  data,  demonstrating  the 






















samples.  In  all  cases,  the  p  value  was  more  significant  in  the  meta‐analysis  dataset, 
indicating  that  the  allelic  effect  was  in  the  same  direction  for  all  eQTLs,  and  that  the 
additional  eQTLs  identified  through  the meta‐analysis  were  simply  a  result  of  increase 
power from the increasing sample size.   
 
A  comparison between  the PAXgene data and  the  results  from a  separate  linkage based 
study (Goring, Curran et al. 2007), also performed in peripheral blood, indicated that 57.3% 
of probes that display a cis eQTL (250kb, FDR 0.05) also show a linkage peak. Although the 
Goring  et  al.  data  was  performed  in  peripheral  blood,  the  cells  were  extracted  and 
underwent a ficoll gradient separation step which will result in a significantly different gene 
expression profile  from whole blood,  and may  account  for  some of  the differences.  The 
















Interestingly, Myers et al.  (Myers, Gibbs et al. 2007), also  investigated  their  identified cis 
effects for primer polymorphisms, and found 13% of their cis effects had known SNPs that 
could account for the results. The similarity of these findings lends credence to the results 
identified  here,  and  suggests  that  cis  effects  are  not  due  to  known  SNPs  within  the 
hybridisation sequence.  
 
A Fisher’s exact  test was performed on  the data  to determine  if  the proportion  that had 
been  identified  as  containing  an  eQTL was  significantly  enriched  for  these  SNP mapping 
probes. An enrichment was observed  in both datasets  (PAXgene, p = 0.02, HapMap, p = 













this was  related  to  the gene expression profile between  the  two cell  types, a differential 
gene  expression  analysis was  conducted.  The  data was  first  refined  to  a  set  of  12,401 
probes  that mapped  to  identical exons between  the  two arrays. Both datasets had been 
normalised  by  quantile  normalisation  (Chapter  4.2.5),  but  to  ensure  there  were  no 
systematic  differences,  the  data was  combined  and  re‐normalised.    An  empirical  Bayes 
approach was  taken  to  identify differential  gene  expression between  the  two databases 
(Chapter 4.2.5). Cis eQTLs  that were detected  in  the PAXgene dataset  reflect probes  that 
have,  on  average,  a  significantly  higher  expression  in  the  PAXgene  dataset  than  in  the 
HapMap dataset  (Wilcoxon Signed‐Ranks test, p = 7.6x10‐7, Fig 4.10a). Likewise, cis eQTLs 
only  found  in  the HapMap dataset were, on  average,  expressed  at  a higher  level  in  the 
HapMap B  cell dataset  (Wilcoxon Signed‐Ranks  test, p = 2.0x10‐4, Fig 4.10b). Probes  that 






















250kb  500kb 250kb 500kb 250kb 500kb 250kb 500kb
Number of 
Tests 
930,456  1,850,599 930,456 1,850,599 1,913,342 3,820,148 1,913,342 3,820,148
Number of 
eQTLs
1,529  1,360 2,487 2,178 1,981 1,799 3,226 2,839
Number of 
unique Probes
470  394 765 658 613 536 994 821
Number of 
unique Genes
460  385 753 647 563 491 903 746
Number of 
unique SNPs 





















coeliac  disease  associated  SNPs  in  an  attempt  to  isolate  a  mechanism  for  disease 
susceptibility. To test for this specifically, all coeliac disease associated SNPs, identified from 
the genome‐wide association study  (van Heel, Franke et al. 2007) or the  follow up  (Hunt, 
Zhernakova et al. 2008) were tested for association with gene expression with all the genes 
from  within  the  coeliac  disease  associated  linkage  disequilibrium  blocks.  Genes  were 
considered  to be significantly expressed  if  the median expression  levels  for all  transcripts 
were greater  than  the null distribution of background and  labelling control array probes. 
The only two cis eQTLs that reached significance were within the genes IL18RAP (p = 5.6x10‐
13)  and  CCR3  (p  =  4.8x10‐6).  Two  coeliac  disease  associated  SNPs  (rs917997  and 
rs13015714), which are  in almost complete  linkage disequilibrium (r2 = 0.96, D’ = 1), both 
appeared to significantly affect the expression of the IL18RAP transcript (Figure 4.11). The 
two  SNPs  span a  large  linkage disequilibrium block, 100kb, which encompasses both  the 
IL18RAP  and  the  IL18R1  genes.  The  minor  alleles  from  the  SNPs  that  affect  IL18RAP 
transcript expression are more common  in coeliac disease patients, suggesting  that  these 
individuals have reduced levels of IL18RAP transcripts.  The cis eQTL appeared to operate in 
the opposite direction  for CCR3, where  the minor allele  increased expression. The  top cis 





but  to ensure  the  finding was not a consequence of an unknown SNP,  the  region around 
the probe binding site was sequenced in 20 genomic DNA samples from Dutch individuals. 
No  new  SNPs were  identified.  This  resequencing was  undertaken  by Miss  Gosia  Trynka 
(UMCG, Groningen, The Netherlands).  
 
Both  IL18RAP  and  CCR3  were  only  expressed  in  the  PAXgene  samples, with  almost  no 
mRNA  expression  detected  in  the  B  cell  HapMap  data  (and  hence  no  cis  eQTLs  were 













associated SNP; as  such  it was  investigated  further.  IL18RAP  is a component of  the  IL‐18 
receptor  complex  that  contains  the  intracellular  signalling  cascade  binding  sites.  IL‐18 
treatment of PBMCs  induces  IFNγ secretion, hence  the  former name  for  IL‐18,  Interferon 
gamma inducing factor (Okamura, Tsutsi et al. 1995). To investigate if the observed mRNA 
effect  resulted  in  a  phenotypic  response;  a  panel  of  38  cryopreserved  PBMCs  were 
stimulated  in vitro with αCD3/αCD28 antibody beads and a dose response of recombinant 
human IL‐18, resulting in IFNγ production (Figure 4.12). All samples were genotyped for the 
coeliac  disease  associated  SNPs,  rs917997 &  rs13015714.  All  samples were  identical  for 
both  SNPs.  Results were  normalised  to  untreated,  activated  IFNγ  expression  values  and 
stratified  by  rs917997  genotype  (Figure  4.13). Only  five minor  allele  homozygotes were 
present in the sample. They were excluded to maintain 80% power (>6 for 2 fold change, SD 
1.5). Although a small difference was observed (P=0.0054), in IFNγ expression between AG 
and  GG  genotypes,  this  was  not  seen  upon  use  of  a  dominant  model  of  inheritance 
(P=0.99).  The  difference was  considered  not  significant  on  the  basis  that  the  data was 
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Illumina  gene  expression  microarrays  contain  short,  50mer  probes  that  bind  to 
complementary sequences on transcript cRNA. All the probe sequences lie within the 3’ end 
of the transcript. 2,697 gene transcripts, detectable using the Illumina Ref 8v2 array, have 
differential  splicing  at  the  3’  end,  resulting  in  shorter  transcripts.  As  a  consequence, 
different probe  sequences  can detect different  isoforms of  the  same  gene. A  systematic 
analysis of all these variants identified 97 cis effects that were specific to one isoform of a 
potential  3’  splice  variant,  an  example  is  shown  for  BRWD1  in  Figure  4.14.  The  allelic 
direction of all cis effects was  identical between the PAXgene and the replication HapMap 
datasets; however  it was noticed  that within  several genes  the direction appeared  to be 
inconsistent when the probe sequence differed. This was the case for fourteen detectable 
genes; POLR2J,  IRF5, LOOC400566, MRPL43, DIP2B, OAS1, TIPRL, C17orf81, PAM, POFUT2, 
PTER, MYOM2, AD11, HLA‐DRB5. Within each of  these  there were at  least  two cis eQTLs 










PAXgene  expression  values,  rs2318331  (mapping  within  COL22A1)  and  NBPF3,  and 
rs12634559  (mapping  within  IL1RAP)  and  CASP8AP2.  There  is  no  apparent  connection 
between COL22A1 and NBPF3; however IL1RAP and CASP8AP2 both appear to be involved 
in  apoptosis  pathways.  Neither  effect was  observed  in  the  HapMap  dataset,  even  at  a 
nominal  uncorrected  p  =  0.05.  These  effects  are  therefore  likely  to  represent multiple 
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IFNγ  production  upon  in  vitro  stimulation  of  PBMCs  with  αCD3/αCD28  antibody  coated  beads, 
followed  by  treatment with  IL‐18  (0.1‐100ng/ml),  IL‐12  (100ng/ml)  or  LPS  (100ng/ml).  Error  bars 

























































































































in modern  complex  disease  genetics.  The  study  performed  here  has  demonstrated  the 
utility of peripheral blood RNA  for detection of cis eQTLs and a  strong correlation with a 
replication  (HapMap)  cohort.  The  meta‐analysis  indicates  that  a  significantly  greater 
number  of  cis  eQTLs  could  be  identified  through  an  increase  in  sample  numbers.  The 
majority of cis eQTLs identified were isolated to one dataset, underlying the importance of 
studying  a  relevant  tissue. Although  for  coeliac disease  this  is  likely  to  be  a  gut derived 
leucocyte population such as intra‐epithelial lymphocytes, this is not practical for the large 
sample numbers that would be required. For other diseases, such as obesity traits it would 
be  sensible  to  study  adipose  tissue,  and  for  neurological  disorders  brain  tissue  (Myers, 
Gibbs et al. 2007; Emilsson, Thorleifsson et al. 2008).  
 
When performing  this  type of  study, care must be  taken  to exclude artefacts, as such all 
probes  were  systematically  investigated  for  potentially  false  eQTL  generating  primer 
polymorphisms. This was a particular problem in the older HapMap data, and less so in the 
PAXgene data, presumably as microarray probes have been re‐designed as more SNPs have 
been  identified. For  the  fourteen genes  that displayed differential allelic directions within 
the same gene for different probes, five (POFUT2, PTER, MYOM2, AD11 and HLA‐DRB5) all 
displayed possible primer polymorphisms, and  it  is possible these may have obscured the 
findings.  For  instance  one  allele may  represent  a  genuine  finding, while  the  other  is  a 
primer polymorphism  that affects hybridisation. The  findings  from Kwan et al., however, 
suggest that there are likely to be some real findings (Kwan, Benovoy et al. 2008). For three 
of these genes, Kwan et al. demonstrated that SNPs in very strong LD (r2 = 0.74 – 1) with the 




Although  in  excess  of  2,000  unique  genotype‐gene  expression  effects were  discovered, 
along with some interesting genetic effects, only two findings are so far relevant to coeliac 
disease. The CCR3 finding  is  interesting, although perhaps  less relevant given the  lack of a 
significant  cis eQTL with  the most  significant  coeliac  SNP. The  IL18RAP  region which has 




IL18RAP  transcript.  Although  IL18RAP  is  not  the  only  transcript  in  the  large  linkage 
disequilibrium block,  it  is a  feasible  candidate  for affecting  coeliac disease. The  lack of a 
significant  finding  in  the  in  vitro  cell  culture  probably  reflects  insufficient  sample  size  to 
detect the effect. As future studies are conducted in coeliac disease, these findings can be 
re‐visited  to  investigate  the  function  of  other  SNPs.  Although  the  individuals  used  here 
were coeliac patients, given the common allele frequency of GWA study variants, the data 











the cis eQTL appears to show the associated allele results  in reduced  IL‐18RAP  levels; this 
seems counter‐intuitive. Since  IL18RAP  is a signalling receptor,  this could  lead  to reduced 
signalling through the IL18 receptor in response to IL‐18. Although IL18RAP is detected here 
as  a  change  in  transcript  abundance,  the  complex  regulatory  nature  of  RNA means  it  is 
impossible  to  be  sure  of  the  mechanism.  Alternatively  spliced  transcripts  have  been 




PBMC  study would be an  ideal next  step  to gaining  some  further  functional data  for  the 
IL18RAP association with coeliac disease.  
 
Alternative splicing  is  just one other mechanism by which changes  in genotype may affect 
function. Micro RNA (miRNA) binding to RNA can affect transcription as well as translation 







reported and  this could be  taken as evidence  that  the enrichment of coeliac SNPs  in  the 
data  set  used  here  was  sufficient  to  detect  the  effect  where  other  studies  had  failed. 




Two  problems  that  arise  by  sampling  whole  blood  rather  than  EBV  cells  are  the 
heterogeneous  cell  mixture  and  the  expression  profile.  The  heterogeneous  cell  profile 
allows  the  investigation of  transcripts expressed  in a wider variety of cells; however, rare 
transcripts in less common cell types can be lost. Only transcripts that are expressed can be 
analysed.  This  is  a  problem  inherent  to  any  RNA  study,  and  is  one  of  the  reasons why 
different  studies often  locate different eQTLs. For example,  the  IL18RAP  transcript  is not 
expressed  in EBV B cell  lines, as used  in most genetic genomics studies (Hunt, Zhernakova 
et  al.  2008),  but  it  is  strongly  expressed  in  peripheral  blood.  The  data  presented  here 
provides strong evidence  that genetical genomic studies are efficient  in peripheral blood, 
even  though  they  have  reduced  power.  This  is  easily  observed  in  Table  4.4, where  the 
HapMap data observed almost twice as many cis eQTLs  in a similar size dataset. The most 
likely reason for this is the increased power from the single cell under study. Given the ease 
of  collection  of  PAXgene  samples  a  large  collection  of  in  excess  of  a  thousand  samples 







The  second  is  that  the  tissue under  study must be as biologically  relevant  to  the disease 
tissue as possible. Since epigenetic and  local  cytokine effects will have an  impact on  the 
gene  expression  profile  of  a  cell,  to  gain  an  insight  into  how  gene  expression  variants 
behave when  they  interact with  the environment,  and  in particular  in disease, a disease 
specific  tissue  assay  is  essential.  This  cannot  be  achieved with  this  type  of  study  simply 
because of the large sample numbers needed. In order to use individual cell specific assays, 
a more  detailed  knowledge  of  the  transcriptome  and methylome  of  the  tissues  under 
investigation  are  required.  This  coupled with  a method  of  identifying  genetic  effects  in 




























ability  to  identify  any  changes  in  the  function  of  these  genes  resulting  from  genetic 
variation  is  fundamental  to  the  field of  functional  genomics.  This  is  especially  important 
since  so much of  the biology  governing  the  genes  identified  is unknown.  To  gain  a  true 
insight into the function of the genome, an un‐biased, hypothesis free, base pair resolution 
approach  needs  to  be  taken.  Once  specific  effects  have  been  identified,  then  a  more 
specific, high‐throughput assay can be used to test larger sample numbers.  
 







The human genome project, which provided a near complete  reference sequence  for  the 
human  genome,  was  completed  in  2004  (a  draft  was  published  in  2001)  at  a  cost  of 
approximately $1billion dollars for >99% of the euchromatic portion of the human genome 
(Venter, Adams et al. 2001;  International Human Genome Sequencing Consortium, 2004; 
Bentley 2006). The heterochromatic portion, a  repeat dense stretch of DNA  found at  the 
centromeres and on specific chromosomes,  is still  to be sequenced effectively.  In 2006, a 
large genome centre, with 30 Sanger dideoxy capillary  sequencing machines, would have 
required approximately one year to repeat this sequencing effort for a single individual, at a 
cost of  around $10 million  (Bentley 2006).  In order  for  sequencing methodologies  to be 
feasible for genetic studies, cost and time savings in the region of 1000x to 10,000x would 
be  required  (Bentley 2006). To emphasise  the  importance  that  cost effective  sequencing 
has to the medical genetics community, a prize of $10 million dollars has been established, 
to  be  awarded  to  the  first  team  from  around  the world  that  can  sequence  100  human 
genomes  in 10 days at a cost of  less than $10,000 per genome (Genomics 2007). Modern 












molecule, an achievement  that earned him his  second Nobel Prize  (Sanger, Nicklen et al. 
1977). This technique was an improvement on earlier attempts from the 1970s to sequence 
DNA and RNA, which required extensive use of hazardous chemicals, and quickly fell out of 
favour  (Min  Jou,  Haegeman  et  al.  1972;  Ball  1973; Maxam  and  Gilbert  1977).  Sanger’s 
method, which  so  revolutionised  genetic  research, was  based  on  a  terminating  dideoxy 




radio‐labelled  ddNTPs,  but  this  was  later  refined  to  use  fluorescently  labelled  ddNTPs 
(Smith, Sanders et al. 1986). Once the DNA polymerase had been allowed to sequence the 
DNA under study, the reaction was stopped, the DNA denatured and run on a gel (one lane 
for  each  base).  The  ddNTPs would  randomly  incorporate  into  the  sequence,  and  hence 
randomly stop the polymerase as  it elongates. By exposing the gel to a detection method 
(X‐rays, or  laser excitation as appropriate),  it  is possible to detect the ddNTP  incorporated 
for each DNA fragment size. The further the DNA polymerase gets before it meets a ddNTP, 


















Some  of  the  problems  associated  with  Sanger  sequencing  in  this  manner  include  the 
requirement to have a known sequencing primer site, and the need for a very pure, single 
sequence  DNA molecule  as  input.  Both  of  these  requirements  necessitated  cloning  the 





The  first major  innovating  in  sequencing  after  the  invention  of  the  Sanger  sequencing 
method  was  the  realisation  that  detection  of  the  pyrophosphate  released  during  DNA 
incorporation allowed accurate sequencing (see Figure 5.1b) (Ronaghi, Karamohamed et al. 
1996).  This  technique,  termed  “sequencing‐by‐synthesis”  allowed  real‐time  detection  of 





The  two  sequencing  technologies  described  above  form  the  basis  for  the  three  most 
popular  high‐throughput  sequencing  platforms  currently  available  (2009).  Traditional 
Sanger or pyrosequencing techniques allowed only a single DNA sequence to be assayed at 
once,  severely  limiting  throughput.  The  major  advantage  with  the  high‐throughput 
platforms was  the  ability  to  sequence  thousands  to millions  of  sequences  at  once.  The 





The  Roche/454  platform  was  the  first  high‐throughput  sequencer  to  be  commercially 
available when it was launched in 2005 (Droege and Hill 2008). The technology behind the 








Once  the PCR  reaction has been performed on  the beads,  they  are  added  to  a picolitre 
plate, one bead per well. A standard pyrosequencing  reaction  is  then performed and  the 
results detected. Since each well contains a single bead, and each bead  is covered  in  the 
PCR  amplified  DNA  from  a  single  sequence,  each  well  is  equivalent  to  a  standard 
pyrosequencing  reaction.  A  typical  run  on  a  Roche  454  instrument  generates  400,000 
sequence reads, each up to 250bp in length in about 7 hours (Droege and Hill 2008).  
 
This  equates  to  approximately  0.1Gb  of  sequence  per  day.  The major  advantage  of  this 
system over  the other high‐throughput platforms on  the market at  the  same  time  is  the 
ability to generate long reads. The major technological disadvantage, apart from the lower 
sequence  coverage,  is  an  inherent problem with  pyrosequencing.  Pyrosequencers  find  it 
very  difficult  to  determine  the  exact  length  of  a  homopolymer  read,  where  multiple 




variant  discovery,  or  RNA  sequencing,  where  longer  reads  are  less  useful,  short  read 






emulsion  PCR  based  system  similar  to  the  454  technique  to  amplify  adapter  ligated 
molecules (Mardis 2008). Once PCR has been completed, the beads are loaded onto a glass 
flow cell which  is used  for  the sequencing reaction. The sequencing  itself begins with  the 
annealing of a universal sequencing primer to the adapter sequence attached to the DNA 
molecule of  interest  (Mardis 2008). A set of 8bp, probes then compete for  ligation to the 




























Genome  Sequencer  FLX  Titanium,  The Applied Biosystems  SOLiD  3  and  The  Illumina Genome Analyzer  II.  Pricing data  is obtained  from  (Mardis  2008) but  represents 
previous versions of all three instruments. At current sequencing throughput, the costs have decreased but the relationship between the three companies is equivalent. For 
comparison traditional Sanger sequencing costs approximately $1000/Mb.  

















Maximum Sequence Output  0.4Gb  20Gb  50Gb 
Mb/hour  40Mb/hour  120Mb/hour  500Mb/hour 
Cost/MB  $85  $6  $6 










releasing  the  fluorescence and  leaving a  free 5’ phosphate group  for  the next eight base 
pair probe to bind. This reaction continues until the desired read length has been obtained. 
This sequenced strand  is then removed and the next sequencing primer  is added, but this 
time one base  further 3’  then the  initial primer. This process repeats a total of  five times 
until  each  base  has  been  interrogated  twice  (Biosystems  2009a).  This  is  the  major 
advantage  to  the  SOLiD  system;  the  ability  to  interrogate  each  base  twice  through  the 
dibase binding. The staggered nature of the encoding results in two fluorescent dye signals 
encoding  every  base,  theoretically  allows  an  even  greater  differentiation  of  sequencing 
error  from  true  polymorphisms.  The  Applied  Biosystems  SOLiD  3  system  can  currently 
generate 50Gb of mappable data from a single flow slide (Biosystems 2009b). This equates 







world,  including  the  Sanger Centre  (Hinxton, UK), which  currently houses  thirty  seven of 
these  instruments.  It  is  not,  however,  the  most  high‐throughput,  producing  only  a 
maximum of 20Gb of data (2009) per run (Illumina 2009). This is equivalent to 3x coverage 
of  the  diploid  human  genome.  The  Illumina  technology  (formerly  Solexa)  is  perhaps  the 
simplest  of  the  high‐throughput  sequencing  strategies,  employing  a  technique 
fundamentally similar to traditional Sanger sequencing. The process (Figure 5.2) relies, like 
the other techniques, on adapter  ligated fragmented DNA. This DNA, after being enriched 
by  PCR,  is  added  to  a  flow  cell  which  is  covered  with  oligonucleotide  sequences 
complementary  to  the  adapter  sequences  (Bentley, Balasubramanian  et  al. 2008). When 
the  adapter  ligated  DNA  is  added,  it  binds  to  the  surface  of  the  flow  cell.  A  bridge 
amplification PCR reaction is performed on a specialised cluster station generating millions 
of clonal fragments in clusters across the surface of the flow cell. The sequencing itself uses 
a  reversible  terminator  technology, whereby  after  a  sequencing primer has been  added, 
fluorescently  labelled  ddNTPs  are  added  and  a DNA  polymerase  performs  a  single  base 
extension (Bentley, Balasubramanian et al. 2008). The clusters are then  imaged to  identify 
the  incorporated base. The  reversible  terminator  technology allows  the  fluorescent  label 
and  the DNA polymerase  terminator  to be  removed. Once  this has happed,  the process 
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repeats  for  as  long  as  desired,  typically  36  to  75  times,  yielding  a  36  to  75  base  pair 






The current  systems on  the market will continue  to expand and produce more  sequence 
data  at  a  lower  cost,  but  at  the  same  time,  companies  such  as  Pacific  Bioscience 
(http://www.pacificbiosciences.com/), Oxford Nanopore (http://www.nanoporetech.com/) 
and  ZS  Genetics  (http://www.zsgenetics.com/)  as  well  as  many  others,  are  actively 
researching  novel  methods  of  sequencing  the  genome.  They  aim  to  produce  “third‐






All  three  currently  available  high‐throughput  systems  are  used  for  similar  applications, 
although  some  are more  suited  for  particular  applications  than  others.  Techniques  that 
require greater read length over a shorter area are obviously more suited towards the short 





One of  the most  important areas  for high‐throughput sequencers use has been mutation 
















Regions  first  need  to  be  enriched  over  the  genomic  DNA  by  microarray  hybridisation 
(Albert, Molla  et  al.  2007),  long‐range  PCR  (Porreca,  Zhang  et  al.  2007)  or  in‐solution 
capture  (Gnirke, Melnikov et al. 2009). Other  than new variant discovery, whole genome 
resequencing projects have been undertaken, with  the aim of generating more  reference 
genomes  in  different  populations  and  species  (Wang, Wang  et  al.  2008; Ahn,  Kim  et  al. 
2009).  The 1000  genomes project  is using  a mixture of  short  read platforms  (SOLiD  and 
Genome Analyzer);  the project aims  to generate complete whole genome  sequence data 





Chromatin‐immuno  precipitation  is  an  ideal  application  for  short  read  sequencers.  In  a 
technology named Chip‐Seq, proteins are cross‐linked to DNA which  is then sonicated. An 
antibody to the protein of interest enriches for the bound DNA which is then separated and 

















Microarray  platforms  have  been  the  mainstay  of  whole  genome  gene  expression 
measurements for many years. Using a two colour, or one colour dye system, they are able 
to  quantify  the  number  of  complementary  sequences  that  hybridise  to  a  glass  array 
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covered  in oligonucleotides. However,  all microarray platforms have  inherent  limitations 
(Dufva 2009). The first  is that only sequences present on the array can be assayed, which 
limits the ability to discover new transcripts. Secondly, the  linear range  is severely  limited 
by  the  number  of  probes  for  each  molecule  and  the  background  fluorescence  level 





High‐throughput  sequencers  have  provided  major  advances  in  the  analysis  of  RNA 
sequences.  Firstly  they  allow  a highly powered  serial  analysis of  gene  expression  (SAGE) 
experiment  to be performed. SAGE, originally  invented  for  traditional Sanger sequencers, 
functions by digesting the 3’ end of all transcripts present within the cell population, that 
possess the restriction site, to generate approximately 15bp tags (Velculescu, Zhang et al. 
1995).  These  tags  are  then  sequenced,  quantified  and mapped  back  to  the  genome  to 
identify the transcript. Sanger sequencing can identify thousands of tags in this manner by 
concatenating  them  together; high‐throughput  sequencers can  sequence millions of  tags, 
allowing comprehensive analysis of the expression  level of genes. SAGE  is analogous to 3’ 
microarrays,  in  that  it only  assays  the  3’  end of  each  transcript  although  it does have  a 






While  SAGE  approaches  are  useful  tools  for  the  analysis  of  gene  expression,  the  ideal 
approach would be  to sequence  in a quantitative  fashion  the entire  transcriptome of  the 
cell population. The  large number of  short  reads available  from  the  Illumina and Applied 
Biosystems systems allowed this approach, termed RNA‐Seq to be developed in 2008. This 
technique, allows  the  study of  transcriptional  levels of  individual  transcripts, as well as a 
study of their sequence, splicing and transcription start sites. For example, in a study of the 
yeast  genome,  75%  of  the  transcriptome  was  found  to  be  transcribed  at  some  level 
(Nagalakshmi,  Wang  et  al.  2008),  while  a  similar  study  in  yeast  found  evidence  of 













of RNA‐Seq data with microarray data,  Fu  et  al.  found  that RNA‐Seq  gave  a  significantly 
better estimate of true protein levels from an estimate of transcript abundance compared 






store  the huge amounts of data  that  the machines generate. The  typical data processing 




















Mapping  the generated sequence reads  to  the genome  is not a new problem and can be 
achieve with  readily  available  tools  such  as  BLAST  (Altschul,  Gish  et  al.  1990),  but  this 
approach can be very slow. Each sequence read from the GA II, is accompanied by a phred‐
like  base  quality  value, which  should  be  incorporated  into  the mapping  probability,  not 
something  that  BLAST  can  achieve.  To  enhance mapping,  and  speed, many  researchers 
have generated new mapping  tools which allow  rapid mapping  (less  than a day per  flow 
cell)  with  the  specific  identification  of  polymorphisms  (SNPs,  indels,  large  structural 











a  compression  technique  from  computer  science,  the  Burrows‐Wheeler  transform,  and 
allows the mapping of millions of reads against an entire genome in a matter of hours on a 
desktop PC. This has been  implemented  in  two  independent mapping algorithms, Bowtie 
(Langmead, Trapnell et al. 2009) and BWA, the successor to maq (Li and Durbin 2009). All 
the  alignment  tools offer  slightly different  applications  and methods of parsing  the data 
which ultimately depends on the end application. The best offer gapped alignments of both 












published  to  date  (May  2009)  has  utilised  only  single  end  sequencing.  Paired  end 
sequencing would  give  a much  greater  assessment of  splicing,  allowing both paired  end 
distance and sequence to be taken into account. The ERANGE package of tools (Mortazavi, 
Williams et al. 2008) uses  the  splice  junction  reads  to gain an accurate estimate of gene 
expression  levels  along with  some  information  on  splicing  events.  The  TopHat  package 
(Trapnell,  Pachter  et  al.  2009)  extends  the  use  of  exon  spanning  reads  to  enable  the 
identification of novel junctions, in association with the Bowtie alignment tool. It first aligns 
the  reads  to  the human genome, with no additional exon‐exon  reads. Un‐mapped  reads 
were then aligned to a novel gene splice junction database constructed from a gene model 
derived from genome mapped reads. The only other RNA‐Seq tool that has been published 
is  a  comprehensive  exon  analysis  package,  G‐Mo.R‐Se  (Gene MOdeling  using  RNA‐Seq) 
(Denoeud, Aury et al. 2008). This package does not use any known information about exon 
structure, just genomic  location mapping. It then attempts to build gene models based on 
reads  that  cluster within  the  genome  and  reads  that  span  them. Although  few  software 
packages are available at present, more will become available as more researchers use the 
RNA‐Seq  technique  particularly  when  costs  are  reduced  and  when  the  computing 
requirements are more accessible. At present, however, researchers using high‐throughput 








encoded  in  the  DNA molecule  which  results  in  changes  in  gene  expression  that  is  not 
derived  from  the Watson & Crick base pair  sequence  (Murrell, Rakyan  et  al. 2005).  This 











monozygotic  twins  compared  to  dizygotic  twins,  even  when  adjusting  for  sequence 
differences  (Kaminsky,  Tang  et  al.  2009).  The  authors  suggest  this  result  occurs  as  the 
dizygotic  twins  arise  from  epigenetically  different  zygotes,  which  if  confirmed  makes 





Methylation within  humans  is  controlled  by  a  group  of methyltransferase  enzymes  (e.g. 
DNMT)  that  ensure  methylation  is  copied  during  DNA  replication  (Turek‐Plewa  and 
Jagodzinski  2005).  Within  the  mammalian  genome,  most  CpG  dinucleotide  bases  are 
methylated.  CpG  islands, which  are  500bp  to  5kb  stretches  of GC  dinucleotide  repeats, 
often found in gene promoters, exhibit a degree of regulation upon the genes expression (if 
found  in  the  promoter)  (Turek‐Plewa  and  Jagodzinski  2005).  Promoter  CpG  islands  are 
usually  found  unmethylated  if  the  gene  is  expressed  and methylated  if  the  gene  is  not 
expressed  in  a  cell  (Feil  and  Berger  2007).  Indeed  experimental  methylation  of  gene 
promoters  containing CpG  islands has been demonstrated  to  silence a gene’s expression 
(Stein,  Razin  et  al.  1982).  This  is  the  primary  function  attributed  to  methylation; 
transcriptional  regulation,  but  the  effect  is  affected  by  a  number  of  different  factors 
primarily the association with the histone code. For example, methylated CpG dinucleotide 
sites have been proposed to bind proteins that recruit histone deacetlyases, which remove 
an  acetyl  group  from   histone  tails  resulting  in  closure of  the DNA  structure  around  the 
histone, preventing  access  for  the  transcriptional machinery  and  repressing  transcription 
(Murrell, Rakyan et al. 2005). The same genes are present in every cell in the body, and the 
current theory is that it is these epigenetic mechanisms that determine a gene’s expression. 
It has been estimated  that within a group of 16 diverse human  tissue, about 18% of  the 






microarray  analysis  to  obtain  whole  genome methylation  profiles  but  this  analysis  was 
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restricted  to  known  CpG  or  proposed  regulatory  sites  within  the  genome  and  hence 




analysis of methylated DNA  that  is available, but  it  is  still extremely expensive  for whole 
genome analysis as it essentially requires the sequencing of the entire human genome each 
time. This will be possible in the near future, but it is not yet a reality for the entire human 
genome,  although  it  has  been  applied  to  smaller  genomes  such  as Arabidopsis  thaliana 
(Lister, O'Malley et al. 2008). The second method  involves the use of an enzyme that will 
only restrict DNA  if  it  is unmethylated (e.g. HpaII or NotI) (Down, Rakyan et al. 2008). The 
restricted material is then analysed by hybridisation to a microarray (Ching, Maunakea et al. 
2005)  or  sequenced  (Shen,  Kondo  et  al.  2007)  to  quantify  the  amount  of  cytosine 
methylation at each genomic location. The third method of quantifying DNA methylation is 
immunoprecipitation of  the DNA using  an  antibody  against m5C, with  the  resultant DNA 
then placed on a microarray or sequenced (Weber, Davies et al. 2005; Weber, Hellmann et 
al. 2007; Down, Rakyan et al. 2008). The advantage of the  immunoprecipitation approach 
(MeDip)  is  that  when  combined  with  appropriate  bioinformatic  tools  (e.g.  Batman), 
accurate, cost effective, bias  free methylation  levels can be achieved within  the analysed 
windows  of  the  genome  (Down,  Rakyan  et  al.  2008).  A major  advantage  to  the MeDip 
approach,  however,  is  the  ability  to  combine  it with  high‐throughput  sequencing  in  an 
experiment analogous to Chip‐Seq, where the  immunoprecipitated DNA  is sequenced and 






from  complete.  Even  though more  information  is  being  gained  about which  regions  are 
methylated,  this  is  confounded by  the huge  variation  that exists between  cell  types  and 
ages (Rakyan, Down et al. 2008; Ronn, Poulsen et al. 2008). Promoter methylation is not a 
universal  phenomenon.  Some  unmethylated  genes  are  not  transcribed;  while  some 
promoters have been described to become methylated in differentiated tissues when they 
are unmethylated  in sperm,  indicating a developmental role for DNA methylation (Weber, 
Hellmann et al. 2007; Zilberman 2007). Using microarray data  limits  the  field of study  for 
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genome‐wide  approaches, while  a  transcript’s  expression  level  can  reliably be measured 
from  a  small  50‐80mer  oligonucleotide; methylation  arrays  by  definition  only  assay  the 
genomic areas on the array.  Irizarry et al., using high density microarrays with 4.6 million 
CpG  sites  spread  across  the  genome, were  able  to determine  genome‐wide methylation 
levels at all  known promoters,  combined with gene expression measurements  from RNA 
Pol II binding for the same genes (Irizarry, Ladd‐Acosta et al. 2009). The authors were able 
to  demonstrate  that most  tissue  specific  DNA methylation was  not  located within  CpG 
islands as had previously been determined, but  in regions ~2kb up or downstream of  the 
islands, regions termed “CpG shores”. There was a strong inverse relationship between CpG 
shore methylation  level and gene expression  (Irizarry,  Ladd‐Acosta et al. 2009). The  idea 
that  differential  methylation  could  be  associated  not  with  CpG  islands,  which  have 
previously been assumed to be the regulatory sites, but at an upstream site makes the use 
of  true  genome‐wide  approaches  to methylation  analysis even more  important. There  is 
also some emerging evidence from histone modifications in C. elegans that epigenetic and 




Understanding  of  the  epigenome  is  still  in  its  infancy,  and  the  availability  of  high‐









regulation  (van  der  Maarel  2008).  It  has  been  recognised  for  some  time  that  the 
methylation patters of cancerous  tissues differs considerably  from normal human  tissues, 
yet  the  cause and  the effect of  this are  still unknown  (Wilson, Davies et al. 2006). Using 
genome‐wide microarray approaches, cancerous tissues were found to display widespread 







to  a  poor  understanding  of  the  epigenome within  normal  human  tissues  but  also  do  to 
inherent  experimental  design  problems.  A  genome‐wide  association  study  using 
methylation  rather  than SNPs would be extremely difficult  to design, due  to  the  inherent 
variation  and  plasticity  in  DNA  methylation.  The  cell  type,  insult,  age,  sex  and 
environmental  conditions would  all  have  to  be  controlled within  both  the  case  and  the 
control  groups. Despite  this,  these  studies  are ongoing  and  improvements  in  technology 
and  our  understanding  of  the  genome  and  epigenome will  facilitate  their  utility  in  the 
future. Studies of DNA methylation  in complex disease are  still  in  their  infancy, and  they 




known  to have  in regulating a genes expression,  the effects may be secondary  to genetic 
polymorphisms, with specific haplotypes resulting  in altered methylation patterns,  leading 
to  differential  expression  (Bock,  Walter  et  al.  2007;  Milani,  Lundmark  et  al.  2009)  or 
possibly  other  as  yet  unknown  effects.  If modifications  of  the  epigenome  such  as  these 























from  the  same  individual. Using  this data, a greater understanding of  the biology of  the 




• Establish  the  suitability  of  paired‐end  RNA‐Seq  for  transcriptome 
measurement and develop analytical and quality control methods 



































and with  the addition of 2ug anti‐CD28  (eBioscience, USA)  to  the  incubating cells. 14x106 






to  the manufacturer’s  instructions  (Sigma Aldrich, UK)  for RNA analysis. 2x106  cells were 
lysed  in  300µl  PUREGENE DNA  Cell  Lysis  Solution  after  removal  of  excess  culture media 
(PUREGENE,  Qiagen,  UK,  158745).  The  lysate  was  added  to  a  1.5ml  RNase/DNase  free 
microcentrifuge tube. RNA was extracted using the RNeasy kit as described in Chapter 2.4.  
 
DNA was extracted  from  the  cell  lysate  according  to  the PUREGENE DNA purification  kit 
(PUREGENE, Qiagen, UK,  158745).  Initially,  4.5µl  of  RNase  (PUREGENE, Qiagen, UK) was 
incubated with the cell lysate for 60 minutes at 37°C. 100µl of protein precipitation solution 
(PUREGENE,  Qiagen,  UK)  was  then  added  to  the  sample  and  mixed  thoroughly.  The 
microcentrifuge tube was spun at 13,000g for 1 minute on the Eppendorf 5418 centrifuge. 
In  a  separate  1.5ml  tube,  the  supernatant  was  added  to  500µl  of  isopropanol  (Sigma 
Aldrich, UK) and  inverted 50 times. The tube was subsequently spun for 1 min at 13,000g 
on the Eppendorf centrifuge. The supernatant was removed and replaced with 1ml of 70% 
ethanol,  after  inverting  the  tube  10  times;  the  sample was  spun  again  for  1 minute  at 
13,000g, the supernatant discarded and the DNA pellet allowed to dry for 15 minutes. The 
pellet was  rehydrated  in 50µl of  tissue culture grade water and quantified by Nanodrop. 















Illumina Genome Analyzer RNA‐Seq  libraries were constructed  from 10µg of  total RNA as 
described  in Chapter 2.10. 6µg of RNase  treated DNA was used  to  construct  the MeDip 
libraries. MeDip  library construction was performed by Dr V Rakyan (ICMS, QMUL, UK) on 
one of the three (Individual 14) individuals only. Briefly DNA was sonicated to a size range 






















Linux  Enterprise  edition  v5.3  (Tikanga)  with  256  Gb  shared  access  RAM.  Analysis  was 















Genome  alignment  was  performed  using  novoalign  v2.03.01  (available  from 
http://www.novocraft.com  under  a  commercial  licence  to  DAvH).  The  human  genome 
assembly,  Build  36  (b36),  was  obtained  from  the  1000  genomes  project,  available  at 
ftp.1000genomes.ebi.ac.uk. Novoalign data was parsed  into appropriate  formats  for  later 
data  analysis.  Pileup  data  for  novoalign  alignments  (used  in  quality  control  scripts) was 
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RNA‐Seq  transcript  level  expression  was  determined  by  calculating  the  number  of 
sequencing  reads  that  mapped  per  kilobase  of  the  transcript  per  million  reads.  The 
resultant  statistic,  RPKM, was  used  to  quantify  transcript  abundance. Uniquely mapping 
reads with an alignment quality  score greater  than 10 were assigned  to exonic  locations 
derived from Ensembl v53 (using the ExonExtractor script written by Dr Lude Franke, ICMS, 
QMUL, UK). This  script compiles all known exon  locations  into an  index and  then assigns 
mapped sequenced reads to the appropriate exon. Gene transcript sizes were determined 
as  the  maximum  non‐redundant  length  of  the  known  Ensembl  transcript  including  all 
known splice variants, transcript start sites and 3’ untranslated regions. Gene lengths were 
determined  with  the  aid  of  Dr  Thomas  Down  (Gurdon  Institute,  Cambridge,  UK).    For 





To determine  splice variant mapping, a complete  spliceosome genome was created  from 
the  Ensembl  database.  This  genome  is  based  on  an  idea  proposed  by Mortazavi  et  al. 
(Mortazavi, Williams et al. 2008), who generated a spliceosome genome containing the last 
and  first  portion  of  each  adjacent  exon  concatenated  together  to  generate  a  short 
consensus  exon‐exon  boundary  sequence  (see  Figure  5.5).  For  this  study,  a  new 
spliceosome genome was created from the Ensemble v53 database which consisted of not 
only the first and last portion of the adjacent exons, but every possible exon combination. 



















boundary  compared  to  adjacent,  un‐spliced  exon  boundaries  or  the median  read  depth 














since  exact  start  and  end  positions  could  not  be  determined,  peaks were  extended  or 
shortened  by  the  sequence  read  length. All  appropriate  sequences were  then  identified 
from the Ensembl reference sequence (Build 18, v53) with 5’ and 3’ intronic splice acceptor 








Genome  analyzer  derived  sequence  from  the  MeDip  samples  was  processed  in 
collaboration by Dr Thomas Down (Gurdon Institute, Cambridge, UK). Reads were mapped 
to  the human  reference genome using maq v0.6.8. Data was normalised  for CpG density 




























selected as  they are easily obtainable,  in sufficient numbers and have a direct role  in  the 
pathogenesis of disease. Cells were obtained  from  three  separate National Blood  service 
blood donors, and were cultured  in duplicate for RNA and DNA, resulting  in RNA and DNA 





The  first  step  in  using  large  volumes  of  sequencing  data  derived  from  high‐throughput 







Two  initial quality control  indices were  identified during  the  initial  testing of  the GA  II at 
Barts  and  The  London.  The  first was  spurious  results  from poor  flow  cell  alignment,  the 
second  resulted was poor mapping of  the data due  to  systemic  sequencing  failures  that 
produced poor quality sequence.   
 
The majority  of  the  experiments  listed  here  were  conducted  using  v1  and  v1.1  of  the 
Illumina Pipeline software, including version 1 of Firecrest. A known error in these software 
packages was the miscalling of reflections from the glass flow cell as an A base, resulting in 
homopolymer  A  reads.  This  generated  spurious  alignments  and  resulted  in  poor  quality 
reads. By  locating each homopolymer  ‘A’  read, and  identifying  the position of  the cluster 






















for  each  subsequent  cycle  of  sequencing.  The  resulting  image,  an  example  of which  is 
displayed  in  5.6b,  shows  the  error  rate  of  the  machine  at  each  cycle.  The  Illumina 
specification for the GA II stated that for a run should generate a 1‐2% error rate. The run 
could  then be assessed on  the proportion of  reads  that mapped  to  the genome above a 
specific  quality  score,  a  benchmark  that  can  be  used  for  subsequent  runs  of  the  same 





MeDip  is  an  established  technique with  several  publications  validating  its  use  for  both 
microarray and sequencing analysis (Weber, Davies et al. 2005; Down, Rakyan et al. 2008); 
RNA‐Seq  on  the  other  hand,  at  the  time  of  the  start  of  this  project  (May  2008)  had  no 
publications.  It  was  therefore  essential  to  perform  preliminary  investigations  using  the 
technique. To achieve this, once RNA‐Seq prepped samples had been sequenced, and the 
sequencing  run  had  passed  the  quality  control  checks,  gene  level  RPKM  levels  were 
calculated. Two  samples were also hybridised  to  Illumina Human Ref 6v3 microarrays,  to 
obtain an  independent estimate of expression  levels. To prevent  spurious mappings,  the 
40,233 microarray  probe  sequences were  aligned  to  the  same  genome  as  the  RNA‐Seq 
data,  providing  an  exact  genome  position  for  each  probe. Non‐unique  or multiple  gene 













The  expression  levels  estimates  between  the  two  methodologies  are  significantly 
correlated, but there  is an obvious bias towards under calling of  low expression values on 
microarrays  (Figure 5.7), this  is  likely to be explained by the  improved  linear range of the 
RNA‐Seq  technique. Removing  the probes with  low detection p values  (p < 0.05) had no 
effect on  the  correlation,  indicating  that  the poor  correlation between RPKM values and 
microarrays does not only  result  from  the  background  fluorescence of  the  arrays  and  is 
more  likely  to  be  due  to  probe  saturation  and  an  impaired  linear  range.  In  almost  all 
instances,  the  correlation  was  poor  as  the microarray  under‐called  an  expression  level 
compared to the RNA‐Seq data. The careful re‐mapping of the microarray probes ensured 
that  there was  limited  gene  annotation  bias  in  these  results.  RPKM  data  appears  to  be 





For  each  of  the  three  samples,  with  two  conditions  each,  IL2  and  GUSB  qPCR  was 
conducted  to ensure  sufficient cellular activation prior  to  sequencing. For each of  the  six 
samples,  the percentage of  IL2 expression  relative  to GUSB was calculated  for both qPCR 
and  RPKM  values.  The  values  correlated  significantly  with  a  Pearson’s  correlation 
coefficient of r2 = 0.95. Although this represents only two genes, it suggests that the RPKM 
data also  significantly correlates with qPCR data. RPKM values have  since been  found by 
other authors to agree closely with qPCR measurements and represent a truly quantitative 

























read  count,  as  well  as  the  altered  gene  annotations.  However,  the  biggest  difference 
between  the  two  scripts appeared  to be  in  the gene  size used  for RPKM calculation  (p < 
2x10‐16, r2 = 0.64).  Ideally the sequencing  itself should be used to determine the  length of 
the gene, however,  this  is not possible due  to  the  limited coverage  (<1X) over  the poorly 





A  least  squares  linear  regression was performed with  gene RPKM  from  the  custom  script  against 
gene RPKM derived from ERANGE, only including values with identical gene sizes. The residuals were 
subsequently plotted against the fitted values with an additional linear regression (blue, r2 = 0.00, p = 
1).  Seventeen  (x) genes had  values with  a greater  than  ten‐fold difference  in RPKM between  the 
conditions.    
 
While  the  UCSC  based  ERANGE  script  estimated  the  absolute  length  of  the  reference 
transcript,  the  custom  script  calculated  the  largest  possible,  non‐redundant  gene  length 
estimate based on  all possible  splice  and UTR  lengths.  If only  values with  identical  gene 
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16  and  17,  (the  naming  is  described  in more  detail  in  Chapter  6) with  each  individual 
cultured  in two activation conditions, resulting  in a total of six samples. A summary of the 
read statistics  is presented  in Table 5.2. On average 68% of the reads mapped uniquely to 
the genome with a mapping quality  in excess of 10; an arbitrary and  liberal  threshold  for 
unique,  quality mapping.  Approximately  72%  of  these  reads mapped  to  known  exonic 
locations, with a further 7% mapping to exon‐exon boundaries; the remaining 19% of reads 
mapped to intronic or other genomic locations. An example of the data obtained is shown 
in  Figure  5.10,  where  all  reads  are  shown  for  the  displayed  genomic  regions.  Highly 
expressed genes have an increased number of intronic reads. If RPKM values are calculated 
with  reads mapping within  introns,  rather  than  exons,  a positive  correlation  is observed 
between intronic RPKM values and exonic RPKM values for all genes (r2 = 0.77, p <2x10‐16), 
indicating  an  increase  in  intronic  reads  as  the  expression  level  increases.  These  intronic 
reads  increase  as  expression  increases  due  to  the  corresponding  increase  in  un‐spliced 















Unactivated Activated Unactivated Activated Unactivated Activated
Total RNA‐Seq reads  60,498,407 60,614,543 28,350,669 34,114,888 26,982,637 27,724,313
Mapped reads 32,363,042 40,426,303 21,290,884 24,271,345 18,532,544 19,893,298
Exonic mapped reads  21,820,431 30,008,811 15,227,578 17,600,199 13,791,626 14,622,069
Splice junction mapped reads  2,639,128 3,962,303 2,131,869 2,438,721 2,044,462 2,039,170
 
Total Methylation reads  40,324,586 22,588,540 X X X X










RNA‐Seq data aligned against  the genome. The y axis corresponds  to cumulative  read depth over each base. Reads map predominantly over exonic  regions with some 







follow  a  binomial,  rather  than  a Gaussian  distribution.  To  calculate  the  gene  expression 





two  activation  conditions,  after  a  conservative  Bonferroni multiple  correction  test.  This 
included 7,224 genes which were upregulated and 4,136 genes that were down regulated. 
Genes were ranked based on meta‐analysis p value between the three individuals followed 
by  the median  fold change  induced between  the  three  individuals. The  top  twenty genes 
are displayed  in Table 5.3. The top 250 genes were significantly enriched for gene protein 






One of  the major advantages of RNA‐Seq over  traditional microarray  technologies  is  the 




a chi‐squared or binomial  test  to  investigate  if one exon has a  lower  read coverage  than 
surrounding exons. In collaboration with Rickard Sandberg (Karolinska Institute, Sweden) a 
total of 10,332 exon  skipping events were  identified  in  this manner, of which 78 passed 
multiple  testing  correction.  There was,  however,  a  positive  correlation  (Spearman’s  r2  = 





















CD44  179.5  349.1 0  374.1  513.8  0  274.8  375.4  0 
ENO1  410.3  873.1 0  404.9  810  0  528.8  788.2  0 
ACTB  437.4  1788.0 0  718.3  1319.4  0  883.2  2199.6  0 
HSP90AB1  167.3  412.1 0  218.3  509  0  219.3  414.6  0 
SPOCK2  439.4  358.4 2.6E‐10  494.4  263.8  0  614.2  315.5  0 
CD69  13.4  401.3 0  37.9  597  0  18.1  263.7  0 
NR4A1  6.0  216.6 0  12.5  118.4  0  10.5  303.5  0 
TPT1  2486.3  3062.8 0  2902.2  3231.6  0  3347.3  3245.8  7.6E‐21 
IRF4  7.5  164.3 0  19  230.2  0  18.2  176.7  0 
RPS3  3682.6  3783.5 0  2569.8  3242.4  0  4303.4  3388.7  3.5E‐198 
B2M  1884.7  3905.6 0  3737.5  5298.4  0  3394.9  4436.9  0 
RPL13  4190.8  2235.6 0  1471.6  916.7  0  3062.4  1932.4  0 
EEF2  1216.8  1648.5 0  1769.5  1092.4  0  2297.9  1736.6  0 
RPLP2  13685.3  7382.1 0  5103.2  2895.6  0  8946.4  5897  0 
PLEC1  103.4  75.7 1.5E‐30  169.5  32.8  0  212.2  103.9  0 
HMHA1  252.9  203.8 0.012  317.4  81.6  0  458.1  187.8  0 
ACTG1  274.6  1175.1 0  459.9  897.3  0  684.7  1483.7  0 
MT‐CYB  1740.8  1824.1 0  1723.6  1575.5  4.2E‐06  702.2  1523.9  0 
LOC728688  21231.1  13826.1 0  2826  8851.9  0  4065.2  10116.7  0 









were calculated for each splice  junction,  including both the exonic and the splice  junction 
reads  for  both  the  canonical  transcript  and  skipped  exons.  Only  exon  junction  events 
supported by at  least  two reads were  included. The vast majority of splice  junction reads 
were derived from the reference transcript and adjacent exon splice junctions; only 4.6% of 






unactivated  conditions.  The  cumulative  counts  (normalised  percentage)  of  the  number  of  exons 




To  identify splice variants, the reads over the skipped exon splice  junctions  (splice RPKM) 
were compared to the value to the surrounding counts (gene RPKM), and a ratio of splice to 
gene RPKM values was computed.  If a splice  junction was present  in all  transcripts  in  the 





splice  junctions detected with greater  than  two splice‐junction  reads have been  reported 
here (Wang, Sandberg et al. 2008).  
 
A  very  strong negative  correlation was  evident  (Spearman’s  r2  =  ‐0.90) between  the  log 
ratio of the splice to gene RPKM ratio and the gene expression value. This seems to indicate 
that as a gene’s expression  is  increased,  there  is an  increased chance of  identifying  rarer 
splice  junctions.  The  most  likely  explanation  for  this  phenomenon  is  that  as  a  genes 
transcription  increases, so does the hnRNA. The hnRNA contains  lots of  incorrectly spliced 
transcripts  that  are  targeted  for  degradation  rather  than  nuclear  export  (Hilleren  and 






TopHat  is a novel splice  junction alignment system  that was  released at  the beginning of 
2009  (Trapnell, Pachter et al. 2009).  It  is a comprehensive splice  junction  identifier that  is 
able  to  identify novel  transcripts without  any prior  knowledge  of  gene  annotations.  The 
advantage  it  has  over  exonskipperv10.pl  apart  from  the  speed  of  the  Bowtie  alignment 
algorithm is the lack of a requirement for a spliceosome genome. Although the spliceosome 
genome used by exonskipperv10.pl uses all possible splice junctions, it still relies on existing 
gene  models  to  define  exons.  TopHat  is  the  current  “Gold‐standard”  bioinformatics 
programme  to  identify  splice  variants.  Although  it  was  not  available  for  much  of  this 

















TopHat  identified  72.3%  of  the  exonskipeprv10.pl  identified  exons,  with  the  default 
threshold of greater than two reads crossing this splice site. This percentage was increased 





the  novoalign mapping  software)  identified more  reads mapping  to  the  splice  junction 
boundary. Out of  all 1,916  skipped  splice  junctions  identified by TopHat, only 261  splice 
junctions mapped with both exons in common to the same annotated transcript. Although 
the  pattern  of  splice  events was  similar  between  the  two methods,  only  14.6%  of  the 
skipped  exons  found  by  exonskipperv10.pl were  detected  in  common  between  the  two 
methods. This represents the relative rarity of these junctions, and the reduced number of 






All  three  individuals were  cultured  in  two  conditions, unactivated and after a  three hour 
αCD3/αCD28 activation. Using a binomial  test of difference comparing splice percentages 
between  the  two conditions,  it was possible  to calculate a p value  for changes  in splicing 
after activation even with a short activation.   Within the three samples, there were 1,034, 
1,044 and 1,128  splices  in common between  the  two activation conditions. A  total of 51 
skipped  exon  junctions  passed multiple  corrections  for  individual  14,  no  junction  were 
significant  for  individual 16, and only  three passed  correction  for  individual 17. All  three 
splices  that  passed  correction  for  individual  17 were  also  significant  after  correction  in 
individual 14. These  three splices  (from two genes, STAR and C12orf48) have no known T 
cell  function.  The  genes  from  individual  14,  which  demonstrated  significant  changes  in 
skipped  isoform expression were enriched  for organelle organization and biogenesis gene 
ontology  terms  (GO:0006996 ). Only one of  these  results has previously been  reported  in 
the  literature as associated with T cell activation  induced splicing  (CD6  ‐  loss of exon 5  is 





splicing was  calculated,  this  yielded  65  skipped  exon  junction.  As  individual  14  has  the 
highest read depth across the genome, this  individual was chosen for this analysis. Of the 
65 splices, four demonstrated significant exon splice events after multiple correction in the 
same  direction.  Three  splices  demonstrated  reduced  exon  skipping  upon  activated 










One  of  the  major  advantages  to  using  the  RNA‐Seq  technique,  rather  than  traditional 
microarray based methods for whole genome expression data is the ability to identify novel 

























Individual 14   Activated  52,214  80.3  8.2 
Individual 16   Unactivated  51,050  80.1  10.5 
Individual 16  Activated  49,436  81.0  10.1 
Individual 17   Unactivated  43,351  75.6  10.2 
Individual 17  Activated  44,988  81.0  10.6 
 
Table 5.4: Genome annotation characteristics of novel transcription peaks 
Novel  peaks  of  transcription within  the  genome were  annotated  for  all  samples.  The ORF  (open 












Within  individual 14 a  total of 8,463 and 5,119 candidate new gene  regions  (novel peaks 
joined by splice reads) were identified in unactivated and activated conditions respectively, 
of which  873 were  found  in  both.  There  is  an  inevitable  high  false  positive  rate  due  to 
sequencing and PCR  induced artefacts. There was more agreement between  the samples 
individual  16  (unactivated:  4,418,  activated:  4,029,  both:  1218)  and  individual  17 
(unactivated:  3,967,  activated:  4,178,  both:  1,219).  It  is  possible  the  discrepancies  are  a 
genuine activation induced effect, however, it is more likely to be an artefact of sequencing. 
An example of a novel gene  region  is  shown  in  Figure 5.13. A  conservative  set of  set of 
1,023 new gene regions were identified in common between all unactivated samples, while 










of  Ensembl  transcripts with  the  exception of  6  regions.  Four of  these  regions  appear  to 
represent  repetitive  sequence,  while  the  remaining  two  regions  demonstrate  a  novel 
spliced  gene  (Figure  5.13b)  and  an  alternative  3’  stop  site.  Perhaps  the most  surprising 









Reads  displayed  in  red were  identified  as  novel  transcription  peaks  that  did  not map  to  known 








The  identification  of  the  exons  displayed  in  Figure  5.13b  validates  the  use  of  the  splice 
junction  reads and demonstrates  that  this approach  is capable of  identifying novel exons 
with  genuine  splice  junction  reads.  Novel  regions  within  known  genes  are  difficult  to 











One  of  the major  advantages  of  high‐throughput  sequencing  based  approaches  for  the 
analysis of both RNA and DNA methylation  is  the ability  to  integrate  the datasets with a 
resolution  not  possible  using  standard microarrays.  The MeDip‐Seq  approach  does  not 
require an a priori assignment of the region of study, allowing an unbiased assessment of 
the entire genome. The primary aim of  this experiment was  to profile  the  transcriptome 
and  illuminate  unique  pathways  or  features  that  may  impact  on  the  analysis  of 
autoimmune disease  associated  genetic  variants  in  CD4
+  T  cells  from healthy  individuals. 
The unique nature of  the assays, however, also allowed an  in depth  look at  the  somatic 
human methylome.   
 
The  past  few  years  have  seen  a  fundamental  change  in  the way methylation  is  viewed, 
especially at non‐promoter sites. Due to the limitations of microarray technologies, specific 
regions  of  the  genome  have  historically  been  the  focus  of  methylation  studies;  these 
include promoters and CpG  islands  (Rakyan, Down et al. 2008). These microarray  studies 
repeatedly  identified  a  negative  correlation  between  gene  expression  and  promoter 
methylation,  identifying promoter methylation as a repressive mark (Rakyan, Hildmann et 
al.  2004;  Shen,  Kondo  et  al.  2007). More  recently  is  has  been  possible  to  look  beyond 
promoter  regions where  it was  found  that gene‐bodies were not universally methylated; 




was analysed  in collaboration with Dr Thomas Down  (Gurdon  Institute Cambridge and Dr 













MeDip‐Seq  data was  first  normalised  for  CpG  density  using  the  Batman  algorithm  after 
mapping to the genome (Down, Rakyan et al. 2008) with minor adjustments accounting for 
the  use  of  paired  end  sequencing  reads  rather  than  microarray  intensity  values.  The 
resulting  normalised  methylation  levels  were  analysed  further  in  150bp  windows.  The 
MeDip  values  strongly  correlated  with  CD4
+  T  cell  methylation  data  from  the  Human 



















Genes were categorised  into  three expression  levels  (a‐c)  (RPKM 0, <1,  ≥1) and  three gene  length 
distributions as defined by Ensemble v52 from the transcription start site (TSS) to the transcription 
termination  site  (TTS). Genes with a  size  range between 5  ‐ 20kb were  subsequently  stratified by 
mean  promoter  methylation  levels  (d),  revealing  no  apparent  correlation  between  promoter 




(5  ‐  20kb)  and  long  (20  ‐  100kb).  Although  gene‐body methylation  has  been  described 
previously,  it  has  not  been  examined within  specific  gene  lengths.  Increased  gene‐body 
methylation  was  found  to  be  a  feature  of  all  gene  lengths,  and was  found  to  steadily 
increase from the 5’ to the 3’ end of the gene as RPKM  levels  increased (Figure 5.15 a‐c). 
Promoter methylation  levels  are  known  to  affect  the  expression  levels  of  genes,  and  it 
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all  exons  in  the  genome were  produced,  and  in  agreement with  previous  reports  from 
limited  bisulphite  sequencing  datasets  (Rakyan,  Hildmann  et  al.  2004),  exons  were 
hypermethylated relative to introns. This hypermethylation was remarkably distinct, clearly 
marking the position of the exon  in the genome and was most evident for  internal exons. 
To  investigate  if  this  exonic  methylation  was  related  to  the  gene‐body  methylation, 
methylation data was  stratified by expression  level  for all  internal exons of  greater  than 










with  gene  transcript  expression  for  621  silent  genes  versus  7,581  expression  genes.  The 
idea  that exonic methylation  itself may generate  the preferential gene‐body methylation 









A  similar  feature  to  exonic methylation was  described  in  the  course  of  this  experiment, 
whereby  the  histone mark,  trimethylation  of  lysine  36  on Histone H3  (H3K36me3), was 
reportedly  associated  preferentially  with  the  exons  of  expressed  genes  relative  to 
unexpressed  gene or  introns  in  several model organisms  (Kolasinska‐Zwierz, Down  et  al. 
















long  term mark, while H3K36me3  is  removed,  suggesting a more acute mark. H3K36me3 







methylation  dynamics  observed  here  were  related  to  development,  exonic 
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hypermethylation  was  investigated  in  the  sperm  data.  The  same  pattern  of  exonic 
methylation was observed in the sperm data where exons appeared to be hypermethylated 
relative  to  introns.  A  differential  methylation  analysis  was  then  performed  to  identify 
differentially methylated genes between the sperm and the CD4
+ T cell MeDip data. Using a 
binomial distribution, and a  threshold of a greater  than 30%  change  in DNA methylation 





the expression dynamics of  the exons within  these genes, RPKM values  for genes within 
each set were calculated. To display the expression profile of each exon set (Figure 5.17 a) 
normalised for gene number, the percentiles of the RPKM data was plotted for each group 






than 1 while  in Set 4, 22% of genes had an RPKM of 0  in  the CD4
+ data and 43% had an 
RPKM  greater  than  1.  This  is  likely  to  be  an  under‐representation  of  the  true  effect  of 
differential  methylation  as  only  a  single  somatic  tissue  has  been  analysed.  A  study  of 
further somatic tissues demonstrates how variable expression can be. Using tissue specific 
RPKM  values  (obtained  from Dr  Rickard  Sandberg with  thanks)  for  nine  somatic  tissues 












below  those  of  Sets  1  and  4,  indicating  a  role  for  silencing  in  CD4
+  T  cells  of  genes 
hypomethylated in sperm. Genes within Sets 2 and 3 are generally small (average size 5kb) 
and  are  strongly  enriched  for  CpG  islands  (TAD  p  <  5x10‐9).  A  gene  ontology  analysis 













Set  2.  The  sperm  genome  is  substantially  less methylated  compared  to  somatic  tissue, 
possibly  to  protect  from  spontaneous  deamination mutations  which  convert  m5C  to 
thiamine, but as a result almost all the CpG islands are completely unmethylated (Holliday 
and  Grigg  1993;  Illingworth,  Kerr  et  al.  2008).  Non‐promoter  CpG  islands  have  been 
identified previously and have been suggested to account for approximately 50% of all CpG 
islands  in  the  genome  (Rakyan  and  Beck  2006;  Illingworth,  Kerr  et  al.  2008).  The  exact 
function of these non‐promoter CpG islands is unknown, but they appear to function in the 
same  manner  as  promoter  CpG  islands  to  suppress  transcription.  As  these  genes  are 
enriched  for  developmental  genes,  it  is  reasonable  to  suggest  that  these  genes may  be 
silenced  during  development  by  methylation  of  regulatory  CpG  sites  within  the  exons 

























similar  analysis was  conducted  on  the methylation  and  expression  data  obtained  for  an 
Arabidopsis  thaliana  data  set  produced  by  Lister  et  al.  (Lister,  O'Malley  et  al.  2008). 





correlation  between  gene  expression  and  exon  specific  hypermethylation  that  was 
observed for the majority of CD4
+ T cell exons was also observed in A. thaliana, and appears 









> 0. Mean methylation profiles were  constructed  for both gene  categories with a  range  including 
250bp  upstream  and  downstream  of  exons.  Exonic  hypermethylation  is  clearly  evident  in  the 










individual;  however,  as  cells  are  available  in  both  activated  and  unactivated  forms,  it 
became possible to identify regions of differential methylation between the two conditions. 
A  total  of  526  regions  (calculated  based  on  1,000bp  windows)  displayed  evidence  of 
differential methylation  levels between  the  two  conditions with  a minimum methylation 
change  of  30%  (Down,  Rakyan  et  al.  2008).  Of  these  regions,  156  mapped  within  67 
different  gene  open  reading  frames.  There  was  no  correlation  between  differential 
methylation and differential expression between the two samples (Pearson’s r2 = 0.02). One 
interesting gene, however, was identified as a result of this analysis. The IL17F gene, found 






Two  tracks  from  the  Ensembl  genome browser, depicting  the  region  around  the  IL17F  and  IL17A 
genes. The six tracks below the genome demonstrate the relative methylation levels (from Batman) 
(Down,  Rakyan  et  al.  2008)  in  150bp  blocks.  The  colours  range  from  completely  unmethylated 
(yellow)  to completely methylated  (blue). The  two  tracks  from sample 14 are derived  from MeDip 
Seq and are hence genome‐wide, while  the other  two  samples are  from a  custom promoter/CpG 
array. 
 
Within  unactivated  cells,  which  display  little  IL‐17F  production  the  promoter  region  is 
heavily unmethylated (RNA‐Seq RPKM = 0), when the samples are activated however, (RNA‐




microarrays  to measure methylation  levels within  promoter  and CpG  sites  (Figure  5.19). 
This  is  in contrast to conventional wisdom, and appears to be  in contrary to the observed 
pattern  at  IL17A  for  sample 14.  The  lack of  a direct  correlation  for  all  samples between 
promoter  methylation  and  gene  expression  changes  probably  represents  the  complex 








for  the  analysis  of  the  transcriptome.  Although  the  technique  still  has  some way  to  go 
before  it  is completely adopted as  the  transcript assay of choice  it  looks  like a promising 
candidate.  Future  studies  such  as  a  thorough  quality  control measurement  of  transcript 
abundance with many replicates on different machines (analogous to MAQC (Shi, Reid et al. 
2006)) need to be carried out before  it gains a more widespread use  in the  literature. The 
technique is capable of detecting both novel and alterations in alternative splicing as well as 
novel regions of  transcription. The analyses performed  in  this chapter demonstrates both 




sequencing data here are now used  routinely  in  the  lab and genome centre  to assay  the 
quality of the run and anecdotally appear to function well. Most of the data produced here 
in  2008/2009 was  produced  at  the maximum  capacity  of  the machine  at  the  time,  the 
almost  exponential  increase  in machine  capacity,  however, means  it  is  now  possible  to 
generate significantly more data  from  less runs on    the machine. The  longer read  lengths 
(100bp  reads  are  now  possible) would  significantly  enhance  the  ability  to  identify  splice 






biology;  this was  achieved  in  several ways.  After  the  tools  had  been  validated,  through 






however,  due  to  the  RNA  intensive  nature  of  the  RNA‐Seq  technique  and  the  need  to 
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preserve  RNA  for  future  studies  (see  Chapter  6)  this was  not  possible,  although  it will 
hopefully be possible in the future.  
 
An  extensive  search was undertaken  for novel  regions of  transcription with  the hope of 
finding  novel  T  cells  genes  that may  explain  some  of  the  genetic  association  signals  for 
coeliac disease (and other autoimmune diseases) seen within gene desert regions. Although 
a  large number of  transcription peaks were  identified, many  represented  read  towers  (a 
PCR  artefact  where  the  same  transcript  is  amplified  over  and  over  again)  or  unknown 
heterochromatic repeats (repeats not present in the reference genome). After exclusion of 
these phenomena, several novel  regions  remained, although  the majority mapped within 
the open  reading  frames of genes. The  strong  correlation between  the number of  these 
peaks and  the gene RPKM  suggests most of  these are  introns  retained  in heterogeneous 
nuclear RNA. It is possible, however, that they may be derived from novel exons, alternative 
transcription  start  sites,  anti‐sense  transcripts  or  micro‐RNA  precursors,  but  a  direct 
analysis of each of these is very difficult with the existing data. It is now technically possible 
(although  still  unpublished)  to  generate  strand  specific  RNA‐Seq  data  for  the  Illumina 
Genome  Analyzer,  this may  aid  in  the  identification  of  these  features.  It  is  difficult  to 
validate  the  novel  peaks  identified  here,  however,  the  identification  of  the  novel  gene 







identified  as  alternatively  spliced  or  associated with  novel  regions  of  transcription.  The 
autoimmune associated gene CD6  (associated with  susceptibility  to multiple  sclerosis  (De 
Jager,  Jia  et  al.  2009)) was,  however,  identified  as  an  alternatively  spliced  gene, which 
demonstrated  an  increased  splicing  upon  T  cell  activation,  a  similar  finding  has  been 
published by Castro et al. in rats and humans under different activation conditions (Castro, 
Oliveira  et  al.  2007).  This  could  have  implications  for  the  association  signal,  although  a 
thorough analysis of the  linkage disequilibrium block of the association would be required 
as well as a functional analysis of the association between genotype and splicing. Although 







evolutionarily  and  developmentally.  This  exonic methylation  is  preferentially  associated 
with expressed genes. The function of this methylation  is unknown, and  it may be related 
to  alternative  splicing patterns by providing  a marker  for  the  locations of  exons.  Indeed 
several protein  components of  the  splicing machinery have been  shown  to bind  to both 
methylated DNA  and  the  sequence  characteristics  that  surround  exon‐intron  boundaries 
(Klose,  Sarraf  et  al.  2005;  Young, Hong  et  al.  2005). How  this  exon  specific methylation 
appears  in  the  first  place  is  an  interesting  question,  especially  given  the  notable  exonic 
hypermethylation seen within silent genes. An obvious answer to this is that at some point 
in  the  individual’s development,  the genes were active, and  the methylation marks have 
remained.  This  seems  an  especially  logical  option  given  the  lack  of  a well  characterised 
human m5C demethylase, allowing the DNMT enzymes to copy the methylation with each 
subsequent  cell  division  and  differentiation    (Patra,  Patra  et  al.  2008).  The  exonic 
hypermethylation data, combined with the RNA‐Seq technique would be a very useful tool 




difficult.    When  averaged  over  the  genome  many  inconsistent  results  were  observed, 
however,  individual  loci  appear  to demonstrate  interesting patterns. Perhaps one of  the 
most  interesting  findings,  identified with no prior knowledge, and without  looking at  the 
individual  loci, was  the  unique methylation  pattern  around  IL17F.  Conventional wisdom 
dictates that when a gene’s promoter is methylated, the expression of the gene should be 
reduced.  At  this  gene’s  promoter,  however,  the  expression  appears  to  increase  upon 
activation, despite an increase in methylation at the promoter. The reasons for this are not 
apparent,  and  the  lack  of  a  cell  number  control  after  three  hours  makes  precise 
interpretation difficult  (although  little expansion would be expected after  three hours of 
culture).  It  is possible, however,  that  in  the majority of  cells  there  is  repression of  IL17F 
transcription upon activation, with corresponding methylation, but  in a small  subset  (e.g. 






This  does,  however,  represent  another  unique  aspect  of  the  genome  and  demonstrates 
that even as some parts of the genome are understood, others still generate challenges, it 
also  shows  the  importance  of  the  tissue  under  study  as  even  CD4
+  T  cells  are  a 
heterogeneous cell type.    
 
In conclusion  the data presented here powerfully demonstrates  the ability of RNA‐Seq  to 
act  as  a  quantitative measure  of  transcript  abundance,  detect  splice  variants  and  novel 
transcription  regions. The  large  linear range allows a unique  integration with methylation 
data sources allowing novel biology to be identified within the genome. Although RNA‐Seq 
could  now  be  used  in  a  genetical  genomics  style  experiment  to  identify  genotype‐gene 
expression correlation, this does not make use of the base pair resolution of the RNA‐Seq 
data. A more powerful approach would be to  investigate allele specific expression directly 























Given  the  recent  advances  in  the discovery of  genetic  variants  associated with  common 




genome,  it  is  logical  to  look  for  possible  regulatory  effects;  such  as  an  effect  on  gene 
expression.  The  exact mechanism  for  the  SNPs  effect  on  gene  expression would  not  be 
elucidated by  this approach, but  it gives a  starting point  for  further  study. The approach 
adopted by most groups has been to use genetical genomics; as used in this thesis (Chapter 










problems  with  this  genetical  genomics  design  including  the  widespread  use  of 
lymphoblastoid  cells,  the  technical  limitations  of  microarrays  and  the  inherent  inter‐
individual  variability.  Lymphoblastoid  cells  gained popularity  for  these  studies  in part  for 
their ease of use. Many laboratories used these cells to maintain DNA stocks on individuals 
for  genotyping  purposes,  so  they were  readily  available  for  other  functional  studies.  It 




































the  maternal  or  paternal  allele  (Reik  and  Walter  2001).  Imprinting  is  defined  by  the 
methylation status of the parental germ cell, which transfers the ubiquitous mark through 






differentiated  from  truly  imprinted  loci  as  it  does  not  appear  to  be  inherited.  This 





2),  in  many  cell  types  and  tissues,  with  particular  emphasis  on  the  lymphoid  system 
(Rajewsky  1996; Hollander,  Zuklys  et  al.  1998). Unlike  imprinted  genes,  the  inactivation 
appears  to  occur  randomly  on  either  the  paternal  or maternal  strand,  and  seems  to  be 
confined to a specific subset of cells, e.g. some T cell subsets display monoallelic expression 
of  IL‐2 while  others  do  not  (Chess  1998; Rhoades,  Singh  et  al.  2000).  In  a  recent  study, 
Gimelbrant et al. used SNP genotyping arrays to assay the  level of monoallelic expression 
within  EBV  transformed  cells  and  estimated  that  up  to  7.5%  of  genes  displayed  this 
phenomenon  (Gimelbrant,  Hutchinson  et  al.  2007).  Although  the  function  of  this 






Rather  than  using  hundreds  or  thousands  of  individuals  and  searching  for  eQTLs,  it  is 
possible  to make  use  of  an  alternative  experiential  design.  A  quantitative  difference  in 
transcript  expression  between  maternal  and  paternal  alleles  has  been  measured  in 
individual  samples  for  several  years  now,  and  has  been  demonstrated  to  be  a  strongly 
heritable trait (Yan, Yuan et al. 2002; Yan and Zhou 2004). With similar methodology to the 
examination of monoallelic expression,  it  is possible to  identify quantitative differences  in 
the  levels  of  two  alleles.  This  assay, which  looks  for  an  allelic  imbalance  termed  allele 
specific expression (ASE) was initially designed to use a combination of PCR and differential 
primer  extension  (Bray,  Buckland  et  al.  2003),  but  more  recent  methods  have  used 
microarray  based  approaches  or  mass  spectrometry.  Lo  et  al.  used  a  standard  SNP 




two  alleles.  A  genomic  DNA  control  is  required  to  control  for  differences  in  sequence 
binding  context  for each  SNP  (Lo, Wang et  al. 2003). This  approach has been utilised  to 
quantify ASE  in white blood cells (Pant, Tao et al. 2006) and  lymphoblastoid cells (Pollard, 
Serre et al. 2008). Although  the direct measurement of  the  two alleles at  the same  time, 
from  the  same  individual,  eliminates  the  inter‐individual  variability  seen  in  genetical 
genomics  studies,  there may  still  be  errors  induced  by  differences  in methylation  state, 
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circadian  rhythm  and  the  tissue  site  studied  (Bell  and  Beck  2009).  Studies  using  this 






Beck  2009;  Verlaan,  Ge  et  al.  2009).  Although  these  have  been  partially  overcome  the 
approaches are still  limited by the  linear range of the microarrays and the  limited number 
of pre‐designed SNPs that can be assayed. 
 
A  separate  and  novel  application  for  the  measurement  of  allele  specific  transcript 
expression  is  an  approached  termed  haplo‐ChIP  (Knight,  Keating  et  al.  2003).  The major 
advantage this approach has over the RNA based methods  is the ability to efficiently gain 
data  from all positions  in  the genome where Pol  II  is bound, not  just  from  the expressed 
exons.  Using  a  combination  of  chromatin  immunoprecipitation  of  phoshorylated 
(elongating) Pol II and mass spectrometry the authors were able to demonstrate that it was 
possible  to not only distinguish between  the  two alleles of a known  imprinted gene, but 
also that it was possible to generate quantifiable data for an allelic transcription imbalance 
at  another  locus  (Knight, Keating et  al. 2003; Knight, Keating et  al. 2004). This  approach 




methylation may  play  a  role  in  some  instances. Methylation  of  the  CpG  rich  promoter 
regions of ASE genes has been suggested to correlate with the propensity for the gene to 
display  ASE  (with  ASE  genes  having  more  variable  CpG  methylation  states)  (Milani, 
Lundmark et al. 2009). Monoallelic expression detection  is  limited by the sensitivity of the 
detection method and despite  its widespread  identification  in  the study by Gimelbrant et 
al., Milani et al. identified only two genes that displayed consistent monoallelic expression 
(Gimelbrant, Hutchinson et al. 2007; Milani, Lundmark et al. 2009).  It  is possible  that  the 
majority of genes identified as expressed from a single allele so far are in fact differentially 
expressed, but the methods used have not been sensitive enough to detect the alternate 






High‐throughput  sequencing holds great promise as a  tool  for  the  identification of allele 
specific  expression.  Since  the  transcriptome  sequencing  technology  re‐sequences  each 
haplotype separately, it should theoretically be possible to identify each allele at an exonic 
heterozygous SNP and  then quantify  the differential expression of  the  two alleles  (Figure 
6.1). The SNP  that  is  typed  in  the exon  can act as a  tagging SNP  for an entire haplotype 
which can then be resolved through further functional studies  if an effect  is  identified. At 
present RNA‐Seq using poly(A) is limited to assaying marker SNPs located within exons, but 
it  is hoped that advances  in sequencing technology will also allow  intronic SNPs to also be 
used  in these assays. This experimental methodology has not been attempted before and 
given  the  limited  number  of  publications  involving  RNA‐Seq  as  a method  the  assay will 
inherently  be  subject  to  as  yet  unidentified  biases.  The  enhanced  linear  range  over 
microarray technology (Chapter 5.3.1) coupled with the ability to interrogate the sequence 
directly  enhances  this  technology’s  usefulness.  Cost  is  also  significant  factor  in  this 













allele  specific  transcript abundance using digital gene expression  (Guo, Yang et al. 2008). 
This severely limits the application of the technology as only the SNPs in the last 18‐20bp of 
transcripts containing  the enzyme digestion site can be assayed.  In the  future sequencing 
based transcriptome methodologies (Digital Gene Expression or Whole Transcriptome) are 
likely to overtake microarrays as the standard for genetical genomics in large sample sizes, 
but only once  the costs are comparable. Using ASE  is a cost effective method  to use  the 
same  data  to  assay  transcript  variability  whilst  also  controlling  for  inter‐individual 
variability. As ASE limits the effects of inter‐personal variation, fewer samples are required 
to  detect  an  effect,  thus  allowing  a  greater  amount  of  cellular manipulation  including 
isolation of specific cell subsets and stimulations.  
 
Several  studies  using  high‐throughput  sequencing  of  the  transcriptome  were  published 
whilst this experiment was in progress, many of them concentrated on genomic imprinting. 
In a survey of over 5000 genes (with sufficient coverage from a single  lane of the Illumina 









be  necessary  to  locate  twenty  people,  all with  the  same  genotype  (heterozygous)  at  a 
specific marker SNP. This can be done by screening a panel of population samples,  in the 
hope of obtaining enough samples (Chapter 3), but this becomes increasingly difficult as the 













al. 2009). All Bio Bank efforts, especially  those not designed  for a  specific  study, have  to 
consider the ethical and  legal  issues of storing huge numbers of anonymised samples and 
ensure that careful  informed consent  is obtained.   Smaller scale Bio Bank projects such as 
the  Cambridge  Bio  Resource  (http://www.cambridgebioresource.org.uk/)  have  more 
specific aims. They aim to recruit volunteers for specific assays such as imaging techniques, 
or  a  blood  donation  for  extraction  and  direct  culture  and  phenotyping  of  cells.  These 
smaller scale studies often have the ability to recall individuals with a defined trait subject 
to  their  consent.  The  ability  to  use  donors with  a  defined  genotype  is  essential  for ASE 
measurement.  The  cost  of  extracting  and  culturing  and  stimulating  individual  cell 
populations necessitates only collecting samples with the required genotypes.   The ability 




























columns  (Qiagen,  UK)  as  described  in  Chapter  2.4.  PBMC  samples  with  appropriate 
genotypes  were  obtained  from  the  Cambridge  BioResource 
(http://www.cambridgebioresource.org.uk/  administered  by  Professor  John  Todd,  CIMR, 
UK). CD4
+ samples were isolated from BioResource samples though negative selection with 




















Sequence  capture  of  cDNA  was  performed  in  a  proof  of  principle  experiment,  on  a 
leucofilter derived sample. Two sequence capture libraries were generated, a gDNA library 
and  a  total  RNA  library  as  described  in  Chapter  2.10.  After  generation  of  the  RNA‐Seq 
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libraries,  1µg  of  each  library  was  hybridised  to  a  Nimblegen  sequence  capture  chip. 
Hybridisation was carried out as defined in the Nimblegen Sequence Capture user guide v1.  
 
After  quantification  and  size  control  of  the  libraries  on  the  Nanodrop  (Nanodrop 
Technologies,  USA)  and  the  Agilent  Bioanalyzer  DNA  7500  (Agilent,  USA),  1µg  of  each 
library  was  added  to  100µg  of  Cot1  DNA  (Invitrogen,  UK,  15279‐011)  in  a  1.5  ml 
microcentrifuge tube. The samples were dried down using a vacuum centrifuge set a 60°C 
(DNA  Concentrator,  VWR,  UK)  to  remove  all  liquid  prior  to  rehydration  with  4.8µl  of 
molecular  biology  grade water  (Sigma  Aldrich, UK, W4502).  The  rehydrated  sample was 
vortexed and briefly spun down on an Eppendorf 5417R Mini Centrifuge with a FA45‐30‐11 
rotor  (Eppendorf, UK).  The  sample was  then  incubated  at  70°C  for  10 minutes.  To  each 
sample  was  added  8µl  of  2x  Hybridisation  Buffer  (Nimblegen,  USA)  and  3.2µl  of  SC 
Hybridisation Component A (Nimblegen, USA). After vortexing and briefly centrifuging the 
samples  they  were  incubated  at  95°C  for  10  minutes  and  then  stored  at  42°C  in  the 




array  containing  oligonucleotides  (60‐100mer)  complementary  to  non‐repeat  regions 







The  regions  were  designed  to  completely  cover  the  entire  linkage  disequilibrium  block 
around the associated  loci (determined from HapMap CEU samples).  In total 79.8% of the 
regions could be  tiled;  resulting  in a  total of 1.27Mb of  the  targeted  regions  tiled on  the 
array  in addition to four  internal control regions. Each base of sequence was covered by a 







sequentially  in PAP  tubes  (Evergreen Scientific, USA, 222‐5450‐G8S). After  removal of  the 
mixer component, the array was submerged in SC Wash Buffer II (Nimblegen, USA) heated 
to 42°C. The array was then placed in a PAP tube containing SC Wash Buffer II (Nimblegen, 
USA) also heated  to 42°C. The  tube was  inverted 10  times and  the array  transferred  to a 
new tube containing 32mls of Stringent Wash Buffer (Nimblegen, USA) at 47.5°C. The tube 
was inverted 10 times and incubated at 47.5°C for 5 minutes before inverting a further 10 
times. This stringent wash was  then repeated a  further  time. The array was  then washed 
sequentially  in  SC Wash  Buffer  I,  II  and  III  (Nimblegen, USA) with  a  2 minute  inversion 
between each wash. The DNA was eluted  in 900µl of Elution Buffer (Nimblegen, USA) and 
450µl of H2O (Sigma Aldrich, UK, W4502) within the Elution Station. The Elution Station was 































To  account  for  the  paired  end  nature  of  the  data,  and  to  enhance mapping,  a  custom 
genome was generated in collaboration with Dr Vincent Plagnol and Dr Barry Healey (CIMR, 
Cambridge, UK). This genome was derived  from Ensemble v52 and contained  the  longest 
transcript  for  each  annotated  gene  (the  CCDS  consensus  sequence, 
http://www.ncbi.nlm.nih.gov/projects/CCDS/CcdsBrowse.cgi,  if  available).  The  transcript 
used contained the maximum number of exons of all annotated transcripts for a gene, but 
the major  spliced  transcript was  also  included.  To  this  genome,  a  single  sequence was 
added per  intron,  extending  40bp  (read  length minus  five base pairs)  into  each  exon  to 




spliced  transcripts.  The  reference  human  genome  was  then  added  with  any  previously 
included bases masked with an “N” base. The reference genome was also masked to ensure 







Reads  were  mapped  to  the  genome  using  novoalign  v2.05  (Novocraft  Technologies, 
Malaysia) in paired end mode. Various mapping setting were used throughout as described 
in Chapter 6.3. A quality  read was defined by an alignment quality  score greater  than or 
equal  to  20  and  a  Phred‐like  (Li, Ruan  et  al.  2008) base quality  score  (derived  from  the 
Illumina Pipeline or calibrated by novoalign as appropriate) greater than or equal to 20. The 
estimated mapping error is 1 read in every 100 mappings. Pileup files were generated using 
the  novoPile  v1.23  tool,  available  from  http://www‐
gene.cimr.cam.ac.uk/vplagnol/software.shtml).  Reads  with  greater  than  five mismatches 








A  chi‐squared  test  was  performed,  at  each  sequenced  SNP  locus,  between  the  alleles 
identified in the forward and reverse directions for each base position. If the p value for this 








For  read  positions  that  exceeded  the  quality  checks  described,  allelic  imbalance  was 
calculated using a custom Perl  script and R Scripts. The p value  for allelic  imbalance was 
calculated  using  a  binomial  distribution,  comparing  the  read  counts  for  the minor  and 






























(to  degrade  the  excess  the  primers)  followed  by  heating  to  80°C  for  10  minutes  (to 
denature  the enzymes). The product was  cleaned up with a  sodium acetate and ethanol 
precipitation. 2µl of the cleaned up sample was then sequenced on an ABI 3730XL (Applied 
Biosystems, UK). For FAM118A, ATHL1 and CALM3, the gel extracted PCR product was used 
without  SAP/EXO  cleanup.  The  ratio  of  each  allele was  then  calculated  at  heterozygous 








cells  (Chapter  5).  Since  a  genetical  genomics  style  experiment  using  high‐throughput 
sequencing, with hundreds of  samples,  is not  a  cost‐effective experiment  at  the present 
time,  alternative  strategies  were  designed  to  investigate  the  function  of  possible  GWA 
study associated variants. Whole transcriptome RNA‐Seq data is ideally suited to the study 
of ASE  since  it has a  large  linear  range and generates base pair quality data.  In  theory  it 
should be suitable for the identification of ASE with fewer artefacts and at more SNPs than 






To  confirm  the  viability  of  the  leucofilters  for  use  in  these  experiments  (and  indeed  for 
those described  in Chapter  5),  several  investigations were  undertaken on  the  leucofilter 
products  themselves. These were designed  to confirm  that  the cells  from  the  leucofilters 
had not been excessively activated as a  result of  contact with  the  filter membrane,  that 





In  the  first  experimental  use  of  leucofilters,  a  variety  of methods were  used  to  extract 
isolated CD4
+ cells. These included positive selection beads (Invitrogen, UK), MACS negative 
selection  beads  (Miltenyi  Biotech,  UK)  and  red  blood  cell  rosetting  negative  selection 
antibodies (Rosettesep, Stem Cell Technologies, Canada). The Rosettesep technology (Stem 











two  sources,  a  buffy  coat  fraction,  derived  from  a National  Blood  Service  donor,  and  a 
leucofilter, derived  from a  separate National Blood  Service donor. Both PBMCs and CD4
+ 
cells  were  cultured  for  22  hours  in  the  presence  of  various  quantities  of  αCD3/αCD28 
antibody coated T cell activation beads. The results, shown in figure 6.2, demonstrate that 





despite  maintaining  membrane  integrity  to  Trypan  Blue.  The  CD4
+  component  does, 
however,  appear  to  still  function  normally.  This  agrees  with  data  from  other  users  of 
leucodeletion  filters  who  were  also  able  to  obtain  functional  CD4








+ cells. A variety of doses of antibodies were  tried, as shown  in Figure 6.3. As  the 
amount of antibody was raised, the concentration of cells obtained fell as the targeted cells 







quantity  of  pure  CD4
+  T  cells,  the  activation  conditions  were  optimised  to  generate  a 
uniform activation in all samples. For this reason the CD3 antibody clone OKT3 was chosen, 
since  the  other  available  CD3  clone  (UCHT1)  has  been  demonstrated  to  only  stimulate 









































Two  leucofilter  sample  derived  CD4
+  cells  were  cultured  for  differing  times  in  the  presence  of 









a  three  hour  incubation was  chosen  for  all  further  studies within  this  experiment.  The 
maximal IL‐2 response was a proxy measure of maximum cellular activation. For the study 
of  cytokines  such  as  IL‐21  these  conditions  would  need  to  be  re‐optimised.  Once  an 
optimum time for activation had been achieved (3 hours), the next step was to achieve the 
maximum activation possible activation through modulation of the CD3 dose. To achieve a 
uniform  activation,  on  different  days,  CD3  antibodies  were  immobilised  on  plates  for 
activation, with the addition of soluble CD28. This enabled greater control over the number 
of  antibodies  in  contact with  each  cell  than  antibodies  immobilised on beads purchased 








concentrations with  the addition of CD28  (2µg/ml)  for  two  leucofilter samples  (L1 & L2). RNA was 
extracted  and qPCR was  conducted  for  IL‐2  and  IL‐21  transcripts  relative  to  β‐actin expression. A 








candidate  individuals to sequence, since  it was  in an exonic  location within a gene region 
that  had  been  associated with  both  T1D  and  coeliac  disease  (although  at  different  loci) 
(Smyth, Plagnol et al. 2008). IL‐2 is also an abundantly produced cytokine from CD4
+ T cells 
that  could  be  studied  relatively  easily.  ASE  is  theoretically  good  at  assaying  genes with 
considerable  inter‐personal variation, caused by genetic and epigenetic  factors outside of 
the  region of  interest.  To  see how much  variation  there was  in  IL‐2 production within  a 
panel  of  individuals,  identical  numbers  of  CD4
+  T  cells  (2x107)  from  18  individuals, with 
similar  viability  and  purity  estimates  (>90%  and  >95%  respectively),  were  activated  for 
three hours and IL‐2  levels were measured. The results, shown  in Figure 6.6, demonstrate 
the  considerable  variation  in  IL‐2 production between donors.  The  greater  than  ten‐fold 
differences seen have no association with genotype at the exonic T1D associated IL‐2 SNP 
under  test  (rs2069763,  p  >  0.05). Due  to  the  considerable  variation  at  the  IL‐2  locus,  a 
population based approach to  identifying genetic variants that may be affecting transcript 
expression  levels  is unlikely to be successful without very  large sample numbers. The ASE 
approach, however, should be an effective means of  identifying which effects are due  to 






and  αCD28  antibodies)  in  culture. All  cells were  cultured  in  parallel. RNA was  extracted  and  IL‐2 
levels were measured relative  to GUSB. Error bars represent  the standard error of  the mean  from 







from  the  panel  of  individuals  cultured  based  on  their  genotype  at  the  IL2  exonic  SNP 
(rs2069763)  locus. These  individuals,  (Individuals 14, 16 and 17) are  the  same  individuals 
described  in Chapter 5. Although these  individuals were chosen based on genotype at this 















the  reads  to  a  reference  genome.  Unlike  in  Chapter  5,  where  the  data  was  used  to 
investigate the structure of the transcriptome, the aim of the mapping strategy here was to 
maximise the number and quality of the reads mapping over the SNP  loci under test. This 









the GA  II  is set to sequence a read  (45bp  in this case)  from either end of the fragmented 







part  of  each  exon;  this  is  termed  the  “spliceosome  genome”.  The  second  reference 
genome, described in Chapter 6.2.5, contains full length reference cDNA transcripts, as well 
as  introns and other genomic  loci. This  is  termed  the  “reference  transcriptome genome” 




of  reads  that mapped  to  the  specific  loci under  test. All  reads were mapped  to both  the 
spliceosome  genome  and  the  reference  transcriptome  genome  using  novoalign with  no 
additional  mapping  options  as  single  end  data.  The  novoalign  mapping  software  is 
explained  in more detail  in Chapter 2.10.2. The data was then also mapped as paired end 
data  to  the  same  genomes.  The  ability  to map  in  a  paired  end  strategy  enhances  the 
accuracy of  the mapping as  the gap between  the  two reads can be  taken  into account  in 
addition  to  the  location of  the  two  reads when  calculating  the mapping probability. The 
data for one representative individual (individual 14 ‐ activated) is shown in Table 6.1. The 





































Data  was  aligned  with  novoalign  to  the  reference  transcriptome  genome  and  the  spliceosome 
genome as paired end and  single end  reads. Data  for a  single  lane of  sequencing  is presented as 
unique reads and as a percentage of all possible sequence reads. Data was aligned with a mismatch 
value of –t 150 which equals approximately five mismatches per 45 base pair read. Paired end data 





The  alignment  results  shown  in  Table  6.1  were  representative  of  all  samples,  and 
demonstrate  the distinct advantage of paired end mapping over  the  single end mapping 
design. When looking at all dbSNPs within the two genomes, the frequency of the reference 
allele was indistinguishable between the single and the paired end mapping data sets. The 


















called a base at a  cluster position  from  the  image  intensity  files. These  scores, however, 
take no  account of  systematic  sequencing  errors or mismatch  statistics. By mapping  the 
data, and  collecting  the mismatch  statistics  for each  cycle  (for each base),  the novoalign 
algorithm  is able  to weight each base  independently, depending upon  the  cycle number, 
and generate an altered base quality score.  If for example there  is systematic error  in the 
instrument  that results  in poor quality sequence,  the  Illumina base quality scores  tend  to 




this  calibration as  they would be evenly distributed  though all  cycle numbers due  to  the 
random  fragmentation  of  the  sequencing  libraries.  After  running  the  base  calibration 
option,  the  number  of  reads  that mapped  uniquely  to  the  genome  increased  by  0.34% 
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(Figure 6.7b). Although  this  is  evidence  that  adjusting  the base  scores  from  the  Illumina 







A  single  lane  of  RNA‐Seq  (080929_5_stim)  was  aligned  to  the  reference  transcriptome  with 
novoalign v2.0.5. 8 million uniquely mapping reads were randomly selected from each alignment file 
and  the mapping  alignments  scores  calculated.  The  three  density plots  depict  the  distribution  of 









used here, however, means that  it  is highly  likely that one end of a read may map to the 





both  reads mapped  to  the same gene, but on  two different contigs. A  regular expression 
match  (regex)  is used within computer code  to match  two pieces of  text, or  identify  text 
with  specific  characteristics.  In  this  case  it  is used  to match  contigs with  the  same  gene 




transcript  name,  even  if  one was  for  intronic  sequence  and  the  other  represented  the 
exonic transcript. The improvement in mapping quality (4.6% more unique reads) that was 










Raw Total Sequences  13,087,880  13,087,880   ‐
Raw Paired Reads  6,543,940  6,543,940   ‐
Pairs Aligned 4,836,860  5,804,148   20.00
Reads Aligned 10,973,057  11,964,000   9.03
Uniquely Aligned Reads  9,080,254  9,593,226   5.65
Aligned With Gaps  428,566  65,030  ‐84.83





mapped  to  the  same  gene,  but  on  different  contigs.  The  median  alignment  score  is  shown  in 
brackets.  Calibration was  performed  only once  on  the  data  using  the  first  10,000  reads. Gapped 
reads represent reads mapping over possible indels up to 7 base pairs. 
 
The alteration  in mapping quality  is significant as although  it may only have a small effect 
on  the  number  of  reads mapping,  the  improved  quality  of  the mapping  should  reduce 
artefacts  within  the  regions  identified.  The  threshold  used  for  ASE  measurement  is  a 












There  are  two  factors  that  affect  the  ability  to  detect  an  allele  specific  imbalance  at  a 











at the given  locus. Three  levels of  imbalance are displayed, 60:40, 67:33 and 70:30. This figure was 
kindly generated by Dr Vincent Plagnol (CIMR, Cambridge).  
 
A  power  calculation  (performed  by  Dr  Vincent  Plagnol,  CIMR,  Cambridge,  UK), 
demonstrated  that  for  a  locus with  a  read depth of 50  and  an  imbalance  ratio of 67:33 
(equivalent  to  one  qPCR  cycle  difference  between  homozygotes),  the  probability  of 
accurately  identifying  the  imbalance, with a p value of 0.001, would be 19%  (Figure 6.8). 




Figure 6.9. A balance must  therefore be made between  the power  to detect a significant 
difference  in  allele  ratios,  and  the  number  of  transcripts  that  can  be  tested.  All  ASE 
reported  in this chapter uses a threshold read depth of 50 to maintain power and assay a 
reasonable number of transcripts. The number of testable transcripts was proportional to 








The number of  transcripts  (with at  least one SNP)  that could be  tested at varying read depths are 





During  this  experiment,  several  biases  were  identified  in  the mapping  of  reads  to  the 
genome, which, if they affect one allele more than the other would generate artificial allelic 
imbalances.  These  biases  are  almost  entirely  in  silico  artefacts,  and  it  was  possible  to 
remove most of them with changes to the analysis.  
 




detection  and  inflating  the  false  positive  rate.  Mapping  with  a  conservative  mapping 
threshold  (allowing no more  than  two mismatches between  the  read and  the  reference) 
appeared  to  inflate  this bias  to  the  largest extent.  In an attempt  to  resolve  this problem, 
two changes were  incorporated  in  to  the mapping process, as  shown  in Figure 6.10. The 
first involved simply relaxing the probability based mismatch threshold within the novoalign 









The effect  that mapping parameters had on  the distribution of  the allelic  ratios  is  shown. Data  is 












the  reference allele. After  these  two additions had been made, a  large proportion of  the 
bias was removed; although a small bias to the reference remained as the frequency of the 
reference allele was 50.7%, exceeding the alternative allele. This small remaining bias most 
likely  derives  from  small  indels  or  novel  SNPs  not  present  in  the  dbSNP  database  and 
mapping within 45bp  (the  sequenced  read  length) of  the  SNP under  test.  If  these novel 
variants were  on  an  alternative  haplotype  to  the  reference  allele  they would  lower  the 
alignment  probability  for  the  non‐reference  reads.  Reads mapping with  an  indel within 





A sample of data was taken  from  Individual 14  to  test  the mapping strategy. Prior to any 
alterations in the mapping method, 806 SNPs were detected with a read depth greater than 
50, of which 207 were significant for  imbalance (26%). Once all dbSNPs had been masked, 
and 5 mismatches were allowed  in  the mapping algorithm,  the number of detected SNPs 
rose to 1,138 of which 269 (18%), were significantly imbalanced.  
 
A bias was  identified  in  the  reads whereby some base positions were composed of  reads 
predominantly mapping  in  the  forward or  reverse direction. Totally  random  reads should 
map equally over a base in both directions. To control for this a two by two chi‐squared test 
was performed at heterozygous SNPs between the allele counts of each base in the forward 
and  reverse  directions.  Positions  with  significant  chi‐squared  values  (p  <  0.05)  were 
discarded. The reasons for this bias are at present unclear, but data from the PhiX control 
lane and genomic DNA  resequencing experiments  seems  to  indicate  that  there  is a non‐
random  stochastic  variation  in  forward  and  reverse  read  depths  over  a  given  locus. 
Although  this  is not a problem when generating consensus sequences, at  the extremes  it 
can generate artificial ASE. The most likely possible explanation for this is a sequence motif 
or  structure which  inhibits  bridge  amplification,  allowing  one  strand  to  be  preferentially 
amplified  into  clusters. The  final quality  control  that was  carried out was  to ensure  that 
over amplification of  the same  fragments  in  the PCR stage of  the  library preparation was 
not generating false ASE with only a small number of unique molecule contributing to the 




given  SNP  locus.  If  the  two  are highly  correlated  (p  <  0.01),  it  is  likely  that  a  significant 
proportion of  the  sequencing  reads have been  clonally amplified,  thus  leading  to a non‐
representative library. When paired end sequencing had been performed, it was possible to 
remove  duplicated molecules  by  locating  reads  with  identical  genomic  positions  (using 
novoPile). This  filter,  combined with  the PCR based  correlation  statistic  removed 10% of 
SNPs. The novoalign algorithm is capable of identifying small indels up to 7bp in length, and 
this was  introduced  into the ASE strategy to prevent spurious  imbalances. Before applying 
any filtering techniques to remove indels, 42% (233/545) of SNPs with an indel within 45bp 
(the  length  of  the  sequence  reads)  were  imbalanced  at  p  <  0.001  in  a  representative 
sample;  for comparison only 7.5% of SNPs without an  indel within 45bp of  the SNP were 
imbalanced after quality control. Any SNP position mapping within 45bp of an insertion or 
deletion  identified from the sequencing was thus removed resulting  in the  loss of 7.8% of 





Testing  for  allele  specific  expression was  performed  by  counting  the  number  of  quality 
bases  of  each  allele  at  each  heterozygous  SNP  position. A  subsequent  binomial  test  for 
equality was then used to identify regions with significant allelic imbalance. Once identified 
biases had been controlled  for,  it was possible  to calculate allelic  imbalance at a  total of 
128,678  SNPs  in  all  four  individuals  (eight  conditions).  The  majority  (94.8%)  of  all  the 
assayable SNPs were present within exons, but 5.8% of all the imbalanced SNPs (p < 0.001) 
were  identified within  intronic sequences (Chi Squared p value = 0.028). This represents a 
small  enrichment  of  ASE  within  intronic  reads  which  probably  reflects  the  increased 
number of small copy number variants or indels present in introns that cannot be detected 
using  the  RNA‐Seq  technique,  but  may  create  artificial  allelic  imbalances.  These  reads 
represent either novel  transcription, or more  likely unspliced heterogeneous nuclear RNA 




widespread  evidence  of  departure  from  the  50:50  ratio  expected  for  equally  expressed 
alleles.  This  approach  has  low  statistical  power  to  detect  differences  with  low  read 
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coverage,  so despite 7.5% of  SNPs being  imbalanced,  this  is  likely  to be  a  low  estimate. 
When restricting this analysis to SNPs with a read depth greater than 100, 260 out of 2,028 





ATHL1  contains  five  exonic  heterozygous  SNPs  in  individual  17.  The  example  data  shown  here  is 
derived  from  the activated condition. P values are derived  from a binomial  test assuming a 50:50 
















algorithm,  Dr  Vincent  Plagnol  (CIMR,  Cambridge,  UK)  systematically  assessed  each 
transcript  containing GWA  study  associated  variants  for  novel  SNPs within  the  RNA‐Seq 
data. A  total of 66 heterozygote  SNPs  (9 novel) were  identified  at positions with  a  read 






The  remaining  SNPs were  located within  two  genes,  IL7R  and  CD6.  IL7R  contains  a  SNP 
associated with multiple  sclerosis  (Lundmark, Duvefelt et al. 2007) and T1D  susceptibility 
(Todd, Walker et al. 2007) while CD6 is associated with just multiple sclerosis (De Jager, Jia 
et al. 2009) at present. No ASE effect was observed  in any  sample at  the  IL2 exonic SNP 
(rs2069763) despite all samples being heterozygous at this locus.   
 
Closer  inspection  revealed  that  the  SNPs within  IL7R map  either  close  to  indels  (within 




in  the  same  direction, with  the  same  haplotype  over‐represented  at  both  SNPs. Within 
individual  16,  three  SNPs  were  close  enough  to  be  phased  (rs61899223,  rs11230562, 
ENSSNP10443844) and again all the allelic directions were consistent, however none of the 
imbalances were significant at  the  read depth obtained.  Individual 17 had  four SNPs  that 
were imbalanced, but after phasing the direction of each SNP was inconsistent, suggesting 
the presence of biases in the measurement, rather than genuine ASE. Further genotyping of 









al.  2008).  This  replication  was  undertaken  by  Jennie  Yang  and  Kate  Downs  (CIMR, 
Cambridge, UK). After the amplification of cDNA and gDNA from the region of interest, and 
amplification  within  bacterial  colonies,  the  amount  of  each  allele  was  quantified  by 

















An alternative method of validation of ASE  is  to directly  sequence  cDNA and gDNA after 
generation of PCR amplicons (Ge, Gurd et al. 2005). An imbalance in an allele would result 
in  differing  peak  heights  at  the  SNP  locus  which  can  be  detected  with  the  PeakPicker 
software  (Ge,  Gurd  et  al.  2005).  This  technique  was  applied  by  Jennie  Yang  (CIMR, 
Cambridge, UK)  to  replicate  the  same  four  loci used  for  the  cloning based  assay  loci  (as 
validation  of  the  technique).  Although  this  method  is  less  sensitive  than  the  cloning 
method,  it does allow a greater number of  loci to be tested with a small amount of RNA. 





genomic  DNA  from  transcripts  with  a  single  imbalanced  SNP.  Unfortunately  when 
replication  (undertaken  by  Jennie  Yang  and  Kate  Downes  (CIMR,  Cambridge,  UK))  was 
attempted,  a  PCR  failure  prevented  sequencing  of  the  amplicons.  Repetition  of  the 










  Number of quality reads  Loci with depth > 50  Loci  with  depth  >  50  at 
heterozygous SNP 
Loci  with  depth  >  50  at 
heterozygous 








Gene  SNPs  Genes  SNPs  Genes  SNPs 
CB00694D 
Unactivated 
10,676,458  10,676,458  0  1,240  8,579  212  331  20  36 
CB00694D 
Activated 
18,258,061  18,258,061  0  2,461  14,963  426  712  60  99 
Individual 14 
Unactivated 
31,136,318  29,070,630  2,065,688  3,424  17,521  595  935  112  165 
Individual 14 
Activated 
42,487,407  30,768,187  11,719,220  4,406  29,790  955  1,608  129  187 
Individual 16 
Unactivated 
20,188,267  15,720,243  4,468,024  2,183  15,009  422  778  44  81 
Individual 16 
Activated 
18,775,488  18,775,488  0  2,109  13,393  363  598  37  55 
Individual 17 
Unactivated 
17,660,892  13,109,018  4,551,874  2,268  14,521  411  710  48  70 
Individual 17 
Activated 



















CB00694D Unactivated  rs11230563 chr11 60532785 1837 90 0.05578 1165 1/35/0/54/0 
CB00694D Unactivated  rs2074225 chr11 60532882 1934 57 0.18490 1027 0/23/0/34/0 
CB00694D Unactivated  rs12360861 chr11 60533649 1975 102 0.00017 1068 70/0/32/0/0 
CB00694D Activated  rs11230563 chr11 60532785 1837 97 0.77680 1165 0/97/0/102/0 
CB00694D Activated  rs2074225 chr11 60532882 1934 114 0.26720 1027 0/52/0/65/0 
CB00694D Activated  rs12360861 chr11 60533649 1975 61 0.34820 1068 103/0/89/0/0 
Individual 14 Unactivated  rs11230562 chr11 60532762 1814 395 2.5x10‐08 1188 0/253/0/179/0 
Individual 14 Unactivated  rs2074225 chr11 60532882 1934 407 0.00090 1068 0/237/0/170/0 
Individual 14 Unactivated  rs1050922 chr11 60541928 2868 862 0.97280 134 430/0/432/0/0 
Individual 14 Activated  rs11230562 chr11 60532762 1814 128 2.7x10‐05 1188 0/88/0/40/0 
Individual 14 Activated  rs2074225 chr11 60532882 1934 116 0.00455 1068 0/72/3/41/0 
Individual 14 Activated  rs1050922 chr11 60541928 2868 290 0.19550 134 133/0/156/1/0 
Individual 16 Activated  rs61899223 chr11 60532679 1731 331 0.27160 1271 0/176/0/155/0 
Individual 16 Activated  rs11230562 chr11 60532762 1814 151 0.00190 1188 0/95/0/56/0 
Individual 16 Activated  ENSSNP10443844 chr11 60532883 1935 147 0.13740 1067 0/83/64/0/0 
Individual 17 Unactivated  rs61899223 chr11 60532679 1731 387 0.00078 1731 0/277/0/160/0 
Individual 17 Unactivated  rs11230563 chr11 60532785 1837 216 1.00000 1837 0/108/0/108/0 
Individual 17 Unactivated  rs2074225 chr11 60532882 1934 144 0.11300 1934 0/82/0/62/0 
Individual 17 Unactivated  ENSSNP10443844 chr11 60532883 1935 162 0.23850 1935 0/73/89/0/0 
Individual 17 Activated  rs61899223 chr11 60532679 1731 361 6.0x10‐05 1731 0/219/0/142/0 
Individual 17 Activated  rs11230563 chr11 60532785 1837 283 0.28460 1837 0/151/0/132/0 
Individual 17 Activated  rs2074225 chr11 60532882 1934 182 0.00026 1934 0/116/0/66/0 



























      RNA‐Seq  RNA Bacterial  gDNA Bacterial   
      Counts    Counts  Counts   
Sample  Gene  SNP  Ref Allele  Alt Allele  p value  Ref Allele  Alt Allele  Ref Allele  Alt Allele  p value 
CB00694D  FAM118A  rs2064068  82  23  2.6x10‐9  229  101  186  150  2.5x10‐4 
Ind. 17   FAM118A  rs2064068  73  25  5.6x10‐7  211  95  168  166  2.4x10‐6 
Ind. 17  CALM3  rs10405893  149  86  1.7x10‐3  202  117  176  167  2.0x10‐3 
Ind. 17  ATHL1  rs1060819  82  223  4.6x10‐17  95  232  196  45  1.3x10‐13 
    Genomic DNA  cDNA 
      Allele Ratio  Allele Ratio 








CB00694D  FAM118A  rs2064068  0.9  0.9  1.8  1.9 
Ind. 17   FAM118A  rs2064068  0.9  1  1.8  1.9 
Ind. 17  CALM3  rs10405893  ‐  1.1  ‐  1.6 








Trynka  et  al.  2009).  Probes  from  the microarray  data  sets  were mapped  to  the  same 
reference transcriptome genome as the RNA‐Seq reads generating identical probe and SNP 
mappings  for  comparison  to  the ASE  data. A meta‐analysis  p  value was  then  calculated 
using a weighted Z test statistic between all eQTL data sets as described in Chapter 4.3.5 to 
generate an overall eQTL meta‐analysis database for the ASE positives SNP transcript pairs. 
A  total of 123 significant eQTLs  (p < 0.05) were detected at SNPs  that were assayable by 
ASE  in  at  least  one  sample. Of  these  27.3%  also  displayed  evidence  of ASE  at  p  <  0.05.  
Some caution is required in interpreting these results as the two methods were conducted 
in very different tissues and use very different methods of assaying differential expression, 
but  this  does  suggest  an  enrichment  of  ASE  positive  SNPs within  the  eQTLs.  This  eQTL 








sequencing efforts  to ensure  they are not  located near other SNPs or  indels, which could 
create an artificial bias  in genotyping and therefore ASE measurements. When comparing 
SNPs genotyped on the Illumina array, to those not present on the array, on average 4.01% 
of  SNPs were  imbalanced  compared  to  7.5%  (p  =  2.7x10‐6).  This  suggests  that  the  SNPs 
which  are  known  to  be  contained  in  regions  with  no  other  SNPs,  indels  or  repetitive 
sequence  are  less  likely  to  be  imbalanced.  Indeed  if  analysis  is  restricted  to  SNPs  that 
passed the HapMap quality filters (The HapMap Consortium, 2005), 4.6% were imbalanced, 
compared  to 7.5%  in  the non‐filtered  set  (p = 2.47x10‐14). To  investigate  the presence of 
other  factors  that may generate  imbalance, Dr Vincent Plagnol  ran RepeatMasker on  the 
reference  transcriptome  reference  genome,  to  identify  low  complexity  and  repeat 











depth  of  50  can  only  be  obtained  over  fairly  highly  expressed  genes.  Indeed  the  power 
calculation in Figure 6.7 suggests that a far higher read depth (>600) would be required to 
capture most  of  the  allelic  imbalances.  For  example  in  the  individual  sample  with  the 





method.  Alternatively  it  should  be  possible  to  assay  ASE  using  chromatin 
immunoprecipitation  of  elongating  RNA  Poll  II,  however,  this  brings  in  an  entirely  new 
technology  with  new  biases  (Knight,  Keating  et  al.  2003).  The  primary  aim  of  this 
experiment is to assay RNA levels, so it is preferable to continue using RNA as the molecule 
under  study. To overcome  these problems, an RNA‐Seq  library was added  to a  sequence 
capture microarray. This was designed as a proof of principle experiment  to  see  if  cDNA 
could be successfully enriched on a sequence capture array. These arrays are densely tiled 






capture array was designed  to capture  three gene  regions containing  the genes  IL2,  IL21, 
TENR, KIAA1109, RGS1 and IL12A. Instead of a normal poly(A) selection library, an RNA‐Seq 
library was constructed using total RNA, with the aim of enhancing the capture of unspliced 





After  sequencing,  a  total  of  7.5%  of  reads  from  the  total  RNA  library mapped  back  to 
captured  regions,  compared  to 9.9%  for  the genomic DNA  control  library  from  the  same 
individual captured on an identical array. An analysis of the reads that did not map back to 
the  region,  however,  demonstrated  that  68%  of  reads  mapped  to  rRNA  pseudogenes, 
indicating that ribosomal RNA was not efficiently removed from the sequence capture array 
during  the  washing  process.  Although  a  relatively  small  amount  mapped  back  to  the 
captured  region  of  interest,  this  equated  to  a  larger  than  400  fold  enrichment  for  the 







RNA‐Seq.  The  genes  in  blue  were  significantly  enriched  on  the  array  compared  to  RNA‐Seq 
(Bonferroni  corrected p < 0.05, binomial  test). Genes marked  in  red were also present within  the 
specified capture regions. A line of equality is shown.  
 
The  sample  of  RNA  that  was  used  to  prepare  the  total  RNA  library  was  also  used  to 
construct a standard poly(A) RNA‐Seq library. When RPKM values were calculated for each 
library, the enrichment from the array could be clearly evidenced (Figure 6.12). There was 
no expression of  IL21, TENR or  IL12A  in either dataset (IL‐21 detected  in captured sample 
only),  indicating  a  lack  of  expression  of  these  genes  in  CD4














molecules.  This means  for  a  typical  10 million  read  lane  from  the  Genome  Analyzer  II 
instrument,  about 1.6 million  reads  are duplicated. Although  this  figure  increases  as  the 
number  of  lanes  increases  (e.g.  Individual  14  ‐  unactivated  is  composed  of  6  different 
lanes),  it represents a relatively  low figure, despite the effect  it has on ASE calling (18% of 
SNPs  removed  at QC  due  to  PCR  artefacts).  In  contrast  the  total  RNA  hybridised  to  the 
sequence  capture  array  had  approximately  86.7%  duplicated  molecules.  This  can  be 




the quality  controls  in place  for  calling allelic expression, e.g.  forward/reverse  read  ratio 




















Within  these  fifteen divergent calls,  fourteen  represented SNPs called as heterozygous  in 
the  genomic  DNA,  but  not  in  the  RNA  (i.e.  homozygotes  in  RNA).  Only  one  SNP  were 
identified  as  heterozygotes  in  RNA‐Seq,  but  not  in  genomic  DNA.  On  inspection  of  the 
cluster plots,  this SNP displayed poor genotype  clustering with  low  intensity values. As a 






sequencing  errors,  but  it  is  difficult  to  validate  these  either  way.  The  remaining  six 
transcripts  all  contain  other  heterozygous  SNPs,  indicating  the most  likely  cause  of  the 
disparity between the genotypes is an RNA‐Seq error. For four of these calls, the read depth 
was lower than 30 with a very low frequency of the alternative allele (≤ 15% hence called as 







Gene Name  Chromosome Start Stop CD4  Sperm
SNRPN  15  22,750,774 22,751,274 0.887  0.320
POLR1D  13  27,092,403 27,092,903 0.070  0.090
TMBIM4  12  64,850,031 64,850,531 0.131  0.095
FAM13A1  4  90,197,346 90,197,846 0.630  0.710












POLR1D  and  FAM13A1)  were  imprinted,  the  methylation  data  from  Chapter  5  was 
interrogated. This was performed under  the hypothesis  that  if a gene were  imprinted,  it 
should have  an  average methylation  level of  approximately  50%  (40‐60%)  and be  either 
hyper or hypomethylated  in sperm (Down, Rakyan et al. 2008). The result of this analysis, 
shown  in  Table  6.7 demonstrates  that  the only  gene with  a  significant  difference  in  the 
methylation  level  between  the  sperm  and  the  somatic  tissue  was  SNRPN,  the  known 
imprinted gene. The three additional genes may represent monoallelic expression, in a non‐






Chapter 5  for  individual 14 was  investigated.  The mean promoter methylation  level was 
obtained for all genes with positive ASE in individual 14 ‐ unactivated. An equal number of 









ASE  and  non‐ASE  genes.  If  a  gene  contained multiple  promoters,  the mean methylation 
value  over  all  promoters  was  used.  Methylation  analysis  of  larger  sample  numbers, 
combined  with  ASE  analysis  would  be  required  to  identify  global  correlations  between 






The  results  in  this  chapter  demonstrate  the  utility  of  high‐throughput  sequencing, 
especially when applied to the transcriptome, for functional analysis of the genome. It was 
not possible to accurately determine the false positive rate with the limited replication data 
and  it  is  possible  that  some  biases  remain  un‐detected  but  a major  source  of  artificial 




This study allowed the  investigation of 1,380 unique genes displaying ASE.  It  is difficult to 
estimate the false positive rate with the amount of replication performed, but the amount 
of RNA required for sequencing and replication prevented any further attempts.  If a gene 
contains  multiple  SNPs  (approximately  44%  of  genes),  all  displaying  ASE  in  the  same 
direction, the probability of the gene being a false positive is likely to be low. The ability to 




relatively  short 45bp  reads, however, prevented  this  in  the majority of  cases;  the  longer 
100bp  reads  that  are  now  available  from  the  GA  II  sequencers  would  be  a  distinct 
advantage  in this  instance and may allow  further analysis of the  false positive rate  in this 
data. To estimate  the  false positive  rate  in genes with  less SNPs,  two sets of genes were 










artefacts.  However,  this  is  a  novel  technique,  with  as  yet  undiscovered  biases,  both 
experimental and  in silico and this value  is  likely to be a considerable underestimate. Two 
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different  external  validation  methods  were  attempted  to  identify  the  accuracy  of  ASE 
measurement  using  RNA‐Seq.  The  SNPs  chosen  for  this  replication were  split  into  three 
groups. The  first group  contained  the  four high probability  SNPs, with multiple SNPs per 
transcript which were all  replicated by bacterial  cloning,  indicating  that  for multiple  SNP 
transcripts  the  RNA‐Seq method  performs well. Once  SNPs  can  be  phased  on  the  same 
haplotype, multi‐SNP meta‐analysis tests for allelic expression can be used to enhance the 
power  of  these  studies  considerably. Although  it was  not  possible  to  estimate  the  false 
positive  rate  accurately,  since  the  replication  PCR  reactions  failed  for  the  other  two 
validation  groups  (resulting  in  the  loss  of  the  remaining  RNA)  it  was  still  possible  to 
sequence the gDNA around the ASE SNP regions. The data quality was on the whole poor, 







within  ASE  positive  genes,  the majority  of  ASE  findings  did  not  replicate.  There  are  a 
number of possible explanations  for  this.  It may be  related  to  the  limited  specificity and 
sensitivity of each method or equally it could represent the very different tissues studied. A 
recent study by Verlaan et al. also attempted to correlate ASE findings from pooled samples 






date, almost all appear  to be able  to be minimised with bioinformatic means and  it was 
possible to nullify them using simple alterations to the mapping and careful quality control 
procedures.  Changes  to  the  library  preparation  protocol  in  the  future  to minimise  PCR 
cycles may also help to reduce PCR induced biases. On average 7.5% of SNPs in each sample 
were  imbalanced. For one sample (individual 14 ‐ unactivated), however, this figure stood 








HapMap SNPs),  combined with  the  slightly elevated ASE  rate  in  introns  (which are more 




repeat  sequences)  is  close  to 50%, whereas  it  is  substantially  lower  for other variants. A 
better genomic control would therefore be required to identify these genomic properties at 
all  SNPs  present  in  the  RNA‐Seq  data.  The  data  from  the  1000  genomes  project 
(http://www.1000genomes.org) may help provide  some of  this data  in  the  future. Taken 




The  novel  indels  that may be  causing  the  imbalance  are  primarily  variants  that  it  is  not 
possible to identify within the RNA‐Seq sequencing data. These are likely to be greater than 
thirteen base pairs but  smaller  than 200 base pairs  in  size, as  this  is  the  size  range  that 







a  fragmentation bias.  It  is possible  that a  single SNP  could  increase  the  likelihood of  the 
divalent  cation  buffer  fragmenting  the  RNA  at  a  specific  site,  or  alter  the  secondary 




There were  two groups of  samples used  in  this experiment. Three  samples derived  from 
leucofilters,  and  one  sample  derived  from  a  population  Bio  Bank.  All  three  leucofilter 
274 
 
samples were  selected  from a panel of eighteen  individuals, all  cultured under  the  same 




personal  variation  and was  located  in  a  region  associated with  both  coeliac  disease  and 
T1D. None of the four samples displayed any  imbalance at this  locus. Using the  leucofilter 
derived  population  samples  was  a  time  consuming  and  costly  process  as  all  eighteen 
samples  were  extracted,  cultured  and  genotyped,  despite  only  three  possessing  the 
required  genotype.  All  the  other  samples  would  be  useful  for  other  SNPs,  but  if  rare 
polymorphisms were  to be  investigated, very  large numbers of  individuals would need  to 
be obtained at a very high cost to collect even a few individuals with the correct genotype. 
The Bio Bank  sample on  the other hand,  is an extremely useful  resource as  it allows  the 
investigation of specific polymorphisms with only a single sample preparation.  
 




generating  a  large  read  depth  over  captured  regions  (greater  than  x1000),  but  also  in 
allowing a genomic DNA sample to be captured as well, generating a genomic control  for 
the ASE measurement. Although  in the proof of principle experiment performed here, the 
resultant  library  was  too  clonal  to  perform  accurate  ASE  measurement,  it  should  be 
possible to reduce this effect in the future while still enriching the RNA prior to sequencing. 
It  is  now  possible  to  generate  entire  libraries  for  the  Genome  Analyzer  II  without 
performing  any PCR  (Kozarewa, Ning  et  al. 2009);  incorporating  this  technology  into  the 
library preparation should  lead  to a much more even  read distribution after elution  from 
the array. Although not an aim of this thesis, the next step in the generation of this method 
would be to optimise the array design and the sequence capture protocol to allow capture 


















genetic  variant  is  having;  does  it  change  for  example  transcriptional  abundance  or  a 
transcription factor binding. Secondly it is then importantly to identify how this effect then 





The  data  generated  here  is  difficult  to  validate  in  a  truly  satisfactory  manner  as  the 
validation methods themselves  (both cloning and direct sequencing) are subject to biases 
resulting from sequence context, GC content and biases in the fragmentation of the RNA. A 
possible  method  of  overcoming  this  would  be  to  use  an  alternative  high‐throughput 
technology  such  as  chromatin  immunoprecipitation  (ChIP)  of  elongating  Pol  II.  This 
technique has been successfully applied  to allelic  imbalances  in  the past, and  in  theory  it 
should  represent  an  attractive method  of  validating  the  results  obtained  here  (Knight, 
Keating et al. 2003).  
 
Although  it  is  difficult  with  present  bioinformatic  tools,  in  the  future  the  technique  of 
measuring ASE by RNA‐Seq should be able  to directly assess allele specific splicing events 
(Hull,  Campino  et  al.  2007).  This  would  involve  directly  identifying  splice  variants, 
quantifying  the  levels  of  each  transcript  and  then  identifying  variants  that  differentially 
express a SNP. 
   
Other  improvements  in  the  RNA‐Seq  protocol  in  the  future  may  allow  a  greater 
understanding of the transcriptome and the way it is regulated. For example, the RNA‐Seq 
data  here  is  non‐stranded;  as  a  result  it  is  impossible  to  work  out  which  strand  the 
transcript  was  transcribed  from  (Gagneur,  Sinha  et  al.  2009).  Were  this  technology 
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available,  it  would  enhance  the  mapping  process  back  to  the  genome,  and  improve 
annotation of novel  transcripts but  it  is unlikely  to have had  a  significant  impact on  the 
detection  of  ASE  especially  since  it  effectively  removes  one  of  the  quality  control 
procedures (forward and reverse bias).  
 
The  mechanism  behind  the  ASE  observed  here  is  unknown,  and  it  is  only  possible  to 
speculate that the variant may be differentially affecting expression through transcription 









use of sequence capture  technologies. The aim  is  that  in  the  future,  it will be possible  to 
make  RNA‐Seq  libraries  from  individual,  very  well  defined  and  phenotyped,  cell 
populations, from only a few thousand cells. These cells could then be accurately assessed 
for ASE at disease associated SNPs  in order to gain an  insight  into the mechanism behind 
the association. 
 
In  conclusion  high‐throughput  sequencing  offers  an  attractive  alternative  to  the 
measurement  of  allele  specific  expression  compared  to  current  technologies.  It  has  the 



















Over  the  course  of  this  thesis,  several major  changes  have  occurred  in  complex  disease 
genetics.  Perhaps  the most  fundamental  of  these  has  been  the massive  increase  in  the 
numbers  of GWA  studies  conducted  (Iles  2008a).  These  studies  have  begun  to  not  only 
illuminate  biological  pathways  that  are  important  in  disease  development  (e.g.  IL23R  in 
Crohn’s disease and psoriasis) but some have generated data that can be used to reliably 
predict  risk.  A  good  example  of  the  direct  application  of  this  includes  recent 
pharmacogenomic  studies, which have powerfully  illustrated how  specific  rare drug  side‐
effects  are  affected  by  a  person’s  genotype.  A  known  side  effect  of  the  antibiotic 
flucloxacillin  is  drug  induced  liver  damage,  but  the  pathogenesis  of  this  is  unknown.  A 
recent  GWA  study  into  patients  who  developed  liver  damage  after  flucloxacillin 
administration  identified  an  association  to  the  MHC  region,  HLA‐B*5701,  which 
demonstrated an allelic odds  ratio of 45    (Daly, Donaldson et al. 2009). This odds  ratio  is 
massively  in  excess of  any non‐HLA  complex disease  associated  variant,  and  it  serves  to 
demonstrate that pharmacogenomics is a plausible reality. It would not be unreasonable to 
suggest  that  subject  to  testing,  genotyping  this  variant  should  be  considered  prior  to 
administration of flucloxacillin but it should be noted that despite the increased risk only 1 
in  every  500  individuals  possessing  this  variant  will  develop  disease.  Apart  from  GWA 
studies,  the  introduction  of  high‐throughput  sequencing  technologies  have  also  been 
crucially  important  in  the  follow‐up of complex disease GWA studies and  these machines 






overlap between autoimmune conditions, with  the  same variants and genes  identified as 
associated with many different conditions. Often  the diseases do not  seem  to be  related 
e.g.  variants within  SH2B3  are  associated with  coeliac  disease  and myocardial  infarction 
(Hunt,  Zhernakova et  al. 2008; Gudbjartsson, Bjornsdottir et  al. 2009). There  are  several 







perturbed  it  has  a  different  result  depending  upon  the  cellular  context.  The  other 
alternative, however, is that there are independent associations within the same gene that 
have  not  yet  been  delineated.  For  example  independent  variants  within  CDKAL1  are 
associated with susceptibility to T2D and psoriasis & Crohn’s disease (Quaranta, Burden et 
al.  2009)  indicating  that  the  effect of  the  SNP may  also be distinct  depending upon  the 
cellular  context  and  epigenetic  status  of  the  cell.  This  cell  specific  effect  has  been well 
demonstrated by malaria researchers studying the Duffy binding protein which is essential 
for  the  Plasmodium  vivax  parasite  to  enter  erythrocytes.  A  SNP  in  the  GATA‐1  binding 
region of the promoter for the Duffy binding protein gene (DARC) has a twenty fold effect 
on gene expression levels with almost no expression in homozygotes (Tournamille, Colin et 
al.  1995).  This  effect  is  only  observed  in  erythrocytes,  as  GATA‐1  expression  is 
predominantly restricted to erythrocytes and as such the effect  is restricted to this  linage 








500,000  SNPs  (Matsuzaki,  Dong  et  al.  2004;  Gunderson,  Steemers  et  al.  2005).  Once 
association  has  been  detected,  however,  LD  is  no  longer  a  help  and  instead  becomes  a 
hindrance. The same problem is also observed when trying to identifying the casual variant 
when studying the functional effects of a haplotype. The challenge then becomes to break 













population and  the  vigilance of  the healthcare  services  to  its diagnosis.  In  some  studies, 
conducted  in more  than  one  population,  stratification  can  become  an  issue, where  one 
haplotype  is more  common  in  a  sub  population  that  another.  This  represents  another 
problem that LD can generate for researchers but can be overcome with population specific 
imputation approaches after sequencing specific loci (Jallow, Teo et al. 2009). Projects such 
as  the  thousand  genomes  project  (http://www.1000genomes.org/) will  further  delineate 
haplotype  blocks  and  will  enhance  the  identification  of  haplotype  structures,  but 
identification of causal variants  is still  likely to require disease specific sequencing efforts. 




of  association  from  within  LD  blocks  may  be  because  of  markedly  different  allele 
frequencies.  If,  for  example,  a  very  rare,  but  deleterious  SNP was  tagged  by  a  common 
haplotype, when  the GWA  study was performed,  an  association would be detected, but 
with a low odds ratio. Only, however, by sequencing the region in a large number of cases 
would  the variant be  identified.  It would  then  require a considerable number of cases  to 
have  sufficient  power  to  confirm  the  association.  The  current  GWA  study methods  are 
identifying more and more common variants, of low effect sizes, and are illustrating regions 
of the genome that could be sequenced to possibly locate novel rare variants. In addition to 









thus  shifted  from  attempting  to  find more  variants,  to  understanding  the  current  ones. 
High‐throughput  sequencing  is  playing  a  major  role  in  this,  primarily  for  resequencing 
studies to  identify novel disease associated SNPs within associated  loci. This was elegantly 
demonstrated by Nejentsev et al. who, after resequencing the exons and splice sites of ten 
disease  genes,  identified  several  novel  rare  SNPs  and  tested  these  new  variants  for 
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association with T1D  (Nejentsev, Walker et  al. 2009). The  result was  a novel  association 
within  the  IFIH1 gene which confers protection  to T1D  (Nejentsev, Walker et al. 2009).  It 
has yet to be  functionally established whether the  IFIH1 mutations  include a true disease 
causing mutation, and  this  requires considerable  functional work, but mutations  in exons 
are likely to be strong functional candidates and those in IFIH1 are all predicted to alter the 
protein  structure.  Common  SNPs  within  IFIH1  have  also  been  predicted  to  alter  the 
expression of the transcript (Liu, Wang et al. 2009).     
 









Even once  a  functional  effect  has been  identified  at  a  given  locus,  extracting  the  causal 
variant  from within  the  haplotype  can  be  difficult.  In  the  case  of  the  plausible  effect  at 
IL23R  it  is  impossible  to say which variant  is actually causing  the effect, even  though one 
SNP appears to have a greater association than the others as this may well be a function of 
the small sample size used. Further experiments on both the DNA, to identify all candidate 
polymorphisms  from  within  the  haplotype,  and  with  cellular  function  assays  would  be 














Complex  disease  genetics  is  still  some way  from  defining  exactly which  polymorphisms 
within a population give  rise  to disease  susceptibility  in  complex disease, but  the  field  is 
gaining  a much  better  insight.  The model  that  is  emerging  at  the moment  appears  to 
implicate lots of different genes, all involved in different aspects of disease pathogenesis. A 
small perturbation in each of these pathway steps, combined with an environmental input 
generates  disease. Many  diseases which  involve  shared  inflammatory  or  immunological 
pathways appear to share genetic associations signals e.g. coeliac disease and T1D (Smyth, 
Plagnol  et  al.  2008). As  a  consequence  it  has  been  suggested  that  the  same  underlying 
genetic  factors may  lead  to  both  coeliac  disease  and  T1D,  generating  a  susceptibility  to 





The  work  in  this  thesis  follows  on  from  discoveries made  by  GWA  studies  in  complex 
diseases. These studies have  identified numerous variants, both SNPs  (WTCCC, 2007) and 
CNVs  (St Clair 2009), associated with disease. Although  for  the vast majority of  these  loci 
the causal variant is not known, it is still possible to investigate the possible function of the 





al. 2007). The approach  taken  involved setting up a  time consuming and  labour  intensive 
assay, tailored specifically to the gene under study. This produced some interesting results, 
implicating  a  haplotype  that  is  associated  with  susceptibility  to  Crohn’s  disease  in 
alterations  in  cytokine  and  receptor  expression.  However,  despite  the  statistical 
association, the data  is not entirely convincing even though all the  individual experiments 
implicate the same haplotype as causing similar effects at the protein and mRNA level and 
the  result  is  biologically  plausible.  Using  a  panel  of  forty  individuals  was  all  that  was 
possible  at  time,  and  on  hindsight  the  experiment  suffers  from  a  lack  of  power.  The 
fundamental flaw is the lack of equal numbers of individuals in each genotype group. If this 









at a  time,  is  to  investigate  them all at once  in a  single  tissue  from multiple donors. This 
process, carried out in Chapter 4, allows correlations to be established between the  levels 
of expression in all genes and SNPs in the genome. The study performed here differed from 
others  that  have  been  published  in  the  literature  before  as  the  participants  were  not 
healthy controls, but rather were all coeliac disease patients, enriched  for coeliac disease 
associated or protective alleles.  It also benefitted  from using an  immunologically relevant 
tissue  type,  rather  than  EBV  transformed  B  cells.  This  was  the  first  association  based 
genetical  genomics  study  to  be  performed  in  peripheral  blood.  This  methodology  is 
effective at identifying expression associated with SNPs close to genes (cis) but is currently 
too weakly powered to identify trans effects. The identification of these trans effects is the 
real  power  of  this  study  design  and  efforts  are  currently  on  going  around  the world  to 
perform  similar  experiments  in much  larger  sample  cohorts. One of  the most  important 
factors when performing this or any other gene expression experiment is to ensure the cell 
under study  is the correct one. This may be extremely difficult as  in many conditions  it  is 
not known whether a genetic variant has  the same effect  in all cell  types, and even  then 
which  cell  type  is  responsible  for disease.  For  example  in  coeliac disease, numerous  cell 







Assaying  function  can  thus  be  performed  fundamentally  in  two ways, with  a  transcript 
specific assay, or in a genome‐wide fashion. The final two chapters of this thesis (Chapters 5 
&  6)  attempted  to  combine  these  two  approaches.  First  annotating  and  describing  the 
transcriptome  and  epigenome  of  CD4
+  T  cells,  and  then  attempting  to  develop  an 
appropriate assay for allele specific expression that combined the strengths of the genome‐
wide approach from Chapter 4 with the ability to set up gene specific culture conditions as 
shown  in Chapter 3. Annotating  the  genome  is  crucial  to understanding  its  relevance  to 










The most  immediate  area  for  follow‐up  from  this  thesis  involves  the  sequence  capture 
methodology for allele specific expression, in conjunction with high‐throughput sequencing. 
 
Use  of  the  sequence  capture  product  is  currently  ongoing,  in  collaboration with  several 
groups, and initial data is very promising that they will generate good non‐clonal data with 
a strong enrichment of  introns, as demonstrated  in Figure 7.1. The ability  to capture ASE 
within  introns  is crucial since this  is the  location of the majority of polymorphisms, which 







Comparison  of  expression  (reads  per  kilobase  per  million,  RPKM)  between  traditional  poly(A) 










design  is  similar  to  the  reference  transcriptome  reference  genome  and  tiles  introns,  the 
reference  cDNA  transcript  and 5’  and 3’  genomic  regions  to maximise  the  capture of  all 
transcripts  within  the  defined  regions.  This  second  generation  cDNA  sequence  capture 
array design  contained a  total of 25  regions associated with  coeliac disease or T1D. This 
experiment  is on‐going and after validation of  the method a  selection of  individuals who 
have volunteered  to donate blood  through  the Cambridge Bio Resource will be asked  to 





rare  variants  that  are difficult  to  identify with population panels. Although  the  ability  to 
sequence  individual  cells with  single molecule  sequencers  in  the  future may make  this 
technique  redundant,  this  technology  is  still  relatively  immature  and  not  capable  of 
generating  the  read depth necessary  to assay ASE, as such sequence capture  looks  like a 








a  unique,  genome‐wide  measure  of  allele  specific  expression  and  allele  specific 
transcription  factor  binding;  this  is  an  area  currently  under  investigation  to  provide 




et al. 2009). This  technology  is still relatively  immature, but  in  the  future  it will provide a 





by paired  end  reads).  The  short 45bp  reads used here  allowed  almost no phasing  to be 




be performed on  two  SNPs  rather  than  each  SNP on  its own,  generating  a more  robust 
statistic for imbalance in the same direction.  
 
Once a disease variant has been  found  to be associated with a disease,  there are several 
methods of  characterising  it, depending upon  its  location. ASE  technologies  should allow 
the  identification of variants  that  lead  to alterations  in  the expression of genes, whether 
they are present  in exons or  introns. This  is, however, still  likely  to  lead  to an associated 
haplotype, rather than a specific variant. To narrow this down to the causal variants, more 
specific functional studies can be undertaken to look at the SNPs of interest. These initially 
involve bioinformatic approaches,  to  see what effect  the SNP has  in  its genomic context, 
e.g. does  it map to a transcription factor binding site, splice site, or protein coding region. 
High‐throughput packages  such as  SNPnexus  (Chelala, Khan et al. 2009)  can  aid  in  these 
scans. The approach then taken depends on the SNPs location. If it were predicted to affect 
the  binding  of  a  transcription  factor,  electro‐mobility  shift  or  chromatin 
immunoprecipitation  assays  can  be  designed  to  assess  the  impact  of  the  SNP  in 
heterozygous and homozygous  individuals. Variants  in promoters can be  investigated with 
transfection of  the  luciferase gene, under  the control of  the variant containing promoter 





in  the  functional  identification of common variants. A current project  is underway  to use 
CD4
+ T  to generate  small RNA  libraries, which after  sequencing on  the Genome Analyzer, 
can be used  to  identify novel small RNAs. These small molecules may map within known 
genes, and  it  is plausible that current associations,  labelled as the gene the SNP maps to, 





2008) has  little or no known  function  in any coeliac disease process, but  it  is a very  large 
gene,  containing  at  least one miRNA,  and  it  is plausible  that  it may  contain other novel 
regulatory RNA molecules.  
 
A  growing  area  of  research  that  has  still  to  make  inroads  into  complex  disease  is  a 
comprehensive analysis of the methylation patterns of patients with and without disease. 
Methylation differences have been described between  somatic  tissue and neoplasms  for 
many years (Irizarry, Ladd‐Acosta et al. 2009), but this has yet to be reliably transferred to 
complex disease. Primarily  this  is due  to  the  inherent differences  in  the methylome both 
between  individuals  (even  between  identical  twins  (Kaminsky,  Tang  et  al.  2009))  and 
individual  cell  types  (Barski  and  Zhao  2009)  but  also  by  technical  limitations  in  the 
measurement  of  methylated  DNA.  These  problems  are  being  overcome,  with  the 
collections  of  large  numbers  of  samples  from  individual  cell  types  and  also  with  the 
application of new technologies to the measurement of methylation (Hodges, Smith et al. 
2009). The impact that environment plays in complex genetics is crucial, and is seems likely 
that methylation may  play  a  role  in modulating  a  person’s  risk  on  top  of  their  genetic 
background.  For  example  autoimmune  disease  development  is  associated with  a  lack  of 
breast  feeding  (Ivarsson,  Hernell  et  al.  2002;  Rosenbauer,  Herzig  et  al.  2008).  It  is 
reasonable  to surmise  that  the effect  is mediated  through  the  immune system, yet some 
people do not develop disease for many years.  It  is plausible that the effect  is “stored”  in 
the genome as an epigenetic mark, e.g. in the form of methylated CpG sites, which could be 
identified by  comparing CpG methylation  levels at each  locus between cases  to controls. 
Since SNPs themselves are able to influence methylation patterns, the interaction between 
the  methylome  and  the  genome  becomes  even  more  crucial  to  understanding  the 
interaction between a person’s genes and the environment (Rakyan and Beck 2006; Bock, 
Walter et al. 2007). These studies are even more complicated than standard GWA studies, 
simply because of  the number of variables  involved. The work on  the normal methylome 
present in this thesis is essential to setting up these kinds of studies.  
 
The  next  few  years  will  be  an  exciting  time  for  genetics.  Although  truly  personalised 
medicine  is  still  a  few  years  away,  several  areas  (particularly  in  pharmacogenomics)  are 
already developing assays that have the ability to directly impact on healthcare delivery to 
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Genome-wide analysis of allelic expression
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Many disease-associated variants identified by genome-wide association (GWA) studies are expected to
regulate gene expression. Allele-specific expression (ASE) quantifies transcription from both haplotypes
using individuals heterozygous at tested SNPs. We performed deep human transcriptome-wide resequencing
(RNA-seq) for ASE analysis and expression quantitative trait locus discovery. We resequenced double
poly(A)-selected RNA from primary CD41 T cells (n5 4 individuals, both activated and untreated conditions)
and developed tools for paired-end RNA-seq alignment and ASE analysis. We generated an average of
20 million uniquely mapping 45 base reads per sample. We obtained sufficient read depth to test 1371
unique transcripts for ASE. Multiple biases inflate the false discovery rate which we estimate to be 50%
for random SNPs. However, after controlling for these biases and considering the subset of SNPs that
pass HapMap QC, 4.6% of heterozygous SNP-sample pairs show evidence of imbalance (P < 0.001). We
validated four findings by both bacterial cloning and Sanger sequencing assays. We also found convincing
evidence for allelic imbalance at multiple reporter exonic SNPs in CD6 for two samples heterozygous at the
multiple sclerosis-associated variant rs17824933, linking GWA findings with variation in gene expression.
Finally, we show in CD41 T cells from a further individual that high-throughput sequencing of genomic
DNA and RNA-seq following enrichment for targeted gene sequences by sequence capture methods offers
an unbiased means to increase the read depth for transcripts of interest, and therefore a method to investi-
gate the regulatory role of many disease-associated genetic variants.
INTRODUCTION
Genome-wide association (GWA) studies using single nucleo-
tide polymorphism (SNP) maps have revolutionized the
mapping of common genetic loci determining susceptibility
to a wide range of common, multifactorial disorders (1), in
particular autoimmune diseases (2). The next steps to follow
up on these findings are the identification of particular
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candidate variants and haplotypes, and the investigation of the
molecular effects of these genetic variants. Because current
evidence suggests that only a small fraction of the causal
loci consists of variants (non-synonymous SNPs, copy-number
variants or indels) directly affecting the protein amino-acid
sequence, we expect a large fraction of the loci to have a regu-
latory role on gene expression via effects on transcription,
message stability and splicing. To investigate the potential
effects of candidate causal variants and haplotypes on gene
regulation researchers have been correlating SNPs with inher-
ited gene expression, known as expression quantitative trait
loci (eQTLs). The combination of genome-wide genotyping
with quantification of mRNA transcripts using microarray
technology in sufficiently large cohorts has already demon-
strated the widespread presence of eQTLs in the human
genome (3–7). Most of these studies (3–5), however, used
lymphoblastoid cell lines immortalized using Epstein Barr
Virus and relied on observing differences between individuals
despite the large inter-individual variability of gene expression
measurements that is not explained by cis genetic variation, in
addition to the limited accuracy of hybridization-based gene
expression assays. This high variability generated by environ-
mental factors and additional non-measured genetic or epige-
netic variability significantly reduces the statistical power for
eQTL discovery. Therefore, measurement of expression
levels across multiple individuals may be so noisy that reliable
correlations between SNP alleles and gene expression levels
cannot always be demonstrated when the difference of
expression between haplotypes is small (less than 1.3 fold).
Moreover, cell lines may not be representative of in vivo
biology and may introduce even greater variability (8–10),
and, therefore, gene expression analyses using purified
primary cell populations are urgently required (6–7,11).
An alternative experimental design well suited to address
these limitations is allele-specific expression (ASE) analysis.
This approach quantifies (un)equal transcription (or splicing)
from the two alleles or haplotypes using RNA samples
from individuals who are heterozygous at the eQTL SNP of
interest. The elegant ASE approach has the major advantage
of assessing expression within an individual rather than
across subjects thereby avoiding major sources of error and
variation.
In parallel, recent advances in high-throughput resequencing
technologies have enabled highly quantitative sequencing-based
analysis of human transcriptomes [RNA-seq (10,12,13)].
Because these techniques separately resequence both haplo-
types, they have the potential to be used for the quantification
of allelic imbalance, provided that a heterozygous SNP which
can be used as a marker for each haplotype exists in the tran-
script of interest. The potential of this method for ASE analy-
sis has been demonstrated in pooled cDNA samples and
human cell lines (14). Here, we extend this approach to
eight independently sequenced human poly(A)-selected tran-
scriptomes obtained from primary cells from healthy donors
using high-throughput paired-end (PE) resequencing. In the
context of the recently identified shared pathways between
multiple autoimmune disorders (2,15) that motivated this
study, many of the most relevant genes in regions identified
by GWA studies are immune genes that are highly expressed
in CD4þ T cells. This observation suggested the use of
primary CD4þ T cells in the current ASE study, thus illustrating
the potential of this approach to identify regulatory effects in
purified primary cell subsets.
RESULTS
Data description
We used Illumina Genome Analyzer II (GAII) high-
throughput resequencing of cDNA libraries obtained from
poly(A)-purified mRNA from four individuals analysed
under T-cell activation (stimulated) or unstimulated conditions
(see Materials and Methods), resulting in a total of eight
samples. We obtained 45 bp reads, the majority of them are
paired end (i.e. containing reads from both the 30 and 50 end
of a 250 bp fragment, see Table 1), that were mapped to a
transcriptome reference sequence set specifically constructed
for PE RNA-seq (see Materials and Methods). This reference
set includes a spliced transcript for each annotated gene
(Ensembl CCDS), as well as additional sequences for introns
and non-standard splice junctions. A full version of the refer-
ence gDNA genome with annotated gene regions masked was
added to enable: capture of transcribed, but not annotated,
chromosome regions; detect gDNA contamination of the
mRNA preparation and importantly to allow assessment of
repetitive sequence. Only reads mapping with high confidence
to a unique location in our reference sequence set (defined as
quality reads, see Materials and Methods) were included in
this study.
Owing to the complex nature of the RNA-seq reference
genome, taking advantage of PE sequence reads relies on
the ability of the mapping algorithm to map ‘chimeric’ frag-
ments: for example, the first read of a pair may map to a non-
standard exon–exon junction sequence and the second read to
the main spliced transcript. An algorithm implementing this
feature was provided by the novoalign (www.novocraft.com)
software package, which we used to align resequencing
reads to our reference set. Another useful feature provided
by novoalign is the ability to set a lower penalty for alignment
when a ‘chimeric’ paired read maps to two sequences that are
part of the same gene.
Transcript coverage
In the absence of experimental biases, the ability to detect an
allelic imbalance using ASE depends on two parameters:
the strength of the allelic imbalance and the read depth at
the reporter heterozygous SNP. We analytically computed
the read depth required to demonstrate allelic imbalance for
different allelic ratios. Power calculations (Fig. 1) show that
for a read depth of 50 and a 67:33 allelic imbalance, which
corresponds to an average of one cycle difference in a qPCR
experiment between individuals homozygous at both alleles
(a two fold difference), the probability to observe a P-value
more significant than 0.001 is 19% (Fig. 1). Therefore, to
remove SNPs providing almost no power to detect allelic
imbalance, we only tested for ASE SNPs with read depth 50.
While this approach is not limited to previously known
SNPs, we first tested 589 673 dbSNPs for ASE (obtained
from Ensembl release 52) and located in annotated spliced

























transcripts (including 50/30 untranslated regions) in order to
limit biases associated with simultaneous SNP discovery and
ASE testing. We also tested for ASE 4 282 208 intronic
dbSNPs but owing to the use of poly(A)-selected mRNA the
vast majority of the SNPs with sufficient read depth were
located in spliced transcripts (96.4%). Heterozygous SNPs
with sufficient read depth were located in highly expressed
transcripts and we obtained sufficient read depth to test 4929
pairs of heterozygous SNPs/samples for allelic imbalance.
Grouping these SNPs by transcripts for each of the eight
samples provided 3107 pairs transcripts/samples with suffi-
cient coverage for ASE analysis. When counting each SNP
uniquely, we had sufficient data to test 1371 transcripts and
2701 SNPs for ASE. In each individual, the number of testable
transcripts (i.e. containing at least one heterozygous SNP with
sufficient read depth) was proportional to the number of
mapped reads (Fig. 2, R2 ¼ 0.91).
Overall distribution of allelic imbalance
When considering the overall distribution of the test statistic,
we found evidence of widespread departure from 1:1 allelic
ratio. Summing over the eight samples, we tested a total of
4929 pairs of heterozygous SNPs/samples with sufficient
read depth (.50), and 370 SNPs (7.5%) showed evidence of
allelic imbalance at P , 0.001 (Table 1). At this significance
level, the estimated theoretical false discovery rate (FDR) is
1%. However, we have identified several biases inflating
the false positive rate (see below for a description). Since
SNPs passing HapMap quality filters are less likely to be
affected by some of these biases (for example, indels close
to an SNP will influence primer/probe hybridization), the
ASE rate for HapMap SNPs is a more reliable estimate of
the true rate of ASE. Indeed, when we restricted the analysis
to the subset of 87 796 dbSNPs in spliced transcripts that
passed HapMap quality filters, the ASE rate was significantly








































































































































































































































































































































































































































































































































































































































































































































Figure 1. Probability to detect an allelic imbalance at P , 0.001 as a function
of the read depth at a single SNP. We considered three levels of allelic imbal-
ance: 60/40, 67/33 and 70/30. The 67/33 scenario corresponds to a two-fold
difference in expression level, i.e. an average of one cycle difference
between individuals homozygous at both alleles in a qPCR experiment.

























were ASE positive (115 out of 2478 heterozygous HapMap
SNPs with sufficient read depth, P ¼ 2.47  10214).
However, our statistical power to detect allelic imbalance is
limited by read depth and, therefore, this estimate of 4.6% is
a lower bound. Indeed, when restricting this analysis to
HapMap SNPs with read depth .100, we found a higher
ASE rate of 7.5% (66 of 878). A complete list of all the het-
erozygous dbSNPs with sufficient read depth for ASE
testing is provided in Supplementary material, Table S1.
Genotyping data and epigenetic effects
Our approach consisting of identifying heterozygous SNPs
using solely the RNA-seq data restricts our ASE analysis to
SNPs for which the observed imbalance level does not
exceed 15–85%, the threshold beyond which SNPs are
called homozygous. With the double purpose of confirming
RNA-seq calls and identifying heterozygous SNPs completely
imbalanced in the RNA-seq data, we therefore genotyped the
four individuals using the Illumina Quad660W BeadChip. We
lowered to 20 the minimum read depth required to call SNPs
in the RNA-seq data and identified 9727 pairs of SNP/samples
shared between RNA-seq and Illumina Quad660W genotyping
chip. Out of these 9727 calls, 6886 are homozygous based on
the genotyping chip data. Out of these 6886 calls, only one call
is inconsistently called heterozygous in RNA-seq (rs7484182
in individual 2) and visual inspection of the genotyping chip
clustering plots showed poor quality data consistent with a
genotyping error.
Conversely, out of the 2841 genotyping chip heterozygous
calls, 14 are homozygous based on the RNA-seq data. Four
of these 14 inconsistent calls were located in the transcript
SNRPN, a known parentally imprinted gene, thus explaining
its monoallelic expression. Three calls were located in
ERAP2, a gene with known complete cis-acting differential
allelic control [but not parentally imprinted, see (16)]. After
removing these, 7 of 2841 calls (0.24%) located in seven
different transcripts remain inconsistent. For four of these
calls (located in IQGAP1, TMBIM4, CALHM2, AL031281.6),
the read depth was ,30 and we observed low levels of
expression of the alternate allele. This is consistent with
either highly skewed allelic expression or simply the result
of random sampling of both alleles at low read depth. The
remaining three calls (located in CD44, VAMP1 and
NAPRT1) may be real, or alternatively the result of unex-
plained artefacts either in the RNA-seq or the genotyping data.
Single locus validation
In order to confirm that some of our findings are not the con-
sequence of technical biases, we selected four pairs of
HapMap SNPs/individuals and validated them using two
different locus-specific assays [clone-based allele-specific
expression (C-BASE) (17) and PeakPicker (18)]. The
C-BASE ASE assay relies on amplification by PCR of
cDNA or genomic DNA fragment containing the reporter het-
erozygous SNP, followed by ligation into a vector and trans-
formation into bacterial competent cells. Bacterial colonies
are genotyped and both SNP alleles are counted, generating
allelic counts reflecting the relative proportion of the two
alleles in vivo. The PeakPicker ASE method uses sequencing
trace data to quantify the relative fluorescent intensity for
both alleles at heterozygous SNPs. The sequencing trace fluor-
escent intensities are summarized by the ratio of peak heights
for both alleles.
We selected four combinations of HapMap SNPs/samples
showing convincing evidence of ASE in the transcriptome
resequencing data for replication using the locus-specific
approach. All four initial RNA-seq results replicated and
PeakPicker/C-BASE provided consistent results (Table 2 and
Supplementary material, Table S2 for details of replication
assay). Note that because we have observed for C-BASE
assay allelic bias even using genomic DNA level as the PCR
template (see, for example, rs1060819 in Table 2), the C-
BASE ASE test uses a 1df goodness-of-fit x2 test for equal
cDNA/gDNA allelic ratio, thus using the gDNA allelic distri-
bution as control. Using gDNA allelic ratio as an internal
control for mRNA imbalance is a more robust design, but
obtaining this gDNA control for high-throughput sequencing
data is, currently, prohibitively expensive owing to the very
large amount of high-throughput resequencing needed to
obtain high read depth for gDNA using whole genomes.
This limitation points to future modifications of the approach
by using sequence capture in order to enrich the cDNA for
target sequences and to increase read depth for genomic
DNA and RNA-seq (see below).
ASE analysis of disease-associated genes
The subset of primary cells used in this study (CD4þ T cells)
was chosen for its relevance to autoimmunity. Therefore, we
reviewed the literature and identified 79 genes previously
associated with autoimmune disorders (2,19). To maximize
the number of testable heterozygous SNPs, we included in
this analysis new heterozygous SNPs not listed in the Ensembl
database but discovered by analysing our transcriptome
Figure 2. Number of transcripts containing at least one heterozygous dbSNP
with read depth 50 (black), 100 (red) and 250 (green) as a function of the
number of quality 45 bp reads. Each point represents one condition/individual
sample. To provide a more intuitive reference, a mean 1 read-depth across
the human genomic DNA requires 65 million 45 bp reads.

























resequencing data. In these 79 genes (Supplementary material,
Table S3), we found 61 heterozygous SNPs with read depth
.50 and eight of them were not listed in dbSNP (13.1%).
These 61 heterozygous SNPs were found in 22 genes, i.e.
28% of the targeted genes, an elevated rate consistent with
a higher expression level of these immune genes in CD4þ
T cells. Counting separately each pair of SNP/individual,
we tested a total of 127 pairs and 13 were imbalanced at P,
0.001. After controlling for the elevated read depth, the fre-
quency of ASE positive pairs of SNP/sample in these 79 tran-
scripts was consistent with genome-wide estimates (P. 0.05).
Firstly, 8 of 13 imbalanced SNPs were located in the mul-
tiple sclerosis-associated gene CD6 (20). In individual 2
(stimulated and unstimulated), two heterozygous exonic
SNPs (HapMap SNP rs2074225 and rs11230562, separated
by 97 bp in the spliced transcript) showed strong level of
imbalance (allelic counts 253/142 at rs11230562 and 237/
170 at rs2074225). Both SNPs were sufficiently close to
obtain phase information from the RNA-seq 45 bp PE reads
(using novoPhase, see Materials and Methods) and these
data confirmed that the same haplotype was over-represented
at both SNPs. Note that a third SNP (rs1050922) in individual
2 had 1:1 allelic ratio but also unexpectedly high read depth
(two fold increase over rs2074225/rs11230562). This could
be the consequence of reads from another transcript mapping
to a homologous region in the CD6 transcript and we
believe that the data at this SNP are artefactual. We also
found three CD6 heterozygous SNPs in individual 3 and
these SNPs were sufficiently close to be phased using the
RNA-seq paired reads. For all three SNPs, the pattern was
consistent after phasing, the same haplotype being over-
represented at all three SNPs (counts 176/155 at rs61899223,
95/56 at rs11230562 and 83/64 at ENSSNP10443844, where
the first number relates to the same haplotype). For individual
4, we found four heterozygous SNPs (including two adjacent
SNPs) but after phasing the data were inconsistent: different
haplotypes were over-represented at different SNPs,
suggesting the possibility of unidentified biases
[e.g. alternative splicing at CD6 (21)]. Given the convincing
evidence of association for individuals 2 and 3, we genotyped
all individuals for the SNP currently strongly associated with
multiple sclerosis in CD6, rs17824933 (20). Both individuals
2 and 3 (but not individuals 1 and 4) were heterozygous at
this SNP. Taken together, these data suggest that the alteration
of CD6 expression in CD4þ T cells is a potential mechanism
for the effect of the multiple sclerosis-associated variant in the
CD6 gene region. SNP phasing obtained from linkage disequi-
librium information at HapMap SNPs rs2074225 and
rs17824933 shows that the minor allele G of rs17824933,
which is more common in multiple sclerosis patients than con-
trols, is associated with lower CD6 expression. However, the
biological interpretation is complex as resting CD6 expression
inhibits T-cell activation, but CD166 ligand engagement of
CD6 enhances T-cell activation (22).
Secondly, we observed an intriguing pattern at ICOSLG, in
which five heterozygous SNPs, all not listed in dbSNPs, were
identified in individual 2 and a strong skew was observed for
four of them. Moreover, after phasing the data, we identified
three distinct haplotypes instead of two, suggesting that the
observed skew is artefactual. We scanned the database of
genomic variants and found that, according to two independent
studies (23,24), the entire gene is located in a copy number vari-
able region. Our data suggest that this copy number variation is
a duplication and that the duplicated gene is expressed: the
additional observed haplotype in individual 2 probably orig-
inates from this duplicated copy. This additional copy is prob-
ably expressed at a lower level than the original transcript
which would explain the imbalance in the RNA-seq data.
Lastly, we identified six heterozygous SNPs in the IL21R
gene (25) for individual 1, two of them imbalanced at P,
0.001. We could phase three of six heterozygous SNPs
(rs2285452, rs3093387 and rs2239928) using the RNA-seq
data, and the trend was consistent with 1.3:1 allelic ratio.
This finding is consistent with a previous report of a IL21R
eQTL using mRNA from the peripheral blood of 110 celiac
cases (7).
Table 2. Comparison of allelic imbalance between mRNA transcriptome resequencing (RNA-seq) and two validation assays: locus-specific bacterial cloning
(C-BASE) and PeakPicker. Both validation assays tested total RNA and genomic DNA. Allele 1 indicates the allele in the reference genome. RNA-seq P-values
use a x2 goodness-of-fit test for a 50–50 allelic ratio. For the C-BASE validation assay P-values test for equal allelic ratio in mRNA and gDNA using a 1df x2
goodness-of-fit test.
Sample Gene SNP mRNA resequencing (RNA-seq) Validation: C-BASE Validation:
PeakPicker
mRNA Counts Total RNA
Counts








































82 223 6.8  10216 95 232 196 145 1.3  10213 0.43 0.86

























Controlling for sequencing chemistry biases
The Illumina GAII sequencing chemistry induces biases that
can increase the rate of false positive ASE. A first issue is
PCR biases over-amplifying identical cDNA fragments, the
final allelic ratio being eventually affected by the presence
of a large number of over-represented identical read clones.
To control for these biases, we identified clonal molecules in
the PE data using as a signature the mapping location for
both reads in a pair (or if one read did not map uniquely,
the first 10 bp of sequence was used as a signature). Identical
mapping location for both 45 bp reads is unlikely to occur ran-
domly, and for each set of clonal read pairs we only included a
single read pair in the analysis. This filtering process removed
on average 10% of the reads from the final analysis (option
rmDup in novoPile). To ensure our ASE results are not
affected by clonality, especially for reads mapping as single
end (SE) data for which the filter described above is not appli-
cable, we also verified that among the reads covering a hetero-
zygous SNP the observed allele was independent of the
position of the SNP within each 45 bp read (see Materials
and Methods).
Secondly, we also observed biases that are specific to
forward/reverse read direction. Therefore, we verified that
for heterozygous SNPs the allelic ratio distribution was con-
sistent for read counts obtained for the reverse and forward
strands. Using a P ¼ 0.01 threshold for both tests, we
removed 18% of heterozygous dbSNPs from ASE testing.
Controlling for in silico mapping biases
In silico artefacts in the mapping procedure can also bias the
allelic ratio distribution and increase the false positive rate.
A general difficulty is the mapping of short reads to a standard
reference sequence that does not match perfectly the genetic
sequence of the sample. In particular, for heterozygous
SNPs, the allele concordant with the reference is more likely
to be mapped, resulting in a bias towards the reference allele
and an inflated rate of false positive ASE.
In silico mapping procedures relying on a conservative
threshold (no more than two mismatches) are heavily affected
by this bias (Fig. 3). We solved these issues by incorporating
two additions to our mapping algorithm. Firstly, for all known
dbSNPs, we replaced the reference allele with the correspond-
ing genetic ambiguity code coding both possible alleles at this
SNP. Secondly, we relaxed the threshold on the number of
mismatches for allowing reads to be mapped in order to
limit the impact of a small number of mismatched SNPs.
Our mapping procedure uses a probability-based alignment
score that typically allows up to five mismatches (option
-t150 in novoalign), and reads with more than five mismatches
were discarded at later stages (see Materials and Methods).
These two additions corrected most of the reference allele
bias (Fig. 3).
Additional differences, such as other heterozygous SNPs
or indels, further contribute to differential mapping of both
haplotypes. The novoalign algorithm provides calls for small
indels (up to 13 bp). Using these calls, we found an increased
proportion of imbalanced SNPs within 45 bp of indels. Before
applying any quality control filter (see above), 42% of
heterozygous SNPs within 45 bp of a called indel were imbal-
anced at P , 0.001 (233 out of 545 calls). This proportion was
11.7% when no indel was called within 45 bp (737 out of 6311
calls). After applying the quality filters, these proportions
became 24% for SNPs within 45 bases of an indel, and
7.5% otherwise. In both cases the difference is highly signifi-
cant (P ,, 10210). These results suggest that the quality
filters capture only a fraction of the artefacts caused by
indels. Consequently, we excluded from our ASE analysis het-
erozygous SNPs within 45 bp of a called indel in the same
individual.
Additional sources of false positive ASE
However, it is likely that even after applying these quality
filters copy number variation and mapping biases still
account for a number of false positive ASE results. In particu-
lar, intermediate size indels larger than 13 bp cannot be
called by novoalign with the settings we used for read
mapping. We used the software Pindel (26) to re-analyse the
RNA-seq data with the purpose of identifying new larger
indels (this tool can detect 1–10 kb indels). However, we
could find new indels within 300 bp of the heterozygous
SNP for only 11 positive ASE results.
In addition, low-complexity or repeat sequence surrounding
heterozygous SNPs is associated with an elevated ASE posi-
tive rate. We used as criteria for low-complexity/repeat
sequences the fact that more than 25% of the 90 bp surround-
ing sequence (45 bp on each side) was masked by RepeatMas-
ker. We found that roughly 12% of the heterozygous SNPs in
this study were located in low-complexity regions. For SNPs
in such low-complexity regions, the ASE positive rate was
23%. Overall, 28% of ASE positive SNPs are located in low-
complexity DNA regions. The ASE rate was also elevated for
intronic SNPs (33/208¼15.8% ASE positive SNPs), which are
more likely to contain small indels.
Lastly, the ASE positive rate was lower for heterozygous
SNPs that passed HapMap quality filters: 115 ASE positive
SNPs out of 2478 ¼ 4.6%, compared with 7.5% for the non-
filtered set (370/4929 heterozygous SNPs). This difference
between HapMap SNPs and non-HapMap SNPs is significant
(P ¼ 2.47  10214) and consistent with the fact that SNPs
passing HapMap quality filters are not likely to be located in
repeat sequences or near indels. A similar reduction of ASE
positive rate was observed for SNPs on the Illumina
Quad660W genotyping chip (32/797 ¼ 4.01%).
To obtain a more accurate assessment of potential biases,
we attempted to validate additional ASE results. We used indi-
vidual 1 data and selected 22 transcripts with a unique imbal-
anced heterozygous SNP in each transcript (Supplementary
material, Table S4). We first resequenced the gDNA to ident-
ify potential indels and obtained usable sequence data for 19
of 22 SNPs. We found only one previously undetected 1 bp
indel within 45 bp of the heterozygous SNP, providing a
likely explanation for the observed imbalance at this SNP.
However, resequencing data showed that 5 of 19 SNPs are
in fact homozygous. None of these five SNPs passed
HapMap QC, and this discrepancy is most likely the conse-
quence of RNA-seq mapping errors with homologous DNA
regions.

























For the remaining 13 SNPs, we designed short-range
primers to resequence both gDNA and total RNA (Supplemen-
tary material, Table S4). Sequence data were usable for 9 of 13
SNPs for which we used the PeakPicker method (18) to quan-
tify potential imbalance. Three of nine SNPs convincingly
validated (cDNA by gDNA allelic ratio .1.5). For two out
of six remaining SNPs, the estimated imbalance from
RNA-seq was low (no more than 60:40) and for these SNPs
the limited sensitivity of the PeakPicker validation assay
when the allelic imbalance is ,1.5-fold can potentially
explain the lack of validation. For the remaining four SNPs,
the PeakPicker validation data showed no evidence of allelic
imbalance in spite of a strong bias observed in the RNA-seq
data and we found no obvious explanation to account for
this discrepancy. In addition to limited sensitivity, the
interpretation is also complicated by the fact that our vali-
dation data used total RNA but the RNA-seq findings used
poly(A)-selected RNA. We did not apply the more sensitive
counting ASE method C-BASE owing to time constraints
and the laborious nature of this assay.
Taken together, these data suggest that several biases, some
of them unknown, increase the FDR. Even if one assumes that
the ASE FDR is relatively small for HapMap SNPs, the differ-
ence in ASE positive rate with non-HapMap SNPs suggests
that the false positive rate among non-HapMap SNPs is
50%. However, this rate could potentially be higher,
especially for heterozygous SNPs surrounded by repeat
sequences or small indels. Thus ‘unproven quality’ SNPs
Figure 3. Effect of mapping parameters (number of mismatches allowed for read mapping, and/or masking dbSNPs from the reference sequence set) on the
allelic ratio distribution using the PE data for individual 2 stimulated at heterozygous dbSNPs passing quality checks and with read depth .50. Red crosses
indicate significant allelic imbalance (P , 0.001). The bottom-right histogram has been generated allowing up to five mismatches and mapping reads to the
masked reference set. Nb, number.

























should only be used for ASE estimation with great caution and
the presence of multiple imbalanced SNPs is required to
provide convincing evidence of ASE. In addition, the corre-
sponding ASE for gDNA is a desirable control.
PE versus SE reads
To compare PE and SE mapping, we used the PE data for indi-
vidual 2 stimulated (as shown in Fig. 3) which we mapped
either as PE or SE reads. Using the frequency of the reference
allele as a diagnostic for in silico mapping issues, the distri-
butions obtained using PE and SE mapping were indistin-
guishable (data not shown). However, using the same quality
threshold, the PE approach mapped 19% more quality reads
than the SE approach. This difference indicates that the PE
approach is more cost-effective than the SE approach for
this ASE design, in addition to other advantages for
RNA-seq experiments including splice junction mapping and
de novo assembly.
Sequence capture
The main limitation of the full poly(A)-selected transcriptome
resequencing is the limited read depth at genes that are insuf-
ficiently expressed. To address these issues, we investigated
the potential of the cDNA enrichment with sequences of inter-
est using recently developed sequence capture methods (27).
As a pilot study, we designed a sequence capture Nimblegen
hybridization array targeting 25 genes located in immune
disorders-associated chromosome regions. We also included,
as a positive control, the FAM118A transcript, a gene ident-
ified in this study and another (4) as an eQTL transcript. In
total we targeted 26 genes and a total sequence length of
1.7 Mb.
Based on available FAM118A eQTL data (4) we used the
Cambridge BioResource [www.cambridgebioresource.org.uk
(28)] to recruit for a blood donation individual 5, selected to
be heterozygous at the FAM118A eQTL. The Cambridge
BioResource is a collection of over 5000 healthy volunteers
in the Cambridge area that can be recalled by genotypes.
Using the Nimblegen capture array, we captured genomic
DNA and cDNA obtained from poly(A)-selected RNA for
this individual. We then resequenced both samples using Illu-
mina GAII sequencer and 76 bp PE reads (9.35 M pairs of
reads for gDNA and 20 M pairs of reads for RNA).
Sequence capture successfully enriched both resulting pro-
ducts with target sequences. In the poly(A)-selected data,
61.58% of the total number of reads and 87.46% of the
uniquely mapping reads mapped within 76 bp of the 1.7 Mb
target sequence. For the gDNA data, these numbers were
76.61% of the total number of reads and 67.27% of the
number of uniquely mapping reads. In contrast, in the
absence of sequence capture for individuals 1–4, we found
that 0.2–0.4% of the full poly(A)-selected transcriptome
reads mapped to the 1.7 Mb regions targeted by the capture
array, indicating that capture enriched for sequences of interest
by an average 200-fold.
However, following sequence capture, we discarded 86.7%
of the RNA reads and 52.96% of the genomic DNA reads
because of PCR clonality issues. Such clonal reads were
identified on the basis of having identical mapping locations
for both reads in a pair. These biases most likely result from
our use of PCR amplification both before and after hybridiz-
ation on the capture array and are particularly problematic
when dealing with limited levels of input DNA/cDNA,
either prior to array capture or following array capture at the
sequencing step. We are currently considering alternative
library preparations and sequence capture protocols to circum-
vent these issues.
Nevertheless, after excluding duplicate clonal reads, we
obtained sufficient data to perform ASE analysis for gDNA
and RNA at the positive control gene FAM118A (Fig. 4).
After applying the quality control procedures described in
this study, we found 43 heterozygous SNPs with read depth
.50 in the gDNA data. Only one SNP was not in dbSNP
and 21 of 43 passed HapMap quality filters. In the RNA
data, we found 21 heterozygous SNPs with read depth .50.
Seven of 21 passed HapMap quality filters and 1 of 21 was
not in dbSNP. Of the 21 heterozygous RNA SNPs, 14 also
had sufficient read depth in the gDNA and as expected the
gDNA data were consistent with a 1:1 allelic ratio
(P.0.001 at all 43 SNPs). The consistency with 1:1 allelic
ratio observed in the gDNA data indicates that no allelic
bias was introduced by the sequence capture, a critical require-
ment for this experimental design.
In contrast, 10 of 21 heterozygous SNPs were significantly
imbalanced in the RNA data at this P , 0.001 threshold (and
14/21 at P, 0.01). Analysis of the RNA data also showed that
77.5% of the heterozygous SNPs with read depth .50 are
intronic SNPs, indicating that the sequence capture approach
retains sufficient read depth even in introns when capturing
cDNA from poly(A)-selected RNA.
DISCUSSION
Using a full poly(A)-selected transcriptome resequencing
approach (RNA-seq) applied to eight CD4þ T-cell samples
obtained in untreated and activated conditions from four
healthy individuals, we performed a transcriptome-wide scan
for ASE. We identified several biases that inflate the ASE
false positive rate and to control for these biases while maxi-
mizing the information obtained from the data, we developed a
novel approach for mapping PE sequence reads to the human
transcriptome. For pairs of HapMap SNPs/samples, the pro-
portion of ASE positive results was 4.6%, a rate significantly
lower than what we observed for the full set of heterozygous
SNPs (7.5%). This comparison shows that for randomly
selected ASE positive heterozygous SNPs of ‘unknown
quality’, the FDR is probably as high as 50%. However, the
fact that, using two independent locus-specific assays, all
four attempted ASE validations at HapMap SNPs were suc-
cessful suggests that this FDR is limited for SNPs that
passed HapMap quality filters. In situations where there is
uncertainty regarding genetic variation in the sequences sur-
rounding the assayed SNPs, the presence of several imbal-
anced SNPs in the same transcript is necessary to provide
reassurance that an ASE finding is indeed a true positive.
Nevertheless, only independent validation can unequivocally

























confirm findings from the genome-wide ASE screening meth-
odology presented here.
Our data show that the effect of indels on the mapping of
short sequencing reads is a major source of false positive for
ASE. Longer sequencing reads, improved analytical methods
and use of PE reads will facilitate indel calling in the future
and longer reads will also improve the reliability of mapping
procedures. However, other biases, some yet to be discovered,
also contribute to the false positive rate. In particular,
a previous study (28) has shown that the RNA fragmentation
and the subsequent gel purification step for the sequencing
library preparation can also introduce biases differentially
affecting both haplotypes. Such biases will not necessarily be
solved by the improvement of DNA sequencing technologies.
An advantage of our full transcriptome resequencing
approach is the ability to interrogate the entire genome for
ASE while avoiding the biases associated with the amplifica-
tion of specific mRNA/cDNA sequences. The drawback is
Figure 4. ASE data for individual 5 following sequence capture for genomic DNA (top) and RNA (bottom) at the FAM118A positive control known eQTL
transcript. Crosses mark the read depth at each heterozygous SNP (only heterozygous SNPs with read depth .50 are shown). Vertical bars show the 99.9%
confidence interval for the imbalance computed as the ratio between the most common and the least common of the two alleles for each heterozygous
SNPs. Red bars mark heterozygous SNPs showing significant imbalance (at P, 0.001). The horizontal bar marks the 1:1 allelic ratio.

























the fact that the current ASE approach is restricted to highly
expressed transcripts also including a heterozygous SNP in
the transcript-encoding sequence. Indeed, read depth is the
key determinant of statistical power for this ASE approach
and the analysis of rested and activated samples in this study
was initially motivated by the need to increase the expression
level of specific transcripts. For example IL2, a T1D
disease-associated gene (www.t1dbase.org), requires acti-
vation to be expressed at a sufficient level for ASE analysis.
To capture more subtle levels of allelic imbalance, an even
greater read depth (as high as 1000) would be beneficial, if
practical, both for a genome-wide screen or locus-specific
validation assay. The rapidly increasing throughput of DNA/
cDNA resequencing technologies will most likely soon
provide that level of read depth for a large number of tran-
scripts, either in poly(A)-selected or even total RNA.
Our preliminary data show that the enrichment of cDNA with
sequences of interest using sequence capture methods (27) fol-
lowed by high-throughput sequencing is an effective way to
increase the read depth at transcripts of interest. Alternatively,
another study (29) has proposed padlock-capture of targeted
sequences containing known SNPs to increase read depth. In
addition to the increased read depth, the sensitivity to detect
introns in preRNA (probably from partially unspliced hetero-
nuclear RNA with a poly(A) tail) provides increased poly-
morphism levels compared with exonic sequences, and
therefore more heterozygous SNPs for ASE testing. Joint
sequencing of genomic DNA, also enriched for the regions of
interest, enables screening of the heterozygous SNPs for 1:1
ratio in genomic DNA, thus facilitating detection of small
indels and repeat sequences that increase the ASE false positive
rate. Our preliminary study using Nimblegen sequence capture
arrays for T-cell total RNA detect retained introns at high read
depth in several genes from target regions. Furthermore, if a
particular transcript is of interest, specific samples can be
selected from a collection of individual volunteers of known
genotype (e.g. www.cambridgebioresource.org.uk) to ensure
the presence of heterozygous SNPs.
A successful combination of sequence capture and deep
sequencing of cDNA generated from total or poly(A)-purified
RNA with sufficient coverage has the potential to simul-
taneously test for ASE, in specific primary cell subsets, most
findings identified by GWA scans, provided that the
expression levels of the transcripts are sufficient and heterozy-
gous SNPs are available. This experiment would be useful not
only to demonstrate a potential regulatory effect of these
disease-associated alleles, but also to fine-map-associated
regions by testing for ASE in carefully selected rare recombi-
nant individuals. Last, repeating the experiment for different
cell subsets will enable the identification of the cell popu-
lations in which this regulatory role exists (28), thus helping
researchers link GWA findings with the molecular function
of these susceptibility alleles.
MATERIALS AND METHODS
Sample description
Primary CD4þ human cells were extracted with Rosettesep
(Stem Cell Technologies, UK) negative selection from leuco-
filters obtained from the National Blood Service (individuals
2, 3 and 4). Cells from individuals 1 and 5, obtained from
venous blood through the Cambridge BioResource (28),
were purified from ficoll-isolated PBMC using Dynabeads
untouched human CD4þ T cells negative selection kit (Invitro-
gen Corp., UK). Purity was assessed by flow cytometry
(.95% for all samples) while viability was assessed by
Trypan blue staining (.93% for all samples). CD4þ T cells
were cultured for 3 h in X-Vivo media with 1% human AB
serum alone (Lonza, UK) or stimulated for 3 h at 378C, 5%
CO2 in plates pre-coated with 1 mg anti-CD3 (clone: OKT3,
eBioscience, USA) with the addition of 2 mg anti-CD28
(eBioscience).
Illumina library construction
RNA was extracted using the RNeasy kit (QIAGEN, UK) fol-
lowing the manufacturer’s instruction. Samples were subjected
to additional DNase treatment using Turbo-DNase (Ambion,
UK). RNA quantification and quality were assessed using
Nanodrop (Nanodrop Technologies, USA) and RNA 6000
Agilent Bioanalyzer chip (Agilent Technologies, USA). A
double poly(A) RNA isolation was performed on 10 mg of
total RNA (Invitrogen). Poly(A) RNA was fragmented for
exactly 5 min at 708C in fragmentation buffer (Ambion)
prior to random hexamer reverse transcription and second
strand synthesis as previously described (10). Illumina GAII
PE adapters were ligated to the DNA and the library generated
according to the standard library generation protocol (Illu-
mina, USA). A 300 bp size range was excised from the
library on 2% agarose gel. The resultant library was subjected
to 15 cycles of PCR (Phusion DNA polymerase, Finnzymes,
Finland). The library was quantified by Nanodrop (Nanodrop
Technologies) and assayed for size using a DNA 7500
Agilent Bioanalyzer chip (Agilent).
Description of mRNA sequencing protocol
Sequencing was performed on GAII (Illumina). Cluster gener-
ation and sequencing was performed according to manufac-
turer’s instructions. Forty-five cycles of sequencing were
performed on n ¼ 8 samples (four individuals) using the
SBS sequencing kit v1 (Illumina) and cycle sequencing kit
v1/2. For the sequence capture sample (individual 5), 76 bp
sequencing reads using SBS sequencing kit v2 were performed.
All the sequencing data used in this study have been submitted
to the short read archive (accession number SRA008367).
ASE validation by C-BASE
cDNA used for ASE validation was synthesized from the frag-
mented total RNA using Superscript III RT kit (Invitrogen).
Forward and reverse PCR primers were designed against con-
served sequences near the SNPs rs2064068, rs10405893 and
rs1060819, in FAM118A, CALM3 and ATHL1, respectively,
to amplify a 200–230 bp product using AmpliTaq Gold
(Applied Biosystems, ABI, Warrington, UK). Primer
sequences are listed in Supplementary material, Table S2.
Both genomic DNA and cDNA, synthesized from fragmented
total RNA, of individuals that are heterozygous at the reporter

























SNP were amplified. PCR products were excised from a 1.5%
agarose gel using a QIAquick gel extraction kit (QIAGEN).
Purified PCR product was ligated into pCR4-TOPO Vector
and transformed chemically into One Shot Top 10 competent
cells (Invitrogen). Transformed cells were spread onto
Luria-Broth agar plates containing Ampicillin and incubated
at 378C overnight. Colonies were picked from the agar
plates and directly inserted into plates with pre-aliquoted
PCR mastermix of AmpliTaq Gold and T3 (50-ATT
AACCCTCACTAAAGGGA-3) and T7 (50-TAATACGACT
CACTATAGGG-30) primers. Colonies were screened using
TaqMan genotyping assays designed by the assay-by-design
service from ABI. Alleles were scored on SDS v2.2.2 software
(ABI) manually and counted.
ASE validation by sequencing
Purified PCR products, as above, were sequenced using the
corresponding forward or reverse primer in duplicate reac-
tions. The sequencing reactions were performed using
Applied Biosystems’ BigDye (version 3.1) chemistry and
resolved using an ABI 3700 Genetic Analyzer. PeakPicker
software v2.0 was used to calculate normalized peak height
ratios as described in (18).
Read alignment
Our reference sequence set was designed for RNA-seq PE
mapping. We used the Ensembl database version 52 to
obtain, for each annotated gene, the transcript with the
largest number of exons and included this main spliced tran-
script in our reference set. Second, we added one sequence
per intron, extending intron boundaries 40 bp on each side to
allow mapping of reads overlapping exon–intron junctions,
but ensuring that 45 bp read would still map uniquely. In
addition, we included one sequence per non-standard exon–
exon junction (up to three skipped exons, i.e. junctions 1–3,
1–4, 1–5 but not 1–6). These junction sequences consist of
40 bp on each side of the exon–exon junction, such that a
45 bp read would have to overlap the junction by at least
5 bp. Last, a version of the reference DNA genome with
masked annotated transcripts was included. This reference
set was designed such that no region longer than 40 bp is rep-
resented twice, thus avoiding multiple mapping issues with
45 bp reads. However, the same SNP can be represented in
different sequences and our final processing merged the data
when a single SNP mapped to multiple sequences (Perl tools
for reference building available at http://www.gene.cimr.cam.
ac.uk/todd/).
Reads were mapped using novoalign V2.05.12 PE mode for
paired reads, using the group mapping option for all the
sequences (main transcript, introns and non-standard exon–
exon junctions) originating from the same transcript (par-
ameters -v 20 20 200 [.]([^_])_). PE mapping also used
adapter trimming (option -a). SE mode was used for SE data
(parameters -t 150). Quality reads were defined as uniquely
mapped reads with phred-scaled probability score (30) 20
(i.e. maximum estimated mapping error rate of 1 per 100
reads). On average, 60% of the total number of sequenced
45 bp passed this quality read threshold. We wrote a tool,
novoPile (available at http://www.gene.cimr.cam.ac.uk/todd/)
to generate a ‘pileup’ file of bases mapping to individual refer-
ence sequence positions directly from the novoalign output.
We excluded from this ‘pileup’ reads with more than five
mismatches. We also filtered out duplicate reads that were
identified in the PE data (option rmDup).
Identifying heterozygous dbSNPs and indels
To call SNPs heterozygous for ASE, we required that, follow-
ing the exclusion of low mapping score reads and low-quality
score calls, the read depth was 50 and the frequency of the
second most common SNP was at least 15%. Genes located in
the HLA region were excluded from this analysis because of
the elevated polymorphism level and potential biases this
polymorphism might introduce during the mapping process.
Indels were called using the output from novoalign. Only
indels supported by at least four independent reads were con-
sidered to be true calls.
Quality filtering for heterozygous SNPs
We used two statistical tests to filter out unreliable heterozy-
gous SNPs. To verify that the allelic call is independent of
the position of the SNP within the 45 base reads, we compared
both distributions of positions using the Kolmogorov–
Smirnov test. SNPs with P-values more significant than 0.01
were excluded. To check for strand-specific biases, we used
a goodness-of-fit x2 test on the 2 by 2 table of allelic calls
by strand. Again, SNPs with P-values more significant than
0.01 were excluded. SNPs within 45 bases of a called indel
were also excluded from this analysis.
When restricting the analysis to HapMap SNPs, we used
HapMap SNPs in the CEPH population with minor allele fre-
quency .1% and call rate .95% (2 239 392 SNPs total and
87 796 of them were located in spliced transcripts).
Testing for allelic imbalance
Testing a single SNP for allelic imbalance uses a x2
goodness-of-fit test for even frequencies of both alleles.
When more than one heterozygous SNP are present in the
same transcript and the phase is known, the counts can be
summed across heterozygous SNPs, counting only once
reads overlapping multiple SNPs. This phasing information
can be obtained directly from the RNA-seq data, provided
that at least one read pair overlaps both heterozygous SNPs.
Tools for phasing data from short PE reads (novoPhase, avail-
able at http://www.gene.cimr.cam.ac.uk/todd/). Alternatively,
SNPs in high linkage disequilibrium can be phased in silico,
provided that this information is available.
Sequence capture and sequencing for individual 5
Sequence capture probes were designed by Nimblegen
(Madison, USA) to tile CCDS reference transcript for the fol-
lowing genes: BACH2, CAPZA1, CD69, CLEC16A, CTLA4,
DEXI, FAM118A (included as a positive control known
eQTL), ICOS, IFIH1, IL2, IL2RA, IL15RA, IL18RAP, IL21,
KIAA1109, LSP1, MAPKAPK2, PFKFB3, PRKCQ, PTPN2,

























RBM17, RGS1, SH2B3, SOCS1, and TAGAP. Probes were also
designed to tile the intronic regionswithin each transcript, extend-
ing 40 bp into the exons on each side to capture retained intronic–
exonic spanning reads since poly(A)-selected RNA contains
preRNA. Oligonucleotide probes (between 60 and 100 bp)
were designed, excluding any sequences mapping to repeat
regions or that were not unique in the human genome permitting
80% of the total 1.7 Mb genomic regions to be tiled. Probes were
synthesized on 385 000 feature glass slide arrays.
Standard Solexa library preps were conducted according to
the manufacturer’s instructions (Illumina). For the RNA
samples, a poly(A)-selected RNA-seq library was constructed
as described above. For the genomic DNA sample, DNA was
extracted from whole blood using the Gentra PUREGENE
DNA Extraction kit (QIAGEN) according to manufacturer’s
instructions. Five micrograms of DNA was fragmented by
sonication (Bioruptor, Diagenode, USA) before a standard
PE library was constructed. After a single gel-extraction step
to size select a 350 bp library, the adapter ligated library
was amplified with 12 cycles of PCR. One microgram of
either genomic DNA or RNA (cDNA) PE Genome Analyzer
library was added to 100 mg of Cot-1 DNA (Invitrogen)
with 1 ml each of the PE enhancing oligos (1 mM). The
libraries were then hybridized to the sequence capture array
for 72 h at 428C according to the manufacturer’s instructions.
Arrays were stringently washed at 47.58C, and hybridized
DNA eluted with NaOH. At multiple stages of the protocol,
DNA size ranges were checked by Agilent Bioanalyzer and
concentration by OD260/280 (Nanodrop). Hybridization and
elution of libraries was undertaken by Roche Nimblegen in
Madison, USA.
SUPPLEMENTARY MATERIAL
Supplementary material is available at HMG online.
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The role of DNA methylation within gene-bodies is receiving increasing attention as 
emerging evidence suggests important links between levels of gene-body methylation and 
gene expression. To gain further insight into the dynamics of gene-body DNA methylation 
in mammals, we generated high-throughput sequencing (HTS)-based whole-genome DNA 
methylation and mRNA profiles for human CD4+ T-cells, and integrated these data with a 
variety of publicly-available HTS-based whole-genome DNA methylation, mRNA and post-
translational histone modification profiles. Surprisingly, we find that expression-related 
DNA methylation dynamics within gene-bodies are in fact exon-centric. Expressed genes in 
the human genome display distinctive peaks of exonic hypermethylation that are 
developmentally dynamic. We show that exonic DNA hypermethylation is also a feature of 
expressed genes in Arabidopsis. Furthermore, exonic DNA methylation is correlated with 
H3K36me3 marking, suggesting these two epigenetic modifications are involved in related 
phenomena. Collectively, our data provide evidence of a novel and evolutionarily conserved 
role for DNA methylation and support the idea that DNA methylation within gene-bodies 
plays important roles in genome function. 
 
DNA methylation is the only known epigenetic modification of the DNA molecule, and an essential 
component of the epigenetic regulatory machinery in vertebrates and various non-vertebrate 
species (Suzuki and Bird 2008). To date, the vast majority of studies aimed at elucidating the role 
of DNA methylation in mammals have been promoter-focused. However, DNA methylation occurs 
genome-wide in mammals, and it is only very recently that suitable functional genomic 
technologies have become available to perform relatively unbiased interrogation of DNA 
methylation profiles in non-promoter regions (which contain ~90% of all CpG sites in a typical 
mammalian genome) (Suzuki & Bird 2008; Hellman & Chess 2007; Rakyan et al. 2008; Rauch et 
al. 2008; Straussman et al. 2009; Ball et al. 2009; Rakyan et al. 2004; Rollins et al. 2006; Khulan et 
al. 2006; Illingworth et al. 2008; Meissner et al. 2008). Within this context, a surprising observation 
has been that gene-bodies are not invariably methylated, but rather display a positive correlation 
with gene expression, which is the opposite to the negative correlation generally observed 
between promoter methylation and gene expression (Suzuki & Bird 2008; Hellman & Chess 2007; 
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Rakyan et al. 2008; Rauch et al. 2008; Straussman et al. 2009; Ball et al. 2009; Rakyan et al. 
2004). These recent findings suggest potentially important and novel roles for DNA methylation in 
genome regulation. A key challenge now is to elucidate the dynamics of gene-body DNA 
methylation so as to better understand the biological significance of this phenomenon. 
 
Results 
Generation of whole-genome DNA methylation and mRNA profiles for human CD4+ T-cells. 
We used MeDIP-seq (Down et al. 2008) to generate a high-resolution whole-genome DNA 
methylation profile for CD4+ T-cells from a single healthy human donor. MeDIP-seq combines 
Methylated DNA Immunoprecipitation (MeDIP) (Weber et al. 2005; Keshet et al. 2006), with 
subsequent high-throughput sequencing (HTS) (Down et al. 2008) (also refer to Methods). 
Summary statistics for our MeDIP-seq data, and mRNA-seq data described below, are provided in 
Table 1. Absolute DNA methylation levels were estimated using the Bayesian Tool for Methylation 
Analysis (BATMAN) algorithm (Down et al. 2008). Comparison of our BATMAN-analyzed MeDIP-
seq data with DNA methylation data for human CD4+ T-cells derived from 1,322 different bisulfite-
PCR amplicons from the Human Epigenome Project (Eckhardt et al. 2006) revealed strong 
correlation between the two datasets across a range of CpG densities (overall Pearson’s R2 = 
0.81, Supplementary Fig. 1).   
 
Next, using mRNA isolated from the same CD4+ T-cells assayed in the MeDIP-seq experiment, we 
generated a whole-genome mRNA expression profile using the HTS-based mRNA-seq protocol 
described by Mortavazi et al (2008). mRNA-seq is ideally suited to studying gene-body DNA 
methylation and expression correlations since it provides full sequence of the mRNAs, digital 
measurement of even very-low level expression, and analysis of alternatively spliced isoforms. 
Expression levels from the mRNA-seq data were quantified using the ‘Reads Per kb per Million 
reads’ (RPKM) method as described previously (Mortavazi et al. 2008 and Methods). Comparison 
of our mRNA-seq data with previously published ChIP-seq profiles for RNA Polymerase II (RNA 
PolII) in human primary CD4+ T-cells (Schones et al. 2008) revealed a strong correlation between 
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mRNA-seq-based expression levels and RNA PolII binding (Supplementary Fig. 2), confirming our 
mRNA-seq data to be a good estimator of gene expression levels. 
 
Gene-body DNA methylation is positively correlated with gene expression across a range of 
gene lengths. We defined promoters as a ~2 kb window centred on the transcriptional start site 
(TSS), and gene-bodies as the genomic region starting from the 5’ end of the second exon to the 
3’ end of the last exon. Consistent with previous reports, we observed that gene-bodies in general 
display substantially higher levels of DNA methylation relative to promoters, but bodies of 
expressed genes are hypermethylated relative to the bodies of silent genes (Fig. 1a) (Hellman & 
Chess 2007; Rakyan et al. 2008; Rauch et al. 2008; Straussman et al. 2009; Ball et al. 2009; 
Rakyan et al. 2004). We then proceeded to make several novel observations related to gene-body 
methylation. First, we found that the expression-related hypermethylation of gene-bodies is a 
feature of short (1 – 5kb), intermediate (5 – 20 kb), and large (20 – 100kb) genes, in all cases 
steadily increasing from the 5’- end and peaking at the transcriptional termination site (TTS) (Fig. 
1a). Interestingly, for short genes the 5’-hypomethylated region extends deep into the gene-body, 
and thus the positive gene-body methylation vs expression correlation is limited to the 3’-half of the 
gene. Second, it is known that DNA methylation at many promoters correlates negatively with gene 
expression (Suzuki & Bird 2008). However, at some promoters it seems that DNA methylation state 
does not correlate with gene expression (Weber et al. 2007). Due to the composite nature of the 
analysis shown in Fig. 1a, it was not possible to determine whether gene-body methylation varies 
as a function of gene expression or rather is negatively correlated with promoter methylation. 
Comparison of gene-body methylation profiles of expressed genes (RPKM > 0) stratified by 
promoter DNA methylation levels, revealed that promoter and gene-body DNA methylation states 
are in fact uncoupled (Fig. 1b). Collectively, our analyses show that gene-body DNA methylation 
varies as a function of gene expression per se, across a wide range of gene lengths. 
 
Exonic DNA hypermethylation is a feature of transcriptional activity. We then performed a 
detailed analysis of the spatial dynamics of gene-body DNA methylation as it has previously been 
reported that exons are hypermethylated relative to introns in mammalian genes (Rakyan et al. 
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2004; Rollins et al. 2006). Remarkably, we observed distinctive peaks of exonic hypermethylation 
(Fig. 2a). These peaks are most prominent at internal exons i.e. not first or last exons. We 
hypothesized that expression-related gene-body hypermethylation and exonic hypermethylation 
are related and therefore generated expression level-stratified composite profiles of ‘isolated’ 
internal exons i.e. exons that are > 200bp in length and flanked by > 2,000 bp of intronic sequence 
on either side so as to minimize the influence of DNA methylation states of neighbouring exons. 
This analysis revealed that both expressed and silent genes contain exons that are 
hypermethylated relative to introns, but exonic hypermethylation is significantly greater in 
expressed genes (P < 10-3, bootstrapped difference-of-means, Fig. 2b). Since exons are 
significantly more CpG dense than introns (Saxonov et al. 2006) and MeDIP enrichment efficiency 
depends on the density of methylated cytosines, we considered the possibility that our 
observations were technical artefacts, even though the BATMAN algorithm was designed to 
correct for this effect (Down et al. 2008). We analyzed a range of CpG density-matched exons and 
introns and found expression-related exonic hypermethylation across a wide range of CpG 
densities, arguing against the possibility that exonic hypermathyltion is a technical artefact of 
MeDIP-seq (Supplementary Fig. 3). Next, given the expression-related nature of this phenomenon, 
we wondered whether the exonic hypermethylation observed in silent genes is due to these genes 
being expressed at extremely low levels that are not detected by mRNA-seq. For the analysis 
shown in Fig. 2b, we in fact used a very stringent definition of ‘silenced’: no mRNA-seq reads 
observed in our data and no evidence of RNA Pol II binding in human CD4+ T-cells in the dataset 
of Schones et al. (2008). As is evident from Fig. 2b, hypermethylation of exons is a bona fide 
feature of silent genes, but clearly more marked in expressed genes. 
 
Exonic DNA methylation is developmentally dynamic. The analysis in Fig. 2b demonstrates 
that the degree of exonic methylation correlates with steady-state expression levels in CD4+ T-
cells, but doesn’t prove that exonic methylation is developmentally dynamic. We therefore decided 
to compare exonic DNA methylation data for CD4+ T-cells generated in this study with MeDIP-seq-
based DNA methylation profiles for human mature spermatozoa from a study we published 
previously (Down et al. 2008). Firstly, our re-analysis revealed that exonic DNA methylation peaks 
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are also observed in sperm (Fig. 3a). From the set of isolated internal exons described above 
(8,682 exons derived from 5,030 protein-coding genes, ranging in size from ~5 – 100 kb), and 
using a threshold of >30% difference in DNA methylation levels (which provides 78% specificity 
and sensitivity of 61% as previously determined in Down et al. 2008), we found 605 exons that are 
developmentally methylated (sets 1 and 2 combined) and 643 exons that are developmentally 
demethylated (set 4) (Fig. 3b). Importantly, and consistent with our observations from Figure 2, 
genes that contain developmentally methylated exons i.e. set 1 (set 2 is discussed separately 
below) are expressed at higher levels compared with genes that contain developmentally 
demethylated exons, i.e. set 4, in CD4+ T-cells: in set 1, 17% of the exons have RPKM = 0, and 
49% have RPKM >1, whereas in set 4, 22% of the exons have RPKM = 0 and 43% have RPKM >1 
(Fig. 3c). A complete list of genes and associated RPKM values for sets 1 – 4 is provided in 
Supplementary Table 1. It is worth noting that exonic DNA methylation is likely to be even more 
dynamic than our data suggest as we have used a stringent definition for differential methylation (> 
30%) and analyzed a single somatic tissue. 
 
Sets 2 and 3 (Fig. 3b) contain exons that are unmethylated in sperm (<30% methylation), and 
either very strongly methylated (>90%, set 2), or unmethylated (<30%, set 3) in CD4+ T-cells. 
Interestingly, gene expression differences between sets 2 and 3 were not as marked as those 
observed between sets 1 and 4, and overall expression levels for sets 2 and 3 were lower 
compared with sets 1 or 4 (Fig. 3c). A more detailed analysis revealed that exons in sets 2 and 3 
are derived mostly from short genes (average size of ~5 kb) that are strongly enriched for CpG 
islands (CGIs) (P < 10-9, chi-squared test) and, based on an analysis of Gene Ontology (GO) terms 
(http://www.geneontology.org/), play key roles in development (Supplementary Table 2). Coupled 
with the fact that these exons are unmethylated in sperm, a key feature of CpG sites within 
promoter CGIs that is thought to reduce their susceptibility to mutation in the germline, we believe 
that ‘exons’ in sets 2 and 3 actually represent gene-body CGIs that function as regulatory elements 
in similar ways to promoter CGIs (Rakyan et al. 2006; Strausmann et al. 2009; Illingworth et al. 
2008). It is important to note that not all short genes or gene-body CGIs display dynamics similar to 
those observed for sets 2 and 3 (refer to Figs. 1a and Supplementary Fig 3). Therefore, our 
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analysis suggests that developmental DNA methylation dynamics at exons have at least two 
functionally distinct roles: the vast majority are positively correlated with gene expression and 
associated with the general phenomenon of gene-body methylation, with the remaining smaller 
proportion most likely functioning as regulatory elements. 
 
Exonic hypermethylation is evolutionarily conserved. Recently, an interdependence between 
gene-body DNA methylation and transcription in Arabidopsis thaliana has been reported (Xhang et 
al. 2006; Vaughn et al. 2007; Zilberman et al. 2007). To determine if exonic hypermethylation is 
evolutionarily conserved, we re-analyzed the whole-genome BS-seq-based DNA methylation and 
mRNA-seq expression data for Arabidopsis generated by Lister et al. 2008. BS-seq involves high-
throughput sequencing of bisulfite-converted DNA, resulting in single-nucleotide resolution DNA 
methylation profiles (Lister et al. 2008; Cokus et al. 2008). Unlike in mammals, DNA methylation in 
Arabidopsis exists in three sequence contexts: CpG, CHG, and asymmetric CHH (H = A, C or T). 
However, the predominant form of DNA methylation in gene-bodies is CpG methylation (Zilberman 
et al. 2007; Lister et al. 2008; Cokus et al. 2008). Our re-analysis of the BS-seq-based CpG 
methylation and mRNA-seq profiles generated by Lister et al. 2008 revealed that expression-
related, exonic hypermethylation is also found in Arabidopsis (Fig. 4). In fact, it is even more 
marked relative to what is observed in human, i.e. exonic hypermthylation in silent genes is not 
observed in Arabidopsis (compare Figs 2a and 4). It is therefore possible that the general 
phenomenon of expression-related exonic hypermethylation is evolutionarily conserved between 
human and Arabidopsis, but the precise dynamics differ. It is also worth noting the very sharp 
transition between exonic and intronic methylation levels revealed by the single nucleotide 
resolution of the BS-seq technique (Fig. 4).  
 
Lister et al. 2008 also generated BS-seq profiles for the met1-3 Arabidopsis mutant that is deficient 
in the maintenance of CpG DNA methylation. Interestingly, the average profile of gene-body CHG 
methylation in these mutants adopts a pattern that is very similar to the wild-type CpG body 
methylation. Our re-analysis of the met1-3 BS-seq profiles showed that exonic hypermethylation of 
CHG sites is not found in the met1-3 mutants (data not shown), suggesting exonic 
 8 
hypermethylation is specific to CpG methylation. 
 
Co-localization of DNA methylation and H3K36me3 at expressed exons. Recently, a similar 
phenomenon for the post-translational histone modification trimethylation of lysine 36 of histone H3 
(H3K36me3) has been reported: exons within expressed genes are preferentially marked with 
H3K36me3 relative to introns and it is evolutionarily conserved in human, mouse and 
Caenorhabditis elegans (although DNA methylation is not found in C. elegans) (Kolasinska-Zwierz 
et al. 2009). We first confirmed this relationship by combining whole-genome ChIP-seq H3K36me3 
profiles for human primary CD4+ T-cells generated by Barski et al 2007, with our mRNA-seq data 
reported here for exactly the same exons analyzed in Figure 2b (Fig. 5a). Consistent with previous 
results, we found that H3K36me3 is strongly enriched within exons of expressed genes 
(Kolasinska-Zwierz et al. 2009). However, a key difference in exon marking by H3K36me3 
compared with DNA methylation is that the former is almost completely absent from exons of silent 
genes, whereas this is not the case for DNA methylation (compare Figs 2b and 5a). We then 
directly compared H3K36me3 and DNA methylation enrichment within isolated internal exons and 
surrounding introns of expressed and silent genes (Fig. 5b). We find that in expressed genes, a 
strong positive correlation exists between DNA methylation and H3K36me3 within exons, whereas 
this correlation is much weaker in the surrounding introns. In silent genes, there is virtually no 
correlation between increasing levels of DNA methylation and H3K36me3 enrichment (Fig 5b). 
Therefore, DNA methylation and H3K36me3 preferentially co-localize within the exons of 
expressed genes, and in other genomic contexts the DNA methylation-H3K36me3 correlation is 
significantly reduced. 
 
Kolasinska-Zwierz et al. (2009) also found that alternatively-spliced exons have lower levels of 
H3K36me3 relative to their adjacent exonic neighbours that are included in the final transcript, 
suggesting a link with the splicing process. They compared H3K36me3 levels in a set of GC%-
matched exon trios where an alternatively-spliced exon is flanked by two constitutive exons, and 
also compared these exons to a control set of trios where all three exons are constitutively 
included. They found alternatively spliced exons display lower levels of H3K36me3 relative to 
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neighbouring constitutive exons and control trios. A similar analysis using the DNA methylation and 
mRNA-seq-derived splice isoform data generated in this study did not yield evidence of alternative 
exons displaying significantly lower DNA methylation signals relative to their constitutive 
neighbours or matched control trios (data not shown). This is not surprising given the appreciable 
levels of DNA hypermethylation that exist in the exons of silent genes. Therefore, H3K36me3 and 




Overall, our analysis of two novel HTS-based datasets we generated, along with 8 previously 
published ones, reveals that exonic hypermethylation is a developmentally dynamic and 
evolutionarily conserved feature of transcriptional activity. So what could be the functional role of 
exonic hypermethylation? It has previously been proposed that gene-body DNA methylation 
silences spurious transcription (Suzuki & Bird 2008). Our data do not necessarily contradict this 
possibility, but do suggest that gene-body, or specifically exonic methylation plays additional roles. 
For example, it has been shown, in a transgenic cell line model, that intragenic DNA methylation 
reduces RNA Pol II elongation efficiency (Lorincz et al. 2004). Therefore, exonic methylation could 
create ‘roadblocks’ that control RNA Pol II processivity, a function that has previously been 
proposed for the SWI/SNF chromatin remodelling complex (Batsche et al. 2006). Alternatively, 
even though we do not find evidence for a dynamic correlation between exonic DNA methylation 
and alternative splicing, it may still be involved in the splicing process by providing a molecular 
marker for exonic location. In this regard, it is interesting that MeCP2, a protein with a strong 
affinity for methylated DNA, is a component of the splicing machinery (Young et al. 2005), and 
prefers to bind DNA sites containing A/T bases adjacent to methylated CpG sites (Klose et al. 
2005) – a genetic signature reminiscent of exon/intron boundaries (exons are twice as CpG rich as 
introns, Saxonov et al. 2006). 
 
Given that exonic DNA methylation is developmentally dynamic, a critical question is how exonic 
hypermethylation is established. Although, the most likely mechanism would occur co-
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transcriptionally, it is hard to reconcile this with the presence of exonic hypermethylation in silent 
genes. One possibility is that the vast majority of genes classified as silent in CD4+ T-cells are in 
fact expressed at an earlier developmental time-point and, assuming exonic methylation is 
established co-transcriptionally, then it is maintained even after the gene is silenced, thereby 
providing a memory of historical transcription. Alternatively, there is the very intriguing possibility 
that the targeting of DNA methylation to exons does not involve transcription, but rather some 
other mechanism such as intrinsic genetic signatures within exons. Further mechanistic and 
biochemical investigations will be required to rigorously explore these various possibilities. 
 
It will also be interesting to establish whether expression-related exonic hypermethylation is found 
in other genomes that harbour DNA methylation. It is unlikely that exonic hypermethylation occurs 
in the fungus Neurospora crassa, since DNA methylation in this organism occurs almost 
exclusively in repeat-elements within the context of non-CpG sites (Selker et al. 2003). On the 
other hand, gene-body CpG methylation is found in Ciona Intestinalis (sea-squirt) (Suzuki et al. 
2007) and Apis Mellifera (Honey Bee) (Wang et al. 2006). However, high-resolution whole-genome 
DNA methylation profiles for these two invertebrates will be required to address this question.  
 
Finally, there is increasing evidence to suggest that DNA methylation aberrations may be 
associated with a wide variety of human complex diseases, and thus it will be important to 
investigate whether perturbation of exon-specific DNA methylation (either due to genetic or 
environmental influences) leads to alterations in gene expression, and thus possibly contribute to 
human disease pathogenesis. Overall, our data provide evidence for previously unknown and 
evolutionarily conserved roles for DNA methylation, and support the idea that exonic DNA 




Isolation of primary human CD+ T-cells. Primary CD4+ T-cells from a single healthy human donor 
were extracted from leucofilters obtained from the National Blood Service, UK. Ethics approval was 
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obtained from the Oxfordshire REC (05/Q1605/89). Filters were kept at 4°C from the time of 
donation until collection. Cells were eluted carefully from the filters by back flushing with 50 ml PBS 
containing 5mM EDTA. CD4+ cells were isolated using negative selection antibodies (Rosettesep, 
Stem Cell Technologies, Canada) over a Ficoll Gradient (Lymphoprep, Axis Shield, UK) according 
to the manufacturer’s instructions. Cell numbers and viability was assessed by 0.2% Trypan Blue 
staining in an automated haemocytometer (Nexcelom Cellometer Auto T4, Nexcelom Bioscience, 
USA); viability exceeded 93% for all samples. Purity was assessed by flow cytometric analysis of 
CD3+ /CD4+  (Immunotools, France) staining and was greater than 95% for all samples. For RNA 
analysis, 1.2 X 107 cells were lysed in RLT Buffer (Qiagen, UK) with added β-ME (Sigma Aldrich, 
UK), and for DNA analysis 2 X 106 cells were lysed in Puregene DNA Cell Lysis Solution (Qiagen, 
UK) according to manufacturer’s instructions. RNA was extracted using the RNeasy kit, while DNA 
was extracted according to the Puregene DNA purification kit with the addition of 4.5 µl RNase 
(Qiagen, UK). RNA and DNA quality was assessed by agarose gel electrophoresis. 
 
Preparation and High Throughput Sequencing (HTS) of MeDIP- and mRNA-seq libraries. 
MeDIP-seq was performed as described previously (Down et al. 2008). mRNA-seq was performed 
according to the instructions supplied by Illumina (USA) that is based on the protocol developed by 
Mortavazi et al. (2008). Sequencing was performed on an Illumina Genome Analyzer II according 
to manufacturer’s instructions (Illumina, USA).  
 
Processing of the MeDIP- and mRNA-seq raw data. MeDIP- and mRNA-seq sequence data 
was extracted using the standard GOAT pipeline v1.0 and aligned against the human genome 
(Build 36, derived from the ‘1000 genomes’ project, available at: ftp.1000genomes.ebi.ac.uk).  For 
mRNA-seq, this was supplemented by a custom genome consisting of the first and last 40 bp of 
each possible exon combination in a gene to represent all possible exon-exon reads in the 
transcriptome.  Alignments were performed using using Maq v0.6.6 (Li et al. 2008) for MeDIP-seq 
or Novoalign v2.0.14 (http://www.novocraft.com) for mRNA-seq. Reads containing homopolymer A 
reads of greater than 20bp were stripped from the sequence prior to analysis to enhance mapping 
speed. All genes and coordinates are derived from Ensembl v52, unless otherwise stated and all 
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sequences were derived from NCBI Build 36. Exon-Exon sequences were derived from Ensembl 
v48, using the Ensembl PERL API. 
 
MeDIP-seq data were analyzed using the BATMAN algorithm that we recently developed13. Briefly, 
BATMAN transforms the output signal from Methyl-DNA immunoprecipitation experiments into 
quantitative measures of DNA methylation. The core principle of the BATMAN algorithm is to 
model the effects of varying density of CpG dinucleotides, and the effect this has on MeDIP 
enrichment of DNA fragments. A detailed description is provided in Reference 12. 
 
For the mRNA-seq data, transcript levels were quantified by calculating Reads Per kb per Million 
reads (RPKM) as described previously (Mortavzi et al. 2008). Briefly, RPKM calculations were 
performed on mapped data by counting any read that overlapped a known Ensembl v52 exon by a 
single base before all reads for a single gene were summed. The length of each transcript was 
determined empirically base by base from Ensembl v52 as the maximum, unduplicated, theoretical 
transcript length for each gene taking into account all known alternate exons and 3’UTRs. Splice 
variants were calculated from reads mapping uniquely to exon-exon boundaries. Briefly reads were 
summed over each possible exon boundary and an RPKM value calculated for each exon pair. 
Read counts over a splice (non-adjacent exons) boundary were compared to the median read 
depth over all the canonical exon boundaries in the transcript to generate % inclusion for the splice 
exon pair. 
 
Bioinformatic of analyses of HTS datasets. MeDIP-seq data was processed by Batman as 
described above. All ChIP-seq data was processed and binned as described in the respective 
publications, and downloaded from the NHLBI web server. Arabidopsis BS-seq data (from Lister et 
al. 2008) was downloaded from GEO in the format of alignments to the TAIR7 reference genome 
sequence, and the methylation state of each CpG was called using a custom Java script which 
counts the fraction of CpGs in the genome which are read as Cs rather than converted to Ts. 
 
 13 
For all plots showing the spatial distributions of marks around a set of features, we extracted the 
relevant feature-set from Ensembl, then used a custom Java script collected all HTS data in a 
window surrounding that feature, sample the data at 20bp intervals relative to the features, and 
calculate 95% bootstrap confidence intervals on the mean value at each sampling point. 
 
CpG island annotation was taken from Ensembl release 46.  Sequences are called as CpG islands 
if a region of 400bp or longer has a CpG observed/expected ratio >0.6, and a C+G content of 
>50%.  
 
Statistics. All correlation coefficients were computed using Pearson's product-moment formula. All 
credible intervals were estimated by bootstrapping.  
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Table and Figure Legends 
Table 1 Data statistics for the MeDIP-seq and mRNA-seq libraries For the mRNA-seq data, 
paired-end (PE) data were treated as distinct single-end (SE) reads. Reads were aligned uniquely 
to either the hg18 genome (MeDIP-seq) or the hg18 genome plus all possible exon-exon 
boundaries (mRNA-seq). The ‘Generated’ column lists the number of raw reads obtained, and the 
‘Aligned’ column lists the number of reads that mapped with a quality score >10 and used for 
subsequent analyses. 
 
Figure 1 Correlation of gene-body DNA methylation with gene expression in the human 
genome (a) MeDIP-seq-based composite gene-body DNA methylation profiles observed in human 
primary CD4+ T-cells. Methylation levels were estimated using the BATMAN algorithm (Down et al. 
2008). Genes were categorized into 3 expression levels that were calculated using the Reads Per 
kb per Million reads (RPKM) method as described previously (also refer to Methods). For RPKM = 
0 genes, no mRNA-seq sequence tags were observed, and therefore these genes can be 
considered as silent; ‘RPKM < 1.0’ genes can be considered as being expressed at very low 
levels. All other genes were included in the ‘RPKM > 1’ category. Gene-lengths refer to the 
distance from the transcriptional start site (TSS) to the end of the last exon (transcriptional 
termination site, TTS) as annotated in the Ensembl v52 database (b) Gene-body DNA methylation 
profiles of expressed genes (RPKM > 0) were stratified by average promoter methylation level 
calculated over a 1 kb window centred on the TSS. Promoters with an average methylation level of 
< 40% were classified as unmethylated (yellow), whereas promoters with an average methylation 
level of > 60% were classified as methylated (blue). Only genes 5 – 20 kb in length were used in 
this analysis. Error bars in (a) and (b) represent 95% credible intervals calculated using 
bootstrapping. 
 
Figure 2 Exonic hypermethylation in expressed genes (a) Gene-body DNA methylation profiles 
(not stratified by gene expression) from Fig. 1a were spatially stratified. Exons are represented by 
grey boxes and intronic sequence is shown with a black line. To minimize the influence of DNA 
methylation states of neighbouring exons in our analyses, we considered only ‘isolated’ internal 
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exons i.e. exons that are > 200bp in length and flanked by > 2,000 bp of intronic sequence on 
either side. (b) The internal exons in (a) were stratified by expression levels. Expressed genes 
have RPKM > 0. In this figure, an additional criteria was used to classify a gene as being silent: 
RPKM = 0 and no evidence of RNA Polymerase II binding in the promoter region based on the 
RNA PolII ChIP-seq data generated by Schones et al. 2008. All error bars in (a) and (b) represent 
95% credible intervals calculated using bootstrapping. 
 
Figure 3 Exonic hypermethylation is developmentally dynamic (a) We re-analyzed the MeDIP-
seq-based DNA methylation profiles for human mature spermatozoa we previously published 
(Down et al. 2008). This figure was generated in a similar manner to Figure 2a (b) Comparison of 
exonic MeDIP-seq DNA methylation data for human CD4+ T-cells and mature spermatozoa. We 
considered only ‘isolated’ internal exons (refer to legend for Fig. 2a), resulting in a final set of 8,682 
exons derived from 5,030 protein-coding genes (ranging in size from ~5 – 100 kb) annotated in the 
Ensembl v52 database. Set 1 (red) contains 424 exons derived from 397 genes, set 2 (green) 
contains 189 exons derived from 182 genes, set 3 (orange) contains 92 exons derived from 87 
genes, set 4 (purple) contains 643 exons derived from 581 genes. (b) Human CD4+ T-cell mRNA-
seq levels were plotted for the genes containing the exons in each of the four data subsets (1 – 4) 
described in (a). Data are presented as the maximum log10 transformed RPKM value present 
below each percentile.     
 
Figure 4 Exonic hypermethylation in Arabidopsis We re-analyzed previously published high-
throughput sequencing (HTS)-based DNA methylation (BS-seq) and gene expression (mRNA-seq) 
data for Arabidopsis (Lister et al. 2008). In Arabidopsis, exons and introns are, on average, much 
shorter than those found in mammalian genomes, and therefore we used a different definition of 
isolated internal exons compared with the human definition (see Legend for Fig. 2). For 
Arabidopsis, we considered only those internal exons that are > 50bp and flanked by > 250bp of 
intronic sequence on either side. This resulted in a final set of 1,491 exons (95% between 50 – 300 
bp in size) derived from 1,103 protein-coding genes. For silent genes (blue) RPKM = 0, whereas 
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for expressed genes (red) RPKM is > 0. All error bars represent 95% credible intervals calculated 
using bootstrapping.  
 
Figure 5 Correlation between exonic DNA hypermethylation and H3K36me3 exon-specific 
marking (a) Mean H3K36me3 tag counts were plotted for the same set of isolated exons 
considered in Fig. 2b but the data were categorized into silent (blue, RPKM = 0) and expressed 
(red, RPKM > 0). All error bars represent 95% credible intervals calculated using bootstrapping. (b) 
We compared H3K36me3 ChIP-seq data for human CD4+ T-cells generated by Barski et al. 
(2007) with our MeDIP-seq data, also CD4+ T-cells, generated in this study. We compared mean 
H3K36me3 tag counts (please refer to Methods) with DNA methylation levels (binned into 5% 
intervals) in the context of internal exons (dark grey) and surrounding introns (light grey) for 
expressed (RPKM > 0) and silent (RPKM = 0) genes. The drop-off in mean H3K36me3 levels 
associated with extremely high DNA methylation calls may be due to a drop-off in the sensitivity of 
Illumina GA II sequencing in regions of low GC% (Quail et al. 2008). Boxes show the 50% credible 
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a b s t r a c t
Coeliac disease is a common complex disease caused by a dietary intolerance to wheat gluten. Suscep-
tibility is determined by both environmental and genetic factors. Coeliac disease results from complex
interactions between the innate immune system, an adaptive T and B cell response and the mucosal
barrier where inﬂammation is ultimately manifested. Genetic variants within the HLA region are well
established, while variants outside of the HLA region have recently been identiﬁed. These variants are
beginning to enhance our understanding of the immunology of the condition. This review focuses on
the immunological pathogenesis of coeliac disease with special reference to the inﬂuence of genetic
susceptibility on disease development.
© 2009 Elsevier Ltd. All rights reserved.
1. A model immunogenetic disease
Coeliac disease is a model complex disease. The condition we
now regard as coeliac disease, received its ﬁrst modern description
in 1888 by Samuel Gee at St Bartholomew’s Hospital in London [1].
It was not until the middle of the next century that Wilhelm Dicke
recognised that ingestion ofwheat ﬂour appeared to be the precipi-
tating factor for symptoms [2]. This seminal observation shaped the
study of coeliac disease and still dominates it to this day. Coeliac
disease is one of the few complex genetic disorders with a well
deﬁned environmental factor (wheat ingestion) that has a deﬁnite
impact on disease. At this point in time, the genetics and pathogen-
esis of coeliac disease are beginning to be understood. The research
interests of the immunologists and the geneticists involved are
beginning to converge as we understand the pathophysiology in
more detail. There are, however, a lot of un-answered questions for
both the genetics and immunology community. As we learn more
about this disease, these two groups of investigators will need to
collaborate on an increasingly close basis to extract the interplay of
a person’s immune response to wheat ingestion upon their unique
genetic background.
2. Coeliac disease symptoms and prevalence
Coeliac disease results from an immune response to ingested
dietary gluten in genetically susceptible individuals. Disease devel-
opment follows a bimodal distribution, presenting either in theﬁrst
few years of life (after solid feeding has commenced) or in middle
∗ Corresponding author. Tel.: +44 02078822330; fax: +44 02078822187.
E-mail address: d.vanheel@qmul.ac.uk (D.A. van Heel).
age. In susceptible individuals, ingestion of gluten and its related
peptides in the form of wheat, barley and rye cereals leads to mal-
absorption in the small intestine. The classical symptoms arising
from coeliac disease include steatorrhea (diarrhoea due to malab-
sorption of fat), weight loss,weakness, and anaemia. These classical
symptoms are becoming increasingly rare as better diagnostic tests
detect patients earlier, when only mild symptoms such as indi-
gestion and anaemia are present despite manifest mucosal lesions
[3,4]. Coeliac disease is indicated by the presence of a combination
of auto-antibodies, but a histological diagnosis through endoscopic
biopsy of the small bowel is almost always required for a deﬁnitive
diagnosis. Treatment with a gluten free diet is usually completely
effective at eliminating symptoms [5].
Current estimatesplace thepopulationprevalenceof coeliacdis-
ease at about 1% [6–8]. This ﬁgure is obtained from sampling large
numbers of people from thepopulation and testing for the presence
of coeliac disease auto-antibodies. Despite this estimated preva-
lenceof 1%, only approximately0.14%of thepopulation is diagnosed
with coeliac disease [9]. The ratio of diagnosed to undiagnosed
cases, in the UK, therefore stands at about 1:7. This represents a
signiﬁcant burden of morbidity within the population.
3. Gluten
The immunogenic portion of wheat in coeliac disease is well
characterised. Gluten, found in the endosperm of cereals includ-
ing wheat, barley and rye, is composed of distinct portions of
monomeric, alcohol soluble gliadins (responsible for the elastic-
ity of dough), and polymeric, prolamine rich glutenins [1]. There
remains some debate about whether oats are capable of inducing
an immune response but it seems likely that oats are generally safe
in the majority of patients [10–13].
1044-5323/$ – see front matter © 2009 Elsevier Ltd. All rights reserved.
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4. The human leucocyte antigen complex
The genetic basis of coeliac disease is traditionally split into
variants within the Human Leucocyte Antigen (HLA) region and
non-HLA variants. The concordance of coeliac disease between
monozygotic twins is very high, 75%, while the concordance
rate between dizygotic twins is still high at 11% [14,15]. This
strong heritability is also evident in family studies where the
risk of coeliac disease is approximately 10% for a sibling of an
affected individual [16]. By way of a comparison, the concordance
rate for Crohn’s disease (another inherited complex disease of
the gastrointestinal tract) is 33% in monozygotic twins, underly-
ing the particularly strong genetic component of coeliac disease
[17].
The ﬁrst genetic association in coeliac disease came in the 1970 s
with the identiﬁcation of an association to the HLA serotypes, HLA-
B8 (originally named HL-A8) and HLA-DR3 (originally HLA-DW3),
with coeliac disease development [18,19]. This associationwas later
reﬁned to identify the HLA-DQ2 serotype as the true association
between the HLA locus and coeliac disease [20]. HLA-DR3, HLA-B8
andHLA-DQ2 are in strong linkage disequilibriumand are inherited
on the same ancestral haplotype [21]. TheDQ2 serotype association
with coeliac disease is mediated entirely through the DQ2.5 hap-
lotype, the other haplotype found with the DQ2 serotype, DQ2.2,
does not appear to predispose to disease [22]. The HLA-DQ2.5 hap-
lotype contains both the alpha and the beta chain of the MHC
molecule. The speciﬁc alleles of the DQ2.5 haplotype are conven-
tionally given the notation DQA1*0501–DQB1*0201. HLA-DQ2.2 on
the other hand contains the alleles DQA1*0201–DQB1*0202. Since
each haplotype is only present on one chromosome it is possible
to generate a combination of DQ2.5 and DQ2.2 molecules on a cells
surface depending upon parental genotype. The DQ2.5 haplotype
can be encoded in cis, where both the alpha and beta chain are
encoded on the same chromosome or in trans with each parent
supplying one chain [17,23].
Possession of the HLA-DQ2 serotype is a very strong risk factor
for coeliac disease development. A study of just over 1000European
coeliac patients found just under 90% possessed the DQ2 serotype
[24]. The remaining patients tend to possess a related DQ8 serotype
or at least one chain of the DQ2 heterodimer (e.g. DQA1*0501 or
DQB1*0201 but not both) [17,24]. The exact conﬁguration of HLA-
DQmolecules that a person inherits directly inﬂuences their coeliac
disease risk. A gene dosage effect has been observed for carriage of
the DQ2.5 haplotypewith homozygotes at 4–6 times increased risk
of disease development [25]. Interestingly patients heterozygous
for the DQ2.5–DQ2.2 also seem to be at a signiﬁcantly increased
risk of coeliac disease [26].
Althoughagenetic associationbetween coeliac disease andvari-
ants in the HLA region is useful for diagnostic criteria and risk
prediction the true goal of all genetic studies should be to gain an
insight into the biology of a condition.
After the identiﬁcation of the genetic association between
coeliac disease and the HLA, much attention was focused on the
mechanism of this association with a view to understanding the
pathogenesis of the disease. The HLA region is a 4Mb region on
chromosome 6p21. It contains all human major histocompatibility
genes aswell as numerous other immune and non-immune system
genes. Theprimary functionof class IIMHCmolecules, likeHLA-DQ,
is to present exogenously derived antigen on the cell surface to T
cell receptors. In the case of coeliac disease, antigen presenting cells
present gluten peptides derived from the gut lumen to T cells, thus
eliciting an immune response. The heterodimers formed from the
DQ2.5 and DQ2.2 haplotypes differ in their peptide binding afﬁnity
forglutenpeptides [27]. Thecoeliacdiseaseassociatedheterodimer,
DQ2.5, binds-gliadin derived epitopeswith amuchhigher afﬁnity
than the non-associated DQ2.2 heterodimer [28,29]. When gluten
peptides do bind to DQ2.2 they elicit an identical T cell response
compared toDQ2.5binding [29], indicating that thebinding charac-
teristics of HLA-DQ and gluten derived peptides are likely to be the
primary mediator of the genetic association between HLA-DQ2.5
and coeliac disease. The increased presentation of gluten epitopes
to T cells by DQ2.5 homozygotes explains the observed gene dosage
effect [29].
A large number of -gliadin derived peptides have been identi-
ﬁed that can activate the immune system within coeliac disease
individuals [30–36]. A 33mer peptide, that is resistant to both
human and rat intestinal brush border enzyme digestion, has been
proposed as one of the primary mediators of this gliadin induced
activation. A large number of peptides that do elicit immune activa-
tion response, however, are not found in this 33mer peptide [34,37].
This leads to the speculation that many different gluten epitopes
may be capable of activating the immune system in the context
of HLA-DQ2. HLA-DQ8 speciﬁc peptides have also been identiﬁed
[35,38].
5. Tissue transglutaminase
Anti-endomysium (EMA) and anti-gliadin IgA antibodies can
be detected in the peripheral blood of coeliac disease patients
prior to treatment [39,40]. EMA represents a particularly effective
biomarker with a sensitivity approaching 98–100% and a positive
predictive value in excess of 93% [41–43]. Apart from being an
extremely useful diagnostic and screening tool, the detection of
EMA provides a key insight into the pathogenesis of the disease. In
1997Dieterichet al. identiﬁed theepitopeofEMAas tissue transglu-
taminase (Transglutaminase Type 2, TG2), an intracellular enzyme
found in the lamina propria thatwas known to interactwith gliadin
in the human jejunal mucosa [44,45]. Gluten itself has a very high
proline and glutamine content, and therefore very few of the neg-
ative residues necessary to bind to the groove of HLA-DQ2 or DQ8
[46]. In order to bind to the groove, gluten derived peptides must
ﬁrst be deamidated, changing key residues fromglutamines to neg-
atively charged glutamates [47,48]. For the many gluten derived
epitopes that have been identiﬁed as putative HLA-DQ2 binding
molecules, deamidation by TG2 appears to be a pre-requisite for
binding andantigenpresentation [30]. TG2 is expressed in the small
bowel, particularly in the laminapropria and there is someevidence
that its expression may be increased in coeliac disease [44,49,50].
Intestinal deposits of TG2 IgA are a hallmark of coeliac disease and
may occur even in a latent form of disease prior to villous atrophy
development [51]. The physiological function of TG2 is not com-
pletely understood, but it does seem to play a role inwound healing
[52,53], cellular apoptosis [54,55] and stabilization of the extracel-
lular matrix proteins (ECM) [56,57]. TG2 is ubiquitously expressed
and has no known human inherited defect syndrome; in addi-
tion TG2 (−/−) knock-out mice appear developmentally normal
with onlyminor ﬁbroblast and thymocyte defects [58,59].Whether
the anti-bodies produced against TG2 are actually deleterious in
coeliac disease has yet to be determined, but it is plausible that
the physiological function of TG2 could be interrupted by anti-
TG2 antibodies, possibly increasing the local inﬂammatory damage
[60].
Although not a classically secreted protein, TG2 does appear to
be secreted from cells and it binds with very high afﬁnity to ECM,
particularly ﬁbronectin [60]. This binding has been implicated in
cross linkinggliadinpeptides, TG2andextra-cellularproteins; lead-
ing to increased levels of gliadin in the lamina propria of coeliac
disease patients [61]. Within the protein rich ECM of the lamina
propria, most TG2 enzymes will be cross linked with proteins, but
even so they appear to be capable of deamidating some gliadin pro-
teins [62]. Activation of TG2 requires millimolar concentrations of
Ca++ and activation is inhibited by guanine nucleotides; the result
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is an enzyme that is often found in the inactive form, both intra-
and extracellularly [63,64].
How TG2 antibodies develop in the ﬁrst place is not yet fully
understood. The original proposition was a hapten-carrier like
model. Here TG2 speciﬁc B cells, that are universally present,
were hypothesized to endocytose a TG2-gliadin dimer, degrade
it intracellularly and present it on the surface in the context of
HLA-DQ2 with gliadin speciﬁc CD4 T cells providing the necessary
cytokine help [65]. This premise relies on the very stable bind-
ing between TG2 and gliadin [66]. The discovery by Pinkas et al.
that TG2 undergoes a large conformational change upon calcium
induced activation opens the intriguing possibility that the anti-
bodies may be directed against a “neo-epitope” that is not present
on un-activated TG2 and therefore shielded from T cells during
thymic selection [64]. Since the antibody based assay to detect IgA
requires calcium and site directed mutagenesis of the TG2 gliadin
binding active site abrogates IgA antibody binding it appears that
calcium activated TG2 is the target of the IgA antibody response
in coeliac disease. What cellular processes activate TG2 in the ﬁrst
place is an intriguing research question that is not fully answered
[67,68].
6. Disease progression
Once gliadin has been presented to CD4 T cells in the con-
text of HLA-DQ2, the T cells release a number of cytokines that
mediate disease. Coeliac disease is classically thought to be a
TH1 mediated disease. Biopsy specimens from the small bowel
of untreated coeliac disease patients reveal signiﬁcantly elevated
levels of interferon gamma (IFN) (over 1000-fold increase) com-
pared to histologically normal controls and in vitro stimulation of
gluten speciﬁc T cell clones with HLA-DQ2 yields an almost clas-
sical TH1 cytokine response [69,70]. Inhibiting this IFN response
abrogates the gliadin induced changes in morphology of in vitro
cultured coeliac gut biopsy specimens [69]. Although thought of
as a TH1 disease, IL-12, the major TH1 polarising cytokine, does not
appear to be expressed at elevated levels in themucosa of untreated
coeliac disease patients and in gut biopsy explants stimulated with
gliadin in vitro [71,72]. IL-18, also a TH1 polarising cytokine, has
been found to be elevated in coeliac disease mucosa compared
to controls [73]. Recent work by De Sabatino et al. has provided
some important insights into the mechanisms of TH1 cell differen-
tiation in the absence of IL-12. Mucosal dendritic cells from coeliac
patients demonstrated elevated levels of Interferon  (IFN), IL-
18 and IL-23p19 compared to controls, however, only blockage of
IFN inhibited the gliadin induced IFN increase in cultured gut
biopsy explants from coeliac patients [74]. IFN has been previ-
ously demonstrated to cause crypt hyperplasia in a foetal gutmodel
upon concomitant CD3 stimulation of T cells andmay play a role in
the differentiation of TH1 cells in coeliac disease [75]. In themucosa
of coeliac disease patients elevated levels of the TH1 deﬁning tran-
scription factor, T-bet have been observed [76,77]. This induction
appears to be dependent on IFN [77].
Recently work has focused more on the newly identiﬁed
cytokine IL-21 as a possible candidate for induction of T-bet, IFN
and hence TH1 polarisation in coeliac disease. There is already evi-
dence that IFN can induce IL-21 secretion from activated T cells
[78]. IL-21 is secreted upon CD3 stimulation of T cells and by NK
cells. The cytokine itself is similar in structure to both IL-2 and IL-
15 [79]. Although some murine work has suggested that IL-21 may
be a TH2 inducing factor, in humans, treatment of CD4 T cells with
IL-21 leads to a signiﬁcant increase in T-bet and IFN production as
well as IL-2R, IL-12R2, IL-18R andMyD88 [79,80]. Several groups
have demonstrated an increase in the levels of IL-21 in the mucosa
of coeliac disease patients compared to controls [81,82]. Inhibition
of IL-21 in gut biopsy samples ablated the IFN response to a gliadin
digest, however, inhibition of another related cytokine primarily
produced by dendritic cells, IL-15, produced a greater inhibition of
the IFN response [81]. In Crohn’s disease, an IL-21 induced rise
in TH1 cytokines has also been observed, but it derives from cells
already polarised to the TH1 phenotype by IL-12 [83]. It is there-
fore possible that IL-21 functions as an autocrine factor from cells
already activated to maintain the secretion of IFN. One of the cen-
tral problems that investigators encounter when studying coeliac
disease is that the best system to understand how the immune cells
and mucosa interact involves in vitro cultured gut biopsy samples.
These provide a good indication of cellular interactions and have
been instrumental in identifying the causes of the IFN response
to gliadin but have made it difﬁcult to identify exactly which cell
type is responsible. The compartment with the largest contribu-
tion to IFN appears to be the intra-epithelial lymphocytes (IEL)
[84]. If IL-21 is acting to maintain the IFN response, it is possible
that it may act directly on these cells; however, given that IL-15
is also necessary for the IFN response, a more synergistic model
seems likely. IL-21 appears to have synergistic effects with IL-15
upon many lymphocyte subsets that are not seen when IL-21 is
administered alone [85]. Of particular interest to coeliac disease
is the interaction of IL-21 and IL-15 both of which are central to
the activation and expansion of the IEL compartment upon gluten
ingestion in coeliac disease. The IELs comprise a mixture of cells
with the majority being TCR+CD8+CD4−or TCR+CD8− CD4−
[86]. The varied functions of IL-21 and how it interacts with the
IL-15 are still being investigated, with information on their syner-
gistic interactions in the intestinal micro-environment only now
beginning to come to light.
7. Innate immune system involvement
IL-21 secreted by CD4+ cells in the lamina propriamay represent
the key link between the adaptive and innate responses to gluten
ingestion in coeliac disease. NKG2D is an IL-15 induced receptor
that acts as a co-stimulatory molecule on CD8+ cells from the jeju-
nalmucosawhich lack CD28 [87,88].MIC (MHCclass I chain-related
genes), represent a class of non-classical HLA genes that serve as
ligands for NKG2D [89,90]. The expression of these genes is highly
regulated and normally restricted to the epithelium [90]. MICA is
induced in dendritic cells by IL-15, and neutralising monoclonal
antibodies directed against IL-15 inhibit MICA increase in coeliac
explants treated with gliadin digests [90,91]. In coeliac disease,
MICA expression in the intestinal epithelium is highly upregulated
from ∼2.5% in controls to ∼30% in untreated cases, a condition that
canbe replicatedby the in vitro addition of gliadin to treated coeliac
disease biopsies [90].
A model is now being developed whereby cells that have previ-
ously been activated to a TH1 phenotype by cytokines such as IFN
can produce IL-21 that interacts with other CD4+ T cells generating
more IFN in the lamina propria, and perhaps more importantly
interacts with IL-15 which stimulates IFN from cells within the
epithelium resulting in the characteristic villous remodelling seen
in coeliac disease [92]. The exact nature of the IL-15–IL-21 inter-
action is unknown and at this point it is only possible to speculate
based on the cytokines’ functions in other tissues. Perhaps themost
interesting question to answer will be how NKG2D, IL-15 and IL-21
interact and in particular how they inﬂuence the response of sus-
ceptible individuals to gliadin peptides. Current understanding of
the pathogenesis is summarised in Fig. 1.
8. The role of the intestinal epithelium
The intestinal epithelium plays a central role in the disease pro-
cess of patients with coeliac disease. Not only is the deregulation
of this barrier the primary cause of symptoms, but it also seems to
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Fig. 1. Current understanding of the pathogenesis of coeliac disease. Gluten is digested in the gut lumen by intestinal peptidases. Fragments such as the p31-43 fragment
activate the intestinal epithelium, releasing IL-15which leads to IFN production from intra-epithelial lymphocytes. Other gluten fragments are deamidated by TG2 and taken
up by dendritic cells, which then present to naive T cells in the context of HLA-DQ2.5. These cells migrate back to the mucosa and once activated produced IL-21 and IFN.
play an active role in disease pathogenesis. The epithelium directly
modulates the immune system beneath it and this regulation is
acutely altered in affected individuals by gliadin. In coeliac dis-
ease, IL-15 is expressed on enterocytes in active disease only, not
in patients treated with a gluten free diet. There is conﬂicting data
as to whether IL-15 is actually secreted or simply expressed on the
cell surface, a conﬂict that will have to be resolved before its role
in the pathogenesis can be completely understood [93,94]. If the
epitheliumwas simply expressing IL-15, this suggests an important
role for cell to cell contact within the epithelial layer. An -gliadin
derived peptide sequence, p31-43, different from that which acti-
vates T cells has been identiﬁed as apossible innate immune system
activator in disease [95]. Several groups have demonstrated that
gliadin peptide digests can activate in vitro matured dendritic cells
leading to an increase in dendritic cell activation markers and
cytokine secretion [96,97]. The p31-43 peptide appears capable of
inducing IL-15 and MICA secretion from the intestinal epithelium
without any adaptive immune system involvement [90]. There is
some evidence that this response is a generalised response in all
individuals, but is ampliﬁed in coeliac disease patients (possibly
due to a lower threshold to IL-15) who only get disease as a result
of adaptive immune system involvement [98].
Zonulin is an intestinal peptide that has been implicated in the
regulation of epithelial tight junctions and hence intestinal per-
meability [99]. Zonulin appears to be released by the intestinal
epithelium in response to -gliadin peptide digests, resulting in
thedisassembly of the tight junction complexes [100]. It is notewor-
thy that only apical administration of gliadin induces this response
[101]. Recent work by Lammers et al. has identiﬁed that gliadin
binds speciﬁcally to CXCR3 on enterocytes, inducing a MyD88
induced release of zonulin, resulting in a greater epithelial perme-
ability [100]. The story is further complicated by the ﬁnding that
the immunodominant 33-mer -gliadin fragment can pass though
epithelial cells by transcytosis, a process enhanced by IFN [102].
This appears to indicate that gliadin can gain access to the basal
surface of the epithelium, and therefore interact directly with the
immune system, via both trans- and para-cellular routes. -gliadin
affects not only the epithelial layer, but also leucocytes. There is
evidence from peripheral blood derived CD14+ monocytes that -
gliadin can induce IL-23 in an IL-1 dependant manner, a function
that is inhibited by an IL1-R antagonist [103]. An increase in CD14+
cells has previously been observed in the lamina propria of coeliac
disease patients, although they do not appear to be the main HLA-
DQ2 antigen presenting cells [104].
Coeliac disease patients respond to -gliadin digests in a very
similar manner as non-coeliac individuals, producing zonulin from
enterocytes and IL-1 from peripheral blood mononuclear cells.
The magnitude of the release is, however, far greater in coeliac
individuals than in healthy controls. Peripheral bloodmononuclear
cells elicit weak IFN responses to gluten in HLA-DQ2+ healthy
subjects after a previous period on a gluten free diet, a response
that is not enhanced by deamidation of the gluten [105]. Some
fragmentsof un-deamidated-gliadinmay therefore act as a gener-
alised immune activating factor. The progression to disease is likely
to rely on a combination of environmental insults and genetic alter-
ations in thehandlingof gliadinby the immunesystemandmucosal
barrier.
9. Genetic impacts on gliadin handling
The most important genetic determinant of coeliac disease is
HLA-DQ2 carriage. The presentation of deamidated gliadin in the
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Fig. 2. The HLA-DQ association with coeliac disease. HLA-DQ2.5 carriage is necessary for disease development, but it is not sufﬁcient. A combination of other genetic factors
inﬂuencing the mucosal barrier, the adaptive and the innate immune system also impact the likelihood of disease development. Wheat ingestion is a known environment
factor that is necessary for disease development but on top of this a number of factors such as timing of gluten ingestion and breast feeding cessation may inﬂuence disease
development [120].
context of HLA-DQ2 or DQ8 makes possession of these serotypes
almost necessary for disease development and yet 30% of the Cau-
casian population also carry HLA-DQ2 and most will eat wheat,
while only 1 in 100 will develop disease. The remaining sus-
ceptibility is thought to be due to a combination of genetic and
environmental factors (Fig. 2). Studies using twins, which are
assumed to share environmental factors, have estimated the per-
centage of non-HLA genetic variantswhich predispose to disease as
approximately 60% [17]. So despite their importance in the patho-
physiology, HLA variants contribute to only about 40% of the sibling
relative risk. To date a large list of variants have been suggested to
predispose to coeliac disease through a combination of linkage and
association studies, a large number of variants, however, do not
stand up to further scrutiny. Only those that have been validated
with convincing evidence in multiple populations are mentioned
here. This does not exclude variants that conclusively associate in
one population as being causal in that population only, they just
require a higher burden of proof.
Genome wide linkage scans aim to identify broad genomic
regions that are inherited within families with multiply affected
members. In coeliac disease, like many common diseases, this
approach has been fairly unsuccessful at locating variants. Link-
age was found to various regions including 5q and 19p, however,
the only genomic region that was replicated with some reliability
in other populations was 2q33, a region that contains the CTLA4,
ICOS and CD28 genes [17]. Even for this region, however, replication
was inconsistent. CTLA4 is an excellent candidate gene for involve-
ment in coeliac disease not only due to its integral involvement in
the suppression of immune responses but also because it has been
implicated as a genetic variant that increases susceptibility to Type
1 diabetes (see below). The regions identiﬁed by linkage were very
large, typically in theMb range and contained numerous genes. For
a full reviewof linkage scansundertaken in coeliac disease and their
results see [17].
10. The genome wide association study era
As sample cohorts have became larger, and genotyping tech-
nologies improved, it is nowpossible to performassociation studies
between a population of cases and controls using single nucleotide
polymorphisms (SNP). This simple genetic analysis is very useful
for following up linkage signals and for testing candidate genes for
association with disease since it is now possible to narrow down
association to a single haplotype. In this manner the 2q33 linkage
peakwasnarroweddowntoanassociatedhaplotypenear theCTLA4
gene [106].
In the past few years it has been possible to design genomewide
association studies involving hundreds of thousands common SNPs
spread across the genome. Each SNP is tested for association with
disease in a large cohort of cases, typically in excess of a thousand
and a similar sized group of controls. After correction for the num-
ber of tests performed it is possible to identify common variants in
thegenome that predispose todisease. Themajor advantages to this
methodology are the increased power over linkage studies, derived
from the large cohorts, the better resolution mapping of the asso-
ciation and the hypothesis free approach. The SNPs tested in these
studies arederived fromThe InternationalHapMapProject and they
aim to genotype variants with a greater than 5% minor allele fre-
quency. This has been estimated to capture approximately 90% of
the genetic variation in theCaucasianpopulation [107,108]. Theﬁrst
genome wide association study in coeliac disease was undertaken
in 2007 [82]. Outside of the HLA-region, the most signiﬁcant ﬁnd-
ing from a cohort of 778 coeliac patients was an association with a
linkage disequilibrium block containing four genes, IL2, IL21, TENR
and KIAA1109. It is remarkable how well two of these genes appear
to ﬁt with the known pathogenesis. Although it is impossible as yet
to deﬁnewhich, if any, of these genes are affected by the associated
variant, given the immunology described above IL21 is an excel-
lent candidate. A follow up to this study in larger sample cohorts
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Table 1
Non HLA variants associated with coeliac disease. Genes currently associated with coeliac disease and their replication in two independent cohorts. A p value cut off of
P=5×10−7 has been applied as a level of genome wide signiﬁcance. Data has been taken from a follow up survey of 1020 top SNPs from the original GWAS, conducted in
separate populations of British, Irish and Dutch origin with appropriately matched controls [82,110,119].













rs2816316 RGS1 0.0012 5.11×10−9 0.1 0.0011 2.58×10−11 0.71 (0.63–0.80)
rs917997 IL1RL1, IL18R1, IL18RAP, SLC9A4 9.06×10−5 1.97×10−6 0.55 3.61E−06 8.49×10−10 1.27 (1.15–1.40)
rs6441961 CCR1, CCR3 0.0028 3.21×10−5 0.21 0.002 3.14×10−7 1.21 (1.10–1.32)
rs17810546 IL12A, SCHIP1 0.00034 7.77×10−7 0.00025 0.00064 1.07×10−9 1.34 (1.19–1.51)
rs1464510 LPP 7.65×10−5 1.21×10−5 0.085 0.29 5.33×10−9 1.21 (1.11–1.31)
rs13119723 IL2, IL21 2.51×10−7 1.23×10−7 0.013 0.00011 5.94×10−13 0.73 (0.65– 0.82)
rs1738074 TAGAP 0.0016 1.19×10−5 0.014 0.00082 6.71×10−8 1.21 (1.11–1.31)
rs653178 SH2B3 (LNK), ATXN2 0.00065 2.98×10−5 0.16 0.017 8.00×10−8 1.19 (1.10–1.30)
rs3087243 CTLA4 1.26×10−6 0.85 (0.80–0.90)
rs333 CCR5 9.18×10−6 0.79 (0.71–0.88)
from theUK, Ireland and TheNetherlands identiﬁed a further seven
variants (Table 1) associated with disease. Almost all have a known
immunological function. A more in depth review of these variants
hasbeenpublishedelsewhere and is outside the scopeof this article
[23]. These variants do, however, allow us to draw some interesting
parallels about the pathogenesis of coeliac and other autoimmune
disorders. The remarkable ﬁnding from the studies undertaken to
date is that almost all of the genes (identiﬁed in a hypothesis-free
manner) are involved in the coeliac disease pathogenesis path-
ways identiﬁed to date. It is also interesting to note the absence
of pathways. For example no variants have so far been identiﬁed,
and replicated in other populations, in themucosal barrier or in the
tissue transglutaminase genes. It is possible this belies the evolu-
tionary importance of the mucosal barrier, while lymphocyte gene
variationmayhave provided a survival advantage. It isworth noting
that H. sapiens only began consuming cereals about 10,000 years
ago [109], with the advent of agriculture, so the variants identi-
ﬁed by genome wide association studies, all of which are common
(and therefore evolutionary ancient), have only received signiﬁcant
negative selective pressures for a very short period of time.
To date, only a very small percentage of the heritability of coeliac
disease can be explained. The sum of all the regions identiﬁed by
genome wide association explains about ∼4% of this heritability,
together with the HLA region (which explains about 34%), two-
thirds of the heritability is still unaccounted for (Fig. 3) [110]. This
problem of missing heritability is not unique to coeliac disease,
and indeed is shared by all common complex diseases. Where this
missing heritability lies is at present, not known. Brendan Maher
elegantly outlined in a recent editorial someof the currenthypothe-
ses that researchers are using to explain the failure of GWAS to
reveal large chunks of the heritability of many common diseases
[111]. Genome-wide studies are designed to capture only common
variants so rare variants with larger effect sizes may contribute to
a large fraction of this heritability. It is also possible that since the
SNP identiﬁed to date are only markers, the true causal SNP may
have considerably larger effect sizes. As it is unlikely that current
sample sizes will be able to capture all genetic variation, collabora-
tion and generation of larger and larger cohorts of cases is the best
way to capture the true genetic variants that predispose to disease.
11. Common genetics of autoimmune diseases
A clinical association between coeliac disease and type 1 dia-
betes (T1D) was ﬁrst identiﬁed in 1969 [112]. The prevalence of
coeliac disease in patients diagnosed with T1D has been esti-
mated at up to 15% in children and 6% in adults [113]. The reason
for this association has never been fully elucidated, but common
mechanisms within the pathogenesis and genetics of the two con-
ditions may provide some insights. The ancestral haplotype, AH8.1,
which contains the coeliac disease associated HLA alleles as well
as more than 250 other MHC and non-MHC genes, appears to
be involved in a myriad of immunological diseases. Carriage of
this haplotype predisposes individuals to T1D, systemic lupus ery-
thematosus, common variable immunodeﬁciency, IgA deﬁciency,
myasthenia gravis, scleroderma, impaired survival after HIV infec-
tion and altered T cell numbers (for a full review see [21]). Apart
from the HLA region and the previously identiﬁed CTLA4 region,
evidence from recent genome wide association studies in coeliac
disease and T1D point toward shared susceptibility variants [110].
Of particular interest is the IL-2, IL21 region which displays inde-
pendent associations to T1Dand coeliac disease [82,114]. The region
is analogous to the Idd3, diabetes associated, region in the non-
obese diabetic (NOD) mouse. In this model IL-21 is essential for
diabetes development [115]. Apart from coeliac disease and T1D,
this regionalsodisplays associationwith rheumatoidarthritis [116],
Grave’s disease [117] andpsoriatic arthritis [118].Whether the same
Fig. 3. Coeliac disease heritability explained. Over the past 100 years many genetic studies have been undertaken in celiac disease. Despite this however, only 34% of the
heritability has been explained. The identiﬁcation of HLA-DQ2.5 association in the 1970s still explains the largest percentage of heritability (∼35%). New variants identiﬁed
by genome wide association have only added an additional 3–4% to this ﬁgure leaving a large amount of the genetic contribution to disease unexplained. This ﬁgure can be
expected to increase, however, once the causal variants within these loci have been identiﬁed.
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gene or variant is involved in all these conditions is not currently
understood. It is possible that there is a shared genetic suscep-
tibility to autoimmunity through variants such as the IL-2, IL-21
locus, that is modulated by other variants both inside and out-
side of the HLA region as well as by environmental factors which
dictate development of disease. A recent collaborative study has
expanded our understanding of the common genetic risk factors
between T1D and coeliac disease. Smyth et al., using a collection
of 8000 T1D cases and 2500 coeliac disease cases, tested variants
convincingly associated with one disorder for association in the
other, and vice versa [119]. The results were surprising, not just for
the commonalities that they demonstrated, but for the differences.
Eight non-HLA coeliac variants were tested in T1D, three of which
(RGS1, IL18RAP, TAGAP) showed convincing evidence of association.
Interesting, IL18RAP and TAGAP, while predisposing to coeliac dis-
ease appear to protect from T1D.When 17 T1D regions were tested
in the coeliac disease samples, three (CTLA4, CCR5, PTPN2) again
showed convincing evidence of association. These results underlie
the important common genetic backgrounds of the two conditions,
and suggest there may be a common genetic contribution, which is
modiﬁed by a further subset of disease speciﬁc genes and environ-
mental insults leading to either T1D or coeliac disease.
Genome wide association studies have provided hypothesis-
free associations with genetic variants and coeliac disease. Asmore
studies are undertaken and more samples added, the number and
type of associated variants will increase. The true goal of genetic
studies should not be to act as a purely predictive diagnostic tool,
but to give an insight into biological function. For the variants iden-
tiﬁed so far almost no function has been identiﬁed. A SNP located
close to the IL18RAP gene appears to correlate with the gene’s
expression in peripheral blood (an eQTL) but this is no guarantee
that the true causal variantwithin this linkage disequilibriumblock
is actually affecting this gene [110]. The eQTL may be totally unre-
lated to disease, especially since the linkage disequilibrium block
contains other genes such as IL-1RL1 which are just as plausible
biological candidates [110]. Just like the studies associatedwith the
HLA-DQ2.5 variant, the identiﬁcation of the causal variant and its
functionwill provide a unique insight into coeliac disease and other
autoimmune disease biology.
The ultimate aim of these genetic studies is not just to be able to
predict disease risk, but to illuminate disease pathways. This under-
standing will demonstrate how immunological and physiological
processes interact with environmental variables on a person’s
genetic background with the ﬁnal aim of developing a meaning-
ful effective treatment for coeliac disease. As work in the ﬁeld of
coeliac disease progresses, both the genetic susceptibility and the
pathogenesis will hopefully become evident in turn leading to bet-
ter disease prediction and treatments for patients.
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Chronic inflammatory diseases have been at the forefront of the new genome-wide association study era.
Conditions such as coeliac disease, type 1 diabetes, Crohn’s disease and ulcerative colitis have all benefited
with multiple loci identified and replicated for each condition. As cohort sample numbers increase and
researchers collaborate and share cohorts, common susceptibility loci are beginning to emerge between sev-
eral diseases. Crohn’s disease and coeliac disease both demonstrate considerable overlap in their common
genetic susceptibility with other related conditions. These shared loci offer an insight into the biology of the
conditions but still present researchers with the problem of attempting to identify the true causal variants.
INTRODUCTION
Chronic inflammatory diseases are defined by long-term
inflammatory processes directed at a particular endogenous
or exogenous antigen. Within this definition, there is consider-
able overlap with autoimmune conditions such as multiple
sclerosis and type 1 diabetes (T1D), but it can also be extended
to cover a range of other conditions that would not normally
be termed ‘autoimmune’, such as inflammatory bowel
disease, idiopathic pulmonary fibrosis and atherosclerosis.
The purpose of this review is not to provide an in-depth analy-
sis of the genetics and pathogenesis of each condition. Instead,
it will focus on a small subset of diseases, with particular
emphasis on recent advances, what we have learned and
how the genetic data have begun to illustrate the defining
biology of the conditions.
Chronic inflammatory diseases have been at the forefront of
a new genetics revolution primarily because they represent a
considerable portion of human morbidity and many are
known to be heritable. In the past 3 years, more than 50
genome-wide association studies (GWAS) have been con-
ducted in around 20 different chronic inflammatory conditions
ranging from asthma to osteoarthritis (Fig. 1) (1,2). The
chronic inflammatory diseases that have been examined by
GWAS are complex diseases, conditions where there is a con-
siderable environmental impact on a polygenic susceptibility
background. Linkage studies were largely unsuccessful at
identifying major components of the heritability of these
traits, with many conditions entering the GWAS era with no
well-replicated findings. Many of these studies were con-
ducted by collaborations based within a single country, each
identifying a few novel, but low risk, alleles. It was soon rea-
lized, however, that even greater patient sample numbers
would be needed to identify alleles with very small odds
ratios. 2008 was the year that saw the successful pooling of
large collections of GWAS data between groups to increase
statistical power and identify further alleles in conditions
such as T1D, type 2 diabetes, Crohn’s disease and colorectal
cancer (3–6).
Two common and debilitating gastrointestinal disorders can
be used to illustrate the journey that many complex diseases
have been following: Crohn’s disease, an inflammatory
response to luminal gut bacterial antigens, and coeliac
disease, an autoimmune inflammatory response in the small
bowel to ingested wheat gluten. At the turn of the millennium,
Crohn’s disease genetics had identified a single linkage region
on chromosome 16, but no definitive loci had been mapped
(7). Today, the loci count stands at 31, with several of these
harbouring multiple independent protective and risk variants
(5,7). Coeliac disease, on the other hand, identified a major
determinant of the heritability in the 1970s, with the identifi-
cation of an association to the HLA complex, but prior to
the GWAS era, other loci have been elusive (8,9).
CROHN’S DISEASE
Crohn’s disease has always been at the forefront of the GWAS
era. It was the subject of one of the very first genome-wide
SNP association scans in 2005. In what would now be
described as a small study, 484 Japanese Crohn’s disease
patients were genotyped for 80 000 SNPs, resulting in an
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association to a haplotype mapping within the TNFSF15 gene
(10). Since then, concerted efforts have been made to not only
replicate this finding, but also to expand cohorts to much
larger sizes and genotype many more SNPs in the hope of
identifying additional associations. One of the first large-scale
genome-wide association scans, published at the end of 2006,
was also conducted in Crohn’s disease and identified associ-
ations within the IL23R gene in two separate case–control
cohorts (11). Although the sample size was not considerably
different from the first study, the major advance came in the
use of high-density SNP arrays, allowing approximately
300 000 haplotype-tagging SNPs, primarily derived from the
International HapMap Project, to be genotyped at once.
These high-density SNP arrays made a huge impact on
complex disease genetics. By the start of 2007, Crohn’s
disease geneticists had three genes, CARD15, TNFSF15 and
IL23R, which could be confidently associated with the con-
dition as a result of association studies and linkage results.
This number was raised over the course of 2007 by a series
of GWAS scans conducted in North American and European
populations (12–16).
A recent meta-analysis, conducted on data from three com-
plete genome-wide scans, replicated association at 11 loci
from the individual scans and identified a further 21 loci (5).
Despite this, however, estimates suggest that these 31 loci
only explain about 20% of the heritability of Crohn’s
disease. This figure comes with several caveats. It is often pos-
tulated that identifying the missing heritability will be aided
by finding the real causal variants, and there now appears to
be some evidence for this. For example, a pre-GWAS
meta-analysis, investigating studies that directly typed the
functional variants of CARD15 in Crohn’s disease, identified
an allelic odds ratio of 4.09 for the 3020insC insertion (17).
The original WTCCC GWAS scan reported an allelic odds
ratio of 1.29, for association with CARD15, in line with the
odds ratios for many of the reported associations (14). The
recent meta-analysis which was able to impute genotypes
from data across two different platforms, however, reported
the odds ratio for carriage of a CARD15 susceptibility allele
as 3.99, suggesting that this variant can be well tagged
through imputation (5).
COMMON GENETICS OF THE INFLAMMATORY
BOWEL DISEASES
Ulcerative colitis and Crohn’s disease have distinct endo-
scopic, histological and pathological features as well as dis-
tinct differential risk factors. For example, smoking is a risk
factor for Crohn’s disease, yet is protective for ulcerative
colitis (18). However, despite these marked differences,
there appears to be some overlap in genetic susceptibility.
To date, two genome-wide association scans have been under-
taken in ulcerative colitis: a non-synonymous SNP scan and
genome-wide SNP scan (19,20). Both identified unique and
overlapping disease associations. More interestingly perhaps
is the overlap between these findings and associations with
Crohn’s disease. By comparing the results obtained from the
Figure 1. Number of loci identified for chronic inflammatory diseases (2008). The sum of the number of loci identified from individual GWAS. Data was
extracted from The National Human Genome Research Initiative Catalogue of Genome Wide Association Study Variants, available at http://www.genome.
gov/gwastudies/ (accessed 28/12/08). Not all loci have been replicated in multiple studies.
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two ulcerative colitis genome-wide association scans, together
with a replication of Crohn’s disease variants in ulcerative
colitis, with the results of the recent Crohn’s disease
meta-analysis, it is possible to see that the underlying shared
susceptibility is attributable to at least nine distinct regions
(1p31, 1q32, 3p21, 5q33, 10p11, 10q21, 10q24, 17q21.2 and
18q11) (19–21).
Crohn’s disease, psoriasis and ankylosing spondylitis share
many similarities and can often co-occur (22). It is not surpris-
ing, therefore, that all three display a common genetic suscep-
tibility at the IL23R locus (11,23,24). Although useful for
prediction of disease risk, the IL23R association also suggests
a role for IL23 in the pathogenesis of the three conditions.
Both Crohn’s disease lamina propria mononuclear cells and
psoriatic lesions display elevated levels of IL-23, a cytokine
believed to be involved in the maintenance of a pro-
inflammatory subset of T cells, termed Th17 cells (25,26). Sar-
coidosis and Crohn’s are both granulomatous inflammatory
diseases that share common clinical features, but rarely
co-occur. A joint GWAS between the two conditions was
able to identify a common susceptibility variant that, after
fine mapping, was located to the C10ORF67 gene (27). This
study elegantly demonstrates that conditions that share clinical
features as well as conditions that co-occur can be associated
with similar common susceptibility variants. Each condition,
however, can also be expected to have unique variants that
do not predispose to the related conditions. It is these variants,
along with environmental insults, that may predispose an
individual to a particular disease.
COELIAC DISEASE
Coeliac disease is a common disorder with an estimated popu-
lation prevalence of 1% (28). There is a 75% concordance rate
within monozygotic twins, making coeliac disease one of the
most heritable complex diseases (29). Almost 90% of
coeliac disease patients carry the HLA-DQ2.5 haplotype,
with many of the remaining patients carrying a related haplo-
type, HLA-DQ8 (30,31). The HLA heterodimers, created by
the associated haplotypes, present gluten peptides to cognate
T cells primarily once the peptide has been de-amidated by
the enzyme tissue transglutaminase (32). Related, but unasso-
ciated, HLA-DQ haplotypes have much lower binding affi-
nities for gluten peptides (32). Estimates place the
heritability of coeliac disease attributable to the HLA
complex, at 35% (33). As a result, particular emphasis has
been placed on identifying the non-HLA genetic risk variants.
In common with many complex diseases, genome-wide
linkage studies were fairly unsuccessful at identifying loci
that consistently replicated among populations in coeliac
disease. Recent data from GWAS have identified eight
regions beyond the HLA, which predispose to coeliac
disease in three European populations (33,34). The largest
allelic odds ratio identified to date, outside of the HLA
complex, is 1.34 (3p21) (34). Associations such as these
only explain a small proportion of the heritability at present
(3–4%). There is, however, the caveat that only tagging
SNPs have been used and the causal variants likely not ident-
ified. The variants identified do, however, identify important
biological pathways that could be hypothesized to be import-
ant in the development of disease. For example, seven of the
eight coeliac disease regions identified contain immune
genes, involved in T or B cell function. These genes have
been identified in a hypothesis-free manner, yet they function
in two of the most important cells in the pathogenesis of the
condition.
COELIAC DISEASE AND TYPE 1 DIABETES
Many autoimmune diseases share common pathways, and
recent GWAS have begun to elucidate the common genetic
loci involved (35). In some cases, these common pathways
can be inferred from commonly occurring loci in the literature;
in the case of coeliac disease, however, this has also been
implicitly tested. There has long been an epidemiological
link between T1D and coeliac disease. Approximately 4.5%
of children and 6% of adults diagnosed with T1D have concur-
rent coeliac disease (36). In addition, T1D patients often
express peripheral blood antibodies to tissue transglutaminase
(a diagnostic marker in coeliac disease) (37). T1D results from
the autoimmune destruction of the insulin-producing b-islet
cells, and clusters within families. The HLA variant that pre-
disposes to coeliac disease, HLA-DQ2, is encoded by the two
alleles DQA10501 and DQB10201 (38). T1D also has very a
strong association to the HLA region, with DQB10302,
DQB10201, DRB10401 and HLA-B all being implicated
(39). One of the strongest T1D associations arises from the
two coeliac-associated alleles, HLA-DQ2 and HLA-DQ8,
but especially when encoded as a heterozygous genotype
(40). Interestingly, this genotype presents only a moderately
increased risk for coeliac disease (41). The mechanism
behind the association with coeliac disease is well documen-
ted, with the heterodimer presenting de-amidated gluten pep-
tides (42). The association with diabetes is less well
understood, although it is reasonable to suppose that the
unique peptide-binding characteristics result in a diabetogenic
peptide being presented to the immune system. To test the
hypothesis that common variants may predispose to both
coeliac disease and T1D, Smyth et al. (43) genotyped all the
currently identified T1D and coeliac disease loci in cohorts
of both T1D and coeliac disease patients in an attempt to
identify any common susceptibility locus. The results demon-
strate the considerable overlap between the two conditions and
offer some further explanation for the epidemiological
overlap. Out of the eight coeliac disease susceptibility loci,
six showed evidence of association with T1D (although the
susceptibility allele differed for IL18RAP and TAGAP). Of
the 17 T1D loci, eight showed evidence of association in
coeliac disease, including CTLA4. The CTLA4 locus received
considerable attention as a linkage peak and candidate gene
for coeliac disease but replication was inconsistent and as a
result, it was never accepted as a true susceptibility locus
(44,45). The result is that seven loci are shared between
T1D and coeliac disease, which given the relatively small
number of total variants identified to date, in each condition,
represents a remarkable shared susceptibility. The variants
detected above are not just shared between T1D and
coeliac; there is also considerable overlap with Graves’
Human Molecular Genetics, 2009, Vol. 18, Review Issue 1 R103
disease, multiple sclerosis and rheumatoid arthritis (Fig. 2).
The greater number of T1D variants identified to date probably
reflects the larger cohorts collected rather than a wider genetic
susceptibility.
From the data collected to date, the hypothesis has been
suggested that there may be a general set of autoimmunity sus-
ceptibility genes which are modulated by disease-specific
genes (such as IL12A in coeliac disease and INS in T1D), as
well as the host’s HLA status (43). The exact combinations
of variants, combined with environmental insults, could deter-
mine which disease a person develops.
WHERE NEXT FOR GENETICS
Despite the large numbers of genome-wide studies established
to date, most diseases have only managed to explain a tiny
additional percentage of the heritability estimates. In an
attempt to explain some of this missing heritability, research-
ers are adopting several complementary strategies. Larger
cohorts of cases are being collected, through either further
patient recruitment or collaboration. The meta-analysis data
generated to date have elegantly demonstrated how increasing
the cohort sample size generates additional statistical power
to detect smaller and smaller odds ratios (5). Advances in
technology and particularly bioinformatics have now made it
possible to perform GWAS using common copy number vari-
ation probes. Studies such as these are currently ongoing.
Many groups are looking to high-throughput sequencing tech-
nology, with the aim of sequencing candidate gene regions
identified by GWAS, to hopefully identify either the causal
or rare variants, depending on the number of samples
sequenced. The results of these studies are likely to define
the next few years of not just chronic inflammatory diseases
genetics, but all complex diseases genetics.
Conflict of Interest statement. None declared.
FUNDING
We would like to acknowledge funding from the Juvenile
Diabetes Research Foundation International, the Wellcome
Trust and Coeliac UK.
REFERENCES
1. Moffatt, M.F., Kabesch, M., Liang, L., Dixon, A.L., Strachan, D., Heath,
S., Depner, M., von Berg, A., Bufe, A., Rietschel, E. et al. (2007) Genetic
Figure 2. Common disease variants. The currently associated loci with T1D, coeliac disease, Graves’ disease, rheumatoid arthritis and multiple sclerosis have
been represented by their nearest gene. The association between the IL2/IL21 linkage disequilibrium block locus, with coeliac disease and T1D/Graves’ appears
to be due to independent variants.
R104 Human Molecular Genetics, 2009, Vol. 18, Review Issue 1
variants regulating ORMDL3 expression contribute to the risk of
childhood asthma. Nature, 448, 470–473.
2. Erlich, H., Valdes, A.M., Noble, J., Carlson, J.A., Varney, M.,
Concannon, P., Mychaleckyj, J.C., Todd, J.A., Bonella, P., Fear, A.L.
et al. (2008) HLA DR-DQ haplotypes and genotypes and type 1 diabetes
risk: analysis of the type 1 diabetes genetics consortium families.
Diabetes, 57, 1084–1092.
3. Cooper, J.D., Smyth, D.J., Smiles, A.M., Plagnol, V., Walker, N.M.,
Allen, J.E., Downes, K., Barrett, J.C., Healy, B.C., Mychaleckyj, J.C.
et al. (2008) Meta-analysis of genome-wide association study data
identifies additional type 1 diabetes risk loci. Nat. Genet., 40, 1399–1401.
4. Zeggini, E., Scott, L.J., Saxena, R., Voight, B.F., Marchini, J.L., Hu, T.,
de Bakker, P.I., Abecasis, G.R., Almgren, P., Andersen, G. et al. (2008)
Meta-analysis of genome-wide association data and large-scale replication
identifies additional susceptibility loci for type 2 diabetes. Nat. Genet., 40,
638–645.
5. Barrett, J.C., Hansoul, S., Nicolae, D.L., Cho, J.H., Duerr, R.H., Rioux,
J.D., Brant, S.R., Silverberg, M.S., Taylor, K.D., Barmada, M.M. et al.
(2008) Genome-wide association defines more than 30 distinct
susceptibility loci for Crohn’s disease. Nat. Genet., 40, 955–962.
6. Houlston, R.S., Webb, E., Broderick, P., Pittman, A.M., Di Bernardo,
M.C., Lubbe, S., Chandler, I., Vijayakrishnan, J., Sullivan, K., Penegar, S.
et al. (2008) Meta-analysis of genome-wide association data identifies
four new susceptibility loci for colorectal cancer. Nat. Genet., 40, 1426–
1435.
7. Hugot, J.P., Laurent-Puig, P., Gower-Rousseau, C., Olson, J.M., Lee, J.C.,
Beaugerie, L., Naom, I., Dupas, J.L., Van Gossum, A., Orholm, M. et al.
(1996) Mapping of a susceptibility locus for Crohn’s disease on
chromosome 16. Nature, 379, 821–823.
8. Falchuk, Z.M., Rogentine, G.N. and Strober, W. (1972) Predominance of
histocompatibility antigen HL-A8 in patients with gluten-sensitive
enteropathy. J. Clin. Invest., 51, 1602–1605.
9. Keuning, J.J., Pena, A.S., van Leeuwen, A., van Hooff, J.P. and
va Rood, J.J. (1976) HLA-DW3 associated with coeliac disease. Lancet, 1,
506–508.
10. Yamazaki, K., McGovern, D., Ragoussis, J., Paolucci, M., Butler, H.,
Jewell, D., Cardon, L., Takazoe, M., Tanaka, T., Ichimori, T. et al. (2005)
Single nucleotide polymorphisms in TNFSF15 confer susceptibility to
Crohn’s disease. Hum. Mol. Genet., 14, 3499–3506.
11. Duerr, R.H., Taylor, K.D., Brant, S.R., Rioux, J.D., Silverberg, M.S.,
Daly, M.J., Steinhart, A.H., Abraham, C., Regueiro, M., Griffiths, A. et al.
(2006) A genome-wide association study identifies IL23R as an
inflammatory bowel disease gene. Science, 314, 1461–1463.
12. Hampe, J., Franke, A., Rosenstiel, P., Till, A., Teuber, M., Huse, K.,
Albrecht, M., Mayr, G., De La Vega, F.M., Briggs, J. et al. (2006) A
genome-wide association scan of nonsynonymous SNPs identifies a
susceptibility variant for Crohn disease in ATG16L1. Nat. Genet., 39,
207–211.
13. Libioulle, C., Louis, E., Hansoul, S., Sandor, C., Farnir, F., Franchimont,
D., Vermeire, S., Dewit, O., de Vos, M., Dixon, A. et al. (2007) Novel
Crohn disease locus identified by genome-wide association maps to a gene
desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet., 3,
e58.
14. Wellcome Trust Case Control Consortium (2007) Genome-wide
association study of 14,000 cases of seven common diseases and 3,000
shared controls. Nature, 447, 661–678.
15. Raelson, J.V., Little, R.D., Ruether, A., Fournier, H., Paquin, B., Van
Eerdewegh, P., Bradley, W.E., Croteau, P., Nguyen-Huu, Q., Segal, J.
et al. (2007) Genome-wide association study for Crohn’s disease in the
Quebec Founder Population identifies multiple validated disease loci.
Proc. Natl Acad. Sci. USA., 104, 14747–14752.
16. Rioux, J.D., Xavier, R.J., Taylor, K.D., Silverberg, M.S., Goyette, P.,
Huett, A., Green, T., Kuballa, P., Barmada, M.M., Datta, L.W. et al.
(2007) Genome-wide association study identifies new susceptibility loci
for Crohn disease and implicates autophagy in disease pathogenesis. Nat.
Genet., 39, 596–604.
17. Economou, M., Trikalinos, T.A., Loizou, K.T., Tsianos, E.V. and
Ioannidis, J.P. (2004) Differential effects of NOD2 variants on Crohn’s
disease risk and phenotype in diverse populations: a metaanalysis.
Am. J. Gastroenterol., 99, 2393–2404.
18. Mahid, S.S., Minor, K.S., Soto, R.E., Hornung, C.A. and Galandiuk, S.
(2006) Smoking and inflammatory bowel disease: a meta-analysis. Mayo
Clin. Proc., 81, 1462–1471.
19. Fisher, S.A., Tremelling, M., Anderson, C.A., Gwilliam, R., Bumpstead,
S., Prescott, N.J., Nimmo, E.R., Massey, D., Berzuini, C., Johnson, C.
et al. (2008) Genetic determinants of ulcerative colitis include the
ECM1 locus and five loci implicated in Crohn’s disease. Nat. Genet., 40,
710–712.
20. Franke, A., Balschun, T., Karlsen, T.H., Sventoraityte, J., Nikolaus, S.,
Mayr, G., Domingues, F.S., Albrecht, M., Nothnagel, M., Ellinghaus, D.
et al. (2008) Sequence variants in IL10, ARPC2 and multiple other loci
contribute to ulcerative colitis susceptibility. Nat. Genet., 40, 1319–1323.
21. Franke, A., Balschun, T., Karlsen, T.H., Hedderich, J., May, S., Lu, T.,
Schuldt, D., Nikolaus, S., Rosenstiel, P., Krawczak, M. et al. (2008)
Replication of signals from recent studies of Crohn’s disease identifies
previously unknown disease loci for ulcerative colitis. Nat. Genet., 40,
713–715.
22. Yates, V.M., Watkinson, G. and Kelman, A. (1982) Further evidence for
an association between psoriasis, Crohn’s disease and ulcerative colitis.
Br. J. Dermatol., 106, 323–330.
23. Liu, Y., Helms, C., Liao, W., Zaba, L.C., Duan, S., Gardner, J., Wise, C.,
Miner, A., Malloy, M.J., Pullinger, C.R. et al. (2008) A genome-wide
association study of psoriasis and psoriatic arthritis identifies new disease
loci. PLoS Genet., 4, e1000041.
24. Wellcome Trust Case Control Consortium and Australo-Anglo-American
Spondylitis Consortium (TASC) (2007) Association scan of 14,500
nonsynonymous SNPs in four diseases identifies autoimmunity variants.
Nat. Genet., 39, 1329–1337.
25. Chan, J.R., Blumenschein, W., Murphy, E., Diveu, C., Wiekowski, M.,
Abbondanzo, S., Lucian, L., Geissler, R., Brodie, S., Kimball, A.B. et al.
(2006) IL-23 stimulates epidermal hyperplasia via TNF and
IL-20R2-dependent mechanisms with implications for psoriasis
pathogenesis. J. Exp. Med., 203, 2577–2587.
26. Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T.B., Oukka, M.,
Weiner, H.L. and Kuchroo, V.K. (2006) Reciprocal developmental
pathways for the generation of pathogenic effector TH17 and regulatory T
cells. Nature, 441, 235–238.
27. Franke, A., Fischer, A., Nothnagel, M., Becker, C., Grabe, N., Till, A., Lu,
T., Muller-Quernheim, J., Wittig, M., Hermann, A. et al. (2008)
Genome-wide association analysis in sarcoidosis and Crohn’s disease
unravels a common susceptibility locus on 10p12.2. Gastroenterology,
135, 1207–1215.
28. Maki, M., Mustalahti, K., Kokkonen, J., Kulmala, P., Haapalahti, M.,
Karttunen, T., Ilonen, J., Laurila, K., Dahlbom, I., Hansson, T. et al.
(2003) Prevalence of celiac disease among children in Finland. New
Engl. J. Med., 348, 2517–2524.
29. Nistico, L., Fagnani, C., Coto, I., Percopo, S., Cotichini, R., Limongelli,
M.G., Paparo, F., D’Alfonso, S., Giordano, M., Sferlazzas, C. et al. (2006)
Concordance, disease progression, and heritability of coeliac disease in
Italian twins. Gut, 55, 803–808.
30. Sollid, L.M., Markussen, G., Ek, J., Gjerde, H., Vartdal, F. and Thorsby,
E. (1989) Evidence for a primary association of celiac disease to a
particular HLA-DQ alpha/beta heterodimer. J. Exp. Med., 169, 345–350.
31. Karell, K., Louka, A.S., Moodie, S.J., Ascher, H., Clot, F., Greco, L.,
Ciclitira, P.J., Sollid, L.M. and Partanen, J. (2003) HLA types in celiac
disease patients not carrying the DQA105-DQB102 (DQ2) heterodimer:
results from the European Genetics Cluster on Celiac Disease. Hum.
Immunol., 64, 469–477.
32. van de Wal, Y., Kooy, Y.M., Drijfhout, J.W., Amons, R., Papadopoulos,
G.K. and Koning, F. (1997) Unique peptide binding characteristics of the
disease-associated DQ(alpha 10501, beta 10201) vs the
non-disease-associated DQ(alpha 10201, beta 10202) molecule.
Immunogenetics, 46, 484–492.
33. van Heel, D.A., Franke, L., Hunt, K.A., Gwilliam, R., Zhernakova, A.,
Inouye, M., Wapenaar, M.C., Barnardo, M.C., Bethel, G., Holmes, G.K.
et al. (2007) A genome-wide association study for celiac disease
identifies risk variants in the region harboring IL2 and IL21. Nat. Genet.,
39, 827–829.
34. Hunt, K.A., Zhernakova, A., Turner, G., Heap, G.A., Franke, L.,
Bruinenberg, M., Romanos, J., Dinesen, L.C., Ryan, A.W., Panesar, D.
et al. (2008) Newly identified genetic risk variants for celiac disease
related to the immune response. Nat. Genet., 40, 395–402.
35. Lettre, G. and Rioux, J.D. (2008) Autoimmune diseases: insights from
genome-wide association studies. Hum. Mol. Genet., 17, R116–R121.
36. Holmes, G.K. (2002) Screening for coeliac disease in type 1 diabetes.
Arch Dis. Child., 87, 495–498.
Human Molecular Genetics, 2009, Vol. 18, Review Issue 1 R105
37. Williams, A.J., Norcross, A.J., Lock, R.J., Unsworth, D.J., Gale, E.A. and
Bingley, P.J. (2001) The high prevalence of autoantibodies to tissue
transglutaminase in first-degree relatives of patients with type 1 diabetes is
not associated with islet autoimmunity. Diabetes Care, 24, 504–509.
38. van Heel, D.A., Hunt, K., Greco, L. and Wijmenga, C. (2005) Genetics in
coeliac disease. Best Pract. Res., 19, 323–339.
39. Nejentsev, S., Howson, J.M., Walker, N.M., Szeszko, J., Field, S.F.,
Stevens, H.E., Reynolds, P., Hardy, M., King, E., Masters, J. et al. (2007)
Localization of type 1 diabetes susceptibility to the MHC class I genes
HLA-B and HLA-A. Nature, 450, 887–892.
40. Thorsby, E. (1997) Invited anniversary review: HLA associated diseases.
Hum. Immunol., 53, 1–11.
41. Dubois, P.C. and van Heel, D.A. (2008) Translational mini-review series
on the immunogenetics of gut disease: immunogenetics of coeliac disease.
Clin. Exp. Immunol., 153, 162–173.
42. Vader, W., Stepniak, D., Kooy, Y., Mearin, L., Thompson, A., van Rood,
J.J., Spaenij, L. and Koning, F. (2003) The HLA-DQ2 gene dose effect in
celiac disease is directly related to the magnitude and breadth of
gluten-specific T cell responses. Proc. Natl Acad. Sci. USA, 100,
12390–12395.
43. Smyth, D.J., Plagnol, V., Walker, N.M., Downes, K., Yang, J.H.M.,
Cooper, J.D., Howson, J.M., Stevens, H.R.M., Wijmenga, C. et al. (2008)
Shared, distinct and opposing genetic factors in type 1 diabetes and celiac
disease. New Engl. J. Med., 359, 2767–2777.
44. Hunt, K.A., McGovern, D.P., Kumar, P.J., Ghosh, S., Travis, S.P.,
Walters, J.R., Jewell, D.P., Playford, R.J. and van Heel, D.A. (2005) A
common CTLA4 haplotype associated with coeliac disease. Eur. J. Hum.
Genet., 13, 440–444.
45. van Belzen, M.J., Mulder, C.J., Zhernakova, A., Pearson, P.L., Houwen,
R.H. and Wijmenga, C. (2004) CTLA4þ49 A/G and CT60
polymorphisms in Dutch coeliac disease patients. Eur. J. Hum. Genet., 12,
782–785.
R106 Human Molecular Genetics, 2009, Vol. 18, Review Issue 1
BioMed Central
Page 1 of 13
(page number not for citation purposes)
BMC Medical Genomics
Open AccessResearch article
Complex nature of SNP genotype effects on gene expression in 
primary human leucocytes
Graham A Heap1, Gosia Trynka†2,3, Ritsert C Jansen†2,4, Marcel Bruinenberg2, 
Morris A Swertz2, Lotte C Dinesen5, Karen A Hunt1, Cisca Wijmenga2,3, 
David A vanHeel1 and Lude Franke*1,2,3
Address: 1Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, London, E1 2AT, UK, 2Genetics 
Department, University Medical Centre Groningen, University of Groningen, 9700 RB Groningen, the Netherlands, 3Complex Genetics Section, 
DBG-Department of Medical Genetics, University Medical Centre Utrecht, 3584 CG Utrecht, the Netherlands, 4Groningen Bioinformatics Centre, 
Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Kerklaan 30, NL-9751 NN Haren, the Netherlands and 
5Gastroenterology Unit, University of Oxford, Oxford OX3 7BN, UK
Email: Graham A Heap - g.heap@qmul.ac.uk; Gosia Trynka - gosia.trynka@gmail.com; Ritsert C Jansen - r.c.jansen@rug.nl; 
Marcel Bruinenberg - m.bruinenberg@medgen.umcg.nl; Morris A Swertz - m.a.swertz@rug.nl; Lotte C Dinesen - lottedinesen@gmail.com; 
Karen A Hunt - k.a.hunt@qmul.ac.uk; Cisca Wijmenga - c.wijmenga@umcutrecht.nl; David A vanHeel - d.vanheel@qmul.ac.uk; 
Lude Franke* - lude@ludesign.nl
* Corresponding author    †Equal contributors
Abstract
Background: Genome wide association studies have been hugely successful in identifying disease
risk variants, yet most variants do not lead to coding changes and how variants influence biological
function is usually unknown.
Methods: We correlated gene expression and genetic variation in untouched primary leucocytes
(n = 110) from individuals with celiac disease – a common condition with multiple risk variants
identified. We compared our observations with an EBV-transformed HapMap B cell line dataset (n
= 90), and performed a meta-analysis to increase power to detect non-tissue specific effects.
Results: In celiac peripheral blood, 2,315 SNP variants influenced gene expression at 765 different
transcripts (< 250 kb from SNP, at FDR = 0.05, cis expression quantitative trait loci, eQTLs). 135
of the detected SNP-probe effects (reflecting 51 unique probes) were also detected in a HapMap
B cell line published dataset, all with effects in the same allelic direction. Overall gene expression
differences within the two datasets predominantly explain the limited overlap in observed cis-
eQTLs. Celiac associated risk variants from two regions, containing genes IL18RAP and CCR3,
showed significant cis genotype-expression correlations in the peripheral blood but not in the B cell
line datasets. We identified 14 genes where a SNP affected the expression of different probes
within the same gene, but in opposite allelic directions. By incorporating genetic variation in co-
expression analyses, functional relationships between genes can be more significantly detected.
Conclusion: In conclusion, the complex nature of genotypic effects in human populations makes
the use of a relevant tissue, large datasets, and analysis of different exons essential to enable the
identification of the function for many genetic risk variants in common diseases.
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Background
Human gene expression levels have a strong heritable
component [1-4]. At some genes, the variance in gene
expression levels is an order of magnitude greater between
unrelated individuals, than between identical twins [5].
Quantitative mRNA levels are key regulators of phenotype
and represent a link between genetic variation and pheno-
typic alterations. A term first introduced by Jansen & Nap
[6], genetical genomics aims to identify the genetic variants
that affect gene expression. By treating gene expression as
a quantitative trait it is possible to correlate gene transcript
expression levels with genomic locations such that expres-
sion quantitative trait loci (eQTLs) can be identified [7].
In the human genome, cis associations, where a genetic
variant affects a transcript that maps to the same locus,
have been predominantly reported [3,8]. Trans effects,
where the genetic variant is distant to the transcript loci,
are much harder to convincingly identify due to inherent
multiple testing problems. Analysis of trans effects
involves several magnitudes more statistical tests than for
cis effects. Although individual studies have reported
human trans associations, no effects have been convinc-
ingly replicated in multiple studies identified for the same
transcript and variant [1,9,10].
Quantitative transcript expression and genotype relation-
ships can be investigated via linkage or association based
methodologies. Linkage studies use a genome wide series
of markers in recombinant in-bred lines or families, to fol-
low the heritability of a trait, whilst association studies
usually compare large number of single nucleotide poly-
morphisms (SNPs) to transcript levels from unrelated
individuals. Despite its extensive use in plant [11,12],
mouse [13,14] and rat [15] models, transcript expression
and genotype correlation studies have only recently been
performed in humans [3,5,8].
Human association studies have centered on RNA
obtained from leukocytes, predominantly Epstein-Barr
virus (EBV) transformed B cell lines from HapMap indi-
viduals [3] or unrelated trios [1]. A large scale genetical
genomics linkage study has recently identified more than
1000 cis regulatory loci across the genome, in primary cry-
opreserved human leukocytes [2], although these are
broad genomic regions rather than variants in more pre-
cisely defined LD blocks. However, the former studies are
limited by their ability to assess transcripts that are signif-
icantly expressed at the point of RNA isolation. Cell
extraction methods, cryopreservation and EBV transfor-
mation all affect individual mRNA expression levels.
These variations in RNA analysis make the choice of anal-
ysis tissue of paramount importance.
Here we present an association based genetical genomics
study using primary cell RNA from peripheral blood sam-
pled from patients in remission from an immune-mediated
disease. Immediate RNA preservation during blood sam-
pling (using the PAXgene system) represents nearly in vivo
human physiological gene expression. Celiac disease is a
common (1% prevalence), inflammatory condition of the
small intestine induced by intake of gluten in wheat, rye
and barley. A strong genetic component has been estab-
lished for disease with a monozygotic concordance of 75%
[16] and 90% of cases possessing the HLA haplotype HLA-
DQ2.5 [17] and the remainder mostly have HLA-DQ8
[18]. Despite the role of the HLA, the risk of disease is still
greater in HLA matched monozygotic twins compared to
HLA matched dizygotic twins [19]. We recently performed
a genome wide association and replication study using sin-
gle nucleotide polymorphisms (SNPs) and identified an
additional eight susceptibility loci that predispose to celiac
disease [20,21]. A surprising finding from this study was
that seven of the eight regions contained promising candi-
date genes expressed in leucocytes of the immune system.
This suggested the feasibility of genetical genomics
approaches using peripheral blood to assess the biological
function of the celiac disease associated risk variants. One
goal of genetical genomics is to uncover previously
unknown biological pathways. If genetic variation affects
the expression of a gene in trans, this suggests a biological
relationship exists between the two loci. To assess this, con-
siderable amounts of effort have been devoted to the devel-
opment and application of statistical frameworks that are
capable of detecting these trans-eQTLs. However, detection
of trans-eQTLs in human populations has proven less suc-
cessful than in mouse, rat and plant recombinant inbred
lines [13,22]. It has been suggested that the extensive
genetic and environmental diversity between human indi-
viduals masks many of the existing trans-effects.
We show that numerous cis-eQTLs can be identified
through an expression analysis of peripheral blood RNA.
We also show many of these are only detectable in periph-
eral blood RNA, and not in EBV-transformed B cell lines.
Through a meta-analysis of these two datasets we identi-
fied numerous additional cis-eQTLs. We show that for
some cis-eQTLs genetic variation does not lead to overall
gene expression changes, but rather leads to shifts in the
types of different splice isoforms that are produced. The
complex nature of genotypic effects on gene expression
limits our ability to fully elucidate the effect on RNA
expression level or sequence and combined with the sig-
nificant multiple testing problems prevented the accurate
identification of trans effects.
Methods
Study population
115 UK celiac disease individuals were recruited from
Barts and the London NHS Trust and the Oxford Radcliffe
Hospitals NHS Trust after informed consent and with eth-
ical approval. Individuals all had a small bowel endo-
scopic biopsy diagnosis of celiac disease, median age of 51
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(23–88), a median age at diagnosis of 42 (1–75), a male
to female sex ratio of 1:3, and a median length of treat-
ment on a gluten free diet of 9.4 years (1–47). Celiac indi-
viduals responding to a gluten free diet typically show no
detectable inflammation (which we confirmed at the
mRNA level in peripheral blood). We also enrolled 22
healthy unrelated UK controls, with a male to female sex
ratio of 1:1.2, but of unknown age.
PAXgene RNA Extraction
2.5 ml of peripheral blood was collected into a PAXgene
tube (Becton Dickinson, UK, 762165). PAXgene vials
were chosen to prevent density gradient centrifugation,
immortalization or in vitro cell culture artifacts changing
mRNA profiles.
PAXgene tubes were mixed gently and incubated at room
temperature for two hours. After collection, tubes were
frozen at -20°C for at least 24 hours followed by storage
at -80°C. RNA was isolated using the PAXgene Blood RNA
isolation kit (Qiagen, UK, 762174). RNA was quantified
using the Nanodrop (Nanodrop Technologies, USA).
Total RNA integrity was analyzed using an Agilent Bioan-
alyzer (Agilent Technologies, USA).
Anti-sense RNA synthesis, amplification, purification and 
hybridization to Illumina expression chips
Anti-sense RNA was synthesized, amplified and purified
using the Ambion Illumina TotalPrep Amplification Kit
(Ambion, USA) following the manufacturers' protocol.
Complementary RNA was hybridized to Illumina
HumanRef-8 v2 Whole Genome BeadChips and scanned
on the Illumina BeadArray Reader. Data was handled
through the Illumina BeadStudio Gene Expression mod-
ule v3.2. All gene expression (MIAME compliant) and
genotype data has been made freely available by submis-
sion to GEO under GSE11501.
Quality control
Five celiac disease samples were excluded from subse-
quent analysis due to poor median probe intensity corre-
lation with all other samples or incorrect sex assignment,
based on an analysis of all the probes that mapped to the
non-pseudoautosomal region of chromosome Y. A data-
set of 110 celiac disease patients and 22 controls was then
used for analysis.
Normalization
Expression probes were mapped to the cDNA sequence from
Ensembl v45_36g [23] and the NCBI build 36 genome
assembly if necessary. Probes that had less than 96%
sequence homology or that mapped to multiple loci were
removed. Subsequent analyses were confined to autosomal
probes, in order to prevent sex specific effects on gene expres-
sion. After removal of probes that map to sex chromosomes,
data was quantile-quantile normalized [24].
Celiac disease sample genotypes
All celiac disease patients were genotyped as previously
described [20] using Illumina Infinium
HumanHap300v1.0 BeadChips.
Peripheral blood eQTL association analysis and false 
discovery rate control
257,013 autosomal SNPs were tested for association with
expression levels in the 110 celiac disease samples that
met analysis criteria of minor allele frequency (MAF) >
0.1, exact Hardy-Weinberg equilibrium P-Value > 0.0001
and call-rate > 0.95. Analyses were confined to those
probe-SNP pairs for which the distance from probe
genomic midpoint to SNP genomic location was less than
250 kb or 500 kb, depending on the analysis performed.
To prevent spurious associations due to outliers, a non-
parametric Spearman's rank correlation analysis was per-
formed. In order to correct for multiple testing we control-
led the false discovery rate (FDR) [25]. The distribution of
all the observed p-values was used to calculate the FDR, by
comparing this distribution to a null-distribution,
obtained from an identical analysis where the expression
phenotypes, relative to the genotypes had been permuted.
Through 1,000 permutations the Spearman's rank correla-
tion P-value threshold could be determined that corre-
sponded to an FDR of 0.01 or 0.05.
Validation panel: HapMap CEU samples
We compared the identified cis-eQTLs in the celiac periph-
eral blood dataset to a published human genetical genom-
ics dataset [3]. We reanalyzed expression data from EBV-
transformed B cell lines (further described as HapMap B
cell line dataset) for 90 CEU HapMap samples [3]. Analyses
were performed as described for the celiac disease samples.
To enable a comparison between the celiac peripheral
blood dataset and the HapMap B cell line dataset, only
SNPs were tested that had been successfully called within
HapMap and that were present on the Illumina
HumanHap300 platform (257,013 SNPs). Although this is
only a subset of all the SNPs that have been called for these
HapMap samples, this subset of SNPs is known to capture
most genetic Caucasian variation well [26].
Analysis of over- and underrepresented biological 
processes and function
We investigated over- or underrepresentation of certain
biological processes or functions through an analysis of
all significant cis-eQTL genes using the Panther Classifica-
tion System [27] (Binomial P-Value, Bonferroni cor-
rected).
Co-expression analysis
Many cis-eQTLs have been detected in human datasets,
but only a few trans-eQTLs have been found [1,3,8,10].
These trans-eQTLs imply a biological relationship
between the trans-locus and the trans-gene and as such
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can provide valuable biological insight. If several of these
were to be identified, they would allow for the reconstruc-
tion of gene networks.
A different, regularly used approach for reconstructing
gene networks is by systematically assessing co-expression
between pairs of genes. We performed such a co-expres-
sion analysis for each probe that comprised a cis-eQTL
and contrasted this to an analysis where the genetic com-
ponent of the cis-eQTL on the probe intensity level had
been removed.
We first investigated whether the identified probe that
comprised a cis-eQTLs (probe distance of 250 kb, FDR of
0.05) showed co-expression with all other probes that
mapped to different chromosomes for both the celiac
peripheral blood dataset and the HapMap B cell line data-
set. We correlated the measured intensity levels with all
other probes that mapped on different chromosomes,
through a Spearman's rank correlation analysis. By apply-
ing Bonferroni correction to account for multiple testing,
sets of significantly correlated transcript-pairs could be
identified.
Subsequently we used partial-correlations, enabling us to
redo this co-expression analysis while effectively remov-
ing the genotypic effect on the probe intensity level for the
probes that constitute the significant cis-eQTLs. Again, by
applying Bonferroni correction, sets of significantly corre-
lated transcript-pairs could be identified.
Results
Celiac disease is an immune mediated disease, dominated
by TH1 cytokine response. Given the importance of tissue
specific RNA profiles, we felt that peripheral blood was an
appropriate medium to study to investigate celiac disease
associated genetic variants. Given the known genetic con-
tribution to disease, we enrolled treated celiac disease
individuals rather than healthy controls, leading to an
enrichment for celiac disease associated genetic variants
and underlying causal variants [20,28]. For 110 celiac dis-
ease samples that passed quality control, both expression
at 19,867 transcripts and genotype data for 257,013 SNPs,
were analyzed.
Gene expression in celiac disease versus healthy control 
samples
To obtain the most accurate reflection of mRNA levels in
peripheral blood leukocytes, whole blood RNA was
immediately fixed during venepuncture in PAXgene vials,
giving a reflection of in vivo RNA expression from whole
blood. One hundred and fifteen treated celiac patients, all
of whom were successfully treated and compliant with a
gluten free diet for at least six months, were enrolled. Sev-
enty percent of celiac disease patients were female,
(66.6% of adult cases diagnosed with celiac disease in the
population are female [29]). In addition, 22 random
healthy control samples were enrolled to obtain a back-
ground RNA expression profile, enabling us to determine
whether the patients indeed did not show ongoing
inflammation. In a sex matched comparison no known
inflammatory disease associated cytokines, including
IFNG [30] and IL2 [31] showed significantly increased
expression (sex matched Wilcoxon Signed-Ranks Test P
value < 0.05) in celiac versus control samples, as was
expected since these patients had been treated with a glu-
ten free diet.
Cis-associations of gene expression with SNPs
Gene expression levels for 19,867 transcripts were ana-
lyzed for significant genotypic effects at 257,013 auto-
somal SNPs, mapping within 500 kb of the centre of the
transcript probes, resulting in 1,850,599 tests. By using a
Spearman's rank correlation coefficient statistic and an
FDR of 0.01 or 0.05, 1,360 and 2,178 different SNP-probe
effects were detected, respectively. These reflect 394 and
658 unique probes, and 1,273 and 2,035 unique SNPs,
respectively (see Table 1).
An identical analysis was performed on publicly available
EBV-transformed B cell line expression and genotype data
for 90 CEU HapMap individuals [3]. Using this dataset
and a SNP-probe distance of 500 kb and FDR of 0.01 or
0.05, 1,799 and 2,839 different SNP-probe effects were
detected, respectively. These reflect 536 and 821 unique
probes, and 1,601 and 2,464 unique SNPs, respectively
(see Table 1). Details of all detected individual cis-eQTLs
are available in Additional file 1.
Distance between SNPs and probes that constitute the cis-
eQTLs
Our analysis was initially confined to probes that had a
midpoint distance to the tested SNPs less than 500 kb.
Analysis of the significant cis-eQTLs SNP-probe distances
(Figure 1) suggests few cis-eQTLs have been missed by
imposing this threshold, as in both datasets for 95% of
the cis-eQTLs, the SNPs map within 250 kb of the probes.
As such it is expected that an increase in statistical power
can be achieved by reducing the distance to 250 kb as less
tests will be performed. Indeed in the celiac peripheral
blood dataset more cis-eQTLs were identified (in total
2,487 different SNP-probe effects were observed, com-
pared to 2,178 in the 500 kb analysis, based on an FDR of
0.05), reflecting 765 unique probes and 2,315 unique
SNPs. For the HapMap B cell line dataset 3,226 different
SNP-probe effects were identified (compared to 2,839 in
the 500 kb analysis, based on an FDR of 0.05), reflecting
994 unique probes and 2,826 unique SNPs (see Table 1).
Subsequent analyses were confined to cis-eQTLs that had
been detected using this 250 kb window analysis.
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Meta-analysis celiac peripheral blood and HapMap B cell 
lines data sets
4,681 Illumina expression probes had oligonucleotide
sequences that are shared between the two different oligo-
nucleotide arrays used (Human Ref8 v2 & Human WG-1
v1). By limiting the analysis to a window size of 250 kb and
only to SNPs that had been successfully genotyped in both
studies, 576 different SNP-probe effects in the celiac
peripheral blood data at a FDR = 0.05 (338 at an FDR =
0.01) were detected. These reflect 573 different SNPs and
197 different probes. In the HapMap B cell line data, 573
different SNP-probe effects were identified at an FDR = 0.05
(290 at an FDR = 0.01), reflecting 573 different SNPs and
189 different probes. A combined meta-analysis of both
cohorts (weighted-Z method) identified 1,133 different
SNP-probe associations at an FDR = 0.05 (428 at an FDR =
0.01) (see Figure 2). These reflect 1,120 SNPs and 328
unique probes. 440 SNP-probe pairs, reflecting 217 differ-
ent probes and 439 different SNPs (FDR = 0.05) were not
detected when either dataset was analyzed separately.
135 identical SNP-Probe effects (reflecting 135 different
SNPs and 51 different probes) had been identified in both
the 110 celiac disease samples and in the 90 HapMap B
cell line samples (FDR = 0.05). In all cases, the combined
meta-P-Value for each of these shared cis-eQTLs was more
significant due to the larger sample size, indicating allelic
effects in the same direction. A comparison between cis-
eQTLs that had been detected in a large scale linkage
based genetical genomics study using RNA obtained from
peripheral blood mononuclear cells [2], and the cis-eQTLs
we detected, indicates that 57.3% (distance 250 kb,
0.05FDR) of probes, displaying a genotypic effect in the
celiac peripheral blood dataset, also show a linkage cis-
eQTL signal. Of note is that CCR3 and IL18RAP are both
identified as cis-eQTLs in both these datasets.
Primer Polymorphisms
While it can be assumed that for most of the detected cis-
eQTLs indeed the probe expression is affected by genetic
variation, it can also be that SNPs, mapping to regions to
which the probe hybridizes, may affect hybridization effi-
cacies and result in cis-eQTLs [32] that are not due to
expression differences. For the celiac peripheral blood
dataset, 10.0% of all Illumina HumanRef-8 v2 probes
map to regions that contain known dbSNP polymor-
phisms. For the HapMap B cell line dataset, 20.5% of all
Illumina HumanRef-6 v1 probes map to known SNPs. For
the probes that make up the identified cis-eQTLs (distance
250 kb, FDR = 0.05) this percentage is significantly higher
for both the celiac peripheral blood analysis (12,5%,
Fisher's Exact test P = 0.02) and even more pronounced
for the HapMap B cell line dataset (29.1%, P = 7.76 × 10-
11). Numbers within brackets in table 1 denote the
number of cis-eQTLs, probes or genes that are potentially
due to these primer polymorphisms. If these primer poly-
morphisms are responsible for different hybridization
efficacies, these SNPs should be in LD with the SNPs that
Table 1: Summary of cis-eQTL findings from celiac peripheral blood and HapMap B cell line data sets
Population 110 celiac disease samples
(Celiac peripheral blood dataset)
90 Caucasian HapMap samples
(HapMap B cell datasets)
Expression 
data
Illumina HumanRef-8 v2 Whole
Genome BeadChip (19,867 mapped transcripts)
Illumina HumanRef-6 v1 Whole
Genome BeadChip (44,791 mapped transcripts)
Genotype data Illumina Infinium HumanHap300 BeadChip 
(257,013 SNPs assessed)
Subset of all HapMap Genotypes present on Illumina Infinium 
HumanHap300 BeadChip (257,013 SNPs assessed)




















1,529 (235) 1,360 (233) 2,487 (372) 2,178 (355) 1,981 (664) 1,799 (623) 3,226 (1,068) 2,839 (988)
Number of 
unique probes
470 (65) 394 (56) 765 (98) 658 (84) 613 (193) 536 (177) 994 (289) 821 (255)
Number of 
unique genes
460 (65) 385 (56) 753 (98) 647 (84) 563 (189) 491 (174) 903 (277) 746 (244)
Number of 
unique SNPs
1,432 (234) 1,273 (230) 2,315 (367) 2,035 (345) 1,743 (628) 1,601 (585) 2,826 (1009) 2,464 (920)
Numbers within brackets denote the number of cis-eQTLs, probes or genes that are potentially due to SNPs that map within the probe and affect the 
hybridization efficacies of these probes.
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make up the cis-eQTLs. We could assess this for those cis-
eQTLs where genotype data was available within HapMap
Phase II for both the SNP that makes up the eQTL and for
the SNPs that map within the probe that constitutes this
particular eQTL. We compared the resulting distribution
of r2 values to a null distribution, generated by calculating
the LD between the SNP that makes up an eQTL and the
SNP that mapped immediately adjacent to the primer pol-
ymorphism SNP. While the mean LD (mean r2 = 0.27) in
the celiac peripheral blood was not significantly higher
than the mean LD in the null distribution (mean r2 = 0.25,
Wilcoxon Mann-Whitney P-Value = 0.86), this was
observed for the HapMap B cell line dataset (mean r2 =
0.46, mean r2 of null distribution = 0.30, Wilcoxon Mann-
Whitney P-Value = 6.3 × 10-8).
Differential gene expression between tissue sample types 
influences cis-eQTL detection
To enable a comparison of gene expression levels between
the HapMap B cell line samples and the celiac peripheral
blood samples, we limited our analysis to 12,401 tran-
scripts that map to identical exons. The expression levels
for these transcripts were quantile normalized. cis-eQTLs
that have only been significantly detected in the celiac
peripheral blood dataset, reflect probes that on average
show higher expression in the celiac peripheral blood
samples compared to HapMap B cell line samples (Wil-
coxon Signed-Ranks test, P = 7.6 × 10-7) (see Figure 3).
Conversely, probes that comprised HapMap B cell line
specific cis-eQTLs were higher expressed than within the
celiac peripheral blood dataset (P = 2.0 × 10-4). As
expected, probes that comprised cis-eQTLs that were com-
mon to both data sets did not show differences in expres-
sion (P = 0.30). Noteworthy is that IL18RAP and CCR3,
both recently identified as being genetically associated
with celiac disease [21], exhibited significant cis-regula-
tion in the celiac peripheral blood dataset but not in the
HapMap B cell line dataset. Cis-effects for these two genes
could be detected as these two genes showed markedly
upregulated expression in the celiac peripheral blood
dataset (expression rank order 12,072 vs. 6,431 and
11,104 vs. 3,602, respectively). These results indicate that
Cumulative genomic distance distribution between SNP and probe midpoint for significant cis-eQTLs (FDR = 0.01, SNP-probe midpoint dista ce < 500 kb) in celiac peripheral blood samplesFigure 1
Cumulative genomic distance distribution between SNP and probe midpoint for significant cis-eQTLs (FDR = 
0.01, SNP-probe midpoint distance < 500 kb) in celiac peripheral blood samples.
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the analysis of different cell types is valuable to gain
insight in the potential functional consequences of dis-
ease associated genetic variants.
Overrepresented biological pathways
The genes, comprising the significant cis-eQTLs (distance
250 kb, FDR = 0.05), showed an overrepresentation of
hydrolase and transferase functions for both datasets, but
'immunity and defense' cis-eQTLs genes were more pre-
dominantly detected in the celiac disease peripheral
blood dataset than in the HapMap B cell line dataset (see
Additional file 2), as might be expected from the differen-
tial RNA profiles of the cells under investigation in each
dataset.
Significant opposite allelic directions for probes, mapping 
within the same genes
The observed concordance in allelic direction for the 135
significant SNP-probe effects, detected in both the 110
celiac peripheral blood and the 90 HapMap B cell line
samples was perfect when probe sequences were identical.
We also assessed whether the allelic directions for cis-
eQTLs probes was the same when multiple significant cis-
eQTL probes mapped within the same genes. We identi-
fied 14 genes (see Table 2) where this was not the case: sig-
nificant cis-eQTL probes with different oligonucleotide
sequences mapped to the same genes but showed oppo-
site allelic directions. For three of the genes, MRPL43,
OAS1 and TIPRL, we re-sequenced the probe regions in
four, four and three individuals with different genotypes,
respectively, and did not discover any polymorphisms,
confirming that these cis-eQTLs do not result from artifi-
cial hybridization differences.
Identification of trans effects and conditioned co-
expression analysis
We used the celiac disease dataset to assess whether signif-
icant trans-eQTLs could be identified (Spearman's rank
Summary of meta-analysis of 4,681 identical probes between the celiac peripheral blood and HapMap B cell line data sets (at an FDR = 0.05, SNP-probe midpoint distance < 250 kb)igure 2
Summary of meta-analysis of 4,681 identical probes between the celiac peripheral blood and HapMap B cell 
line data sets (at an FDR = 0.05, SNP-probe midpoint distance < 250 kb).
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correlation test P-Value < 1 × 10-12, FDR = 0.05). Two
trans-eQTLs were detected: rs2318331 (mapping within
COL22A1) with GI_48093066 (NBPF3) and rs12634559
(mapping downstream of IL1RAP) with GI_16306505
(CASP8AP2). However, these trans-eQTLs were not
detected in the HapMap B cell line dataset, even after
relaxing the nominal Spearman rank correlation P-value
to 0.05.
As trans-eQTLs implicate (direct or indirect) biological
relationships, it is somewhat disappointing that none
were clearly identified. An alternative way to identify bio-
logical relationships is by using co-expression analysis
(although such an analysis does not have the aim to iden-
tify or explain trans-eQTLs). We conducted such a co-
expression analysis and compared it to a co-expression
analysis that also takes the genetic variation into account.
First, co-expression was assessed between each of the
probes that constitute cis-eQTLs (SNP-probe midpoint
distance < 250 kb, FDR = 0.05) and all other probes (Fig-
ure 4a) that do not map to the same chromosome, by cal-
culating all pair-wise Spearman correlation coefficients.
This resulted in 13,003,505 and 42,270,807 pair-wise
tests for the celiac peripheral blood dataset (using 765 dif-
ferent cis-probes) and the HapMap B cell line dataset
(using 994 different cis-probes), respectively. Through
Bonferroni correction we accounted for multiple testing,
resulting in the identification of 50,821 and 168,292 sig-
nificantly correlated transcript-pairs respectively (Spear-
man's correlation test P-Value < 0.05 after multiple testing
correction).
Subsequently, we redid this co-expression analysis after
having removed the genotypic effect on the probe inten-
sity level for the probes that constitute the significant cis-
eQTLs (Figure 4b). We observed a considerably increased
number of significantly correlated transcript-pairs: 54,773
(an increase of 7.8%) and 258,874 (an increase of
53.8%), respectively.
To validate whether this increase in co-expressed tran-
scripts reflects known biology, we assessed a collection
of 80,350 known biological interactions (derived on 17
April 2007 from KEGG [33], BioGrid [34], Reactome
[35], BIND [36], HPRD [37] and IntAct [38]). For the
celiac peripheral blood dataset 91 of the 50,821
(0.179%) significantly correlated transcript-pairs that
had been identified in the unconditioned co-expression
analysis are known to interact. In the conditioned co-
expression analysis 106 of the 54,773 (0.194%) tran-
script pairs were known to interact, indicating an 8.0%
increase in the proportion of known biological interac-
tions that was identified. Comparable results were
obtained for the HapMap B cell line dataset: For the
unconditioned co-expression analysis 334 of the
168,292 (0.195%) significant transcript-pairs are known
to interact. In the conditioned co-expression analysis
634 of the 258.874 (0.245%) significant transcript-pairs
are known to biologically interact, representing an
increase of 23.4% in the proportion of known interac-
tions among the most significantly co-expressed tran-
script-pairs.
Differential Gene Expression between tissue types results in differential cis-eQTL detection Differential gene expression between the celiac data et and the HapMap dataset is represent d as  hi togram of log f ld changeFigu  3
Differential Gene Expression between tissue types results in differential cis-eQTL detection Differential gene 
expression between the celiac dataset and the HapMap dataset is represented as a histogram of log fold 
change. a) Density plot of log fold change for cis-eQTLs detected in celiac dataset but not in HapMap samples (FDR = 0.01, 
SNP-probe midpoint distance < 250 kb). b) Density plot of log fold change for cis-eQTLs detected in HapMap dataset but not 
in the celiac dataset, c) Density plot of log fold change for cis-eQTLs detected in both data sets. P values derived from a Wil-
coxon Signed-Ranks Test.
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Table 2: Genes containing multiple probes that are affected by SNPs that also affect other probes in the same gene, but with opposite 
allelic directions
Source SNP HUGO Spearman Probe Unique Illumina 
Identifier*
Probe Sequence Number of dbSNP 
polymorphisms known 
within probe region
Celiac rs1131383 POLR2J -0.48 GI_62422568 ILMN_1657317 0
HapMap rs1131383 POLR2J 0.57 GI_21704275 4210731 0
Celiac rs1901198 IRF5 -0.6 GI_38683857 ILMN_1670576 0
HapMap rs1901198 IRF5 0.5 GI_38683858 1770358 0
Celiac rs6565724 LOC400566 0.67 GI_62177143 ILMN_1713803 0
HapMap rs6565724 LOC400566 -0.72 GI_37544593 6040008 0
HapMap rs6565724 LOC400566 -0.74 GI_42661283 103170403 0
Celiac rs2863095 MRPL43 0.45 GI_28872731 ILMN_1652147 0
Celiac rs2863095 MRPL43 -0.49 GI_28872733 ILMN_1700477 0
HapMap rs2863095 MRPL43 0.58 GI_28872731 3940465 0
HapMap rs2863095 MRPL43 -0.61 GI_28872733 5900487 0
HapMap rs4768933 DIP2B 0.42 GI_17457388 101780735 0
HapMap rs4768933 DIP2B -0.44 GI_39930390 3940278 0
Celiac rs10774679 OAS1 -0.54 GI_74229010 ILMN_1658247 0
Celiac rs10774679 OAS1 0.51 GI_74229012 ILMN_1672606 0
HapMap rs3177979 OAS1 0.63 GI_8051620 2100154 0
HapMap rs3177979 OAS1 -0.72 GI_8051622 2100048 0
Celiac rs1040404 TIPRL -0.47 GI_73088904 ILMN_1779432 0
Celiac rs1040404 TIPRL 0.5 GI_73088933 ILMN_1781457 0
HapMap rs222851 C17orf81 -0.72 GI_44662825 6380129 0
HapMap rs222851 C17orf81 0.64 GI_44662829 2760301 0










HapMap rs2838859 POFUT2 -0.48 GI_34147486 5900341 1
HapMap rs2838859 POFUT2 0.45 Hs.300736 106110059 0
Celiac rs7084722 PTER -0.43 GI_47933342 ILMN_1795336 0
HapMap rs7084722 PTER 0.48 GI_20070185 5570040 1






























Meta-analysis of different significant but opposite allelic effects of SNPs (FDR = 0.05, SNP-probe midpoint distance < 250 kb) in the celiac peripheral 
blood dataset and HapMap B cell line data set. Shown are 14 genes that contain probes for either of the two platforms but that show opposite allelic 
directions. If probes have identical identifiers on the two platforms, but different oligonucleotide sequences, the oligonucleotide sequences are indicated.
*As provided by Illumina platform record.
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Figure 4c provides an example for Ubiquitin (UBA52), for
which a strong cis-eQTL was observed for probe
GI_15451941 with rs2314664 (Spearman's correlation
coefficient P-Value = 1.11 × 10-16) in the HapMap B cell
line dataset. Within this probe three other polymorphism
map (rs6554, rs34040670 and rs3209501), of which
rs6554 is in near perfect LD with rs2314664 (r2 = 0.98,
HapMap CEU population), suggesting this cis-eQTL does
not reflect a real expression difference, but rather a differ-
ence in hybridization efficacy. Co-expression with other
genes is already present in an unconditioned co-expres-
sion analysis, because the distribution of co-expression
for UBA52 with all other genes differs significantly from a
theoretical null-distribution (Wilcoxon-Mann Whitney P-
Value < 1 × 10-12). However, in the conditioned co-expres-
sion analysis, this difference is more pronounced (see fig-
ure 4c). When confining this analysis to a set of 156
known interactions for UBA52, overall co-expression was
significantly stronger for these pairs of genes in the condi-
tioned (mean absolute Spearman's correlation coefficient
= 0.39) than in the unconditioned co-expression analysis
(mean absolute Spearman's correlation coefficient = 0.20,
Wilcoxon-Mann Whitney P-Value < 10-50).
Discussion
We have demonstrated the use of peripheral blood RNA
samples for the detection of cis-eQTLs and have shown
that there is strong allelic concordance with cis-eQTLs that
also had been detected in a HapMap B cell line dataset.
These results indicate that a meta-analysis with larger sam-
ple size and hence statistical power results in a considera-
ble increase in the detected cis-eQTL even though the
arrays that had been used were different. Some cis-eQTLs
can be observed across multiple tissue types, in all cases in
the same allelic direction, suggesting a major conserved
function. However most of the detected cis-eQTLs in these
datasets were only detected in one of the two tissues, sug-
gesting that more insight can be gained in the functional
consequences of genetic variation by performing genetical
genomics studies using different types of cells and tissues.
This point is particularly relevant for identifying the func-
tion of risk variants for common diseases: for example
study immune tissues for immune-mediated diseases, adi-
pose tissue for obesity traits [8], brain tissue for neurolog-
ical traits [10]. Genetical genomics experiments
performed in outbred human populations are addition-
ally complex and in addition to tissue specific RNA pro-
files, care should be taken to investigate alternative RNA
sequence events, primer polymorphisms that generate
false eQTLs and strong cis-eQTLs that obscure weaker trans
effects.
It is attractive to assume most of the observed cis-eQTLs
reflect overall gene expression level alterations. However,
we did observe 14 genes (Table 2) where different probes
showed significant opposite allelic effects. For at least five
out of the 14 genes (POFUT2, PTER, MYOM2, ADI1 and
HLA-DRB5) polymorphisms within the probe are known
to exist in dbSNP. For each of these genes, it may be that
one cis-eQTL for instance reflects a real expression differ-
ence, whereas the other reflects a hybridization effect due
to the presence of these SNPs within the probe. However,
recently Kwan et al [39] provided another potential expla-
nation, as they showed for three of the 14 genes (IRF5,
MRPL43 and PTER), using Affymetrix GeneChip Human
Exon 1.0 ST Arrays, that different genetic variants can
result in premature 3' termination events. The SNPs that
make up these cis-eQTLs are all in strong linkage disequi-
librium with the SNPs Kwan et al described (IRF5:
rs7808907 and rs6969930: D' = 1, R2 = 0.74 rs2863095,
MRPL43: rs2863095 and rs12241232: D' = 0.89, R2 =
0.75, PTER: rs7909832 and rs1055340: D' = 1, R2 = 1),
supporting our observations. Kwan et al examined differ-
ent exonic effects through an independent validation
using quantitative RT-PCR (out of a total of 25 validated
genes) and estimated that only 39% of the detected cis-
eQTLs influence overall gene expression levels. For the
remaining cis-eQTLs genetic variation results in prelimi-
nary terminated transcripts (18%), not initiated tran-
scripts (11%), transcripts that are spliced differentially
(26%) or a combination of these (6%). We acknowledge
that our use of oligonucleotide arrays, predominantly tar-
geting the 3' end of genes, gives a more limited picture of
splicing since only 3' termination events can be seen.
However, the data presented above and alluded to by
Kwan et al [39] suggest that SNP genotypes can have a sig-
nificant effect on alternatively spliced transcript isoforms.
This additional layer of complexity should be examined in
future genetical genomics experiments to fully elucidate
the genotypic effects on RNA.
Although the two trans-effects identified (IL1RAP and
CASP8AP2) are interestingly both involved in an apopto-
sis pathway, these trans-eQTLs were not detected in the
HapMap B cell line dataset. These trans-eQTL results are in
strong contrast to the number of cis-eQTLs we detected
within the two data sets. This results primarily from the
limited statistical power to detect trans-eQTLs, due to the
number of statistical tests that need to be performed.
Additionally, in order to cause a trans-effect, more inter-
mediate biological steps are required that introduces addi-
tional biological noise, lessening the correlation between
genotype and trans-gene expression. Cis-eQTLs can have a
significant impact on the co-expression of genes; this gen-
otypic variation may hinder the identification of signifi-
cant trans effects. This adds an additional layer of
complexity to the analysis of genotypic effects on gene
expression in outbred populations.
As it has been one of the goals of genetical genomics to
identify biological relationships we suggest that the con-
ditioned co-expression analysis we carried out here, might
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Cis-effects obscure detection of co-expression with other genes a) Co-expression for significant cis-eQTLs was determined; resulting in the id ntification of co-expression pa rs with generally low absolute correlation oeffi ients b) Through re oval of the ge otypic effect on the cis-eQTL obe, for some cis-eQTL  strong co-expressi n ca  be mor  asily detectedF g r  4
Cis-effects obscure detection of co-expression with other genes a) Co-expression for significant cis-eQTLs was 
determined; resulting in the identification of co-expression pairs with generally low absolute correlation coeffi-
cients b) Through removal of the genotypic effect on the cis-eQTL probe, for some cis-eQTLs strong co-
expression can be more easily detected. c) An example for UBA52 indicates that a conditioned co-expression analysis can 
help to identify meaningful biological relationships: Within the conditioned co-expression distribution (indicated in dark blue) 
there are more strongly co-expressed genes, opposed to an unconditioned analysis (indicated in red). This is supported by an 
analysis of 156 known interacting genes for UBA52: In the conditioned co-expression analysis (indicated in light blue) co-
expression is generally much stronger than in the unconditioned analysis (indicated in yellow).
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help to uncover these: We have shown that more known
biological relationships can be identified when using
genetical genomics to perform co-expression analyses that
have been conditioned on genotype. An explanation for
this observation is that cis-eQTLs sometimes convolute
co-expression, as is exemplified for UBA52, where primer
polymorphisms probably affect hybridization characteris-
tics.
Conclusion
This study shows that PAXgene isolated peripheral blood
RNA is a powerful resource for investigating functional
consequences of genetic variation. We have shown that
for some of the cis-eQTLs the functional consequences are
more complex than previously assumed. Additionally,
these findings imply that biological relationships can be
extracted in outbred populations, although in a somewhat
different manner than what is commonly used to detect
biological relationships through trans-eQTLs in inbred
model organisms.
As this study has only combined genetics with genomics,
we envision more extensive integrative approaches, incor-
porating e.g. epigenetics and proteomics, will help to
improve the detection of previously unknown biological
pathways.
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